activity_comment	activity_id	assay_chembl_id	assay_description	assay_type	canonical_smiles	data_validity_comment	molecule_chembl_id	relation	standard_type	standard_units	standard_value	target_chembl_id	target_organism	type	units	value
	2147371	CHEMBL922156	Activity of human Pyk2 kinase at 1 uM	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	=	Activity	%	90.0	CHEMBL5469	Homo sapiens	Activity	%	90.0
	2147371	CHEMBL922156	Activity of human Pyk2 kinase at 1 uM	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	=	Activity	%	90.0	CHEMBL5469	Homo sapiens	Activity	%	90.0
	2148596	CHEMBL929143	Inhibition of recombinant PYK2	B	CN(c1ccccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O.Cl		CHEMBL541649	=	IC50	nM	31.0	CHEMBL5469	Homo sapiens	IC50	nM	31.0
	2182403	CHEMBL941302	Inhibition of Pyk2	B	CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4c(c3)CCC(=O)N4)ncc2C(F)(F)F)c1		CHEMBL514554	>	IC50	nM	1000.0	CHEMBL5469	Homo sapiens	IC50	nM	1000.0
Not Active	2381831	CHEMBL939559	Inhibition of Pyk2-Y402 phosphorylation in human BT474 cells at 100 uM after 24 hrs by Western blotting	B	Cl.Nc1cc(N)c(N)cc1N		CHEMBL456559		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2381854	CHEMBL939563	Inhibition of recombinant full length Pyk2 autophosphorylation expressed in baculovirus by SDS-PAGE	B	Cl.Nc1cc(N)c(N)cc1N		CHEMBL456559		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2381857	CHEMBL939566	Inhibition of recombinant Pyk2 at 1 uM	B	Cl.Nc1cc(N)c(N)cc1N		CHEMBL456559		Activity			CHEMBL5469	Homo sapiens	Activity		
	2470330	CHEMBL992507	Inhibition of PTK2B at 3 uM	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2O1		CHEMBL521179	<	Inhibition	%	10.0	CHEMBL5469	Homo sapiens	INH	%	10.0
	2476668	CHEMBL1024920	Binding affinity to human PYK2 at 10 uM relative to control	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167	=	Activity	%	27.3	CHEMBL5469	Homo sapiens	Activity	%	27.3
Not Evaluated	2476871	CHEMBL1024920	Binding affinity to human PYK2 at 10 uM relative to control	B	NC(=O)c1ccc(-c2cc(C(N)=O)c(N)c(-c3ccc(S(N)(=O)=O)cc3)c2)cc1		CHEMBL514582		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Evaluated	2478710	CHEMBL1024920	Binding affinity to human PYK2 at 10 uM relative to control	B	N#Cc1c(NC(=O)c2ccccc2)sc2c1CCCC2		CHEMBL233000		Activity			CHEMBL5469	Homo sapiens	Activity		
	2479522	CHEMBL988916	Binding affinity to human PYK2	B	CCS(=O)(=O)Nc1ccc2c(c1)/C(=C(/Nc1ccc(CN3CCCCC3)cc1)c1ccccc1)C(=O)N2		CHEMBL514409	=	Kd	nM	10.0	CHEMBL5469	Homo sapiens	Kd	nM	10.0
Not Evaluated	2479768	CHEMBL1024920	Binding affinity to human PYK2 at 10 uM relative to control	B	N#Cc1ccc(-c2cnc3[nH]cc(NC(=O)c4cccnc4)c3c2)cc1		CHEMBL516312		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Evaluated	2480565	CHEMBL1024920	Binding affinity to human PYK2 at 10 uM relative to control	B	O=C1Nc2ccccc2/C1=C/c1ccc[nH]1		CHEMBL86755		Activity			CHEMBL5469	Homo sapiens	Activity		
Active	2480767	CHEMBL1024920	Binding affinity to human PYK2 at 10 uM relative to control	B	CCS(=O)(=O)Nc1ccc2c(c1)/C(=C(/Nc1ccc(CN3CCCCC3)cc1)c1ccccc1)C(=O)N2		CHEMBL514409		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Evaluated	2577389	CHEMBL1024920	Binding affinity to human PYK2 at 10 uM relative to control	B	CC(=O)c1c(-c2ccncc2)[nH]c(-c2ccncc2)c1C		CHEMBL526901		Activity			CHEMBL5469	Homo sapiens	Activity		
	2588050	CHEMBL960612	Inhibition of GST-tagged pyk2 assessed as inhibition of poly-Glu-Tyr phosphorylation	B	Cn1ccc2cc(Nc3ncc(C(F)(F)F)c(NCc4ccccn4)n3)ccc21		CHEMBL470314	=	IC50	nM	1200.0	CHEMBL5469	Homo sapiens	IC50	nM	1200.0
	2588053	CHEMBL960612	Inhibition of GST-tagged pyk2 assessed as inhibition of poly-Glu-Tyr phosphorylation	B	FC(F)(F)c1cnc(Nc2ccc3[nH]ncc3c2)nc1NCc1ccccn1		CHEMBL471526	=	IC50	nM	600.0	CHEMBL5469	Homo sapiens	IC50	nM	600.0
	2588056	CHEMBL960612	Inhibition of GST-tagged pyk2 assessed as inhibition of poly-Glu-Tyr phosphorylation	B	O=C1Cc2cc(Nc3nccc(NCc4ccccn4)n3)ccc2N1		CHEMBL471697	>	IC50	nM	10000.0	CHEMBL5469	Homo sapiens	IC50	nM	10000.0
	2588059	CHEMBL960612	Inhibition of GST-tagged pyk2 assessed as inhibition of poly-Glu-Tyr phosphorylation	B	Cc1cnc(Nc2ccc3c(c2)CC(=O)N3)nc1NCc1ccccn1		CHEMBL471698	>	IC50	nM	3000.0	CHEMBL5469	Homo sapiens	IC50	nM	3000.0
	2588062	CHEMBL960612	Inhibition of GST-tagged pyk2 assessed as inhibition of poly-Glu-Tyr phosphorylation	B	O=C1Cc2cc(Nc3ncc(Cl)c(NCc4ccccn4)n3)ccc2N1		CHEMBL511152	>	IC50	nM	1000.0	CHEMBL5469	Homo sapiens	IC50	nM	1000.0
	2588065	CHEMBL960612	Inhibition of GST-tagged pyk2 assessed as inhibition of poly-Glu-Tyr phosphorylation	B	O=C1Cc2cc(Nc3ncc(Br)c(NCc4ccccn4)n3)ccc2N1		CHEMBL470316	=	IC50	nM	580.0	CHEMBL5469	Homo sapiens	IC50	nM	580.0
	2588068	CHEMBL960612	Inhibition of GST-tagged pyk2 assessed as inhibition of poly-Glu-Tyr phosphorylation	B	N#Cc1cnc(Nc2ccc3c(c2)CC(=O)N3)nc1NCc1ccccn1		CHEMBL470317	=	IC50	nM	1800.0	CHEMBL5469	Homo sapiens	IC50	nM	1800.0
	2588071	CHEMBL960612	Inhibition of GST-tagged pyk2 assessed as inhibition of poly-Glu-Tyr phosphorylation	B	O=C1Cc2cc(Nc3ncc(C(F)(F)F)c(NCc4ccccn4)n3)ccc2N1		CHEMBL471357	=	IC50	nM	680.0	CHEMBL5469	Homo sapiens	IC50	nM	680.0
	2588074	CHEMBL960612	Inhibition of GST-tagged pyk2 assessed as inhibition of poly-Glu-Tyr phosphorylation	B	O=C1Cc2cc(Nc3ncc(C(F)(F)F)c(NCc4ccccc4)n3)ccc2N1		CHEMBL471520	=	IC50	nM	120.0	CHEMBL5469	Homo sapiens	IC50	nM	120.0
	2588077	CHEMBL960612	Inhibition of GST-tagged pyk2 assessed as inhibition of poly-Glu-Tyr phosphorylation	B	CN(c1cccc(CNc2nc(Nc3ccc4c(c3)CC(=O)N4)ncc2C(F)(F)F)c1)S(C)(=O)=O		CHEMBL513744	=	IC50	nM	190.0	CHEMBL5469	Homo sapiens	IC50	nM	190.0
	2588080	CHEMBL960612	Inhibition of GST-tagged pyk2 assessed as inhibition of poly-Glu-Tyr phosphorylation	B	CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4c(c3)CC(=O)N4)ncc2C(F)(F)F)c1		CHEMBL487246	>	IC50	nM	1100.0	CHEMBL5469	Homo sapiens	IC50	nM	1100.0
	2588083	CHEMBL960612	Inhibition of GST-tagged pyk2 assessed as inhibition of poly-Glu-Tyr phosphorylation	B	CS(=O)(=O)c1ccccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F		CHEMBL488089	=	IC50	nM	15.0	CHEMBL5469	Homo sapiens	IC50	nM	15.0
	2588086	CHEMBL960612	Inhibition of GST-tagged pyk2 assessed as inhibition of poly-Glu-Tyr phosphorylation	B	O=C1Cc2cc(Nc3ncc(C(F)(F)F)c(NCc4ccccc4S(=O)(=O)N4CCCC4)n3)ccc2N1		CHEMBL529889	=	IC50	nM	17.0	CHEMBL5469	Homo sapiens	IC50	nM	17.0
	2588089	CHEMBL960612	Inhibition of GST-tagged pyk2 assessed as inhibition of poly-Glu-Tyr phosphorylation	B	O=C1Cc2cc(Nc3ncc(C(F)(F)F)c(N[C@@H]4CCCCNC4=O)n3)ccc2N1		CHEMBL488446	=	IC50	nM	49.0	CHEMBL5469	Homo sapiens	IC50	nM	49.0
	2588092	CHEMBL960612	Inhibition of GST-tagged pyk2 assessed as inhibition of poly-Glu-Tyr phosphorylation	B	CN(C)[C@@H]1CCC[C@H]1Nc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F		CHEMBL487227	=	IC50	nM	53.0	CHEMBL5469	Homo sapiens	IC50	nM	53.0
	2588095	CHEMBL960612	Inhibition of GST-tagged pyk2 assessed as inhibition of poly-Glu-Tyr phosphorylation	B	O=C1CCc2cc(Nc3ncc(C(F)(F)F)c(NCc4ccccn4)n3)ccc2N1		CHEMBL520059	=	IC50	nM	210.0	CHEMBL5469	Homo sapiens	IC50	nM	210.0
	2588098	CHEMBL960612	Inhibition of GST-tagged pyk2 assessed as inhibition of poly-Glu-Tyr phosphorylation	B	O=C1CCCc2cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc2N1		CHEMBL487228	=	IC50	nM	33.0	CHEMBL5469	Homo sapiens	IC50	nM	33.0
	2588101	CHEMBL960612	Inhibition of GST-tagged pyk2 assessed as inhibition of poly-Glu-Tyr phosphorylation	B	CN(c1ccccc1CNc1nc(Nc2ccc3c(c2)CNC3=O)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL487229	=	IC50	nM	5.0	CHEMBL5469	Homo sapiens	IC50	nM	5.0
	2588104	CHEMBL960612	Inhibition of GST-tagged pyk2 assessed as inhibition of poly-Glu-Tyr phosphorylation	B	CN(C)[C@@H]1CCC[C@H]1Nc1nc(Nc2ccc3c(c2)CCCNC3=O)ncc1C(F)(F)F		CHEMBL518905	=	IC50	nM	143.0	CHEMBL5469	Homo sapiens	IC50	nM	143.0
	2588107	CHEMBL960612	Inhibition of GST-tagged pyk2 assessed as inhibition of poly-Glu-Tyr phosphorylation	B	CN(C)[C@@H]1CCC[C@H]1Nc1nc(Nc2ccc3c(c2)CCS3(=O)=O)ncc1C(F)(F)F		CHEMBL472211	=	IC50	nM	67.0	CHEMBL5469	Homo sapiens	IC50	nM	67.0
	2588110	CHEMBL960612	Inhibition of GST-tagged pyk2 assessed as inhibition of poly-Glu-Tyr phosphorylation	B	CN(C)[C@@H]1CCC[C@H]1Nc1nc(Nc2ccc3c(c2)CN(C)S3(=O)=O)ncc1C(F)(F)F		CHEMBL487057	=	IC50	nM	25.0	CHEMBL5469	Homo sapiens	IC50	nM	25.0
	2588113	CHEMBL960612	Inhibition of GST-tagged pyk2 assessed as inhibition of poly-Glu-Tyr phosphorylation	B	CN(C)[C@@H]1CCC[C@H]1Nc1nc(Nc2ccc(S(C)(=O)=O)cc2)ncc1C(F)(F)F		CHEMBL519418	=	IC50	nM	95.0	CHEMBL5469	Homo sapiens	IC50	nM	95.0
	2588116	CHEMBL960612	Inhibition of GST-tagged pyk2 assessed as inhibition of poly-Glu-Tyr phosphorylation	B	CN(c1ccccc1CNc1nc(Nc2ccc(S(C)(=O)=O)cc2)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL488247	=	IC50	nM	35.0	CHEMBL5469	Homo sapiens	IC50	nM	35.0
	2588119	CHEMBL960612	Inhibition of GST-tagged pyk2 assessed as inhibition of poly-Glu-Tyr phosphorylation	B	CNS(=O)(=O)c1ccc(Nc2ncc(C(F)(F)F)c(N[C@@H]3CCC[C@H]3N(C)C)n2)cc1		CHEMBL509485	=	IC50	nM	154.0	CHEMBL5469	Homo sapiens	IC50	nM	154.0
	2588126	CHEMBL960612	Inhibition of GST-tagged pyk2 assessed as inhibition of poly-Glu-Tyr phosphorylation	B	CC(=O)N1C2CCC1c1cc(Nc3ncc(C(F)(F)F)c(N[C@@H]4CCC[C@H]4N(C)C)n3)ccc12		CHEMBL455680	=	IC50	nM	6.0	CHEMBL5469	Homo sapiens	IC50	nM	6.0
	2588133	CHEMBL960612	Inhibition of GST-tagged pyk2 assessed as inhibition of poly-Glu-Tyr phosphorylation	B	CN(c1ccccc1CNc1nc(Nc2ccc3c(c2)CS(=O)(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL452341	=	IC50	nM	2.0	CHEMBL5469	Homo sapiens	IC50	nM	2.0
	2588136	CHEMBL960612	Inhibition of GST-tagged pyk2 assessed as inhibition of poly-Glu-Tyr phosphorylation	B	CN(C)[C@@H]1CCC[C@H]1Nc1nc(Nc2ccc3c(c2)CS(=O)(=O)N3)ncc1C(F)(F)F		CHEMBL452342	=	IC50	nM	50.0	CHEMBL5469	Homo sapiens	IC50	nM	50.0
	2588143	CHEMBL962346	Inhibition of Pyk2 by fluorescence polarization assay	B	CN(c1ccccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL472212	=	IC50	nM	31.0	CHEMBL5469	Homo sapiens	IC50	nM	31.0
	2593594	CHEMBL1024920	Binding affinity to human PYK2 at 10 uM relative to control	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	=	Activity	%	14.7	CHEMBL5469	Homo sapiens	Activity	%	14.7
	2593797	CHEMBL1024920	Binding affinity to human PYK2 at 10 uM relative to control	B	Cc1ccc(O)cc1Nc1ccnc(Nc2cccc(C(N)=O)c2)n1		CHEMBL249097	=	Activity	%	16.2	CHEMBL5469	Homo sapiens	Activity	%	16.2
Not Evaluated	2593860	CHEMBL1024920	Binding affinity to human PYK2 at 10 uM relative to control	B	NC(=O)c1ccc(Nc2cc(-c3ccc(F)cc3)[nH]n2)cc1		CHEMBL511337		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Evaluated	2594063	CHEMBL1024920	Binding affinity to human PYK2 at 10 uM relative to control	B	Nc1ncnc2c1c(-c1cccc(O)c1)cn2C1CCNCC1		CHEMBL450519		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Evaluated	2595006	CHEMBL1024920	Binding affinity to human PYK2 at 10 uM relative to control	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL478649		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Evaluated	2595275	CHEMBL1024920	Binding affinity to human PYK2 at 10 uM relative to control	B	Cc1ccc(C(=O)Nc2cccc(C(C)(C)C)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL515466		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Evaluated	2596203	CHEMBL1024920	Binding affinity to human PYK2 at 10 uM relative to control	B	Cc1ccc(NC(=O)c2cccc(N3CCCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL1964275		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Evaluated	2596406	CHEMBL1024920	Binding affinity to human PYK2 at 10 uM relative to control	B	CN(C)c1ccc(-c2cc3ncccc3c(NCCCCN)n2)cc1		CHEMBL282342		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Evaluated	2597675	CHEMBL1024920	Binding affinity to human PYK2 at 10 uM relative to control	B	O=C(Nc1n[nH]c2nc(-c3cccc(O)c3)ccc12)C1CC1		CHEMBL408019		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Evaluated	2597878	CHEMBL1024920	Binding affinity to human PYK2 at 10 uM relative to control	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454		Activity			CHEMBL5469	Homo sapiens	Activity		
	2704631	CHEMBL1054866	Inhibition of PTK2 at 10 uM by HotSpot assay relative to control	B	Cc1cc(O)cc(-c2nn(CC#N)cc2-c2cc(NC[C@H](C)O)nc(-c3cccnc3)n2)c1		CHEMBL560733	=	Inhibition	%	3.43	CHEMBL5469	Homo sapiens	INH	%	3.43
	2721706	CHEMBL1055108	Inhibition of Pyk2 at 1 uM	B	C[C@@H](Oc1cc(-c2cnc3ccccn23)sc1C(N)=O)c1ccc(CNC(C)(C)C)cc1OC(F)F		CHEMBL551079	<	Inhibition	%	50.0	CHEMBL5469	Homo sapiens	INH	%	50.0
	2892119	CHEMBL1061158	Binding constant for full-length PTK2B	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	uM	10.0
	2892120	CHEMBL1061158	Binding constant for full-length PTK2B	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	uM	10.0
	2892121	CHEMBL1061158	Binding constant for full-length PTK2B	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	=	Kd	nM	520.0	CHEMBL5469	Homo sapiens	Kd	nM	520.0
	2892122	CHEMBL1061158	Binding constant for full-length PTK2B	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	uM	10.0
	2892123	CHEMBL1061158	Binding constant for full-length PTK2B	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	=	Kd	nM	990.0	CHEMBL5469	Homo sapiens	Kd	nM	990.0
	2892124	CHEMBL1061158	Binding constant for full-length PTK2B	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	uM	10.0
	2892125	CHEMBL1061158	Binding constant for full-length PTK2B	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	uM	10.0
	2892126	CHEMBL1061158	Binding constant for full-length PTK2B	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	uM	10.0
	2892127	CHEMBL1061158	Binding constant for full-length PTK2B	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	uM	10.0
	2892128	CHEMBL1061158	Binding constant for full-length PTK2B	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	uM	10.0
	2892129	CHEMBL1061158	Binding constant for full-length PTK2B	B	COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1		CHEMBL483321	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	uM	10.0
	2892130	CHEMBL1061158	Binding constant for full-length PTK2B	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	uM	10.0
	2892131	CHEMBL1061158	Binding constant for full-length PTK2B	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	uM	10.0
	2892132	CHEMBL1061158	Binding constant for full-length PTK2B	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	uM	10.0
	2892133	CHEMBL1061158	Binding constant for full-length PTK2B	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	uM	10.0
	2892134	CHEMBL1061158	Binding constant for full-length PTK2B	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	uM	10.0
	2892135	CHEMBL1061158	Binding constant for full-length PTK2B	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	uM	10.0
	2892136	CHEMBL1061158	Binding constant for full-length PTK2B	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	uM	10.0
	2892137	CHEMBL1061158	Binding constant for full-length PTK2B	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	uM	10.0
	2892138	CHEMBL1061158	Binding constant for full-length PTK2B	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	uM	10.0
	2892139	CHEMBL1061158	Binding constant for full-length PTK2B	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	uM	10.0
	2892140	CHEMBL1061158	Binding constant for full-length PTK2B	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	uM	10.0
	2892141	CHEMBL1061158	Binding constant for full-length PTK2B	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	uM	10.0
	2892142	CHEMBL1061158	Binding constant for full-length PTK2B	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	=	Kd	nM	2000.0	CHEMBL5469	Homo sapiens	Kd	nM	2000.0
	2892143	CHEMBL1061158	Binding constant for full-length PTK2B	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	uM	10.0
	2892144	CHEMBL1061158	Binding constant for full-length PTK2B	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	660.0	CHEMBL5469	Homo sapiens	Kd	nM	660.0
	2892145	CHEMBL1061158	Binding constant for full-length PTK2B	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	uM	10.0
	2892146	CHEMBL1061158	Binding constant for full-length PTK2B	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	uM	10.0
	2892147	CHEMBL1061158	Binding constant for full-length PTK2B	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	uM	10.0
	2892148	CHEMBL1061158	Binding constant for full-length PTK2B	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	uM	10.0
	2892149	CHEMBL1061158	Binding constant for full-length PTK2B	B	NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL440084	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	uM	10.0
	2892150	CHEMBL1061158	Binding constant for full-length PTK2B	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	uM	10.0
	2892151	CHEMBL1061158	Binding constant for full-length PTK2B	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	3.5	CHEMBL5469	Homo sapiens	Kd	nM	3.5
	2892152	CHEMBL1061158	Binding constant for full-length PTK2B	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	=	Kd	nM	600.0	CHEMBL5469	Homo sapiens	Kd	nM	600.0
	2892153	CHEMBL1061158	Binding constant for full-length PTK2B	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	82.0	CHEMBL5469	Homo sapiens	Kd	nM	82.0
	2892154	CHEMBL1061158	Binding constant for full-length PTK2B	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	=	Kd	nM	2600.0	CHEMBL5469	Homo sapiens	Kd	nM	2600.0
	2892155	CHEMBL1061158	Binding constant for full-length PTK2B	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	uM	10.0
	2892156	CHEMBL1061158	Binding constant for full-length PTK2B	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	uM	10.0
	2921969	CHEMBL1052937	Inhibition of PTK2B assessed as enzyme activity at 1 uM relative to untreated control	B	Cc1ccc2c(Nc3ccc(Cl)cc3)nccc2c1Nc1ncccc1-c1ncnc2[nH]cnc12.Cl.Cl.Cl		CHEMBL3215582	=	Activity	%	40.0	CHEMBL5469	Homo sapiens	Activity	%	40.0
	2938449	CHEMBL1041416	Inhibition of PYK2 at 1 uM	B	Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1		CHEMBL583042	=	Inhibition	%	6.0	CHEMBL5469	Homo sapiens	INH	%	6.0
Not Active	2979580	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	Cc1ccc(C(=O)NCCCn2ccnc2)c(C2CCN(C(=O)/C=C/c3cccc(O)c3)CC2)n1		CHEMBL570900		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2979581	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	Cc1ccc(C(=O)NCCc2c[nH]c3ccccc23)c(C2CCN(C(=O)c3ccc(NC(N)=S)cc3)CC2)n1		CHEMBL568827		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2979582	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	CCOc1ccccc1CNC(=O)c1ccc(C)nc1C1CCN(C(=O)/C=C/c2cccc(O)c2)CC1		CHEMBL584320		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2979583	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	Cc1ccc(C(=O)NCCc2cccs2)c(C2CCN(C(=O)c3nc4ccccc4nc3O)CC2)n1		CHEMBL569976		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2979584	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	CC(=O)Nc1ccc(O)c(C(=O)N2CCC(c3nc(C)ccc3C(=O)NCCc3cccs3)CC2)c1		CHEMBL569767		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2979585	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	CCCOCCNC(=O)c1ccc(C)nc1C1CCN(C(=O)c2cc(NC(C)=O)ccc2O)CC1		CHEMBL569323		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2979586	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	Cc1ccc(C(=O)Nc2nnc(C(C)(C)C)s2)c(C2CCN(C(=O)c3nc4ccccc4nc3O)CC2)n1		CHEMBL571771		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2979587	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	COc1ccc(C(N)=O)cc1NC(=O)c1csc(C2CCN(C(=O)c3cc4ccccc4o3)CC2)n1		CHEMBL567533		Activity			CHEMBL5469	Homo sapiens	Activity		
	2979588	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	C=CCOC(=O)NCCSc1nc2ccc(NC(=O)c3csnn3)cc2s1		CHEMBL569324	=	Inhibition	%	33.0	CHEMBL5469	Homo sapiens	INH	%	33.0
	2979589	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	C=CCOC(=O)NCCSc1nc2ccc(NC(=O)CSc3ccccn3)cc2s1		CHEMBL569450	=	Inhibition	%	22.0	CHEMBL5469	Homo sapiens	INH	%	22.0
	2979590	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	C=CCOC(=O)NCCSc1nc2ccc(NC(=O)[C@H]3CC(=O)c4ccccc43)cc2s1		CHEMBL567573	=	Inhibition	%	11.0	CHEMBL5469	Homo sapiens	INH	%	11.0
	2979591	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	C=CCOC(=O)NCCSc1nc2ccc(NC(=O)CSc3nc(C)cc(C)n3)cc2s1		CHEMBL583437	=	Inhibition	%	19.0	CHEMBL5469	Homo sapiens	INH	%	19.0
	2979592	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	COc1ccc(NC(C)=O)cc1NS(=O)(=O)c1ccc(NC(C)=O)cc1		CHEMBL569536	=	Inhibition	%	18.0	CHEMBL5469	Homo sapiens	INH	%	18.0
	2979593	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	Cc1ccc(C(=O)NCCc2cc3ccccc3[nH]2)c(C2CCN(C(=O)CNC(=O)Nc3ccccc3)CC2)n1		CHEMBL570677	=	Inhibition	%	6.0	CHEMBL5469	Homo sapiens	INH	%	6.0
	2979594	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	CC(=O)Nc1ccc(S(=O)(=O)NNC(=O)Nc2ccccc2-c2ccccc2)cc1Cl		CHEMBL583009	=	Inhibition	%	24.0	CHEMBL5469	Homo sapiens	INH	%	24.0
	2979595	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	O=C(NCC(=O)N1CCC2(CC1)CCN(C(=O)Cc1n[nH]c(=O)c3ccccc13)C2)c1ccco1		CHEMBL567763	=	Inhibition	%	18.0	CHEMBL5469	Homo sapiens	INH	%	18.0
Active	2979596	CHEMBL1046196	Binding affinity to human Pyk2 FERM domain by LC/MS depletion assay	B	C=CCOC(=O)NCCSc1nc2ccc(NC(=O)c3csnn3)cc2s1		CHEMBL569324		Activity			CHEMBL5469	Homo sapiens	Activity		
	2979597	CHEMBL1050505	Inhibition of Pyk2-mediated stimulation of human SF767 glioma cell migration at 5 uM by radial migration assay relative to control	B	C=CCOC(=O)NCCSc1nc2ccc(NC(=O)c3csnn3)cc2s1		CHEMBL569324	=	Inhibition	%	50.0	CHEMBL5469	Homo sapiens	INH	%	50.0
	2979598	CHEMBL1046195	Inhibition of Pyk2-mediated stimulation of human SF767 glioma cell migration at 50 uM by radial migration assay relative to control	B	C=CCOC(=O)NCCSc1nc2ccc(NC(=O)c3csnn3)cc2s1		CHEMBL569324	=	Inhibition	%	85.0	CHEMBL5469	Homo sapiens	INH	%	85.0
Not Active	2979599	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	C=CCOC(=O)NCCSc1nc2ccc(NC(=O)c3c([N+](=O)[O-])c(C)nn3C)cc2s1		CHEMBL568859		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2979600	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	C=CCOC(=O)NCCSc1nc2ccc(NC(=O)c3ccc([N+](=O)[O-])cc3F)cc2s1		CHEMBL585710		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2979601	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	C=CCOC(=O)NCCSc1nc2ccc(NC(=O)c3coc4c3C(=O)CCC4)cc2s1		CHEMBL570885		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2979602	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	C=CCOC(=O)NCCSc1nc2ccc(NC(=O)c3c(C)noc3C)cc2s1		CHEMBL569024		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2979603	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	C=CCOC(=O)NCCSc1nc2ccc(NC(=O)c3cc(NC(C)=O)cc(NC(C)=O)c3)cc2s1		CHEMBL576276		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2979604	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	C=CCOC(=O)NCCSc1nc2ccc(NC(=O)c3cccc(C#N)c3)cc2s1		CHEMBL569751		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2979605	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	C=CCOC(=O)NCCSc1nc2ccc(NC(=O)c3ccccc3S(C)(=O)=O)cc2s1		CHEMBL570884		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2979606	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	C=CCOC(=O)NCCSc1nc2ccc(NC(=O)c3cc(C)n(C)n3)cc2s1		CHEMBL570883		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2979607	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	C=CCOC(=O)NCCSc1nc2ccc(NC(=O)Cc3nc(C)sc3C)cc2s1		CHEMBL569765		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2979608	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	C=CCOC(=O)NCCSc1nc2ccc(NC(=O)CNC(=O)OC)cc2s1		CHEMBL569752		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2979609	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	C=CCOC(=O)NCCSc1nc2ccc(NC(=O)/C=C/c3ccc([N+](=O)[O-])o3)cc2s1		CHEMBL568376		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2979610	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	C=CCOC(=O)NCCSc1nc2ccc(NC(=O)C3CCN(C(=O)c4ccccc4)CC3)cc2s1		CHEMBL567977		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2979611	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	C=CCOC(=O)NCCSc1nc2ccc(NC(=O)CS(=O)(=O)c3ccc(C)cc3)cc2s1		CHEMBL567765		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2979612	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	C=CCOC(=O)NCCSc1nc2ccc(NC(=O)Cc3ccc([N+](=O)[O-])cc3)cc2s1		CHEMBL568177		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2979613	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	C=CCOC(=O)NCCSc1nc2ccc(NC(=O)[C@H]3CCCN3C(=O)c3cccs3)cc2s1		CHEMBL565651		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2979614	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	C=CCOC(=O)NCCSc1nc2ccc(NC(=O)C(C)(C)n3cncn3)cc2s1		CHEMBL567575		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2979615	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	C=CCOC(=O)NCCSc1nc2ccc(NC(=O)C3(C#N)CC3)cc2s1		CHEMBL568749		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2979616	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	C#CC[C@H](NC(C)=O)C(=O)Nc1ccc2nc(SCCNC(=O)OCC=C)sc2c1		CHEMBL583642		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2979617	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	C=COC(=O)NCCSc1nc2ccc(NC(=O)[C@H]3CCOC3)cc2s1		CHEMBL566483		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2979618	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	C=COC(=O)NCCSc1nc2ccc(NC(=O)CCn3c(=O)oc4ccccc43)cc2s1		CHEMBL585495		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2979619	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	CC(=O)Nc1ccc(S(=O)(=O)NNC(=O)Nc2c(C(C)C)cccc2C(C)C)cc1Cl		CHEMBL567534		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2979620	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	N#Cc1c(Cl)cccc1Oc1ccc(S(=O)(=O)Nc2ccc(S(=O)(=O)Nc3ccccn3)cc2)cc1		CHEMBL566942		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2979621	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	Cc1cc(NS(=O)(=O)c2ccc3c(c2)CN(C(=O)C(F)(F)F)CC3)nc(C)n1		CHEMBL568410		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2979622	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	COC(=O)c1ccc(NS(=O)(=O)c2ccc(NC(C)=O)c(Cl)c2)cc1OC		CHEMBL565853		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2979623	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	O=C(N1CCc2ccc(S(=O)(=O)Nc3ccc(Cl)nn3)cc2C1)C(F)(F)F		CHEMBL567154		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2979624	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	CCCCNS(=O)(=O)c1cccc(NC(=O)CNC(=O)c2ccoc2)c1		CHEMBL567153		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2979625	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	COc1ccc(OC)c(NC(=S)NCC(=O)N[C@@H](CC(C)C)C(N)=O)c1		CHEMBL568391		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2980658	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	Cc1cc(C)cc(NC(=O)N2CCC3(CCN(C(=O)CCCC[C@@H]4SC[C@@H]5NC(=O)N[C@H]45)C3)CC2)c1		CHEMBL565650		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2980659	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	COc1ccccc1NC(=O)N1CCC2(CC1)CCN(S(=O)(=O)c1sc(NC(C)=O)nc1C)C2		CHEMBL567978		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2980660	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	O=C(NCC(=O)N1CCC2(CC1)CCN(C(=S)NC[C@@H]1CCCO1)C2)c1ccco1		CHEMBL567768		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2980661	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	O=C(CN1CCCN(C(=O)CNC(=O)c2ccco2)CC1)NCCc1ccccc1		CHEMBL567761		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2980662	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	O=C(CN1CCCN(C(=O)CNC(=O)C(F)(F)F)CC1)Nc1ccc(F)cc1F		CHEMBL566944		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2980663	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	CC(C)(C)c1cc(O)nc(SCC(=O)N2CCCN(CC(=O)Nc3ccccc3C(C)(C)C)CC2)n1		CHEMBL586056		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2980664	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	Cc1cccc(C)c1NC(=O)CN1CCCN(C(=O)CNC(=O)c2ccco2)CC1		CHEMBL567762		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2980665	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	O=C(NNC(=O)[C@H]1CCCNC1=O)c1csc(C2CCN(C(=O)NCCC3=CCCCC3)CC2)n1		CHEMBL585677		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2980666	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	O=C(COc1ccccc1)NNC(=O)c1csc(C2CCN(C(=O)NCCC3=CCCCC3)CC2)n1		CHEMBL585514		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2980667	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	O=C(NNC(=O)c1n[nH]c2ccccc12)c1csc(C2CCN(C(=O)NCCC3=CCCCC3)CC2)n1		CHEMBL576597		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2980668	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	O=C(Nc1ccccc1N1CCOCC1)c1csc(C2CCN(C(=O)NCCC3=CCCCC3)CC2)n1		CHEMBL568625		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2980669	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	CCOC(=O)c1nc(NC(=O)c2csc(C3CCN(C(=O)NCCC4=CCCCC4)CC3)n2)cn1C		CHEMBL566482		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2980670	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	CN(C)c1ccc(NC(=S)N2CCC(c3nc(C(=O)NC[C@@H]4COc5ccccc5O4)cs3)CC2)cc1		CHEMBL585497		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2980671	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	CN(C)c1ccc(NC(=S)N2CCC(c3nc(C(=O)NCCOc4ccccc4Cl)cs3)CC2)cc1		CHEMBL568638		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2980672	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	CN(C)c1ccc(NC(=S)N2CCC(c3nc(C(=O)NC[C@H](c4ccc[nH]4)C(F)(F)F)cs3)CC2)cc1		CHEMBL568426		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2980673	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	CN(C)c1ccc(NC(=S)N2CCC(c3nc(C(=O)NCCc4c[nH]c5ccc(F)cc45)cs3)CC2)cc1		CHEMBL568623		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2980674	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	CCOC(=O)NNC(=O)c1csc(C2CCN(C(=O)Cc3c[nH]c4ccccc34)CC2)n1		CHEMBL568390		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2980675	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	Cc1nc(C)c(C(=O)NNC(=O)c2csc(C3CCN(C(=O)Cc4c[nH]c5ccccc45)CC3)n2)s1		CHEMBL567121		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2980676	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	O=C(NNC(=O)c1csc(C2CCN(C(=O)Cc3c[nH]c4ccccc34)CC2)n1)C1=CCC=C1		CHEMBL565649		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2980677	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	COc1ccc(C(N)=O)cc1NC(=O)c1csc(C2CCN(C(=O)c3cnn(-c4ccccc4)c3C)CC2)n1		CHEMBL566730		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2980678	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	COc1ccc(C(=O)CCC(=O)N2CCC(c3nc(C(=O)Nc4cc(C(N)=O)ccc4OC)cs3)CC2)cc1		CHEMBL568375		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2980679	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	CC(=O)Nc1cccc(OCCCNC(=O)c2csc(C3CCN(C(=O)C4CCCCC4)CC3)n2)c1		CHEMBL582800		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2980680	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	COc1ccc(C(N)=O)cc1NC(=O)c1csc(C2CCN(C(=O)c3cc(OC)c4ccccc4n3)CC2)n1		CHEMBL568193		Activity			CHEMBL5469	Homo sapiens	Activity		
Not Active	2980681	CHEMBL1050504	Inhibition of HA-epitope-tagged Pyk2 FERM domain expressed in HEK293 cells assessed as inhibition of binding to 12A10 antibody by ELISA	B	COc1ccc(C(N)=O)cc1NC(=O)c1csc(C2CCN(C(=O)C#Cc3ccccc3)CC2)n1		CHEMBL568389		Activity			CHEMBL5469	Homo sapiens	Activity		
	3021191	CHEMBL1037540	Inhibition of human PyK2 Y402 autophosphorylation expressed in 293T cells by immunofluorescence assay	B	CNc1ccn(-c2ccccc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc3cc(OC)c(OC)cc23)cn1		CHEMBL585927	=	IC50	nM	110.0	CHEMBL5469	Homo sapiens	IC50	uM	0.11
	3021192	CHEMBL1037538	Inhibition of human Pyk2 by HTRF assay	B	CNc1ccn(-c2ccccc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc3cc(OC)c(OC)cc23)cn1		CHEMBL585927	=	IC50	nM	35.0	CHEMBL5469	Homo sapiens	IC50	uM	0.035
	3021193	CHEMBL1037538	Inhibition of human Pyk2 by HTRF assay	B	COc1cc2nccc(Oc3ccc(NC(=O)c4c(N(C)C)ccn(-c5ccccc5)c4=O)nc3)c2cc1OC		CHEMBL572237	=	IC50	nM	200.0	CHEMBL5469	Homo sapiens	IC50	uM	0.2
	3021194	CHEMBL1037538	Inhibition of human Pyk2 by HTRF assay	B	COCCNc1ccn(-c2ccccc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc3cc(OC)c(OC)cc23)cn1		CHEMBL568729	=	IC50	nM	50.0	CHEMBL5469	Homo sapiens	IC50	uM	0.05
	3021195	CHEMBL1037538	Inhibition of human Pyk2 by HTRF assay	B	COc1cc2nccc(Oc3ccc(NC(=O)c4c(NC5CCOCC5)ccn(-c5ccccc5)c4=O)nc3)c2cc1OC		CHEMBL570846	=	IC50	nM	44.0	CHEMBL5469	Homo sapiens	IC50	uM	0.044
	3021196	CHEMBL1037538	Inhibition of human Pyk2 by HTRF assay	B	COc1cc2nccc(Oc3ccc(NC(=O)c4c(N5CCN(C)CC5)ccn(-c5ccccc5)c4=O)nc3)c2cc1OC		CHEMBL570643	=	IC50	nM	2800.0	CHEMBL5469	Homo sapiens	IC50	uM	2.8
	3021197	CHEMBL1037538	Inhibition of human Pyk2 by HTRF assay	B	COc1cc2nccc(Oc3ccc(NC(=O)c4c(Nc5ccccc5)ccn(-c5ccccc5)c4=O)nc3)c2cc1OC		CHEMBL570647	=	IC50	nM	1500.0	CHEMBL5469	Homo sapiens	IC50	uM	1.5
	3021198	CHEMBL1037538	Inhibition of human Pyk2 by HTRF assay	B	COCCNc1ccn(-c2ccccc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc3cc(OC)ccc23)cn1		CHEMBL570955	=	IC50	nM	120.0	CHEMBL5469	Homo sapiens	IC50	uM	0.12
	3021199	CHEMBL1037538	Inhibition of human Pyk2 by HTRF assay	B	CNc1ccn(Cc2ccccc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc3cc(OC)c(OC)cc23)cn1		CHEMBL570706	=	IC50	nM	170.0	CHEMBL5469	Homo sapiens	IC50	uM	0.17
	3021200	CHEMBL1037538	Inhibition of human Pyk2 by HTRF assay	B	COc1cc2nccc(Oc3ccc(NC(=O)c4cc(-c5cccs5)cn(-c5ccccc5)c4=O)nc3)c2cc1OC		CHEMBL570380	=	IC50	nM	53.0	CHEMBL5469	Homo sapiens	IC50	uM	0.053
	3021201	CHEMBL1037538	Inhibition of human Pyk2 by HTRF assay	B	COc1cc2nccc(Oc3ccc(NC(=O)c4cc(-c5cccnc5)cn(-c5ccccc5)c4=O)nc3)c2cc1OC		CHEMBL570365	=	IC50	nM	33.0	CHEMBL5469	Homo sapiens	IC50	uM	0.033
	3021202	CHEMBL1037538	Inhibition of human Pyk2 by HTRF assay	B	COc1cc2nccc(Oc3ccc(NC(=O)c4cc(Cc5ccccc5)cn(-c5ccccc5)c4=O)nc3)c2cc1OC		CHEMBL570369	=	IC50	nM	49.0	CHEMBL5469	Homo sapiens	IC50	uM	0.049
	3021203	CHEMBL1037538	Inhibition of human Pyk2 by HTRF assay	B	COc1ccc2c(Oc3ccc(NC(=O)c4cc(-c5cccnc5)cn(-c5ccccc5)c4=O)nc3)ccnc2c1		CHEMBL570381	=	IC50	nM	430.0	CHEMBL5469	Homo sapiens	IC50	uM	0.43
	3021204	CHEMBL1037538	Inhibition of human Pyk2 by HTRF assay	B	COc1ccc2c(Oc3ccc(NC(=O)c4cc(-c5cnccn5)cn(-c5ccccc5)c4=O)nc3)ccnc2c1		CHEMBL570189	=	IC50	nM	1000.0	CHEMBL5469	Homo sapiens	IC50	uM	1.0
	3021218	CHEMBL1037540	Inhibition of human PyK2 Y402 autophosphorylation expressed in 293T cells by immunofluorescence assay	B	COc1cc2nccc(Oc3ccc(NC(=O)c4cc(-c5cccs5)cn(-c5ccccc5)c4=O)nc3)c2cc1OC		CHEMBL570380	=	IC50	nM	1120.0	CHEMBL5469	Homo sapiens	IC50	uM	1.12
	3021219	CHEMBL1037540	Inhibition of human PyK2 Y402 autophosphorylation expressed in 293T cells by immunofluorescence assay	B	COc1cc2nccc(Oc3ccc(NC(=O)c4cc(Cc5ccccc5)cn(-c5ccccc5)c4=O)nc3)c2cc1OC		CHEMBL570369	=	IC50	nM	310.0	CHEMBL5469	Homo sapiens	IC50	uM	0.31
	3052463	CHEMBL1072501	Residual activity of PYK2 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	98.0	CHEMBL5469	Homo sapiens	Residual activity	%	98.0
	3052715	CHEMBL1043794	Residual activity of PYK2 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	105.0	CHEMBL5469	Homo sapiens	Residual activity	%	105.0
	3054024	CHEMBL1071354	Residual activity of PYK2 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	54.0	CHEMBL5469	Homo sapiens	Residual activity	%	54.0
	3055311	CHEMBL1072501	Residual activity of PYK2 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	102.0	CHEMBL5469	Homo sapiens	Residual activity	%	102.0
	3055563	CHEMBL1043794	Residual activity of PYK2 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	97.0	CHEMBL5469	Homo sapiens	Residual activity	%	97.0
	3056868	CHEMBL1071354	Residual activity of PYK2 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	95.0	CHEMBL5469	Homo sapiens	Residual activity	%	95.0
	3057120	CHEMBL1072501	Residual activity of PYK2 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	103.0	CHEMBL5469	Homo sapiens	Residual activity	%	103.0
	3058440	CHEMBL1043794	Residual activity of PYK2 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	109.0	CHEMBL5469	Homo sapiens	Residual activity	%	109.0
	3059724	CHEMBL1071354	Residual activity of PYK2 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	113.0	CHEMBL5469	Homo sapiens	Residual activity	%	113.0
	3213851	CHEMBL1111267	Inhibition of PYK2 at 5 uM	B	O=C(Nc1ccccc1Cl)c1cnc2ccc(C3CCNCC3)cn12.O=C(O)C(=O)O		CHEMBL1077739	=	Inhibition	%	0.0	CHEMBL5469	Homo sapiens	INH	%	0.0
	3224943	CHEMBL1101496	Inhibition of FAK2 at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1-c1cnc(CO)cn1		CHEMBL1081678	<	Inhibition	%	50.0	CHEMBL5469	Homo sapiens	INH	%	50.0
	3226322	CHEMBL1101496	Inhibition of FAK2 at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1Cc1ccc(CN(C)C)cc1		CHEMBL1078665	<	Inhibition	%	50.0	CHEMBL5469	Homo sapiens	INH	%	50.0
	3302209	CHEMBL1117898	Inhibition of PYK2	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cc(COc3cccnc3)n[nH]2)cc1		CHEMBL1084269	=	IC50	nM	637.0	CHEMBL5469	Homo sapiens	IC50	nM	637.0
	3302304	CHEMBL1117898	Inhibition of PYK2	B	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	=	IC50	nM	14.0	CHEMBL5469	Homo sapiens	IC50	nM	14.0
	3316523	CHEMBL1117898	Inhibition of PYK2	B	CN(c1ccccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL472212	=	IC50	nM	11.0	CHEMBL5469	Homo sapiens	IC50	nM	11.0
	3316805	CHEMBL1120364	Inhibition of PYK2 at 1 uM	B	O=C(Nc1cccc(-n2ccc3c(NC(=O)c4ccccc4)nccc32)c1)c1ccc(N2CCOCC2)c(C(F)(F)F)c1		CHEMBL1084450	=	Inhibition	%	23.0	CHEMBL5469	Homo sapiens	INH	%	23.0
	3326154	CHEMBL1168775	Inhibition of PTK2B at 10 uM by HotSpot assay	B	CC(=O)Nc1cccc(-c2ccc(-c3ccnc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)n3)cn2)c1.Cl		CHEMBL1164847	<	Inhibition	%	50.0	CHEMBL5469	Homo sapiens	INH	%	50.0
	3332122	CHEMBL1166833	Inhibition of PYK2 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(F)ccc3F)CCN4)cn2)CC1		CHEMBL1165499	<	Inhibition	%	50.0	CHEMBL5469	Homo sapiens	INH	%	50.0
	3333537	CHEMBL1166833	Inhibition of PYK2 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cn2)CC1		CHEMBL1164180	=	Inhibition	%	71.0	CHEMBL5469	Homo sapiens	INH	%	71.0
	3334942	CHEMBL1166833	Inhibition of PYK2 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3Cl)CCN4)cn2)CC1		CHEMBL1164181	<	Inhibition	%	50.0	CHEMBL5469	Homo sapiens	INH	%	50.0
	3336362	CHEMBL1166833	Inhibition of PYK2 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3c(F)ccc(F)c3Cl)CCN4)cn2)CC1		CHEMBL1164265	<	Inhibition	%	50.0	CHEMBL5469	Homo sapiens	INH	%	50.0
	3337634	CHEMBL1166833	Inhibition of PYK2 at 1 uM	B	O=C(O)c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1		CHEMBL1163510	<	Inhibition	%	50.0	CHEMBL5469	Homo sapiens	INH	%	50.0
	3338965	CHEMBL1166833	Inhibition of PYK2 at 1 uM	B	O=C(c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1)N1CCCCC1		CHEMBL1163518	<	Inhibition	%	50.0	CHEMBL5469	Homo sapiens	INH	%	50.0
	3339219	CHEMBL1166833	Inhibition of PYK2 at 1 uM	B	COC1CCN(C(=O)c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cc2)CC1		CHEMBL1163567	=	Inhibition	%	68.0	CHEMBL5469	Homo sapiens	INH	%	68.0
	3340522	CHEMBL1166833	Inhibition of PYK2 at 1 uM	B	O=C(c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1)N1CCC(N2CCCC2)CC1		CHEMBL1163559	=	Inhibition	%	90.8	CHEMBL5469	Homo sapiens	INH	%	90.8
	3341904	CHEMBL1166833	Inhibition of PYK2 at 1 uM	B	FC(F)(F)c1ccc(Cl)cc1CN1CCNc2ncc(-c3ccnc(N4CCNCC4)c3)cc21		CHEMBL1163566	=	Inhibition	%	87.0	CHEMBL5469	Homo sapiens	INH	%	87.0
	3343351	CHEMBL1166833	Inhibition of PYK2 at 1 uM	B	CC(=O)N1CCN(c2cc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)ccn2)CC1		CHEMBL1163565	=	Inhibition	%	84.0	CHEMBL5469	Homo sapiens	INH	%	84.0
	3358777	CHEMBL1175243	Inhibition of PYK2 at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cccnc4)c3)cc2C(F)(F)F)CC1		CHEMBL1171523	=	Inhibition	%	0.4	CHEMBL5469	Homo sapiens	INH	%	0.4
	3359219	CHEMBL1175243	Inhibition of PYK2 at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cnc5[nH]ccc5c4)c3)cc2C(F)(F)F)CC1		CHEMBL1170139	=	Inhibition	%	0.15	CHEMBL5469	Homo sapiens	INH	%	0.15
	3443506	CHEMBL1244272	Inhibition of FAK2 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2ccc(Br)c(O)c2)c2c(N)ncnc21		CHEMBL1241578	=	Inhibition	%	11.0	CHEMBL5469	Homo sapiens	INH	%	11.0
	3443723	CHEMBL1244272	Inhibition of FAK2 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1		CHEMBL1081312	=	Inhibition	%	31.0	CHEMBL5469	Homo sapiens	INH	%	31.0
	3444878	CHEMBL1244272	Inhibition of FAK2 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2ccc3ncccc3c2)c2c(N)ncnc21		CHEMBL1233882	=	Inhibition	%	5.0	CHEMBL5469	Homo sapiens	INH	%	5.0
	3445276	CHEMBL1244948	Binding affinity to PYK2	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	41.0	CHEMBL5469	Homo sapiens	Kd	nM	41.0
	3445502	CHEMBL1244272	Inhibition of FAK2 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	COc1ccc(-c2nn(C3CCC3)c3ncnc(N)c23)cc1OC		CHEMBL1233881	=	Inhibition	%	-1.0	CHEMBL5469	Homo sapiens	INH	%	-1.0
	3445719	CHEMBL1244272	Inhibition of FAK2 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21		CHEMBL1241674	=	Inhibition	%	2.0	CHEMBL5469	Homo sapiens	INH	%	2.0
	3445914	CHEMBL1244272	Inhibition of FAK2 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2cccc(O)c2)c2c(N)ncnc21		CHEMBL1230790	=	Inhibition	%	94.0	CHEMBL5469	Homo sapiens	INH	%	94.0
	3446104	CHEMBL1244272	Inhibition of FAK2 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	Cn1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21		CHEMBL1234815	=	Inhibition	%	45.0	CHEMBL5469	Homo sapiens	INH	%	45.0
	3446204	CHEMBL1244344	Inhibition of PTK2B	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	=	IC50	nM	134.0	CHEMBL5469	Homo sapiens	IC50	nM	134.0
	3448595	CHEMBL1244948	Binding affinity to PYK2	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	uM	10.0
	3449029	CHEMBL1244948	Binding affinity to PYK2	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	660.0	CHEMBL5469	Homo sapiens	Kd	nM	660.0
	3449316	CHEMBL1244948	Binding affinity to PYK2	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	82.0	CHEMBL5469	Homo sapiens	Kd	nM	82.0
	3449494	CHEMBL1244948	Binding affinity to PYK2	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL1240703	=	Kd	nM	1500.0	CHEMBL5469	Homo sapiens	Kd	nM	1500.0
	3449826	CHEMBL1244948	Binding affinity to PYK2	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	uM	10.0
	3450220	CHEMBL1244948	Binding affinity to PYK2	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	uM	10.0
	3463339	CHEMBL1251599	Inhibition of PTK2B at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300	=	Inhibition	%	2.0	CHEMBL5469	Homo sapiens	INH	%	2.0
	3463883	CHEMBL1251599	Inhibition of PTK2B at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	COc1ccccc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1		CHEMBL1254209	=	Inhibition	%	4.0	CHEMBL5469	Homo sapiens	INH	%	4.0
	3464102	CHEMBL1251599	Inhibition of PTK2B at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	O=C(NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1I)c1cccs1		CHEMBL577784	=	Inhibition	%	15.0	CHEMBL5469	Homo sapiens	INH	%	15.0
	3556522	CHEMBL1285616	Inhibition of PTK2 at 1 uM	B	CN1C[C@@H]2C[C@H]1CN2c1cc(F)c(-c2ccnc3c(-c4cccc5[nH]ncc45)c(-c4ccncc4)nn23)c(F)c1		CHEMBL1276179	=	Inhibition	%	15.0	CHEMBL5469	Homo sapiens	INH	%	15.0
	3603123	CHEMBL1291220	Inhibition of PTK2B at 10 uM	B	O=C(Cc1cccc2cnccc12)Nc1scnc1-c1cscn1		CHEMBL1288160	=	Inihibition	%	6.0	CHEMBL5469	Homo sapiens	Inihibition	%	6.0
Active	4404877	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C(Nc1ccc2oc(-c3cccnc3)nc2c1)c1cc2ccccc2o1		CHEMBL1497274	=	IC50	nM	5021.0	CHEMBL5469	Homo sapiens	IC50	um	5.021
Not Active	4404878	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=c1c(/C=N/O)c(Nc2ccccc2)nc2ccccn12		CHEMBL3194875	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Active	4404879	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C1Nc2ccc(NS(=O)(=O)c3cccs3)c3cccc1c23		CHEMBL1526645	=	IC50	nM	5321.0	CHEMBL5469	Homo sapiens	IC50	um	5.321
Active	4404880	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Oc1ccccc1-c1nc(NCCN2CCOCC2)c2ccccc2n1		CHEMBL1497316	=	IC50	nM	9709.0	CHEMBL5469	Homo sapiens	IC50	um	9.709
Not Active	4404881	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	COc1cc(C2Nc3ccc4ncccc4c3C3=C2C(=O)CC(C)(C)C3)cc(OC)c1O		CHEMBL1409126	=	IC50	nM	16400.0	CHEMBL5469	Homo sapiens	IC50	um	16.4
Active	4404882	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Cc1cc(OCC(=O)Nc2cc(-c3nn4c(C)nnc4s3)ccc2C)ccc1Cl		CHEMBL1369422	=	IC50	nM	2704.0	CHEMBL5469	Homo sapiens	IC50	um	2.704
Active	4404883	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C(Oc1ccccc1Cl)c1ccccc1P(=O)(O)O		CHEMBL1536594	=	IC50	nM	4489.0	CHEMBL5469	Homo sapiens	IC50	um	4.489
Not Active	4404884	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CN1CCc2nc3sc(C(=O)C45CC6CC(CC(C6)C4)C5)c(N)c3cc2C1		CHEMBL1594483	=	IC50	nM	13750.0	CHEMBL5469	Homo sapiens	IC50	um	13.75
Active	4404885	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=[N+]([O-])c1cc(/C=N\Nc2nccs2)ccc1O		CHEMBL3199451	=	IC50	nM	3145.0	CHEMBL5469	Homo sapiens	IC50	um	3.145
Not Active	4404886	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=[N+]([O-])c1cccc(/C=C/c2nc3cc([N+](=O)[O-])ccc3[nH]2)c1		CHEMBL1575547	=	IC50	nM	19970.0	CHEMBL5469	Homo sapiens	IC50	um	19.97
Not Active	4404887	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=c1cc(-c2ccco2)oc2c1ccc1ccccc12		CHEMBL1339786	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4404888	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	NC(=O)c1sc2nc3c(c(-c4ccco4)c2c1N)CCC3		CHEMBL1329801	=	IC50	nM	10180.0	CHEMBL5469	Homo sapiens	IC50	um	10.18
Not Active	4404889	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Cc1n[nH]c(C)c1N=Nc1cc(Cl)ccc1Cl		CHEMBL1300005	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Active	4404890	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	c1ccc(-c2nccc(-c3ccc(-n4cnc5ccccc54)cc3)n2)cc1		CHEMBL1380059	=	IC50	nM	2637.0	CHEMBL5469	Homo sapiens	IC50	um	2.637
Not Active	4404891	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	N#Cc1cnn2c1nc(N1CCCCC1)c1ccccc12		CHEMBL1380296	>	IC50	nM	2570.0	CHEMBL5469	Homo sapiens	IC50	um	2.57
Active	4404892	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CCOc1ccc2nc(NC3=NC(=O)CC(c4ccc(OC)cc4)N3)nc(C)c2c1		CHEMBL1576310	=	IC50	nM	5847.0	CHEMBL5469	Homo sapiens	IC50	um	5.847
Not Active	4404893	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C(NCCc1c[nH]c2ccccc12)C1CCN(c2nnc(N3CCCC3=O)s2)CC1		CHEMBL1537500	=	IC50	nM	22670.0	CHEMBL5469	Homo sapiens	IC50	um	22.67
Not Active	4404894	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Cc1ccccc1-c1ccc(Nc2ccc(N3CCOCC3)cc2)nn1		CHEMBL1576374	=	IC50	nM	14550.0	CHEMBL5469	Homo sapiens	IC50	um	14.55
Active	4404895	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CN1CCN(c2ccc(N)c(N3CCN(C)CC3)c2)CC1		CHEMBL1488628	=	IC50	nM	6034.0	CHEMBL5469	Homo sapiens	IC50	um	6.034
Not Active	4404896	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Nc1ccc2c(c1)C(=O)C(=O)c1ccccc1-2		CHEMBL417727	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Active	4404897	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C(Nc1ccc(-c2nc3cc(NC(=O)c4cccs4)ccc3[nH]2)cc1)c1cccs1		CHEMBL600336	=	IC50	nM	3974.0	CHEMBL5469	Homo sapiens	IC50	um	3.974
Not Active	4404898	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CC(C)c1nc(SCC(=O)N2CCCC2)c2ccccc2n1		CHEMBL1319919	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Active	4404899	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CCC1=NNc2cccc3c(OC)ccc1c23		CHEMBL1447467	=	IC50	nM	2151.0	CHEMBL5469	Homo sapiens	IC50	um	2.151
Not Active	4404900	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Clc1ccc2[nH]cc(-c3nnnn3-c3ccccc3)c2c1		CHEMBL1399844	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4404901	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C(NCCCN1CCCCCC1)c1ccc(CS(=O)(=O)Cc2ccccc2F)o1		CHEMBL1498705	=	IC50	nM	13100.0	CHEMBL5469	Homo sapiens	IC50	um	13.1
Active	4404902	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=c1oc(-c2ccc(Br)o2)nc2ccccc12		CHEMBL1498729	=	IC50	nM	2660.0	CHEMBL5469	Homo sapiens	IC50	um	2.66
Not Active	4404903	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	N#Cc1nc(-c2ccc(OCc3ccc(Cl)cc3)cc2)oc1N1CCC(C(N)=O)CC1		CHEMBL1331178	>	IC50	nM	858.0	CHEMBL5469	Homo sapiens	IC50	um	0.858
Not Active	4404904	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CN1C(=O)/C(=C/c2cn(CC(=O)N3CCCCC3)c3ccccc23)c2ccccc21		CHEMBL1341067	=	IC50	nM	46650.0	CHEMBL5469	Homo sapiens	IC50	um	46.65
Not Active	4404905	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CCOc1ccc(S(=O)(=O)N(CC(=O)N/N=C/c2ccc(-c3ccc([N+](=O)[O-])cc3)o2)c2ccccc2)cc1		CHEMBL1988401	=	IC50	nM	15810.0	CHEMBL5469	Homo sapiens	IC50	um	15.81
Not Active	4404906	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C(Nc1cccnc1)c1c(O)c2cccc3c2n(c1=O)CC3		CHEMBL1498987	>	IC50	nM	23100.0	CHEMBL5469	Homo sapiens	IC50	um	23.1
Not Active	4404907	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	COC(=O)Cc1ccc2c3ccccc3n(C)c2c1		CHEMBL1408947	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Active	4404908	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C(ONc1ccc(N=NC(=O)c2ccccc2O)cc1)c1ccccc1		CHEMBL1360493	=	IC50	nM	5494.0	CHEMBL5469	Homo sapiens	IC50	um	5.494
Not Active	4404909	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CN1CCc2c(sc3ncn4nc(-c5ccccc5O)nc4c23)C1		CHEMBL1499183	=	IC50	nM	17850.0	CHEMBL5469	Homo sapiens	IC50	um	17.85
Not Active	4404910	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CC(C)c1nc2[nH]nc(N)c2c2c1CCC2		CHEMBL1577214	=	IC50	nM	22280.0	CHEMBL5469	Homo sapiens	IC50	um	22.28
Active	4404911	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=P(O)(O)c1ccccc1OCc1ccccc1		CHEMBL1577281	=	IC50	nM	2212.0	CHEMBL5469	Homo sapiens	IC50	um	2.212
Active	4404912	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C1CCCC2=C1C(c1cccs1)Nc1ccc3ncccc3c12		CHEMBL1459901	=	IC50	nM	4657.0	CHEMBL5469	Homo sapiens	IC50	um	4.657
Not Active	4404913	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C(O)c1cccc(S(=O)(=O)Nc2ccccc2Cl)c1		CHEMBL1421068	=	IC50	nM	17250.0	CHEMBL5469	Homo sapiens	IC50	um	17.25
Not Active	4404914	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C(CSc1nc(C2CC2)nc2ccccc12)N1CCc2ccccc2C1		CHEMBL1459977	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4404915	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Cc1ccc2c(Cl)cc(Cl)c(OCc3nnc(-c4ccccc4)o3)c2n1		CHEMBL1320591	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4404916	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Cc1ccccc1NC1=C/C(=N\S(=O)(=O)c2cccs2)c2ccccc2C1=O		CHEMBL3189714	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4404917	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	C=C(c1cccc2ccccc12)P(=O)(O)O		CHEMBL1538815	=	IC50	nM	26980.0	CHEMBL5469	Homo sapiens	IC50	um	26.98
Active	4404918	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C(N/N=C/c1cccc(F)c1)c1cc(-c2ccco2)nc2ccccc12		CHEMBL1706577	=	IC50	nM	2253.0	CHEMBL5469	Homo sapiens	IC50	um	2.253
Not Active	4404919	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	N#Cc1cnn2c1nc(N1CCOCC1)c1ccccc12		CHEMBL1332391	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Active	4404920	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Oc1[nH]c2ccccc2c1/C=N/c1ccc2c(c1)OCCO2		CHEMBL3197885	=	IC50	nM	6346.0	CHEMBL5469	Homo sapiens	IC50	um	6.346
Not Active	4405747	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CCc1ccc(OCC(=O)Nc2ccc(-c3nc4ccccc4o3)c(O)c2)cc1		CHEMBL1329712	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4413129	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C(OCCNC1=NS(=O)(=O)c2ccccc21)c1cccnc1		CHEMBL1342206	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Active	4413130	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	COc1ccc(/N=C/c2c(O)[nH]c3ccccc23)cc1OC		CHEMBL3189853	=	IC50	nM	3775.0	CHEMBL5469	Homo sapiens	IC50	um	3.775
Active	4413131	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CCCn1c(NC(=O)c2ccc(Cl)c(S(=O)(=O)N3CCCC3)c2)nc2ccccc21		CHEMBL1302158	=	IC50	nM	2718.0	CHEMBL5469	Homo sapiens	IC50	um	2.718
Active	4413132	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CC1(C)CCCN(C(=O)c2coc(=O)c(Br)c2)C1		CHEMBL1539325	=	IC50	nM	5229.0	CHEMBL5469	Homo sapiens	IC50	um	5.229
Not Active	4413133	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Cc1ccc(-c2onc3ccc(C=O)cc23)cc1		CHEMBL1372905	=	IC50	nM	30090.0	CHEMBL5469	Homo sapiens	IC50	um	30.09
Not Active	4413134	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Cc1cc(NC(=O)CSc2nc(C(C)C)nc3ccccc23)no1		CHEMBL1604871	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Active	4413135	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	COC(=O)c1cccc2c1-c1ccccc1/C2=N/O		CHEMBL2005690	=	IC50	nM	6714.0	CHEMBL5469	Homo sapiens	IC50	um	6.714
Not Active	4413136	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CN(C)/C=N/C(=O)/C(C#N)=C1\CCc2ccccc2N1		CHEMBL3190626	=	IC50	nM	11550.0	CHEMBL5469	Homo sapiens	IC50	um	11.55
Not Active	4413137	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CCc1c(C)nc(SCC(=O)c2cccs2)c(C#N)c1C		CHEMBL1342667	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Active	4413138	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CC(=O)c1ccc(NC(=O)c2ccc3nc(-c4ccco4)c(-c4ccco4)nc3c2)cc1		CHEMBL1500600	=	IC50	nM	1241.0	CHEMBL5469	Homo sapiens	IC50	um	1.241
Not Active	4413139	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	C=CCn1c(P(=O)(O)c2ccccc2)nc2ccccc21		CHEMBL1558223	=	IC50	nM	26580.0	CHEMBL5469	Homo sapiens	IC50	um	26.58
Not Active	4413140	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CCc1ccc2[nH]c3nnc(N)c-3cc2c1		CHEMBL1596723	=	IC50	nM	24940.0	CHEMBL5469	Homo sapiens	IC50	um	24.94
Not Active	4413141	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	COC(=O)c1ccc(COc2ccc(/C=C(\C#N)c3nc4ccccc4[nH]3)cc2OC)o1		CHEMBL1422472	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4413142	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	COc1nnc(-c2ccc(N3CCCCC3)c(NC(C)=O)c2)c2ccccc12		CHEMBL1422628	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Active	4413143	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	COc1ccccc1CNC(=O)COC(=O)c1cc(-c2ccco2)nc2ccccc12		CHEMBL1361703	=	IC50	nM	5794.0	CHEMBL5469	Homo sapiens	IC50	um	5.794
Active	4413144	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=c1oc2ccccc2n1CCn1c2ccccc2c2nc3ccccc3nc21		CHEMBL1370120	=	IC50	nM	2083.0	CHEMBL5469	Homo sapiens	IC50	um	2.083
Not Active	4413145	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CCc1nc(SCC(=O)NNC(=O)C2CCCCC2)c2ccccc2n1		CHEMBL1452509	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4413146	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	N#C/C(=N\Nc1c(Cl)cccc1Cl)C(=O)NN		CHEMBL3189172	=	IC50	nM	28180.0	CHEMBL5469	Homo sapiens	IC50	um	28.18
Not Active	4413147	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C(O)c1ccccc1OCCOCCOc1ccccc1C(=O)O		CHEMBL1492243	=	IC50	nM	18170.0	CHEMBL5469	Homo sapiens	IC50	um	18.17
Active	4413148	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	C[C@H]1CCCC(=O)CCC/C=C/c2cc(O)cc(O)c2C(=O)O1		CHEMBL454173	=	IC50	nM	6922.0	CHEMBL5469	Homo sapiens	IC50	um	6.922
Active	4413149	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	COCCN(Cc1ccccc1)P(=O)(O)c1ccccc1OCC(=O)O		CHEMBL1303547	=	IC50	nM	7636.0	CHEMBL5469	Homo sapiens	IC50	um	7.636
Active	4413150	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Nc1ncnc2nc(-c3ccccc3)cc(-c3ccc(F)cc3)c12		CHEMBL1492266	=	IC50	nM	3318.0	CHEMBL5469	Homo sapiens	IC50	um	3.318
Active	4413151	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Cc1ccc2nsnc2c1S(=O)(=O)Nc1cccc2nsnc12		CHEMBL1531790	=	IC50	nM	6700.0	CHEMBL5469	Homo sapiens	IC50	um	6.7
Active	4413152	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Cc1ccc(C(=O)NNC(=O)CSc2n[nH]c3c4cc(F)ccc4nc-3n2)cc1		CHEMBL1401938	=	IC50	nM	5246.0	CHEMBL5469	Homo sapiens	IC50	um	5.246
Not Active	4413153	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	COC(=O)c1ccccc1NC(=O)c1c(Br)cnn1C		CHEMBL1501744	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4413154	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C(CCCn1c(=S)[nH]c2ccccc2c1=O)N1CCN(c2cccc(Cl)c2)CC1		CHEMBL1462307	=	IC50	nM	16070.0	CHEMBL5469	Homo sapiens	IC50	um	16.07
Active	4413155	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C(Cn1c2ccccc2c(=O)c2ccccc21)N/N=C/c1cc([N+](=O)[O-])ccc1N1CCCCCC1		CHEMBL3192969	=	IC50	nM	1943.0	CHEMBL5469	Homo sapiens	IC50	um	1.943
Active	4413156	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C(OCC(=O)N1CCN(C(=O)c2ccco2)CC1)c1cc(-c2ccc(Cl)c(Cl)c2Cl)nc2ccccc12		CHEMBL1492553	=	IC50	nM	5941.0	CHEMBL5469	Homo sapiens	IC50	um	5.941
Active	4413157	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Cc1ccc(C(=O)COC(=O)c2ccc3c(c2)C(=O)N(c2cccc4ncccc24)C3=O)cc1C		CHEMBL1570763	=	IC50	nM	7657.0	CHEMBL5469	Homo sapiens	IC50	um	7.657
Active	4413158	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=P(O)(O)c1ccccc1OCCCCCOc1ccccc1P(=O)(O)O		CHEMBL1414554	=	IC50	nM	2230.0	CHEMBL5469	Homo sapiens	IC50	um	2.23
Active	4413159	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C(COc1ccc(/C=N/NC(=O)c2cc3ccccc3o2)cc1Cl)Nc1ccccc1		CHEMBL1714669	=	IC50	nM	2647.0	CHEMBL5469	Homo sapiens	IC50	um	2.647
Active	4413160	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C(Oc1ccccc1)c1c(Cl)cccc1P(=O)(O)O		CHEMBL1502065	=	IC50	nM	6435.0	CHEMBL5469	Homo sapiens	IC50	um	6.435
Not Active	4413161	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Cc1ccsc1C1Nc2ccc3ncccc3c2C2=C1C(=O)CC(C)(C)C2		CHEMBL1344542	=	IC50	nM	10050.0	CHEMBL5469	Homo sapiens	IC50	um	10.05
Not Active	4413162	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Oc1nc(Nc2ccccc2)cc2ccccc12		CHEMBL1402456	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Active	4413163	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	COc1ccc2nc(C)cc(SCC(=O)N/N=C/c3cccc4ccccc34)c2c1		CHEMBL1986591	=	IC50	nM	2567.0	CHEMBL5469	Homo sapiens	IC50	um	2.567
Active	4413164	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Cc1ccc(-c2cc(-c3ccc(F)cc3)nc3ncnc(N)c23)cc1		CHEMBL1384281	=	IC50	nM	288.0	CHEMBL5469	Homo sapiens	IC50	um	0.288
Not Active	4413165	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C(Nc1cccc(-c2nc3ncccc3o2)c1)c1sc2ccccc2c1Cl		CHEMBL1453834	>	IC50	nM	23100.0	CHEMBL5469	Homo sapiens	IC50	um	23.1
Not Active	4413166	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C(N/N=C/c1ccc2ccccc2c1)c1ccc(COc2ccc3c(c2)CCC3)o1		CHEMBL3197709	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Active	4413167	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	N#Cc1cccc(NC(=O)CSc2ccc3c4c(cccc24)C(=O)c2ccccc2-3)c1		CHEMBL1323013	=	IC50	nM	4869.0	CHEMBL5469	Homo sapiens	IC50	um	4.869
Not Active	4413168	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CCOC(=O)CSc1nc(C(C)C)nc2ccccc12		CHEMBL1402735	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4413169	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	c1ccc2c3c([nH]c2c1)-c1n[nH]cc1CC3		CHEMBL512649	=	IC50	nM	10450.0	CHEMBL5469	Homo sapiens	IC50	um	10.45
Active	4413170	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C(O)c1ccc(F)c(S(=O)(=O)Nc2ccccc2Cl)c1		CHEMBL1305250	=	IC50	nM	4085.0	CHEMBL5469	Homo sapiens	IC50	um	4.085
Not Active	4413171	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	COc1cc(C2Nc3ccc4ncccc4c3C3=C2C(=O)CCC3)cc(OC)c1O		CHEMBL1598471	=	IC50	nM	12650.0	CHEMBL5469	Homo sapiens	IC50	um	12.65
Not Active	4413172	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CCc1ccc2nc(SCC(=O)N(CC)CC)c(C#N)cc2c1		CHEMBL1581059	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4413173	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C(O)c1ccc(F)c(S(=O)(=O)Nc2ccccc2)c1		CHEMBL1424837	=	IC50	nM	13130.0	CHEMBL5469	Homo sapiens	IC50	um	13.13
Not Active	4413174	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C(Oc1ccc(-c2cnc3ccccc3n2)cc1)c1ccc(Br)o1		CHEMBL1581188	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4413175	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	COc1ccc(-c2coc3cc4oc(=O)cc(C)c4cc23)cc1F		CHEMBL1598666	=	IC50	nM	12470.0	CHEMBL5469	Homo sapiens	IC50	um	12.47
Not Active	4413176	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CCOC(=O)CNC(=O)c1sc2ncnc(N3CCc4ccccc4C3)c2c1C		CHEMBL1345665	=	IC50	nM	41740.0	CHEMBL5469	Homo sapiens	IC50	um	41.74
Not Active	4413177	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CCOC(=O)c1cnc2ccc(C)cc2c1Nc1ccc(N2CCOCC2)cc1		CHEMBL1503392	=	IC50	nM	47700.0	CHEMBL5469	Homo sapiens	IC50	um	47.7
Active	4413178	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Cc1cc(NC(=O)Cc2cccs2)no1		CHEMBL578585	=	IC50	nM	6636.0	CHEMBL5469	Homo sapiens	IC50	um	6.636
Active	4413179	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C1c2ccccc2C(=O)N1c1ccc2[nH]c(-c3ccc(Br)o3)nc2c1		CHEMBL1403448	=	IC50	nM	6109.0	CHEMBL5469	Homo sapiens	IC50	um	6.109
Active	4413180	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	COc1ccc(-c2cc3ccccc3oc2=O)cc1NC(=S)NC(=O)c1ccc2c(c1)OCCO2		CHEMBL1323696	=	IC50	nM	1323.0	CHEMBL5469	Homo sapiens	IC50	um	1.323
Active	4413181	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Cc1ccc2nc(-c3ccc(Br)o3)oc(=O)c2c1		CHEMBL1345770	=	IC50	nM	1537.0	CHEMBL5469	Homo sapiens	IC50	um	1.537
Active	4413182	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CC1CCN(c2ncnc3[nH]cnc23)CC1		CHEMBL511499	=	IC50	nM	8617.0	CHEMBL5469	Homo sapiens	IC50	um	8.617
Active	4413183	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	COc1cc(/N=C/c2c(O)[nH]c3ccccc23)cc(OC)c1OC		CHEMBL3197990	=	IC50	nM	3146.0	CHEMBL5469	Homo sapiens	IC50	um	3.146
Not Active	4413184	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C1NCCc2c1[nH]c1c(Cl)ccc(Cl)c21		CHEMBL1345945	=	IC50	nM	10200.0	CHEMBL5469	Homo sapiens	IC50	um	10.2
Not Active	4413185	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CCOC(=O)C1=C(c2ccccc2)OC(N)=C(C#N)C1c1cccs1		CHEMBL1521351	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Active	4413186	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C(COc1ccccc1)Nc1sc2c(c1C(=O)NCc1cccnc1)CCCC2		CHEMBL1542790	=	IC50	nM	3683.0	CHEMBL5469	Homo sapiens	IC50	um	3.683
Active	4413187	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Cc1cc(OCC(=O)Nc2ccc(N3CCN(C(=O)c4ccco4)CC3)cc2)cc(C)c1Cl		CHEMBL1363851	=	IC50	nM	5956.0	CHEMBL5469	Homo sapiens	IC50	um	5.956
Not Active	4413188	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CCn1c(=O)c(C(=O)Nc2nc3ccccc3[nH]2)c(O)c2ccccc21		CHEMBL1533366	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4413189	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	COC(=O)C1=C(CSCc2ccco2)NC(=O)NC1c1cc(C)ccc1C		CHEMBL1567756	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Active	4413190	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C(Nc1ccccc1[N+](=O)[O-])C1=C(O)CCn2c1nc1ccccc12		CHEMBL1386091	=	IC50	nM	4509.0	CHEMBL5469	Homo sapiens	IC50	um	4.509
Active	4413191	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Cc1cc(C)cc(OCC(=O)Nc2ccc(N3CCCC3)cc2)c1		CHEMBL1581750	=	IC50	nM	7739.0	CHEMBL5469	Homo sapiens	IC50	um	7.739
Not Active	4413192	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	N#CCSc1nc(Nc2ccc3c(c2)OCO3)c2ccccc2n1		CHEMBL1306004	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Active	4413193	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	COc1ccc(-n2nc(C(=O)Nc3ccc(OC)c(OC)c3)c3c4ccccc4n(C)c3c2=O)cc1		CHEMBL1528600	=	IC50	nM	4254.0	CHEMBL5469	Homo sapiens	IC50	um	4.254
Active	4413194	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	N#C/C(C(N)=O)=C1/CCc2ccccc2N1		CHEMBL1346314	=	IC50	nM	2368.0	CHEMBL5469	Homo sapiens	IC50	um	2.368
Not Active	4413195	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CCOc1ccc(-n2c(SCc3nc(-c4ccc(C)cc4)no3)nnc2-c2ccncc2)cc1		CHEMBL1363966	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4413196	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	COc1ccc([N+](=O)[O-])cc1COc1cc(C)cc2oc(=O)cc(-c3ccccc3)c12		CHEMBL1336563	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Active	4413197	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C(N/N=C/C=C/c1ccc([N+](=O)[O-])cc1)c1cccs1		CHEMBL3197958	=	IC50	nM	6608.0	CHEMBL5469	Homo sapiens	IC50	um	6.608
Not Active	4413198	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	COCCO/C(O)=C1\C(C)=NC2=C(C(=O)CC(c3cccs3)C2)C1c1ccsc1		CHEMBL3198219	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4413199	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CO/C(O)=C1\C(C)=NC2=C(C(=O)CC(c3cccs3)C2)C1c1ccsc1		CHEMBL1969704	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4413200	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	N#Cc1ccc(-c2cccnc2)nc1SCc1ccc(Cl)cc1Cl		CHEMBL1376484	>	IC50	nM	7720.0	CHEMBL5469	Homo sapiens	IC50	um	7.72
Not Active	4413201	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=Cc1ccc2noc(-c3ccccc3)c2c1		CHEMBL1543513	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4413202	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C(CSc1nc(C2CC2)nc2ccccc12)NCc1ccc2c(c1)OCO2		CHEMBL1533978	>	IC50	nM	7720.0	CHEMBL5469	Homo sapiens	IC50	um	7.72
Active	4413203	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C(Nc1cccc(-c2cn3ccccc3n2)c1)c1cc2ccccc2oc1=O		CHEMBL1364528	=	IC50	nM	4500.0	CHEMBL5469	Homo sapiens	IC50	um	4.5
Not Active	4413204	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Cn1c2ccccc2c(=O)n2c(=O)c3ccccc3cc12		CHEMBL1543789	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4413205	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Cc1nnc(NC(=O)CSc2nc(C(C)C)nc3ccccc23)s1		CHEMBL1331799	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4413206	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	COc1ccc(C(=O)c2sc3nc(-c4ccccc4)ccc3c2N)cc1OC		CHEMBL1386978	=	IC50	nM	12010.0	CHEMBL5469	Homo sapiens	IC50	um	12.01
Active	4413207	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	COc1ccc(/N=C/c2c(O)[nH]c3ccccc23)cc1		CHEMBL3196959	=	IC50	nM	5504.0	CHEMBL5469	Homo sapiens	IC50	um	5.504
Active	4413208	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Nc1c(C(=O)Nc2nc3ccccc3s2)sc2nc(-c3cccs3)ccc12		CHEMBL1387110	=	IC50	nM	6727.0	CHEMBL5469	Homo sapiens	IC50	um	6.727
Not Active	4413209	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	COc1ccc(-n2nc(C(=O)NCC(=O)Nc3ccccn3)c3ccccc3c2=O)cc1Cl		CHEMBL1387238	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4413210	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Oc1ccc2ccccc2c1/C=N/c1ccc(N2CCOCC2)cc1		CHEMBL3199005	=	IC50	nM	10600.0	CHEMBL5469	Homo sapiens	IC50	um	10.6
Not Active	4413211	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	COC(=O)c1cc(Cl)c(NC(=O)/C=C/c2ccc(Cl)cc2)cc1OC		CHEMBL1482891	>	IC50	nM	2570.0	CHEMBL5469	Homo sapiens	IC50	um	2.57
Not Active	4413212	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C1Cc2ccccc2C(=O)N1CCc1ccccc1		CHEMBL1331912	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4413213	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Cc1c(C(N)=O)c(N)c(C(=O)c2ccccc2)n1-c1ccccc1		CHEMBL1307211	=	IC50	nM	56740.0	CHEMBL5469	Homo sapiens	IC50	um	56.74
Active	4413214	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CCOc1cc(/C=C2/NC(=S)NC2=O)ccc1OCc1ccc([N+](=O)[O-])cc1		CHEMBL1482979	=	IC50	nM	3765.0	CHEMBL5469	Homo sapiens	IC50	um	3.765
Active	4413215	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C(Nc1ccc(-n2nncc2-c2ccco2)cc1)c1cc2ccccc2oc1=O		CHEMBL1347829	=	IC50	nM	1898.0	CHEMBL5469	Homo sapiens	IC50	um	1.898
Active	4413216	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C(Nc1ccc(-c2cc3ccccc3oc2=O)c(Cl)c1)c1cccnc1		CHEMBL1337717	=	IC50	nM	3989.0	CHEMBL5469	Homo sapiens	IC50	um	3.989
Not Active	4413217	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C1Cc2ccccc2C(=O)N1Cc1ccccc1		CHEMBL1466516	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Active	4413218	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	COc1ccc(-c2cc3ccccc3oc2=O)cc1NC(=O)c1ccc(Br)o1		CHEMBL1388603	=	IC50	nM	1573.0	CHEMBL5469	Homo sapiens	IC50	um	1.573
Active	4413219	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	COc1cccc(CN2CC(=O)C(c3nc(-c4ccc(Cl)cc4)cs3)=C2N)c1		CHEMBL1466539	=	IC50	nM	5591.0	CHEMBL5469	Homo sapiens	IC50	um	5.591
Not Active	4413220	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C(CSc1nnc2scc(-c3ccccc3)n12)Nc1nsc(-c2ccccc2)n1		CHEMBL1427609	>	IC50	nM	2570.0	CHEMBL5469	Homo sapiens	IC50	um	2.57
Not Active	4413221	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Cc1ccc2[nH]c3c(NCc4ccco4)ncnc3c2c1		CHEMBL1583898	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Active	4413222	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Cc1n[nH]c(NC=C2C(=O)CC(C)(C)CC2=O)c1-c1ccc(Cl)cc1		CHEMBL3198948	=	IC50	nM	9186.0	CHEMBL5469	Homo sapiens	IC50	um	9.186
Active	4413223	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C1c2ccccc2C(=O)C1c1ccnc2ccccc12		CHEMBL1427801	=	IC50	nM	4749.0	CHEMBL5469	Homo sapiens	IC50	um	4.749
Not Active	4413224	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CC(C)(C)C(=O)Nc1nc2c(s1)COc1ccccc1-2		CHEMBL1388620	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Active	4413225	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Cc1ccc(OCC(=O)Nc2ccc(-c3nc4ncccc4o3)cc2)c(C)c1		CHEMBL1456621	=	IC50	nM	6606.0	CHEMBL5469	Homo sapiens	IC50	um	6.606
Active	4413226	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	COc1ccc(-c2cc3ccccc3oc2=O)cc1NC(=O)c1ccc(Br)o1		CHEMBL1388603	=	IC50	nM	1573.0	CHEMBL5469	Homo sapiens	IC50	um	1.573
Active	4413227	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Cc1ccsc1C1Nc2ccc3ncccc3c2C2=C1C(=O)CCC2		CHEMBL1456712	=	IC50	nM	3817.0	CHEMBL5469	Homo sapiens	IC50	um	3.817
Not Active	4413228	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	FC(F)(F)c1cnc2c(c1)Nc1ccccc1S2		CHEMBL1506606	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Active	4413229	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C1C(c2ccnc3ccccc23)=C(O)c2ccccc21		CHEMBL1467405	=	IC50	nM	3108.0	CHEMBL5469	Homo sapiens	IC50	um	3.108
Not Active	4413230	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C1C(=O)c2ccccc2-c2ccccc21		CHEMBL51931	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4413231	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C(Nc1ccc(N2CCCC2)cc1)C(c1ccccc1)c1ccccc1		CHEMBL1417890	=	IC50	nM	11610.0	CHEMBL5469	Homo sapiens	IC50	um	11.61
Active	4413232	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C1Nc2ccccc2/C1=C/c1cnc[nH]1		CHEMBL261692	=	IC50	nM	8776.0	CHEMBL5469	Homo sapiens	IC50	um	8.776
Active	4413233	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	COc1ccc(-c2ccc3c(N)c(C(=O)c4ccc(OC)c(OC)c4)sc3n2)cc1		CHEMBL1328311	=	IC50	nM	4281.0	CHEMBL5469	Homo sapiens	IC50	um	4.281
Not Active	4413234	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Cc1ccc(Cl)cc1NC1=C/C(=N\S(=O)(=O)c2cccs2)c2ccccc2C1=O		CHEMBL2006503	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4413235	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Cn1c(SCC(=O)c2ccc3c(c2)Cc2ccccc2-3)nnc1-c1ccccc1		CHEMBL1584932	>	IC50	nM	2570.0	CHEMBL5469	Homo sapiens	IC50	um	2.57
Active	4413236	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CCOc1ccc(NC2=NC(=O)S/C2=C\c2ccc(Cl)cc2)cc1		CHEMBL1574619	=	IC50	nM	2794.0	CHEMBL5469	Homo sapiens	IC50	um	2.794
Active	4413237	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Cc1ccc(OC(=O)c2ccccc2P(=O)(O)O)cc1		CHEMBL1507343	=	IC50	nM	9744.0	CHEMBL5469	Homo sapiens	IC50	um	9.744
Not Active	4413238	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Cc1ccc2cc3cc(C(=O)NCc4ccc5c(c4)OCO5)oc3nc2c1		CHEMBL1428762	=	IC50	nM	46540.0	CHEMBL5469	Homo sapiens	IC50	um	46.54
Active	4413239	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	COc1ccc(-c2nnc(Nc3nc4c(OC)cccc4s3)o2)cc1		CHEMBL1349451	=	IC50	nM	9064.0	CHEMBL5469	Homo sapiens	IC50	um	9.064
Active	4413240	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Cn1c(SCC(=O)Nc2ccc3nc(SCC(=O)N4CCCC4)sc3c2)nnc1-c1ccc(N)cc1		CHEMBL1349382	=	IC50	nM	2498.0	CHEMBL5469	Homo sapiens	IC50	um	2.498
Not Active	4413241	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Cc1cc2cc3c(N)[nH]nc3nc2cc1C		CHEMBL1613444	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4413242	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C(COc1ccc(/C=N/NC(=O)c2cc3ccccc3o2)cc1Br)Nc1ccccc1		CHEMBL1968356	>	IC50	nM	2570.0	CHEMBL5469	Homo sapiens	IC50	um	2.57
Not Active	4413243	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C(Nc1cccc(-c2nc3ncccc3o2)c1)c1sc2cc(Cl)ccc2c1Cl		CHEMBL1546584	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4413244	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=Cc1ccc2noc(-c3ccc(F)cc3)c2c1		CHEMBL1406232	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Active	4413245	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C(N/N=C1/C(=O)c2cccc3cccc1c23)c1ccc(Cl)cc1		CHEMBL1971613	=	IC50	nM	4307.0	CHEMBL5469	Homo sapiens	IC50	um	4.307
Not Active	4413246	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	N#Cc1ccccc1/C=N/Nc1nc(-c2ccccc2)c2cc(Cl)ccc2n1		CHEMBL1973729	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4413247	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	COC(=O)CSc1nc(C(C)C)nc2ccccc12		CHEMBL1468599	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Active	4413248	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	COc1cc2nc(-c3ccc(Br)o3)oc(=O)c2cc1OC		CHEMBL1468746	=	IC50	nM	1907.0	CHEMBL5469	Homo sapiens	IC50	um	1.907
Not Active	4413249	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CCN(CC)S(=O)(=O)c1cc([N+](=O)[O-])ccc1NNC(=O)Nc1ccccc1		CHEMBL1468758	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4413250	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CCOCCO/C(O)=C1\C(C)=NC2=C(C(=O)CC(c3cccs3)C2)C1c1ccsc1		CHEMBL3208943	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4413251	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Cc1oc(-c2ccccc2)cc1C(=O)Nc1cccc2ccccc12		CHEMBL1586048	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Active	4413252	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	COc1ccc(-c2cnc(N)nc2-c2ccc(OC)cc2O)cc1		CHEMBL1327038	=	IC50	nM	3495.0	CHEMBL5469	Homo sapiens	IC50	um	3.495
Active	4413253	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	C=CCNC(=O)c1ccccc1NC(=O)c1ccc(Cl)c(S(=O)(=O)Nc2ccccc2)c1		CHEMBL1350854	=	IC50	nM	2124.0	CHEMBL5469	Homo sapiens	IC50	um	2.124
Not Active	4413254	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CCN1CCc2c(sc(N)c2C#N)C1		CHEMBL1390871	=	IC50	nM	23640.0	CHEMBL5469	Homo sapiens	IC50	um	23.64
Not Active	4413255	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CCN(CC)C(=O)CSc1nc(N)c2c3c(sc2n1)CC(C)CC3		CHEMBL1469476	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Active	4413256	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CN(C)c1cc2c(c(N(C)C)c1)C(=O)c1ccccc1C2=O		CHEMBL1351180	=	IC50	nM	2133.0	CHEMBL5469	Homo sapiens	IC50	um	2.133
Active	4413257	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CN(C)CCN1CCc2ccccc21		CHEMBL422471	=	IC50	nM	6462.0	CHEMBL5469	Homo sapiens	IC50	um	6.462
Active	4413258	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CC(=O)Nc1ccc(Nc2ncc([N+](=O)[O-])c(Nc3ccc(NC(C)=O)cc3)n2)cc1		CHEMBL1469742	=	IC50	nM	2444.0	CHEMBL5469	Homo sapiens	IC50	um	2.444
Not Active	4413259	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CCOC(=O)c1sc2c(c1C)C(c1cccs1)C1=C(O)CCCC1=N2		CHEMBL1548265	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4413260	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Cc1oc2c(c1C(=O)c1ccccc1)C(=O)C(=O)c1ccccc1-2		CHEMBL1470135	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4413261	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CN1C(=O)c2cccc3c(S(=O)(=O)NCc4ccco4)ccc1c23		CHEMBL1452574	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4413262	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C(CSc1nc(C2CC2)nc2ccccc12)Nc1ccc2c(c1)OCCO2		CHEMBL1391809	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4413263	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C1C(=O)c2c(C(=O)c3ccccc3)coc2-c2ccccc21		CHEMBL1327816	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4413264	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CC(C)c1nc2[nH]nc(N)c2c2c1CCCC2		CHEMBL1491961	=	IC50	nM	14730.0	CHEMBL5469	Homo sapiens	IC50	um	14.73
Not Active	4413265	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Cc1n[nH]c(NC=C2C(=O)CC(C)(C)CC2=O)c1-c1ccccc1		CHEMBL3196625	=	IC50	nM	20960.0	CHEMBL5469	Homo sapiens	IC50	um	20.96
Active	4413266	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CC(C)(C)C(=O)NC(=C(Cl)Cl)P(=O)(O)O		CHEMBL1587782	=	IC50	nM	9259.0	CHEMBL5469	Homo sapiens	IC50	um	9.259
Not Active	4413267	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	C=CCn1c(SCC(=O)N2CCCC2)nc2scc(-c3cccs3)c2c1=O		CHEMBL1470433	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4413268	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	COc1ccc(OC)c(NS(=O)(=O)Cc2ccccc2)c1		CHEMBL1531090	=	IC50	nM	11950.0	CHEMBL5469	Homo sapiens	IC50	um	11.95
Not Active	4413269	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CC(=O)c1ccc(NCC(=O)N2CCN(c3ccccc3)CC2)cc1		CHEMBL1431555	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4413270	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=c1c2cccc3c2c(nn1CN1CCOCC1)-c1ccccc1-3		CHEMBL1588187	>	IC50	nM	7720.0	CHEMBL5469	Homo sapiens	IC50	um	7.72
Not Active	4413271	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CCOC(=O)C1=C(c2ccccc2)OC(N)=C(C#N)C1C1CCCCC1		CHEMBL1374203	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4413272	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CC(C)(C)c1cc(NC(=O)COC(=O)c2ccc3c(=O)n4c(nc3c2)CCC4)n(-c2ccccc2)n1		CHEMBL1549437	>	IC50	nM	23100.0	CHEMBL5469	Homo sapiens	IC50	um	23.1
Active	4413273	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CN1CCN(c2ccc(N)cc2)CC1		CHEMBL341473	=	IC50	nM	2828.0	CHEMBL5469	Homo sapiens	IC50	um	2.828
Active	4413274	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CCCCn1c(CN2C(=O)c3ccccc3C2=O)nc2ccccc2c1=O		CHEMBL1413819	=	IC50	nM	5642.0	CHEMBL5469	Homo sapiens	IC50	um	5.642
Active	4413275	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	COc1ccc(C(=O)Nc2nc3ccc4nc(C)sc4c3s2)cc1		CHEMBL1392806	=	IC50	nM	1449.0	CHEMBL5469	Homo sapiens	IC50	um	1.449
Not Active	4413276	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CCOC(=O)c1cnn(-c2ncnc3sc(CC)cc23)c1N		CHEMBL1313045	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4413277	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CCc1nc(SCC(=O)N2CCCC2)c2ccccc2n1		CHEMBL1313009	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4413278	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	COC(=O)c1[nH]c2ccc(C)cc2c1NC(=O)CN1CCCc2ccccc21		CHEMBL1549732	=	IC50	nM	15190.0	CHEMBL5469	Homo sapiens	IC50	um	15.19
Active	4413279	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CCOC(=O)c1cccc2c1-c1ccccc1/C2=N/O		CHEMBL1996902	=	IC50	nM	7485.0	CHEMBL5469	Homo sapiens	IC50	um	7.485
Not Active	4413280	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Cc1nn2c(c1-c1ccccc1)N=C1CCCC(O)=C1C2c1ccccc1		CHEMBL1432402	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4413281	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CCOC(=O)CSc1nc(C2CC2)nc2ccccc12		CHEMBL1471739	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Active	4413282	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Cc1c(N2C(=O)c3ccc4c5c(ccc(c35)C2=O)CC4)c(=O)n(-c2ccccc2)n1C		CHEMBL1313195	=	IC50	nM	2266.0	CHEMBL5469	Homo sapiens	IC50	um	2.266
Not Active	4413283	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	c1cc2ccc3ccc(CN4CCOCC4)c4ccc(c1)c2c34		CHEMBL1452997	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Active	4413284	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Nc1ncnc2oc(-c3ccco3)c(-c3ccco3)c12		CHEMBL1334484	=	IC50	nM	2921.0	CHEMBL5469	Homo sapiens	IC50	um	2.921
Active	4413285	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	COc1cccc(/N=c2\oc3ccc(OC)cc3cc2-c2nc3ccccc3[nH]2)c1		CHEMBL2002223	=	IC50	nM	1780.0	CHEMBL5469	Homo sapiens	IC50	um	1.78
Active	4413286	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C(Nc1cccc(-c2nc3ccccc3[nH]2)c1)c1cccc(NC(=O)c2ccco2)c1		CHEMBL580819	=	IC50	nM	5028.0	CHEMBL5469	Homo sapiens	IC50	um	5.028
Not Active	4413287	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CCOC(=O)c1ccc(NC2=CC(=O)C(=O)c3ccccc32)cc1		CHEMBL1550490	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Not Active	4413288	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	COc1ccc(-c2nc(-c3cccs3)c(-c3cccs3)[nH]2)cc1OC		CHEMBL1488460	>	IC50	nM	69500.0	CHEMBL5469	Homo sapiens	IC50	um	69.5
Active	4413289	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CSc1nc2ccc3nc(NC(=O)c4cccs4)sc3c2s1		CHEMBL1565236	=	IC50	nM	6501.0	CHEMBL5469	Homo sapiens	IC50	um	6.501
Active	4413290	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	Cc1cc(N)ccc1N1CCCC1.Cl		CHEMBL1432963	=	IC50	nM	1825.0	CHEMBL5469	Homo sapiens	IC50	um	1.825
Active	4413291	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	O=C(N/N=C/c1ccc(F)cc1)c1cc(-c2ccco2)nc2ccccc12		CHEMBL1704267	=	IC50	nM	2006.0	CHEMBL5469	Homo sapiens	IC50	um	2.006
Not Active	4413292	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	COc1ccc2nc(O)c(-c3noc(-c4ccccc4)n3)cc2c1		CHEMBL1353989	>	IC50	nM	2570.0	CHEMBL5469	Homo sapiens	IC50	um	2.57
Active	4413293	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CCN(CC)c1ccc2cc(-c3nc4ccccc4[nH]3)c(=O)oc2c1		CHEMBL374632	=	IC50	nM	2324.0	CHEMBL5469	Homo sapiens	IC50	um	2.324
Active	4413294	CHEMBL1614388	PUBCHEM_BIOASSAY: TR-FRET counterscreen for FAK inhibitors: dose-response biochemical high throughput screening assay to identify inhibitors of Proline-rich tyrosine kinase 2 (Pyk2). (Class of assay: confirmatory) [Related pubchem assays: 794, 727, 810 ]	B	CC(C(=O)O)N1C(=O)/C(=C/C=C/c2ccco2)SC1=S		CHEMBL255881	=	IC50	nM	1068.0	CHEMBL5469	Homo sapiens	IC50	um	1.068
	5120074	CHEMBL1648817	Inhibition of PTK2B at 10 uM after 60 mins by TR-FRET assay	B	O=c1[nH]nc(-c2ccnc(NC3CCOCC3)c2)n1-c1ccc2ccccc2c1		CHEMBL1644620	=	Inhibition	%	2.0	CHEMBL5469	Homo sapiens	INH	%	2.0
	5120127	CHEMBL1648817	Inhibition of PTK2B at 10 uM after 60 mins by TR-FRET assay	B	O=c1n(Cc2ccncc2)nc(-c2ccnc(NC3CCCCC3)c2)n1-c1ccc2ccccc2c1		CHEMBL1644642	=	Inhibition	%	6.0	CHEMBL5469	Homo sapiens	INH	%	6.0
	5120168	CHEMBL1648817	Inhibition of PTK2B at 10 uM after 60 mins by TR-FRET assay	B	O=c1[nH]nc(-c2ccnc(NC3CCCOC3)c2)n1-c1ccc2ccccc2c1		CHEMBL1644619	=	Inhibition	%	11.0	CHEMBL5469	Homo sapiens	INH	%	11.0
	5120303	CHEMBL1648697	Inhibition of human Pyk2 at 10 uM after 60 mins by TR-FRET assay	B	S=c1[nH]nc(-c2ccncc2)n1-c1ccc2ccccc2c1		CHEMBL1644616	=	Inhibition	%	98.0	CHEMBL5469	Homo sapiens	INH	%	98.0
	5123817	CHEMBL1645761	Inhibition of PTK2B at 1 uM	B	CCN1C(=O)CCC(C)(C)c2ccc(Nc3ncc(Cl)c(Nc4c(F)cccc4C(=O)NC)n3)cc21		CHEMBL1644812	=	Inhibition	%	98.0	CHEMBL5469	Homo sapiens	INH	%	98.0
	5139733	CHEMBL1648817	Inhibition of PTK2B at 10 uM after 60 mins by TR-FRET assay	B	O=c1n(Cc2ccccn2)nc(-c2ccnc(NC3CCOCC3)c2)n1-c1ccc2ccccc2c1		CHEMBL1644615	=	Inhibition	%	-7.0	CHEMBL5469	Homo sapiens	INH	%	-7.0
	5139750	CHEMBL1648817	Inhibition of PTK2B at 10 uM after 60 mins by TR-FRET assay	B	O=c1[nH]nc(-c2ccnc(NC3CCCCC3)c2)n1-c1ccc2ccccc2c1		CHEMBL1644618	=	Inhibition	%	-3.0	CHEMBL5469	Homo sapiens	INH	%	-3.0
	5139757	CHEMBL1648817	Inhibition of PTK2B at 10 uM after 60 mins by TR-FRET assay	B	O=c1n(C2CCOCC2)nc(-c2ccnc(NC3CCCCC3)c2)n1-c1ccc2ccccc2c1		CHEMBL1644639	=	Inhibition	%	-2.0	CHEMBL5469	Homo sapiens	INH	%	-2.0
	5243760	CHEMBL1685864	Inhibition of Pyk2 at 0.1 uM	B	Cc1ccc2cc(-c3n[nH]c4ccc(NC5CCN(Cc6ccccc6)CC5)cc34)[nH]c2c1		CHEMBL1684543	=	Inhibition	%	66.0	CHEMBL5469	Homo sapiens	INH	%	66.0
	5243868	CHEMBL1686080	Inhibition of Pyk2 at 1 uM	B	Cc1ccc2cc(-c3n[nH]c4ccc(NC5CCN(Cc6ccccc6)CC5)cc34)[nH]c2c1		CHEMBL1684543	=	Inhibition	%	10.0	CHEMBL5469	Homo sapiens	INH	%	10.0
	5243981	CHEMBL1685864	Inhibition of Pyk2 at 0.1 uM	B	Cc1ccc2cc(-c3n[nH]c4ccc(NC5CCNC5)cc34)[nH]c2c1		CHEMBL1684654	=	Inhibition	%	71.0	CHEMBL5469	Homo sapiens	INH	%	71.0
	5244089	CHEMBL1686080	Inhibition of Pyk2 at 1 uM	B	Cc1ccc2cc(-c3n[nH]c4ccc(NC5CCNC5)cc34)[nH]c2c1		CHEMBL1684654	=	Inhibition	%	8.0	CHEMBL5469	Homo sapiens	INH	%	8.0
	5244962	CHEMBL1685864	Inhibition of Pyk2 at 0.1 uM	B	O=C(Cc1ccc2cc(-c3n[nH]c4cccnc34)[nH]c2c1)c1ccccc1		CHEMBL1684662	=	Inhibition	%	87.0	CHEMBL5469	Homo sapiens	INH	%	87.0
	5245070	CHEMBL1686080	Inhibition of Pyk2 at 1 uM	B	O=C(Cc1ccc2cc(-c3n[nH]c4cccnc34)[nH]c2c1)c1ccccc1		CHEMBL1684662	=	Inhibition	%	38.0	CHEMBL5469	Homo sapiens	INH	%	38.0
	5245221	CHEMBL1685864	Inhibition of Pyk2 at 0.1 uM	B	Cc1ccc2cc(-c3n[nH]c4ccc(NS(=O)(=O)c5ncn(C)c5C)cc34)[nH]c2c1		CHEMBL1684525	=	Inhibition	%	79.0	CHEMBL5469	Homo sapiens	INH	%	79.0
	5246051	CHEMBL1686080	Inhibition of Pyk2 at 1 uM	B	Cc1ccc2cc(-c3n[nH]c4ccc(NS(=O)(=O)c5ncn(C)c5C)cc34)[nH]c2c1		CHEMBL1684525	=	Inhibition	%	24.0	CHEMBL5469	Homo sapiens	INH	%	24.0
	5249447	CHEMBL1686798	Inhibition of PTK2B at 10 uM	B	O=C(Cc1cccc2cnccc12)Nc1scc(Cl)c1-c1ncn[nH]1		CHEMBL1682017	=	Inhibition	%	-5.0	CHEMBL5469	Homo sapiens	INH	%	-5.0
	6196678	CHEMBL1776848	Inhibition of human Pyk2	B	Cc1cc(Nc2nc(N[C@@H](C)c3ccc(F)cn3)c(C#N)cc2F)n[nH]1		CHEMBL1774056	=	IC50	nM	129.0	CHEMBL5469	Homo sapiens	IC50	uM	0.129
	6210053	CHEMBL1781247	Inhibition of PYK2 at 4 uM by mobility shift assay	B	Cc1cc(-c2cccc(N)c2)c(/C=C2\C(=O)Nc3ccccc32)[nH]1		CHEMBL1778718	=	Inhibition	%	86.5	CHEMBL5469	Homo sapiens	INH	%	86.5
	6220240	CHEMBL1787944	Inhibition of PYK2 assessed as reduction in peptide substrate phosphorylation by fluorimetric method	B	CN(c1ccccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL472212	=	IC50	nM	31.0	CHEMBL5469	Homo sapiens	IC50	nM	31.0
	6220241	CHEMBL1787944	Inhibition of PYK2 assessed as reduction in peptide substrate phosphorylation by fluorimetric method	B	CN(C)[C@@H]1CCC[C@H]1Nc1nc(Nc2ccc(S(C)(=O)=O)cc2)ncc1C(F)(F)F		CHEMBL519418	=	IC50	nM	95.0	CHEMBL5469	Homo sapiens	IC50	nM	95.0
	6220242	CHEMBL1787944	Inhibition of PYK2 assessed as reduction in peptide substrate phosphorylation by fluorimetric method	B	CNS(=O)(=O)c1ccc(Nc2ncc(C(F)(F)F)c(N[C@@H]3CCC[C@H]3N(C)C)n2)cc1		CHEMBL509485	=	IC50	nM	140.0	CHEMBL5469	Homo sapiens	IC50	nM	140.0
	6220243	CHEMBL1787944	Inhibition of PYK2 assessed as reduction in peptide substrate phosphorylation by fluorimetric method	B	CN(C)[C@@H]1CCC[C@H]1Nc1nc(Nc2ccc(S(=O)(=O)NC3CC3)cc2)ncc1C(F)(F)F		CHEMBL1783837	=	IC50	nM	140.0	CHEMBL5469	Homo sapiens	IC50	nM	140.0
	6220244	CHEMBL1787944	Inhibition of PYK2 assessed as reduction in peptide substrate phosphorylation by fluorimetric method	B	CN=[S+](C)([O-])c1ccc(Nc2ncc(C(F)(F)F)c(N[C@@H]3CCC[C@H]3N(C)C)n2)cc1		CHEMBL2029180	=	IC50	nM	67.0	CHEMBL5469	Homo sapiens	IC50	nM	67.0
	6220245	CHEMBL1787944	Inhibition of PYK2 assessed as reduction in peptide substrate phosphorylation by fluorimetric method	B	CCN=[S+](C)([O-])c1ccc(Nc2ncc(C(F)(F)F)c(N[C@@H]3CCC[C@H]3N(C)C)n2)cc1		CHEMBL2029181	=	IC50	nM	32.0	CHEMBL5469	Homo sapiens	IC50	nM	32.0
	6220246	CHEMBL1787944	Inhibition of PYK2 assessed as reduction in peptide substrate phosphorylation by fluorimetric method	B	CC(C)N=[S+](C)([O-])c1ccc(Nc2ncc(C(F)(F)F)c(N[C@@H]3CCC[C@H]3N(C)C)n2)cc1		CHEMBL2029182	=	IC50	nM	22.0	CHEMBL5469	Homo sapiens	IC50	nM	22.0
	6220247	CHEMBL1787944	Inhibition of PYK2 assessed as reduction in peptide substrate phosphorylation by fluorimetric method	B	CN(C)[C@@H]1CCC[C@H]1Nc1nc(Nc2ccc([S+](C)(=N)[O-])cc2)ncc1C(F)(F)F		CHEMBL2029183	=	IC50	nM	65.0	CHEMBL5469	Homo sapiens	IC50	nM	65.0
	6220248	CHEMBL1787944	Inhibition of PYK2 assessed as reduction in peptide substrate phosphorylation by fluorimetric method	B	CN=[S+](C)([O-])c1ccc(Nc2ncc(C(F)(F)F)c(N[C@@H]3CCC[C@H]3N(C)C)n2)cc1		CHEMBL2029180	=	IC50	nM	43.0	CHEMBL5469	Homo sapiens	IC50	nM	43.0
	6220249	CHEMBL1787944	Inhibition of PYK2 assessed as reduction in peptide substrate phosphorylation by fluorimetric method	B	CCN=[S+](C)([O-])c1ccc(Nc2ncc(C(F)(F)F)c(N[C@@H]3CCC[C@H]3N(C)C)n2)cc1		CHEMBL2029181	=	IC50	nM	16.0	CHEMBL5469	Homo sapiens	IC50	nM	16.0
	6220250	CHEMBL1787944	Inhibition of PYK2 assessed as reduction in peptide substrate phosphorylation by fluorimetric method	B	CC[S+]([O-])(=NC)c1ccc(Nc2ncc(C(F)(F)F)c(N[C@@H]3CCC[C@H]3N(C)C)n2)cc1		CHEMBL2448536	=	IC50	nM	21.0	CHEMBL5469	Homo sapiens	IC50	nM	21.0
	6220251	CHEMBL1787944	Inhibition of PYK2 assessed as reduction in peptide substrate phosphorylation by fluorimetric method	B	CN=[S+](C)([O-])c1ccc(Nc2ncc(C(F)(F)F)c(N[C@@H]3CCC[C@H]3N(C)C)n2)cc1		CHEMBL2029180	=	IC50	nM	67.0	CHEMBL5469	Homo sapiens	IC50	nM	67.0
	6220252	CHEMBL1787944	Inhibition of PYK2 assessed as reduction in peptide substrate phosphorylation by fluorimetric method	B	CCN=[S+](C)([O-])c1ccc(Nc2ncc(C(F)(F)F)c(N[C@@H]3CCC[C@H]3N(C)C)n2)cc1		CHEMBL2029181	=	IC50	nM	63.0	CHEMBL5469	Homo sapiens	IC50	nM	63.0
	6220253	CHEMBL1787945	Inhibition of PYK2 by PYK2-LI-COR cellular assay	B	CN(c1ccccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL472212	=	IC50	nM	63.0	CHEMBL5469	Homo sapiens	IC50	nM	63.0
	6220254	CHEMBL1787945	Inhibition of PYK2 by PYK2-LI-COR cellular assay	B	CN(C)[C@@H]1CCC[C@H]1Nc1nc(Nc2ccc(S(C)(=O)=O)cc2)ncc1C(F)(F)F		CHEMBL519418	=	IC50	nM	60.0	CHEMBL5469	Homo sapiens	IC50	nM	60.0
	6220255	CHEMBL1787945	Inhibition of PYK2 by PYK2-LI-COR cellular assay	B	CNS(=O)(=O)c1ccc(Nc2ncc(C(F)(F)F)c(N[C@@H]3CCC[C@H]3N(C)C)n2)cc1		CHEMBL509485	=	IC50	nM	88.0	CHEMBL5469	Homo sapiens	IC50	nM	88.0
	6220256	CHEMBL1787945	Inhibition of PYK2 by PYK2-LI-COR cellular assay	B	CN(C)[C@@H]1CCC[C@H]1Nc1nc(Nc2ccc(S(=O)(=O)NC3CC3)cc2)ncc1C(F)(F)F		CHEMBL1783837	=	IC50	nM	95.0	CHEMBL5469	Homo sapiens	IC50	nM	95.0
	6220257	CHEMBL1787945	Inhibition of PYK2 by PYK2-LI-COR cellular assay	B	CN=[S+](C)([O-])c1ccc(Nc2ncc(C(F)(F)F)c(N[C@@H]3CCC[C@H]3N(C)C)n2)cc1		CHEMBL2029180	=	IC50	nM	76.0	CHEMBL5469	Homo sapiens	IC50	nM	76.0
	6220258	CHEMBL1787945	Inhibition of PYK2 by PYK2-LI-COR cellular assay	B	CCN=[S+](C)([O-])c1ccc(Nc2ncc(C(F)(F)F)c(N[C@@H]3CCC[C@H]3N(C)C)n2)cc1		CHEMBL2029181	=	IC50	nM	10.0	CHEMBL5469	Homo sapiens	IC50	nM	10.0
	6220259	CHEMBL1787945	Inhibition of PYK2 by PYK2-LI-COR cellular assay	B	CC(C)N=[S+](C)([O-])c1ccc(Nc2ncc(C(F)(F)F)c(N[C@@H]3CCC[C@H]3N(C)C)n2)cc1		CHEMBL2029182	=	IC50	nM	34.0	CHEMBL5469	Homo sapiens	IC50	nM	34.0
	6220260	CHEMBL1787945	Inhibition of PYK2 by PYK2-LI-COR cellular assay	B	CN(C)[C@@H]1CCC[C@H]1Nc1nc(Nc2ccc([S+](C)(=N)[O-])cc2)ncc1C(F)(F)F		CHEMBL2029183	=	IC50	nM	320.0	CHEMBL5469	Homo sapiens	IC50	nM	320.0
	6220261	CHEMBL1787945	Inhibition of PYK2 by PYK2-LI-COR cellular assay	B	CN=[S+](C)([O-])c1ccc(Nc2ncc(C(F)(F)F)c(N[C@@H]3CCC[C@H]3N(C)C)n2)cc1		CHEMBL2029180	=	IC50	nM	29.0	CHEMBL5469	Homo sapiens	IC50	nM	29.0
	6220262	CHEMBL1787945	Inhibition of PYK2 by PYK2-LI-COR cellular assay	B	CCN=[S+](C)([O-])c1ccc(Nc2ncc(C(F)(F)F)c(N[C@@H]3CCC[C@H]3N(C)C)n2)cc1		CHEMBL2029181	=	IC50	nM	22.0	CHEMBL5469	Homo sapiens	IC50	nM	22.0
	6220263	CHEMBL1787945	Inhibition of PYK2 by PYK2-LI-COR cellular assay	B	CC[S+]([O-])(=NC)c1ccc(Nc2ncc(C(F)(F)F)c(N[C@@H]3CCC[C@H]3N(C)C)n2)cc1		CHEMBL2448536	=	IC50	nM	24.0	CHEMBL5469	Homo sapiens	IC50	nM	24.0
	6220264	CHEMBL1787945	Inhibition of PYK2 by PYK2-LI-COR cellular assay	B	CN=[S+](C)([O-])c1ccc(Nc2ncc(C(F)(F)F)c(N[C@@H]3CCC[C@H]3N(C)C)n2)cc1		CHEMBL2029180	=	IC50	nM	98.0	CHEMBL5469	Homo sapiens	IC50	nM	98.0
	6220265	CHEMBL1787945	Inhibition of PYK2 by PYK2-LI-COR cellular assay	B	CCN=[S+](C)([O-])c1ccc(Nc2ncc(C(F)(F)F)c(N[C@@H]3CCC[C@H]3N(C)C)n2)cc1		CHEMBL2029181	=	IC50	nM	37.0	CHEMBL5469	Homo sapiens	IC50	nM	37.0
	6221265	CHEMBL1787827	Inhibition of PTK2B at 10 uM	B	S=c1[nH]nc(-c2ccncc2)n1-c1ccc2ccccc2c1		CHEMBL1644616	=	Inhibition	%	1.0	CHEMBL5469	Homo sapiens	INH	%	1.0
	6341003	CHEMBL1827628	Activity of PYK2 kinase at 1 uM	B	CC(=O)Nc1cn2nc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)ccc2n1		CHEMBL1822054	=	Activity	%	99.0	CHEMBL5469	Homo sapiens	Activity	%	99.0
	6353476	CHEMBL1825788	Inhibition of PTK2B at 10 uM	B	O=C(Cn1c(=O)ccc2cc(C(F)(F)F)ccc21)Nc1scc(Br)c1-c1ncn[nH]1		CHEMBL1822146	=	Inhibition	%	-5.0	CHEMBL5469	Homo sapiens	INH	%	-5.0
	6385823	CHEMBL1838358	Inhibition of human PYK2 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	Nc1c(F)c(NCCCc2ccccc2)c(F)c2c1c(=O)c(C(=O)O)cn2C1CC1		CHEMBL1834114	<	Inhibition	%	35.0	CHEMBL5469	Homo sapiens	INH	%	35.0
	6385824	CHEMBL1838358	Inhibition of human PYK2 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	Nc1c(F)c(NCCNc2ccccn2)c(F)c2c1c(=O)c(C(=O)O)cn2C1CCCC1		CHEMBL1834318	<	Inhibition	%	35.0	CHEMBL5469	Homo sapiens	INH	%	35.0
	6385825	CHEMBL1838358	Inhibition of human PYK2 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	C[C@H]1COc2c(NCCNc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23		CHEMBL1834323	<	Inhibition	%	35.0	CHEMBL5469	Homo sapiens	INH	%	35.0
	6385826	CHEMBL1838358	Inhibition of human PYK2 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	CC(C)[C@@H]1COc2c(NCCNc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23		CHEMBL1834324	<	Inhibition	%	35.0	CHEMBL5469	Homo sapiens	INH	%	35.0
	6385827	CHEMBL1838358	Inhibition of human PYK2 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	Nc1c(F)c(NCCNc2ccccn2)c2c3c1c(=O)c(C(=O)O)cn3C1(CCCC1)CO2		CHEMBL1834330	<	Inhibition	%	35.0	CHEMBL5469	Homo sapiens	INH	%	35.0
	7567138	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7567597	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl		CHEMBL105442	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7568068	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL180022	=	Kd	nM	8000.0	CHEMBL5469	Homo sapiens	Kd	nM	8000.0
	7568536	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	CSc1cccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)c1		CHEMBL386051	=	Kd	nM	5000.0	CHEMBL5469	Homo sapiens	Kd	nM	5000.0
	7568968	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	=	Kd	nM	600.0	CHEMBL5469	Homo sapiens	Kd	nM	600.0
	7569111	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7569571	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7570043	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7570506	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1		CHEMBL450786	=	Kd	nM	910.0	CHEMBL5469	Homo sapiens	Kd	nM	910.0
	7571087	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21		CHEMBL1614701	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7571544	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	=	Kd	nM	190.0	CHEMBL5469	Homo sapiens	Kd	nM	190.0
	7572020	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7572457	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	82.0	CHEMBL5469	Homo sapiens	Kd	nM	82.0
	7573068	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL513909	=	Kd	nM	310.0	CHEMBL5469	Homo sapiens	Kd	nM	310.0
	7573525	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7574028	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7574436	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Kd	nM	1.1	CHEMBL5469	Homo sapiens	Kd	nM	1.1
	7575046	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	=	Kd	nM	81.0	CHEMBL5469	Homo sapiens	Kd	nM	81.0
	7575507	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7575536	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1.Cl		CHEMBL1908395	=	Kd	nM	760.0	CHEMBL5469	Homo sapiens	Kd	nM	760.0
	7576001	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	660.0	CHEMBL5469	Homo sapiens	Kd	nM	660.0
	7576409	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7577020	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1		CHEMBL1173655	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7577515	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)NC(C)c1nccs1		CHEMBL1908396	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7577985	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F		CHEMBL1230020	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7578390	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1		CHEMBL1287853	=	Kd	nM	220.0	CHEMBL5469	Homo sapiens	Kd	nM	220.0
	7579410	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL1230609	=	Kd	nM	14.0	CHEMBL5469	Homo sapiens	Kd	nM	14.0
	7579884	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1		CHEMBL1908397	=	Kd	nM	760.0	CHEMBL5469	Homo sapiens	Kd	nM	760.0
	7580353	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21		CHEMBL1241674	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7580756	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7580944	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL379218	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7581329	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	=	Kd	nM	990.0	CHEMBL5469	Homo sapiens	Kd	nM	990.0
	7581774	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	=	Kd	nM	3100.0	CHEMBL5469	Homo sapiens	Kd	nM	3100.0
	7582245	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7582709	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7583109	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	=	Kd	nM	2600.0	CHEMBL5469	Homo sapiens	Kd	nM	2600.0
	7583290	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1		CHEMBL1908391	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7583687	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	Cc1ccc2nc(NCCN)c3ncc(C)n3c2c1		CHEMBL249697	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7584132	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	OCCn1cc(-c2ccc3c(c2)CC/C3=N\O)c(-c2ccncc2)n1		CHEMBL525191	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7584603	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7585065	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	=	Kd	nM	29.0	CHEMBL5469	Homo sapiens	Kd	nM	29.0
	7585469	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7585620	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7586028	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7586474	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7586945	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7587581	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7588000	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1		CHEMBL377300	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7588453	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7588924	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	COc1c(Cl)cc2c([nH]c3cnccc32)c1NC(=O)c1cccnc1C		CHEMBL608154	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7588933	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7589546	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7589970	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	41.0	CHEMBL5469	Homo sapiens	Kd	nM	41.0
	7590437	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3c(cc2OC)CCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL464552	=	Kd	nM	76.0	CHEMBL5469	Homo sapiens	Kd	nM	76.0
	7590920	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7591519	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7591941	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7592444	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7592897	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1		CHEMBL1236107	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7593486	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	=	Kd	nM	520.0	CHEMBL5469	Homo sapiens	Kd	nM	520.0
	7593921	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7593951	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1908394	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7594424	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	=	Kd	nM	2000.0	CHEMBL5469	Homo sapiens	Kd	nM	2000.0
	7594876	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	=	Kd	nM	390.0	CHEMBL5469	Homo sapiens	Kd	nM	390.0
	7595454	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7595930	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7596401	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7596848	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7597437	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7597910	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7598380	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	10000.0	CHEMBL5469	Homo sapiens	Kd	nM	10000.0
	7598822	CHEMBL1908429	Binding constant for PYK2 kinase domain	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	3.5	CHEMBL5469	Homo sapiens	Kd	nM	3.5
	7961141	CHEMBL1931552	Inhibition of PYK2	B	CN(C)CCN1CCN(C(=O)c2cc(C(C)(C)C)sc2NC(=O)Nc2cccc(Cl)c2Cl)CCC1=O		CHEMBL1929238	>	IC50	nM	30000.0	CHEMBL5469	Homo sapiens	IC50	uM	30.0
	7961142	CHEMBL1931552	Inhibition of PYK2	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	=	IC50	nM	400.0	CHEMBL5469	Homo sapiens	IC50	uM	0.4
	7997660	CHEMBL1944392	Inhibition of PTK2B at 1 uM	B	CNC(=O)c1cccc(F)c1Nc1nc(Nc2ccc3c(c2)NC(=O)[C@@H](NC(=O)N2CCCC2)CC3(C)C)ncc1Cl		CHEMBL1939492	=	Inhibition	%	90.0	CHEMBL5469	Homo sapiens	INH	%	90.0
	8004416	CHEMBL1943600	Inhibition of human PYK2 in HL-60 cells lysate assessed as reduction of labeling of acyl-phosphate ATP probe at 100 nM	B	C[C@H]1COc2c(NCCCn3cccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23		CHEMBL1940980	<	Inhibition	%	35.0	CHEMBL5469	Homo sapiens	INH	%	35.0
	8004417	CHEMBL1943600	Inhibition of human PYK2 in HL-60 cells lysate assessed as reduction of labeling of acyl-phosphate ATP probe at 100 nM	B	C[C@H]1COc2c(NCCCn3cccn3)c(F)c(N)c3c(=O)c(C#N)cn1c23		CHEMBL1940981	<	Inhibition	%	35.0	CHEMBL5469	Homo sapiens	INH	%	35.0
	8004418	CHEMBL1943600	Inhibition of human PYK2 in HL-60 cells lysate assessed as reduction of labeling of acyl-phosphate ATP probe at 100 nM	B	C[C@H]1COc2c(NCCCc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23		CHEMBL1940987	<	Inhibition	%	35.0	CHEMBL5469	Homo sapiens	INH	%	35.0
	8004419	CHEMBL1943600	Inhibition of human PYK2 in HL-60 cells lysate assessed as reduction of labeling of acyl-phosphate ATP probe at 100 nM	B	C[C@H]1COc2c(NCCCc3ccccn3)c(F)c(N)c3c(=O)c(C#N)cn1c23		CHEMBL1940990	<	Inhibition	%	35.0	CHEMBL5469	Homo sapiens	INH	%	35.0
Not Active	8012271	CHEMBL1941705	Inhibition of PYK2 at 10 uM by colorimetric analysis	B	Clc1ccc(-n2cc(-c3ccncc3)nn2)cc1		CHEMBL1938953		Inhibition	%		CHEMBL5469	Homo sapiens	INH		
Not Active	8012272	CHEMBL1941705	Inhibition of PYK2 at 10 uM by colorimetric analysis	B	Clc1cccc(-n2cc(-c3ccncc3)nn2)c1		CHEMBL1938954		Inhibition	%		CHEMBL5469	Homo sapiens	INH		
Not Active	8012273	CHEMBL1941705	Inhibition of PYK2 at 10 uM by colorimetric analysis	B	Clc1ccc(-n2nncc2-c2ccncc2)cc1		CHEMBL62965		Inhibition	%		CHEMBL5469	Homo sapiens	INH		
Not Active	8012274	CHEMBL1941705	Inhibition of PYK2 at 10 uM by colorimetric analysis	B	Clc1cccc(-n2nncc2-c2ccncc2)c1		CHEMBL303351		Inhibition	%		CHEMBL5469	Homo sapiens	INH		
	8047163	CHEMBL1959388	Inhibition of PTK2B at 1 uM	B	CN1CCN(c2ccc(Nc3nc(N)c(C(=O)c4ccc5c(c4)OCCO5)s3)cc2)CC1		CHEMBL1956070	<	Inhibition	%	50.0	CHEMBL5469	Homo sapiens	INH	%	50.0
	8061592	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	-1.9	CHEMBL5469	Homo sapiens	Inhibition	%	-1.9
	8061699	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	4.25	CHEMBL5469	Homo sapiens	Inhibition	%	4.25
	8061923	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	5.64	CHEMBL5469	Homo sapiens	Inhibition	%	5.64
	8062114	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	5.59	CHEMBL5469	Homo sapiens	Inhibition	%	5.59
	8062230	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	5.1	CHEMBL5469	Homo sapiens	Inhibition	%	5.1
	8062454	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	8.49	CHEMBL5469	Homo sapiens	Inhibition	%	8.49
	8062616	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	12.93	CHEMBL5469	Homo sapiens	Inhibition	%	12.93
	8062938	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	7.52	CHEMBL5469	Homo sapiens	Inhibition	%	7.52
	8063070	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	3.97	CHEMBL5469	Homo sapiens	Inhibition	%	3.97
	8063294	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	-0.14	CHEMBL5469	Homo sapiens	Inhibition	%	-0.14
	8063461	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	5.54	CHEMBL5469	Homo sapiens	Inhibition	%	5.54
	8063793	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	1.97	CHEMBL5469	Homo sapiens	Inhibition	%	1.97
	8063975	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	25.21	CHEMBL5469	Homo sapiens	Inhibition	%	25.21
	8064314	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	4.49	CHEMBL5469	Homo sapiens	Inhibition	%	4.49
	8064524	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	-3.27	CHEMBL5469	Homo sapiens	Inhibition	%	-3.27
	8064886	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	-5.6	CHEMBL5469	Homo sapiens	Inhibition	%	-5.6
	8065052	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	10.5	CHEMBL5469	Homo sapiens	Inhibition	%	10.5
	8065392	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	6.61	CHEMBL5469	Homo sapiens	Inhibition	%	6.61
	8065567	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	-0.64	CHEMBL5469	Homo sapiens	Inhibition	%	-0.64
	8065906	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	1.13	CHEMBL5469	Homo sapiens	Inhibition	%	1.13
	8066116	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	3.14	CHEMBL5469	Homo sapiens	Inhibition	%	3.14
	8066476	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	1.04	CHEMBL5469	Homo sapiens	Inhibition	%	1.04
	8066642	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	0.18	CHEMBL5469	Homo sapiens	Inhibition	%	0.18
	8066990	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	5.36	CHEMBL5469	Homo sapiens	Inhibition	%	5.36
	8067165	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	13.08	CHEMBL5469	Homo sapiens	Inhibition	%	13.08
	8067389	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	2.8	CHEMBL5469	Homo sapiens	Inhibition	%	2.8
	8067510	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	3.58	CHEMBL5469	Homo sapiens	Inhibition	%	3.58
	8067720	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	3.87	CHEMBL5469	Homo sapiens	Inhibition	%	3.87
	8067944	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	0.03	CHEMBL5469	Homo sapiens	Inhibition	%	0.03
	8068079	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	38.94	CHEMBL5469	Homo sapiens	Inhibition	%	38.94
	8068243	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	6.52	CHEMBL5469	Homo sapiens	Inhibition	%	6.52
	8068467	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	1.87	CHEMBL5469	Homo sapiens	Inhibition	%	1.87
	8068592	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	9.53	CHEMBL5469	Homo sapiens	Inhibition	%	9.53
	8068990	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	6.27	CHEMBL5469	Homo sapiens	Inhibition	%	6.27
	8069115	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	3.99	CHEMBL5469	Homo sapiens	Inhibition	%	3.99
	8069339	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	4.06	CHEMBL5469	Homo sapiens	Inhibition	%	4.06
	8069410	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	95.87	CHEMBL5469	Homo sapiens	Inhibition	%	95.87
	8069795	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	7.64	CHEMBL5469	Homo sapiens	Inhibition	%	7.64
	8069921	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	1.0	CHEMBL5469	Homo sapiens	Inhibition	%	1.0
	8070145	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	1.23	CHEMBL5469	Homo sapiens	Inhibition	%	1.23
	8070317	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	3.6	CHEMBL5469	Homo sapiens	Inhibition	%	3.6
	8070666	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	1.78	CHEMBL5469	Homo sapiens	Inhibition	%	1.78
	8070740	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	8.56	CHEMBL5469	Homo sapiens	Inhibition	%	8.56
	8070964	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	72.39	CHEMBL5469	Homo sapiens	Inhibition	%	72.39
	8071121	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	5.57	CHEMBL5469	Homo sapiens	Inhibition	%	5.57
	8071471	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	-4.16	CHEMBL5469	Homo sapiens	Inhibition	%	-4.16
	8071644	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	4.13	CHEMBL5469	Homo sapiens	Inhibition	%	4.13
	8071993	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	3.36	CHEMBL5469	Homo sapiens	Inhibition	%	3.36
	8072307	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	0.22	CHEMBL5469	Homo sapiens	Inhibition	%	0.22
	8072464	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	-0.13	CHEMBL5469	Homo sapiens	Inhibition	%	-0.13
	8072813	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	0.67	CHEMBL5469	Homo sapiens	Inhibition	%	0.67
	8072980	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	-1.24	CHEMBL5469	Homo sapiens	Inhibition	%	-1.24
	8073204	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	3.71	CHEMBL5469	Homo sapiens	Inhibition	%	3.71
	8073329	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	1.98	CHEMBL5469	Homo sapiens	Inhibition	%	1.98
	8073672	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	1.76	CHEMBL5469	Homo sapiens	Inhibition	%	1.76
	8073905	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	-4.43	CHEMBL5469	Homo sapiens	Inhibition	%	-4.43
	8074057	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	-1.17	CHEMBL5469	Homo sapiens	Inhibition	%	-1.17
	8074281	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	6.99	CHEMBL5469	Homo sapiens	Inhibition	%	6.99
	8074411	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	-0.29	CHEMBL5469	Homo sapiens	Inhibition	%	-0.29
	8074792	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	5.56	CHEMBL5469	Homo sapiens	Inhibition	%	5.56
	8074919	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	6.74	CHEMBL5469	Homo sapiens	Inhibition	%	6.74
	8075254	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	0.28	CHEMBL5469	Homo sapiens	Inhibition	%	0.28
	8075491	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	-0.18	CHEMBL5469	Homo sapiens	Inhibition	%	-0.18
	8075856	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	7.05	CHEMBL5469	Homo sapiens	Inhibition	%	7.05
	8075998	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	-5.44	CHEMBL5469	Homo sapiens	Inhibition	%	-5.44
	8076370	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	3.38	CHEMBL5469	Homo sapiens	Inhibition	%	3.38
	8076504	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	15.15	CHEMBL5469	Homo sapiens	Inhibition	%	15.15
	8076728	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	93.11	CHEMBL5469	Homo sapiens	Inhibition	%	93.11
	8076830	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	0.29	CHEMBL5469	Homo sapiens	Inhibition	%	0.29
	8077077	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	-7.23	CHEMBL5469	Homo sapiens	Inhibition	%	-7.23
	8077429	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	6.6	CHEMBL5469	Homo sapiens	Inhibition	%	6.6
	8077580	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	-4.13	CHEMBL5469	Homo sapiens	Inhibition	%	-4.13
	8077804	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	-9.62	CHEMBL5469	Homo sapiens	Inhibition	%	-9.62
	8077947	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	3.82	CHEMBL5469	Homo sapiens	Inhibition	%	3.82
	8078310	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	-2.28	CHEMBL5469	Homo sapiens	Inhibition	%	-2.28
	8078412	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	-0.89	CHEMBL5469	Homo sapiens	Inhibition	%	-0.89
	8078636	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	1.86	CHEMBL5469	Homo sapiens	Inhibition	%	1.86
	8078662	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	26.96	CHEMBL5469	Homo sapiens	Inhibition	%	26.96
	8078886	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	80.14	CHEMBL5469	Homo sapiens	Inhibition	%	80.14
	8079002	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	4.97	CHEMBL5469	Homo sapiens	Inhibition	%	4.97
	8079384	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	-2.91	CHEMBL5469	Homo sapiens	Inhibition	%	-2.91
	8079526	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	4.2	CHEMBL5469	Homo sapiens	Inhibition	%	4.2
	8079889	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	-1.9	CHEMBL5469	Homo sapiens	Inhibition	%	-1.9
	8080218	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	1.17	CHEMBL5469	Homo sapiens	Inhibition	%	1.17
	8080470	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	2.4	CHEMBL5469	Homo sapiens	Inhibition	%	2.4
	8080585	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	6.48	CHEMBL5469	Homo sapiens	Inhibition	%	6.48
	8080809	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	-1.91	CHEMBL5469	Homo sapiens	Inhibition	%	-1.91
	8080973	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	-1.09	CHEMBL5469	Homo sapiens	Inhibition	%	-1.09
	8081108	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	2.85	CHEMBL5469	Homo sapiens	Inhibition	%	2.85
	8081332	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	-2.53	CHEMBL5469	Homo sapiens	Inhibition	%	-2.53
	8081476	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	94.93	CHEMBL5469	Homo sapiens	Inhibition	%	94.93
	8081803	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	1.0	CHEMBL5469	Homo sapiens	Inhibition	%	1.0
	8082055	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	16.46	CHEMBL5469	Homo sapiens	Inhibition	%	16.46
	8082392	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	5.66	CHEMBL5469	Homo sapiens	Inhibition	%	5.66
	8082565	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	-6.28	CHEMBL5469	Homo sapiens	Inhibition	%	-6.28
	8082912	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	4.2	CHEMBL5469	Homo sapiens	Inhibition	%	4.2
	8083068	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	96.81	CHEMBL5469	Homo sapiens	Inhibition	%	96.81
	8083391	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	9.11	CHEMBL5469	Homo sapiens	Inhibition	%	9.11
	8083645	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	-7.07	CHEMBL5469	Homo sapiens	Inhibition	%	-7.07
	8083979	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	-2.24	CHEMBL5469	Homo sapiens	Inhibition	%	-2.24
	8084164	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	-3.71	CHEMBL5469	Homo sapiens	Inhibition	%	-3.71
	8084506	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	4.27	CHEMBL5469	Homo sapiens	Inhibition	%	4.27
	8084667	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	14.28	CHEMBL5469	Homo sapiens	Inhibition	%	14.28
	8084891	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	20.94	CHEMBL5469	Homo sapiens	Inhibition	%	20.94
	8084989	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	2.77	CHEMBL5469	Homo sapiens	Inhibition	%	2.77
	8085245	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	-8.39	CHEMBL5469	Homo sapiens	Inhibition	%	-8.39
	8085469	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	-6.73	CHEMBL5469	Homo sapiens	Inhibition	%	-6.73
	8085577	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	6.37	CHEMBL5469	Homo sapiens	Inhibition	%	6.37
	8085766	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	6.43	CHEMBL5469	Homo sapiens	Inhibition	%	6.43
	8085990	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	43.23	CHEMBL5469	Homo sapiens	Inhibition	%	43.23
	8086105	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	4.48	CHEMBL5469	Homo sapiens	Inhibition	%	4.48
	8086491	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	10.76	CHEMBL5469	Homo sapiens	Inhibition	%	10.76
	8086590	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	3.01	CHEMBL5469	Homo sapiens	Inhibition	%	3.01
	8086814	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	3.23	CHEMBL5469	Homo sapiens	Inhibition	%	3.23
	8087025	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	4.56	CHEMBL5469	Homo sapiens	Inhibition	%	4.56
	8087183	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	14.33	CHEMBL5469	Homo sapiens	Inhibition	%	14.33
	8087521	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	19.0	CHEMBL5469	Homo sapiens	Inhibition	%	19.0
	8087883	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	8.03	CHEMBL5469	Homo sapiens	Inhibition	%	8.03
	8088025	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	4.67	CHEMBL5469	Homo sapiens	Inhibition	%	4.67
	8088397	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	3.11	CHEMBL5469	Homo sapiens	Inhibition	%	3.11
	8088525	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	8.62	CHEMBL5469	Homo sapiens	Inhibition	%	8.62
	8088749	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	-0.4	CHEMBL5469	Homo sapiens	Inhibition	%	-0.4
	8088842	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	4.43	CHEMBL5469	Homo sapiens	Inhibition	%	4.43
	8089194	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	38.23	CHEMBL5469	Homo sapiens	Inhibition	%	38.23
	8089342	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	5.17	CHEMBL5469	Homo sapiens	Inhibition	%	5.17
	8089566	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	3.24	CHEMBL5469	Homo sapiens	Inhibition	%	3.24
	8089686	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	3.02	CHEMBL5469	Homo sapiens	Inhibition	%	3.02
	8089866	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	-1.87	CHEMBL5469	Homo sapiens	Inhibition	%	-1.87
	8090090	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	0.52	CHEMBL5469	Homo sapiens	Inhibition	%	0.52
	8090255	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	57.72	CHEMBL5469	Homo sapiens	Inhibition	%	57.72
	8090422	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	2.45	CHEMBL5469	Homo sapiens	Inhibition	%	2.45
	8090646	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	1.99	CHEMBL5469	Homo sapiens	Inhibition	%	1.99
	8090785	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	3.33	CHEMBL5469	Homo sapiens	Inhibition	%	3.33
	8090990	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	6.4	CHEMBL5469	Homo sapiens	Inhibition	%	6.4
	8091214	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	7.76	CHEMBL5469	Homo sapiens	Inhibition	%	7.76
	8091351	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	7.83	CHEMBL5469	Homo sapiens	Inhibition	%	7.83
	8091506	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	11.75	CHEMBL5469	Homo sapiens	Inhibition	%	11.75
	8091730	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	6.44	CHEMBL5469	Homo sapiens	Inhibition	%	6.44
	8091846	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	0.49	CHEMBL5469	Homo sapiens	Inhibition	%	0.49
	8092207	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	4.92	CHEMBL5469	Homo sapiens	Inhibition	%	4.92
	8092358	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	9.07	CHEMBL5469	Homo sapiens	Inhibition	%	9.07
	8092582	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	4.47	CHEMBL5469	Homo sapiens	Inhibition	%	4.47
	8092730	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	8.02	CHEMBL5469	Homo sapiens	Inhibition	%	8.02
	8093083	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	13.96	CHEMBL5469	Homo sapiens	Inhibition	%	13.96
	8093171	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	7.84	CHEMBL5469	Homo sapiens	Inhibition	%	7.84
	8093395	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	3.13	CHEMBL5469	Homo sapiens	Inhibition	%	3.13
	8093535	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	92.37	CHEMBL5469	Homo sapiens	Inhibition	%	92.37
	8093898	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	27.54	CHEMBL5469	Homo sapiens	Inhibition	%	27.54
	8094018	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	6.54	CHEMBL5469	Homo sapiens	Inhibition	%	6.54
	8094242	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	45.19	CHEMBL5469	Homo sapiens	Inhibition	%	45.19
	8094422	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	1.24	CHEMBL5469	Homo sapiens	Inhibition	%	1.24
	8094597	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	93.4	CHEMBL5469	Homo sapiens	Inhibition	%	93.4
	8094977	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	10.12	CHEMBL5469	Homo sapiens	Inhibition	%	10.12
	8095117	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	5.52	CHEMBL5469	Homo sapiens	Inhibition	%	5.52
	8095544	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	6.51	CHEMBL5469	Homo sapiens	Inhibition	%	6.51
	8095685	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	78.02	CHEMBL5469	Homo sapiens	Inhibition	%	78.02
	8096057	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	6.05	CHEMBL5469	Homo sapiens	Inhibition	%	6.05
	8096174	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	11.11	CHEMBL5469	Homo sapiens	Inhibition	%	11.11
	8096398	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	7.35	CHEMBL5469	Homo sapiens	Inhibition	%	7.35
	8096537	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	6.66	CHEMBL5469	Homo sapiens	Inhibition	%	6.66
	8096917	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	4.63	CHEMBL5469	Homo sapiens	Inhibition	%	4.63
	8097064	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	-5.04	CHEMBL5469	Homo sapiens	Inhibition	%	-5.04
	8097375	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	9.58	CHEMBL5469	Homo sapiens	Inhibition	%	9.58
	8097595	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	7.75	CHEMBL5469	Homo sapiens	Inhibition	%	7.75
	8097745	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	-0.92	CHEMBL5469	Homo sapiens	Inhibition	%	-0.92
	8098102	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	-5.8	CHEMBL5469	Homo sapiens	Inhibition	%	-5.8
	8098446	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	-3.42	CHEMBL5469	Homo sapiens	Inhibition	%	-3.42
	8098626	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	0.0	CHEMBL5469	Homo sapiens	Inhibition	%	0.0
	8098811	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	95.48	CHEMBL5469	Homo sapiens	Inhibition	%	95.48
	8099035	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	97.76	CHEMBL5469	Homo sapiens	Inhibition	%	97.76
	8099179	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	3.8	CHEMBL5469	Homo sapiens	Inhibition	%	3.8
	8099321	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	59.02	CHEMBL5469	Homo sapiens	Inhibition	%	59.02
	8099545	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	1.46	CHEMBL5469	Homo sapiens	Inhibition	%	1.46
	8099739	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	-1.69	CHEMBL5469	Homo sapiens	Inhibition	%	-1.69
	8099886	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	94.9	CHEMBL5469	Homo sapiens	Inhibition	%	94.9
	8100110	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	4.06	CHEMBL5469	Homo sapiens	Inhibition	%	4.06
	8100256	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	9.57	CHEMBL5469	Homo sapiens	Inhibition	%	9.57
	8100596	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	6.56	CHEMBL5469	Homo sapiens	Inhibition	%	6.56
	8100736	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	6.05	CHEMBL5469	Homo sapiens	Inhibition	%	6.05
	8100960	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	1.47	CHEMBL5469	Homo sapiens	Inhibition	%	1.47
	8101120	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	5.98	CHEMBL5469	Homo sapiens	Inhibition	%	5.98
	8101262	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	3.37	CHEMBL5469	Homo sapiens	Inhibition	%	3.37
	8101486	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	-6.53	CHEMBL5469	Homo sapiens	Inhibition	%	-6.53
	8101671	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	6.17	CHEMBL5469	Homo sapiens	Inhibition	%	6.17
	8101924	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	2.76	CHEMBL5469	Homo sapiens	Inhibition	%	2.76
	8102079	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	9.22	CHEMBL5469	Homo sapiens	Inhibition	%	9.22
	8102303	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	9.7	CHEMBL5469	Homo sapiens	Inhibition	%	9.7
	8102434	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	6.37	CHEMBL5469	Homo sapiens	Inhibition	%	6.37
	8102778	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	-2.02	CHEMBL5469	Homo sapiens	Inhibition	%	-2.02
	8102956	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	-2.12	CHEMBL5469	Homo sapiens	Inhibition	%	-2.12
	8103376	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	1.28	CHEMBL5469	Homo sapiens	Inhibition	%	1.28
	8103514	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	3.38	CHEMBL5469	Homo sapiens	Inhibition	%	3.38
	8103888	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	-0.9	CHEMBL5469	Homo sapiens	Inhibition	%	-0.9
	8104073	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	0.44	CHEMBL5469	Homo sapiens	Inhibition	%	0.44
	8104445	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	15.75	CHEMBL5469	Homo sapiens	Inhibition	%	15.75
	8104591	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	9.59	CHEMBL5469	Homo sapiens	Inhibition	%	9.59
	8104929	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	6.64	CHEMBL5469	Homo sapiens	Inhibition	%	6.64
	8105293	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	3.12	CHEMBL5469	Homo sapiens	Inhibition	%	3.12
	8105459	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	11.3	CHEMBL5469	Homo sapiens	Inhibition	%	11.3
	8105821	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	5.39	CHEMBL5469	Homo sapiens	Inhibition	%	5.39
	8106101	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	-2.17	CHEMBL5469	Homo sapiens	Inhibition	%	-2.17
	8106266	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	9.78	CHEMBL5469	Homo sapiens	Inhibition	%	9.78
	8106646	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	65.46	CHEMBL5469	Homo sapiens	Inhibition	%	65.46
	8106775	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	-0.93	CHEMBL5469	Homo sapiens	Inhibition	%	-0.93
	8106999	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	16.48	CHEMBL5469	Homo sapiens	Inhibition	%	16.48
	8107120	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	3.44	CHEMBL5469	Homo sapiens	Inhibition	%	3.44
	8107292	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	1.9	CHEMBL5469	Homo sapiens	Inhibition	%	1.9
	8107516	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	3.52	CHEMBL5469	Homo sapiens	Inhibition	%	3.52
	8107717	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	9.96	CHEMBL5469	Homo sapiens	Inhibition	%	9.96
	8107852	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	1.12	CHEMBL5469	Homo sapiens	Inhibition	%	1.12
	8108076	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	25.41	CHEMBL5469	Homo sapiens	Inhibition	%	25.41
	8108234	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	-3.85	CHEMBL5469	Homo sapiens	Inhibition	%	-3.85
	8108409	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	0.45	CHEMBL5469	Homo sapiens	Inhibition	%	0.45
	8108633	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	5.25	CHEMBL5469	Homo sapiens	Inhibition	%	5.25
	8108780	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	5.71	CHEMBL5469	Homo sapiens	Inhibition	%	5.71
	8108922	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	19.67	CHEMBL5469	Homo sapiens	Inhibition	%	19.67
	8109146	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	4.11	CHEMBL5469	Homo sapiens	Inhibition	%	4.11
	8109260	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	13.41	CHEMBL5469	Homo sapiens	Inhibition	%	13.41
	8109614	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	8.77	CHEMBL5469	Homo sapiens	Inhibition	%	8.77
	8109785	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	4.13	CHEMBL5469	Homo sapiens	Inhibition	%	4.13
	8110141	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	6.76	CHEMBL5469	Homo sapiens	Inhibition	%	6.76
	8110420	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	4.14	CHEMBL5469	Homo sapiens	Inhibition	%	4.14
	8110586	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	-1.38	CHEMBL5469	Homo sapiens	Inhibition	%	-1.38
	8110810	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	1.42	CHEMBL5469	Homo sapiens	Inhibition	%	1.42
	8110968	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	-5.89	CHEMBL5469	Homo sapiens	Inhibition	%	-5.89
	8111315	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	0.73	CHEMBL5469	Homo sapiens	Inhibition	%	0.73
	8111442	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	3.88	CHEMBL5469	Homo sapiens	Inhibition	%	3.88
	8111832	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	-2.94	CHEMBL5469	Homo sapiens	Inhibition	%	-2.94
	8112037	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	-0.77	CHEMBL5469	Homo sapiens	Inhibition	%	-0.77
	8112398	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	1.44	CHEMBL5469	Homo sapiens	Inhibition	%	1.44
	8112566	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	0.13	CHEMBL5469	Homo sapiens	Inhibition	%	0.13
	8112962	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	0.12	CHEMBL5469	Homo sapiens	Inhibition	%	0.12
	8113114	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	13.66	CHEMBL5469	Homo sapiens	Inhibition	%	13.66
	8113474	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	8.55	CHEMBL5469	Homo sapiens	Inhibition	%	8.55
	8113598	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	5.26	CHEMBL5469	Homo sapiens	Inhibition	%	5.26
	8113822	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	7.9	CHEMBL5469	Homo sapiens	Inhibition	%	7.9
	8113938	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	-4.8	CHEMBL5469	Homo sapiens	Inhibition	%	-4.8
	8114114	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	11.68	CHEMBL5469	Homo sapiens	Inhibition	%	11.68
	8114338	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	1.85	CHEMBL5469	Homo sapiens	Inhibition	%	1.85
	8114470	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	9.54	CHEMBL5469	Homo sapiens	Inhibition	%	9.54
	8114746	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	3.32	CHEMBL5469	Homo sapiens	Inhibition	%	3.32
	8115136	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	4.45	CHEMBL5469	Homo sapiens	Inhibition	%	4.45
	8115301	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	8.44	CHEMBL5469	Homo sapiens	Inhibition	%	8.44
	8115645	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	8.1	CHEMBL5469	Homo sapiens	Inhibition	%	8.1
	8115778	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	1.89	CHEMBL5469	Homo sapiens	Inhibition	%	1.89
	8116002	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	22.98	CHEMBL5469	Homo sapiens	Inhibition	%	22.98
	8116161	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	-4.01	CHEMBL5469	Homo sapiens	Inhibition	%	-4.01
	8116364	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	4.02	CHEMBL5469	Homo sapiens	Inhibition	%	4.02
	8116722	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	8.6	CHEMBL5469	Homo sapiens	Inhibition	%	8.6
	8116894	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	2.23	CHEMBL5469	Homo sapiens	Inhibition	%	2.23
	8117118	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	20.75	CHEMBL5469	Homo sapiens	Inhibition	%	20.75
	8117289	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	1.57	CHEMBL5469	Homo sapiens	Inhibition	%	1.57
	8117447	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	8.7	CHEMBL5469	Homo sapiens	Inhibition	%	8.7
	8117801	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	5.42	CHEMBL5469	Homo sapiens	Inhibition	%	5.42
	8118163	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	4.15	CHEMBL5469	Homo sapiens	Inhibition	%	4.15
	8118279	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	-1.77	CHEMBL5469	Homo sapiens	Inhibition	%	-1.77
	8118675	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	12.59	CHEMBL5469	Homo sapiens	Inhibition	%	12.59
	8118811	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	6.41	CHEMBL5469	Homo sapiens	Inhibition	%	6.41
	8119035	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	5.02	CHEMBL5469	Homo sapiens	Inhibition	%	5.02
	8119082	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	9.58	CHEMBL5469	Homo sapiens	Inhibition	%	9.58
	8119306	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	93.13	CHEMBL5469	Homo sapiens	Inhibition	%	93.13
	8119465	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	85.43	CHEMBL5469	Homo sapiens	Inhibition	%	85.43
	8119632	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	-2.77	CHEMBL5469	Homo sapiens	Inhibition	%	-2.77
	8119856	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	8.14	CHEMBL5469	Homo sapiens	Inhibition	%	8.14
	8119975	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	-0.72	CHEMBL5469	Homo sapiens	Inhibition	%	-0.72
	8120338	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	-0.75	CHEMBL5469	Homo sapiens	Inhibition	%	-0.75
	8120498	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	18.78	CHEMBL5469	Homo sapiens	Inhibition	%	18.78
	8120699	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	6.98	CHEMBL5469	Homo sapiens	Inhibition	%	6.98
	8120923	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	45.29	CHEMBL5469	Homo sapiens	Inhibition	%	45.29
	8121051	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	-3.24	CHEMBL5469	Homo sapiens	Inhibition	%	-3.24
	8121447	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	0.11	CHEMBL5469	Homo sapiens	Inhibition	%	0.11
	8121614	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	4.23	CHEMBL5469	Homo sapiens	Inhibition	%	4.23
	8121777	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	10.63	CHEMBL5469	Homo sapiens	Inhibition	%	10.63
	8122001	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	7.34	CHEMBL5469	Homo sapiens	Inhibition	%	7.34
	8122122	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	5.81	CHEMBL5469	Homo sapiens	Inhibition	%	5.81
	8122484	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	11.91	CHEMBL5469	Homo sapiens	Inhibition	%	11.91
	8122604	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	5.92	CHEMBL5469	Homo sapiens	Inhibition	%	5.92
	8122828	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	12.06	CHEMBL5469	Homo sapiens	Inhibition	%	12.06
	8122995	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	6.46	CHEMBL5469	Homo sapiens	Inhibition	%	6.46
	8123361	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	2.32	CHEMBL5469	Homo sapiens	Inhibition	%	2.32
	8123639	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	97.96	CHEMBL5469	Homo sapiens	Inhibition	%	97.96
	8123789	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	4.69	CHEMBL5469	Homo sapiens	Inhibition	%	4.69
	8124180	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	-4.12	CHEMBL5469	Homo sapiens	Inhibition	%	-4.12
	8124299	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	1.64	CHEMBL5469	Homo sapiens	Inhibition	%	1.64
	8124662	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	2.42	CHEMBL5469	Homo sapiens	Inhibition	%	2.42
	8124827	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	1.18	CHEMBL5469	Homo sapiens	Inhibition	%	1.18
	8125051	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	-1.26	CHEMBL5469	Homo sapiens	Inhibition	%	-1.26
	8125252	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	-1.83	CHEMBL5469	Homo sapiens	Inhibition	%	-1.83
	8125382	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	-0.35	CHEMBL5469	Homo sapiens	Inhibition	%	-0.35
	8125774	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	-6.94	CHEMBL5469	Homo sapiens	Inhibition	%	-6.94
	8125938	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	20.11	CHEMBL5469	Homo sapiens	Inhibition	%	20.11
	8126326	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	6.52	CHEMBL5469	Homo sapiens	Inhibition	%	6.52
	8126441	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	-2.3	CHEMBL5469	Homo sapiens	Inhibition	%	-2.3
	8126665	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	18.6	CHEMBL5469	Homo sapiens	Inhibition	%	18.6
	8126801	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	7.28	CHEMBL5469	Homo sapiens	Inhibition	%	7.28
	8127147	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	3.19	CHEMBL5469	Homo sapiens	Inhibition	%	3.19
	8127314	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	14.44	CHEMBL5469	Homo sapiens	Inhibition	%	14.44
	8127680	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	19.35	CHEMBL5469	Homo sapiens	Inhibition	%	19.35
	8127968	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	5.25	CHEMBL5469	Homo sapiens	Inhibition	%	5.25
	8128120	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	14.24	CHEMBL5469	Homo sapiens	Inhibition	%	14.24
	8128511	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	10.54	CHEMBL5469	Homo sapiens	Inhibition	%	10.54
	8128630	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	28.54	CHEMBL5469	Homo sapiens	Inhibition	%	28.54
	8128854	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	86.62	CHEMBL5469	Homo sapiens	Inhibition	%	86.62
	8128991	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	0.55	CHEMBL5469	Homo sapiens	Inhibition	%	0.55
	8129386	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	-7.75	CHEMBL5469	Homo sapiens	Inhibition	%	-7.75
	8129575	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	2.07	CHEMBL5469	Homo sapiens	Inhibition	%	2.07
	8129714	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	1.2	CHEMBL5469	Homo sapiens	Inhibition	%	1.2
	8129938	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	1.77	CHEMBL5469	Homo sapiens	Inhibition	%	1.77
	8130099	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	-0.29	CHEMBL5469	Homo sapiens	Inhibition	%	-0.29
	8130271	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	-2.3	CHEMBL5469	Homo sapiens	Inhibition	%	-2.3
	8130495	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	1.39	CHEMBL5469	Homo sapiens	Inhibition	%	1.39
	8130655	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	24.8	CHEMBL5469	Homo sapiens	Inhibition	%	24.8
	8130995	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	0.08	CHEMBL5469	Homo sapiens	Inhibition	%	0.08
	8131134	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	43.63	CHEMBL5469	Homo sapiens	Inhibition	%	43.63
	8131478	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	6.71	CHEMBL5469	Homo sapiens	Inhibition	%	6.71
	8131645	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	11.01	CHEMBL5469	Homo sapiens	Inhibition	%	11.01
	8131869	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	22.91	CHEMBL5469	Homo sapiens	Inhibition	%	22.91
	8132010	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	8.39	CHEMBL5469	Homo sapiens	Inhibition	%	8.39
	8132296	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	6.67	CHEMBL5469	Homo sapiens	Inhibition	%	6.67
	8132443	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	5.04	CHEMBL5469	Homo sapiens	Inhibition	%	5.04
	8132667	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	3.05	CHEMBL5469	Homo sapiens	Inhibition	%	3.05
	8132835	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	-1.7	CHEMBL5469	Homo sapiens	Inhibition	%	-1.7
	8133180	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	-4.51	CHEMBL5469	Homo sapiens	Inhibition	%	-4.51
	8133318	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	5.27	CHEMBL5469	Homo sapiens	Inhibition	%	5.27
	8133714	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	0.57	CHEMBL5469	Homo sapiens	Inhibition	%	0.57
	8133894	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	29.22	CHEMBL5469	Homo sapiens	Inhibition	%	29.22
	8134266	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	-4.88	CHEMBL5469	Homo sapiens	Inhibition	%	-4.88
	8134426	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	2.94	CHEMBL5469	Homo sapiens	Inhibition	%	2.94
	8134834	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	-3.21	CHEMBL5469	Homo sapiens	Inhibition	%	-3.21
	8134994	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	81.34	CHEMBL5469	Homo sapiens	Inhibition	%	81.34
	8135333	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	2.41	CHEMBL5469	Homo sapiens	Inhibition	%	2.41
	8135474	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	3.75	CHEMBL5469	Homo sapiens	Inhibition	%	3.75
	8135698	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	5.59	CHEMBL5469	Homo sapiens	Inhibition	%	5.59
	8135819	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	-0.55	CHEMBL5469	Homo sapiens	Inhibition	%	-0.55
	8136211	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	1.0	CHEMBL5469	Homo sapiens	Inhibition	%	1.0
	8136355	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	32.31	CHEMBL5469	Homo sapiens	Inhibition	%	32.31
	8136645	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	14.66	CHEMBL5469	Homo sapiens	Inhibition	%	14.66
	8137004	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	6.27	CHEMBL5469	Homo sapiens	Inhibition	%	6.27
	8137167	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	-0.21	CHEMBL5469	Homo sapiens	Inhibition	%	-0.21
	8137511	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	2.8	CHEMBL5469	Homo sapiens	Inhibition	%	2.8
	8137659	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	2.01	CHEMBL5469	Homo sapiens	Inhibition	%	2.01
	8137883	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	2.8	CHEMBL5469	Homo sapiens	Inhibition	%	2.8
	8138049	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2	Outside typical range	CHEMBL234838	=	Inhibition	%	-10.61	CHEMBL5469	Homo sapiens	Inhibition	%	-10.61
	8138228	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	88.56	CHEMBL5469	Homo sapiens	Inhibition	%	88.56
	8138452	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	-1.25	CHEMBL5469	Homo sapiens	Inhibition	%	-1.25
	8138600	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	8.21	CHEMBL5469	Homo sapiens	Inhibition	%	8.21
	8138758	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	0.3	CHEMBL5469	Homo sapiens	Inhibition	%	0.3
	8138982	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	-0.07	CHEMBL5469	Homo sapiens	Inhibition	%	-0.07
	8139167	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	20.14	CHEMBL5469	Homo sapiens	Inhibition	%	20.14
	8139326	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	3.75	CHEMBL5469	Homo sapiens	Inhibition	%	3.75
	8139550	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	13.32	CHEMBL5469	Homo sapiens	Inhibition	%	13.32
	8139664	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	8.29	CHEMBL5469	Homo sapiens	Inhibition	%	8.29
	8140029	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	4.76	CHEMBL5469	Homo sapiens	Inhibition	%	4.76
	8140152	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	8.01	CHEMBL5469	Homo sapiens	Inhibition	%	8.01
	8140376	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	-0.54	CHEMBL5469	Homo sapiens	Inhibition	%	-0.54
	8140535	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	10.21	CHEMBL5469	Homo sapiens	Inhibition	%	10.21
	8140678	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	7.0	CHEMBL5469	Homo sapiens	Inhibition	%	7.0
	8140902	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	9.57	CHEMBL5469	Homo sapiens	Inhibition	%	9.57
	8140980	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	45.84	CHEMBL5469	Homo sapiens	Inhibition	%	45.84
	8141204	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	59.71	CHEMBL5469	Homo sapiens	Inhibition	%	59.71
	8141334	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	8.74	CHEMBL5469	Homo sapiens	Inhibition	%	8.74
	8141494	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	2.47	CHEMBL5469	Homo sapiens	Inhibition	%	2.47
	8141718	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	12.24	CHEMBL5469	Homo sapiens	Inhibition	%	12.24
	8141837	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	-2.5	CHEMBL5469	Homo sapiens	Inhibition	%	-2.5
	8142222	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	-3.39	CHEMBL5469	Homo sapiens	Inhibition	%	-3.39
	8142390	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	-8.67	CHEMBL5469	Homo sapiens	Inhibition	%	-8.67
	8142790	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	2.41	CHEMBL5469	Homo sapiens	Inhibition	%	2.41
	8142939	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	-7.76	CHEMBL5469	Homo sapiens	Inhibition	%	-7.76
	8143318	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	-4.77	CHEMBL5469	Homo sapiens	Inhibition	%	-4.77
	8143505	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	5.41	CHEMBL5469	Homo sapiens	Inhibition	%	5.41
	8143888	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	16.51	CHEMBL5469	Homo sapiens	Inhibition	%	16.51
	8144002	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	7.02	CHEMBL5469	Homo sapiens	Inhibition	%	7.02
	8144226	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	3.86	CHEMBL5469	Homo sapiens	Inhibition	%	3.86
	8144365	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	11.7	CHEMBL5469	Homo sapiens	Inhibition	%	11.7
	8144719	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	7.42	CHEMBL5469	Homo sapiens	Inhibition	%	7.42
	8144872	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	2.65	CHEMBL5469	Homo sapiens	Inhibition	%	2.65
	8145233	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	5.1	CHEMBL5469	Homo sapiens	Inhibition	%	5.1
	8145546	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	89.96	CHEMBL5469	Homo sapiens	Inhibition	%	89.96
	8145670	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	1.43	CHEMBL5469	Homo sapiens	Inhibition	%	1.43
	8146055	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	55.07	CHEMBL5469	Homo sapiens	Inhibition	%	55.07
	8146175	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	-2.35	CHEMBL5469	Homo sapiens	Inhibition	%	-2.35
	8146399	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	2.56	CHEMBL5469	Homo sapiens	Inhibition	%	2.56
	8146559	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	10.22	CHEMBL5469	Homo sapiens	Inhibition	%	10.22
	8146726	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	-2.32	CHEMBL5469	Homo sapiens	Inhibition	%	-2.32
	8146950	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	6.22	CHEMBL5469	Homo sapiens	Inhibition	%	6.22
	8147119	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	-4.15	CHEMBL5469	Homo sapiens	Inhibition	%	-4.15
	8147261	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1	Outside typical range	CHEMBL477979	=	Inhibition	%	-10.5	CHEMBL5469	Homo sapiens	Inhibition	%	-10.5
	8147485	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	-1.0	CHEMBL5469	Homo sapiens	Inhibition	%	-1.0
	8147638	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	0.23	CHEMBL5469	Homo sapiens	Inhibition	%	0.23
	8147825	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	3.05	CHEMBL5469	Homo sapiens	Inhibition	%	3.05
	8148049	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	3.82	CHEMBL5469	Homo sapiens	Inhibition	%	3.82
	8148207	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	59.47	CHEMBL5469	Homo sapiens	Inhibition	%	59.47
	8148545	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	10.1	CHEMBL5469	Homo sapiens	Inhibition	%	10.1
	8148684	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	6.1	CHEMBL5469	Homo sapiens	Inhibition	%	6.1
	8149046	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	-0.03	CHEMBL5469	Homo sapiens	Inhibition	%	-0.03
	8149205	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	7.64	CHEMBL5469	Homo sapiens	Inhibition	%	7.64
	8149429	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	3.85	CHEMBL5469	Homo sapiens	Inhibition	%	3.85
	8149563	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	12.86	CHEMBL5469	Homo sapiens	Inhibition	%	12.86
	8149885	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	10.71	CHEMBL5469	Homo sapiens	Inhibition	%	10.71
	8150010	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	0.04	CHEMBL5469	Homo sapiens	Inhibition	%	0.04
	8150234	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	0.95	CHEMBL5469	Homo sapiens	Inhibition	%	0.95
	8150394	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	29.68	CHEMBL5469	Homo sapiens	Inhibition	%	29.68
	8150738	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	0.15	CHEMBL5469	Homo sapiens	Inhibition	%	0.15
	8150903	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	77.78	CHEMBL5469	Homo sapiens	Inhibition	%	77.78
	8151290	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	-4.62	CHEMBL5469	Homo sapiens	Inhibition	%	-4.62
	8151467	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	6.02	CHEMBL5469	Homo sapiens	Inhibition	%	6.02
	8151829	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	7.77	CHEMBL5469	Homo sapiens	Inhibition	%	7.77
	8151983	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	6.13	CHEMBL5469	Homo sapiens	Inhibition	%	6.13
	8152395	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	13.75	CHEMBL5469	Homo sapiens	Inhibition	%	13.75
	8152553	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	10.43	CHEMBL5469	Homo sapiens	Inhibition	%	10.43
	8152891	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	4.0	CHEMBL5469	Homo sapiens	Inhibition	%	4.0
	8153030	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	10.26	CHEMBL5469	Homo sapiens	Inhibition	%	10.26
	8153254	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	8.63	CHEMBL5469	Homo sapiens	Inhibition	%	8.63
	8153391	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	10.9	CHEMBL5469	Homo sapiens	Inhibition	%	10.9
	8153772	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	9.33	CHEMBL5469	Homo sapiens	Inhibition	%	9.33
	8153905	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	4.6	CHEMBL5469	Homo sapiens	Inhibition	%	4.6
	8154226	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	6.54	CHEMBL5469	Homo sapiens	Inhibition	%	6.54
	8154576	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	12.9	CHEMBL5469	Homo sapiens	Inhibition	%	12.9
	8154735	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	-0.72	CHEMBL5469	Homo sapiens	Inhibition	%	-0.72
	8155079	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	-1.1	CHEMBL5469	Homo sapiens	Inhibition	%	-1.1
	8155255	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	95.56	CHEMBL5469	Homo sapiens	Inhibition	%	95.56
	8155640	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	-8.03	CHEMBL5469	Homo sapiens	Inhibition	%	-8.03
	8155818	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	-3.19	CHEMBL5469	Homo sapiens	Inhibition	%	-3.19
	8156180	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	-2.0	CHEMBL5469	Homo sapiens	Inhibition	%	-2.0
	8156392	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	14.25	CHEMBL5469	Homo sapiens	Inhibition	%	14.25
	8156766	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	8.24	CHEMBL5469	Homo sapiens	Inhibition	%	8.24
	8156909	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	10.61	CHEMBL5469	Homo sapiens	Inhibition	%	10.61
	8157253	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	10.79	CHEMBL5469	Homo sapiens	Inhibition	%	10.79
	8157618	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	11.81	CHEMBL5469	Homo sapiens	Inhibition	%	11.81
	8157748	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	14.21	CHEMBL5469	Homo sapiens	Inhibition	%	14.21
	8158133	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	-2.43	CHEMBL5469	Homo sapiens	Inhibition	%	-2.43
	8158383	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	12.42	CHEMBL5469	Homo sapiens	Inhibition	%	12.42
	8158541	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	12.2	CHEMBL5469	Homo sapiens	Inhibition	%	12.2
	8158765	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	9.43	CHEMBL5469	Homo sapiens	Inhibition	%	9.43
	8158934	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	9.57	CHEMBL5469	Homo sapiens	Inhibition	%	9.57
	8159069	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	10.04	CHEMBL5469	Homo sapiens	Inhibition	%	10.04
	8159293	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	12.3	CHEMBL5469	Homo sapiens	Inhibition	%	12.3
	8159413	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	9.35	CHEMBL5469	Homo sapiens	Inhibition	%	9.35
	8159768	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	12.28	CHEMBL5469	Homo sapiens	Inhibition	%	12.28
	8159909	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	5.1	CHEMBL5469	Homo sapiens	Inhibition	%	5.1
	8160133	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	6.96	CHEMBL5469	Homo sapiens	Inhibition	%	6.96
	8160270	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	9.37	CHEMBL5469	Homo sapiens	Inhibition	%	9.37
	8160420	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	3.63	CHEMBL5469	Homo sapiens	Inhibition	%	3.63
	8160644	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	-2.8	CHEMBL5469	Homo sapiens	Inhibition	%	-2.8
	8160714	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	9.96	CHEMBL5469	Homo sapiens	Inhibition	%	9.96
	8160938	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	10.25	CHEMBL5469	Homo sapiens	Inhibition	%	10.25
	8161088	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	11.22	CHEMBL5469	Homo sapiens	Inhibition	%	11.22
	8161231	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	19.81	CHEMBL5469	Homo sapiens	Inhibition	%	19.81
	8161455	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	32.59	CHEMBL5469	Homo sapiens	Inhibition	%	32.59
	8161580	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	5.14	CHEMBL5469	Homo sapiens	Inhibition	%	5.14
	8161942	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	39.63	CHEMBL5469	Homo sapiens	Inhibition	%	39.63
	8162072	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	1.5	CHEMBL5469	Homo sapiens	Inhibition	%	1.5
	8162296	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	13.13	CHEMBL5469	Homo sapiens	Inhibition	%	13.13
	8162456	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	6.22	CHEMBL5469	Homo sapiens	Inhibition	%	6.22
	8162709	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	10.83	CHEMBL5469	Homo sapiens	Inhibition	%	10.83
	8163081	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	21.75	CHEMBL5469	Homo sapiens	Inhibition	%	21.75
	8163250	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	10.31	CHEMBL5469	Homo sapiens	Inhibition	%	10.31
	8163608	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	16.82	CHEMBL5469	Homo sapiens	Inhibition	%	16.82
	8163731	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	10.74	CHEMBL5469	Homo sapiens	Inhibition	%	10.74
	8163955	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	4.18	CHEMBL5469	Homo sapiens	Inhibition	%	4.18
	8164089	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	96.04	CHEMBL5469	Homo sapiens	Inhibition	%	96.04
	8164453	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	4.26	CHEMBL5469	Homo sapiens	Inhibition	%	4.26
	8164608	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	14.27	CHEMBL5469	Homo sapiens	Inhibition	%	14.27
	8164976	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	2.44	CHEMBL5469	Homo sapiens	Inhibition	%	2.44
	8165270	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	37.78	CHEMBL5469	Homo sapiens	Inhibition	%	37.78
	8165411	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	57.84	CHEMBL5469	Homo sapiens	Inhibition	%	57.84
	8165778	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	84.58	CHEMBL5469	Homo sapiens	Inhibition	%	84.58
	8165904	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	5.7	CHEMBL5469	Homo sapiens	Inhibition	%	5.7
	8166128	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	8.51	CHEMBL5469	Homo sapiens	Inhibition	%	8.51
	8166266	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	7.64	CHEMBL5469	Homo sapiens	Inhibition	%	7.64
	8166620	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	7.31	CHEMBL5469	Homo sapiens	Inhibition	%	7.31
	8166721	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	25.18	CHEMBL5469	Homo sapiens	Inhibition	%	25.18
	8166945	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	84.35	CHEMBL5469	Homo sapiens	Inhibition	%	84.35
	8167033	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	7.69	CHEMBL5469	Homo sapiens	Inhibition	%	7.69
	8167398	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	66.79	CHEMBL5469	Homo sapiens	Inhibition	%	66.79
	8167562	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	2.95	CHEMBL5469	Homo sapiens	Inhibition	%	2.95
	8167919	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	19.36	CHEMBL5469	Homo sapiens	Inhibition	%	19.36
	8168267	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	10.14	CHEMBL5469	Homo sapiens	Inhibition	%	10.14
	8168408	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	97.69	CHEMBL5469	Homo sapiens	Inhibition	%	97.69
	8168768	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	3.23	CHEMBL5469	Homo sapiens	Inhibition	%	3.23
	8168932	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	21.57	CHEMBL5469	Homo sapiens	Inhibition	%	21.57
	8169298	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	9.87	CHEMBL5469	Homo sapiens	Inhibition	%	9.87
	8169602	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	95.7	CHEMBL5469	Homo sapiens	Inhibition	%	95.7
	8169736	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	10.14	CHEMBL5469	Homo sapiens	Inhibition	%	10.14
	8169960	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	12.98	CHEMBL5469	Homo sapiens	Inhibition	%	12.98
	8170105	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	8.32	CHEMBL5469	Homo sapiens	Inhibition	%	8.32
	8170454	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	3.22	CHEMBL5469	Homo sapiens	Inhibition	%	3.22
	8170594	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	12.55	CHEMBL5469	Homo sapiens	Inhibition	%	12.55
	8170953	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	14.22	CHEMBL5469	Homo sapiens	Inhibition	%	14.22
	8171150	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	7.87	CHEMBL5469	Homo sapiens	Inhibition	%	7.87
	8171367	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	4.56	CHEMBL5469	Homo sapiens	Inhibition	%	4.56
	8171591	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	13.0	CHEMBL5469	Homo sapiens	Inhibition	%	13.0
	8171732	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	88.33	CHEMBL5469	Homo sapiens	Inhibition	%	88.33
	8171885	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	5.82	CHEMBL5469	Homo sapiens	Inhibition	%	5.82
	8172109	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	9.51	CHEMBL5469	Homo sapiens	Inhibition	%	9.51
	8172241	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	13.61	CHEMBL5469	Homo sapiens	Inhibition	%	13.61
	8172593	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	8.37	CHEMBL5469	Homo sapiens	Inhibition	%	8.37
	8172735	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	17.06	CHEMBL5469	Homo sapiens	Inhibition	%	17.06
	8172959	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	12.24	CHEMBL5469	Homo sapiens	Inhibition	%	12.24
	8173095	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	-7.23	CHEMBL5469	Homo sapiens	Inhibition	%	-7.23
	8173260	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	71.04	CHEMBL5469	Homo sapiens	Inhibition	%	71.04
	8173484	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	11.47	CHEMBL5469	Homo sapiens	Inhibition	%	11.47
	8173625	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	8.59	CHEMBL5469	Homo sapiens	Inhibition	%	8.59
	8173936	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	12.77	CHEMBL5469	Homo sapiens	Inhibition	%	12.77
	8174292	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	9.3	CHEMBL5469	Homo sapiens	Inhibition	%	9.3
	8174440	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	19.37	CHEMBL5469	Homo sapiens	Inhibition	%	19.37
	8174786	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	9.89	CHEMBL5469	Homo sapiens	Inhibition	%	9.89
	8174929	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	9.34	CHEMBL5469	Homo sapiens	Inhibition	%	9.34
	8175153	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	29.72	CHEMBL5469	Homo sapiens	Inhibition	%	29.72
	8175289	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	11.98	CHEMBL5469	Homo sapiens	Inhibition	%	11.98
	8175545	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	11.68	CHEMBL5469	Homo sapiens	Inhibition	%	11.68
	8175932	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	9.35	CHEMBL5469	Homo sapiens	Inhibition	%	9.35
	8176085	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	96.74	CHEMBL5469	Homo sapiens	Inhibition	%	96.74
	8176458	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	9.99	CHEMBL5469	Homo sapiens	Inhibition	%	9.99
	8176590	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	20.56	CHEMBL5469	Homo sapiens	Inhibition	%	20.56
	8176814	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	46.42	CHEMBL5469	Homo sapiens	Inhibition	%	46.42
	8176944	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	2.99	CHEMBL5469	Homo sapiens	Inhibition	%	2.99
	8177310	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	12.83	CHEMBL5469	Homo sapiens	Inhibition	%	12.83
	8177448	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	5.72	CHEMBL5469	Homo sapiens	Inhibition	%	5.72
	8177836	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	16.46	CHEMBL5469	Homo sapiens	Inhibition	%	16.46
	8177976	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	9.77	CHEMBL5469	Homo sapiens	Inhibition	%	9.77
	8178200	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	9.16	CHEMBL5469	Homo sapiens	Inhibition	%	9.16
	8178288	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	24.18	CHEMBL5469	Homo sapiens	Inhibition	%	24.18
	8178639	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	10.06	CHEMBL5469	Homo sapiens	Inhibition	%	10.06
	8178788	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	1.01	CHEMBL5469	Homo sapiens	Inhibition	%	1.01
	8179012	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	8.49	CHEMBL5469	Homo sapiens	Inhibition	%	8.49
	8179135	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	9.03	CHEMBL5469	Homo sapiens	Inhibition	%	9.03
	8179503	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	3.79	CHEMBL5469	Homo sapiens	Inhibition	%	3.79
	8179640	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	45.83	CHEMBL5469	Homo sapiens	Inhibition	%	45.83
	8179897	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	24.68	CHEMBL5469	Homo sapiens	Inhibition	%	24.68
	8180121	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	13.34	CHEMBL5469	Homo sapiens	Inhibition	%	13.34
	8180275	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	17.83	CHEMBL5469	Homo sapiens	Inhibition	%	17.83
	8180431	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	11.25	CHEMBL5469	Homo sapiens	Inhibition	%	11.25
	8180655	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	9.24	CHEMBL5469	Homo sapiens	Inhibition	%	9.24
	8180803	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	8.05	CHEMBL5469	Homo sapiens	Inhibition	%	8.05
	8181160	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	15.72	CHEMBL5469	Homo sapiens	Inhibition	%	15.72
	8181291	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	3.76	CHEMBL5469	Homo sapiens	Inhibition	%	3.76
	8181655	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	12.08	CHEMBL5469	Homo sapiens	Inhibition	%	12.08
	8181794	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	29.47	CHEMBL5469	Homo sapiens	Inhibition	%	29.47
	8182018	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	80.56	CHEMBL5469	Homo sapiens	Inhibition	%	80.56
	8182181	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	10.01	CHEMBL5469	Homo sapiens	Inhibition	%	10.01
	8182545	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	4.12	CHEMBL5469	Homo sapiens	Inhibition	%	4.12
	8182637	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	6.18	CHEMBL5469	Homo sapiens	Inhibition	%	6.18
	8182861	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	3.98	CHEMBL5469	Homo sapiens	Inhibition	%	3.98
	8182983	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	8.88	CHEMBL5469	Homo sapiens	Inhibition	%	8.88
	8183356	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	6.52	CHEMBL5469	Homo sapiens	Inhibition	%	6.52
	8183485	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	7.74	CHEMBL5469	Homo sapiens	Inhibition	%	7.74
	8183709	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	2.83	CHEMBL5469	Homo sapiens	Inhibition	%	2.83
	8183851	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	8.61	CHEMBL5469	Homo sapiens	Inhibition	%	8.61
	8183987	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	3.28	CHEMBL5469	Homo sapiens	Inhibition	%	3.28
	8184211	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	-1.09	CHEMBL5469	Homo sapiens	Inhibition	%	-1.09
	8184477	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	15.19	CHEMBL5469	Homo sapiens	Inhibition	%	15.19
	8184624	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	7.86	CHEMBL5469	Homo sapiens	Inhibition	%	7.86
	8185005	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	16.45	CHEMBL5469	Homo sapiens	Inhibition	%	16.45
	8185154	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	31.68	CHEMBL5469	Homo sapiens	Inhibition	%	31.68
	8185509	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	41.3	CHEMBL5469	Homo sapiens	Inhibition	%	41.3
	8185640	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	-1.67	CHEMBL5469	Homo sapiens	Inhibition	%	-1.67
	8185864	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	17.83	CHEMBL5469	Homo sapiens	Inhibition	%	17.83
	8186003	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	11.33	CHEMBL5469	Homo sapiens	Inhibition	%	11.33
	8186368	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	6.54	CHEMBL5469	Homo sapiens	Inhibition	%	6.54
	8186532	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	14.29	CHEMBL5469	Homo sapiens	Inhibition	%	14.29
	8186895	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	9.36	CHEMBL5469	Homo sapiens	Inhibition	%	9.36
	8187217	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	8.94	CHEMBL5469	Homo sapiens	Inhibition	%	8.94
	8187341	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	13.6	CHEMBL5469	Homo sapiens	Inhibition	%	13.6
	8187565	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	14.36	CHEMBL5469	Homo sapiens	Inhibition	%	14.36
	8187713	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	10.95	CHEMBL5469	Homo sapiens	Inhibition	%	10.95
	8188066	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	1.96	CHEMBL5469	Homo sapiens	Inhibition	%	1.96
	8188209	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	6.41	CHEMBL5469	Homo sapiens	Inhibition	%	6.41
	8188568	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	3.04	CHEMBL5469	Homo sapiens	Inhibition	%	3.04
	8188842	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	10.55	CHEMBL5469	Homo sapiens	Inhibition	%	10.55
	8188990	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	11.51	CHEMBL5469	Homo sapiens	Inhibition	%	11.51
	8189214	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	8.31	CHEMBL5469	Homo sapiens	Inhibition	%	8.31
	8189370	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	44.0	CHEMBL5469	Homo sapiens	Inhibition	%	44.0
	8189519	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	3.96	CHEMBL5469	Homo sapiens	Inhibition	%	3.96
	8189743	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	0.92	CHEMBL5469	Homo sapiens	Inhibition	%	0.92
	8189875	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	12.13	CHEMBL5469	Homo sapiens	Inhibition	%	12.13
	8190231	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	15.6	CHEMBL5469	Homo sapiens	Inhibition	%	15.6
	8190371	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	7.93	CHEMBL5469	Homo sapiens	Inhibition	%	7.93
	8190595	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	10.75	CHEMBL5469	Homo sapiens	Inhibition	%	10.75
	8190732	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	17.91	CHEMBL5469	Homo sapiens	Inhibition	%	17.91
	8190896	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	11.65	CHEMBL5469	Homo sapiens	Inhibition	%	11.65
	8191120	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	15.96	CHEMBL5469	Homo sapiens	Inhibition	%	15.96
	8191258	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	18.39	CHEMBL5469	Homo sapiens	Inhibition	%	18.39
	8191578	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	8.75	CHEMBL5469	Homo sapiens	Inhibition	%	8.75
	8191924	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	59.87	CHEMBL5469	Homo sapiens	Inhibition	%	59.87
	8192073	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	4.52	CHEMBL5469	Homo sapiens	Inhibition	%	4.52
	8192426	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	-0.09	CHEMBL5469	Homo sapiens	Inhibition	%	-0.09
	8192570	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	13.96	CHEMBL5469	Homo sapiens	Inhibition	%	13.96
	8192794	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	5.28	CHEMBL5469	Homo sapiens	Inhibition	%	5.28
	8192930	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	5.9	CHEMBL5469	Homo sapiens	Inhibition	%	5.9
	8193202	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	19.63	CHEMBL5469	Homo sapiens	Inhibition	%	19.63
	8193571	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	21.88	CHEMBL5469	Homo sapiens	Inhibition	%	21.88
	8193728	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	14.07	CHEMBL5469	Homo sapiens	Inhibition	%	14.07
	8194101	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	1.2	CHEMBL5469	Homo sapiens	Inhibition	%	1.2
	8194232	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	10.32	CHEMBL5469	Homo sapiens	Inhibition	%	10.32
	8194456	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	12.54	CHEMBL5469	Homo sapiens	Inhibition	%	12.54
	8194587	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	39.1	CHEMBL5469	Homo sapiens	Inhibition	%	39.1
	8194954	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	13.45	CHEMBL5469	Homo sapiens	Inhibition	%	13.45
	8195087	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	6.77	CHEMBL5469	Homo sapiens	Inhibition	%	6.77
	8195475	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	15.02	CHEMBL5469	Homo sapiens	Inhibition	%	15.02
	8195614	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	58.6	CHEMBL5469	Homo sapiens	Inhibition	%	58.6
	8195936	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	6.19	CHEMBL5469	Homo sapiens	Inhibition	%	6.19
	8196277	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	2.62	CHEMBL5469	Homo sapiens	Inhibition	%	2.62
	8196427	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	5.62	CHEMBL5469	Homo sapiens	Inhibition	%	5.62
	8196651	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	15.22	CHEMBL5469	Homo sapiens	Inhibition	%	15.22
	8196779	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	5.83	CHEMBL5469	Homo sapiens	Inhibition	%	5.83
	8197144	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	5.23	CHEMBL5469	Homo sapiens	Inhibition	%	5.23
	8197281	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	4.61	CHEMBL5469	Homo sapiens	Inhibition	%	4.61
	8197556	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	4.56	CHEMBL5469	Homo sapiens	Inhibition	%	4.56
	8197920	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	-1.12	CHEMBL5469	Homo sapiens	Inhibition	%	-1.12
	8198077	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	27.35	CHEMBL5469	Homo sapiens	Inhibition	%	27.35
	8198439	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	-3.88	CHEMBL5469	Homo sapiens	Inhibition	%	-3.88
	8198793	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	18.9	CHEMBL5469	Homo sapiens	Inhibition	%	18.9
	8198924	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	8.33	CHEMBL5469	Homo sapiens	Inhibition	%	8.33
	8199296	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	15.68	CHEMBL5469	Homo sapiens	Inhibition	%	15.68
	8199430	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	18.04	CHEMBL5469	Homo sapiens	Inhibition	%	18.04
	8199654	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	13.92	CHEMBL5469	Homo sapiens	Inhibition	%	13.92
	8199817	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	34.63	CHEMBL5469	Homo sapiens	Inhibition	%	34.63
	8199955	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	11.97	CHEMBL5469	Homo sapiens	Inhibition	%	11.97
	8200179	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	13.09	CHEMBL5469	Homo sapiens	Inhibition	%	13.09
	8200283	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	8.2	CHEMBL5469	Homo sapiens	Inhibition	%	8.2
	8200622	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	13.42	CHEMBL5469	Homo sapiens	Inhibition	%	13.42
	8200996	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	47.53	CHEMBL5469	Homo sapiens	Inhibition	%	47.53
	8201126	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	3.08	CHEMBL5469	Homo sapiens	Inhibition	%	3.08
	8201485	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	7.81	CHEMBL5469	Homo sapiens	Inhibition	%	7.81
	8201618	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	21.16	CHEMBL5469	Homo sapiens	Inhibition	%	21.16
	8201842	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	-4.54	CHEMBL5469	Homo sapiens	Inhibition	%	-4.54
	8201897	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	14.13	CHEMBL5469	Homo sapiens	Inhibition	%	14.13
	8202121	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	9.54	CHEMBL5469	Homo sapiens	Inhibition	%	9.54
	8202261	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	6.28	CHEMBL5469	Homo sapiens	Inhibition	%	6.28
	8202428	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	9.18	CHEMBL5469	Homo sapiens	Inhibition	%	9.18
	8202652	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	6.63	CHEMBL5469	Homo sapiens	Inhibition	%	6.63
	8202777	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	7.36	CHEMBL5469	Homo sapiens	Inhibition	%	7.36
	8203131	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	11.21	CHEMBL5469	Homo sapiens	Inhibition	%	11.21
	8203262	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	7.03	CHEMBL5469	Homo sapiens	Inhibition	%	7.03
	8203486	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	10.87	CHEMBL5469	Homo sapiens	Inhibition	%	10.87
	8203632	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	11.8	CHEMBL5469	Homo sapiens	Inhibition	%	11.8
	8203990	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	15.14	CHEMBL5469	Homo sapiens	Inhibition	%	15.14
	8204156	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	13.17	CHEMBL5469	Homo sapiens	Inhibition	%	13.17
	8204517	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	10.12	CHEMBL5469	Homo sapiens	Inhibition	%	10.12
	8204622	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	7.96	CHEMBL5469	Homo sapiens	Inhibition	%	7.96
	8204846	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	14.74	CHEMBL5469	Homo sapiens	Inhibition	%	14.74
	8204961	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	11.44	CHEMBL5469	Homo sapiens	Inhibition	%	11.44
	8205334	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	15.81	CHEMBL5469	Homo sapiens	Inhibition	%	15.81
	8205470	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	6.94	CHEMBL5469	Homo sapiens	Inhibition	%	6.94
	8205694	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	5.11	CHEMBL5469	Homo sapiens	Inhibition	%	5.11
	8205833	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	13.43	CHEMBL5469	Homo sapiens	Inhibition	%	13.43
	8206189	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	-2.74	CHEMBL5469	Homo sapiens	Inhibition	%	-2.74
	8206465	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	10.37	CHEMBL5469	Homo sapiens	Inhibition	%	10.37
	8206608	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	-1.15	CHEMBL5469	Homo sapiens	Inhibition	%	-1.15
	8207012	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	9.44	CHEMBL5469	Homo sapiens	Inhibition	%	9.44
	8207138	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	19.37	CHEMBL5469	Homo sapiens	Inhibition	%	19.37
	8207362	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	10.36	CHEMBL5469	Homo sapiens	Inhibition	%	10.36
	8207492	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	14.11	CHEMBL5469	Homo sapiens	Inhibition	%	14.11
	8207848	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	39.0	CHEMBL5469	Homo sapiens	Inhibition	%	39.0
	8207993	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	9.94	CHEMBL5469	Homo sapiens	Inhibition	%	9.94
	8208349	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	7.68	CHEMBL5469	Homo sapiens	Inhibition	%	7.68
	8208515	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	7.22	CHEMBL5469	Homo sapiens	Inhibition	%	7.22
	8208739	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	3.97	CHEMBL5469	Homo sapiens	Inhibition	%	3.97
	8208872	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	17.56	CHEMBL5469	Homo sapiens	Inhibition	%	17.56
	8209201	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	7.79	CHEMBL5469	Homo sapiens	Inhibition	%	7.79
	8209317	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	29.71	CHEMBL5469	Homo sapiens	Inhibition	%	29.71
	8209541	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	8.82	CHEMBL5469	Homo sapiens	Inhibition	%	8.82
	8209691	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	15.45	CHEMBL5469	Homo sapiens	Inhibition	%	15.45
	8210051	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	7.29	CHEMBL5469	Homo sapiens	Inhibition	%	7.29
	8210192	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	5.55	CHEMBL5469	Homo sapiens	Inhibition	%	5.55
	8210552	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	-9.91	CHEMBL5469	Homo sapiens	Inhibition	%	-9.91
	8210811	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	6.59	CHEMBL5469	Homo sapiens	Inhibition	%	6.59
	8210955	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	6.43	CHEMBL5469	Homo sapiens	Inhibition	%	6.43
	8211179	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	11.6	CHEMBL5469	Homo sapiens	Inhibition	%	11.6
	8211349	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	4.55	CHEMBL5469	Homo sapiens	Inhibition	%	4.55
	8211696	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	14.5	CHEMBL5469	Homo sapiens	Inhibition	%	14.5
	8211825	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	9.91	CHEMBL5469	Homo sapiens	Inhibition	%	9.91
	8212181	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	6.1	CHEMBL5469	Homo sapiens	Inhibition	%	6.1
	8212322	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	6.44	CHEMBL5469	Homo sapiens	Inhibition	%	6.44
	8212546	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	9.12	CHEMBL5469	Homo sapiens	Inhibition	%	9.12
	8212679	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	13.93	CHEMBL5469	Homo sapiens	Inhibition	%	13.93
	8213073	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	7.64	CHEMBL5469	Homo sapiens	Inhibition	%	7.64
	8213202	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	9.52	CHEMBL5469	Homo sapiens	Inhibition	%	9.52
	8213530	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	0.8	CHEMBL5469	Homo sapiens	Inhibition	%	0.8
	8213867	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	12.15	CHEMBL5469	Homo sapiens	Inhibition	%	12.15
	8214014	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	6.65	CHEMBL5469	Homo sapiens	Inhibition	%	6.65
	8214375	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	10.34	CHEMBL5469	Homo sapiens	Inhibition	%	10.34
	8214509	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	9.67	CHEMBL5469	Homo sapiens	Inhibition	%	9.67
	8214733	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	9.71	CHEMBL5469	Homo sapiens	Inhibition	%	9.71
	8214885	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O	Outside typical range	CHEMBL2062290	=	Inhibition	%	-14.7	CHEMBL5469	Homo sapiens	Inhibition	%	-14.7
	8215136	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	10.57	CHEMBL5469	Homo sapiens	Inhibition	%	10.57
	8215513	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	10.69	CHEMBL5469	Homo sapiens	Inhibition	%	10.69
	8215677	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	13.21	CHEMBL5469	Homo sapiens	Inhibition	%	13.21
	8216020	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	87.3	CHEMBL5469	Homo sapiens	Inhibition	%	87.3
	8216139	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	18.51	CHEMBL5469	Homo sapiens	Inhibition	%	18.51
	8216363	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	9.64	CHEMBL5469	Homo sapiens	Inhibition	%	9.64
	8216499	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	7.82	CHEMBL5469	Homo sapiens	Inhibition	%	7.82
	8216861	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	9.39	CHEMBL5469	Homo sapiens	Inhibition	%	9.39
	8216995	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	12.31	CHEMBL5469	Homo sapiens	Inhibition	%	12.31
	8217219	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	9.85	CHEMBL5469	Homo sapiens	Inhibition	%	9.85
	8217393	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	6.6	CHEMBL5469	Homo sapiens	Inhibition	%	6.6
	8217524	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	8.23	CHEMBL5469	Homo sapiens	Inhibition	%	8.23
	8217748	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	11.96	CHEMBL5469	Homo sapiens	Inhibition	%	11.96
	8217849	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	-2.28	CHEMBL5469	Homo sapiens	Inhibition	%	-2.28
	8218188	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	5.76	CHEMBL5469	Homo sapiens	Inhibition	%	5.76
	8218315	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	5.61	CHEMBL5469	Homo sapiens	Inhibition	%	5.61
	8218539	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	5.72	CHEMBL5469	Homo sapiens	Inhibition	%	5.72
	8218682	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	32.25	CHEMBL5469	Homo sapiens	Inhibition	%	32.25
	8219037	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	47.76	CHEMBL5469	Homo sapiens	Inhibition	%	47.76
	8219197	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	-9.86	CHEMBL5469	Homo sapiens	Inhibition	%	-9.86
	8219447	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	9.24	CHEMBL5469	Homo sapiens	Inhibition	%	9.24
	8219671	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	8.65	CHEMBL5469	Homo sapiens	Inhibition	%	8.65
	8219832	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	7.72	CHEMBL5469	Homo sapiens	Inhibition	%	7.72
	8220001	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	5.45	CHEMBL5469	Homo sapiens	Inhibition	%	5.45
	8220225	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	10.19	CHEMBL5469	Homo sapiens	Inhibition	%	10.19
	8220354	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	96.55	CHEMBL5469	Homo sapiens	Inhibition	%	96.55
	8220692	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	12.79	CHEMBL5469	Homo sapiens	Inhibition	%	12.79
	8220830	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	18.33	CHEMBL5469	Homo sapiens	Inhibition	%	18.33
	8221054	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	44.0	CHEMBL5469	Homo sapiens	Inhibition	%	44.0
	8221190	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	11.2	CHEMBL5469	Homo sapiens	Inhibition	%	11.2
	8221547	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	90.63	CHEMBL5469	Homo sapiens	Inhibition	%	90.63
	8221712	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	8.05	CHEMBL5469	Homo sapiens	Inhibition	%	8.05
	8222067	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	25.65	CHEMBL5469	Homo sapiens	Inhibition	%	25.65
	8222165	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	3.24	CHEMBL5469	Homo sapiens	Inhibition	%	3.24
	8222389	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	5.43	CHEMBL5469	Homo sapiens	Inhibition	%	5.43
	8222523	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	10.5	CHEMBL5469	Homo sapiens	Inhibition	%	10.5
	8222865	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	12.08	CHEMBL5469	Homo sapiens	Inhibition	%	12.08
	8223009	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	18.8	CHEMBL5469	Homo sapiens	Inhibition	%	18.8
	8223233	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	91.0	CHEMBL5469	Homo sapiens	Inhibition	%	91.0
	8223362	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	5.27	CHEMBL5469	Homo sapiens	Inhibition	%	5.27
	8223523	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	0.28	CHEMBL5469	Homo sapiens	Inhibition	%	0.28
	8223747	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	-3.39	CHEMBL5469	Homo sapiens	Inhibition	%	-3.39
	8223997	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	12.83	CHEMBL5469	Homo sapiens	Inhibition	%	12.83
	8224159	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	11.38	CHEMBL5469	Homo sapiens	Inhibition	%	11.38
	8224553	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	7.47	CHEMBL5469	Homo sapiens	Inhibition	%	7.47
	8224688	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	11.02	CHEMBL5469	Homo sapiens	Inhibition	%	11.02
	8225026	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	5.71	CHEMBL5469	Homo sapiens	Inhibition	%	5.71
	8225384	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	10.66	CHEMBL5469	Homo sapiens	Inhibition	%	10.66
	8225522	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	11.72	CHEMBL5469	Homo sapiens	Inhibition	%	11.72
	8225881	CHEMBL1962159	GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	96.37	CHEMBL5469	Homo sapiens	Inhibition	%	96.37
	8226039	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	0.77	CHEMBL5469	Homo sapiens	Inhibition	%	0.77
	8226388	CHEMBL1962158	GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	8.24	CHEMBL5469	Homo sapiens	Inhibition	%	8.24
inactive	9617710	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1n[nH]c2ccc(-c3cncc(OCCN)c3)cc12		CHEMBL1967887	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617711	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Nc1ncnc2onc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL213505	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617712	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC(=O)c1cccc(-c2cnc3[nH]ccc3c2)c1		CHEMBL2000568	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617713	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1ccc(NC(=O)Nc2ccc(-c3csc4ncnc(N)c34)cc2)cc1C		CHEMBL2000335	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9617714	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	=	Ki	nM	3.162	CHEMBL5469	Homo sapiens	pKi		8.5
active	9617715	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cn1cc(-c2cnn3c(N)c(-c4ccc(NC(=O)Nc5cccc(C(F)(F)F)c5)cc4)cnc23)cn1		CHEMBL1988717	=	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9617716	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	N#CCOc1ccc(Nc2nc(Nc3cccc(S(N)(=O)=O)c3)ncc2Br)cc1		CHEMBL1987034	=	Ki	nM	10.0	CHEMBL5469	Homo sapiens	pKi		8.0
active	9617717	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCCn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1993941	=	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617718	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1Cl		CHEMBL377383	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9617719	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12		CHEMBL2005886	=	Ki	nM	25.12	CHEMBL5469	Homo sapiens	pKi		7.6
inactive	9617720	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C(Nc1ccc2[nH]ncc2c1)c1ccc(Cl)cc1		CHEMBL1973808	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617721	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC(C)Oc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL2000429	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617722	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL481491	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617723	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC(=O)Nc1c(C(N)=O)sc2ccc(Cl)c(Cl)c12		CHEMBL1973142	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617724	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1ccc(NC(=O)Nc2ccc(NC(=O)c3csc4ncnc(N)c34)cc2)cc1		CHEMBL1972576	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617725	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	NCC(NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1		CHEMBL1990254	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617726	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4nc(N)nc(N)c34)cc2)c1		CHEMBL1973145	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617727	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1cccc(C(=O)Nc2cnc3[nH]cc(-c4ccccc4)c3c2)c1		CHEMBL1982924	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617728	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1		CHEMBL1992342	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617729	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCCC(=O)Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3-c3ccccc3)cc12		CHEMBL2005936	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9617730	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cc(Cl)ccc1NC(=S)NNC(=O)C(O)(c1ccccc1)c1ccccc1		CHEMBL1988173	=	Ki	nM	1000.0	CHEMBL5469	Homo sapiens	pKi		6.0
inactive	9617731	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc(C(N)=O)c3)cc2)c1		CHEMBL1971141	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617732	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	N#CC1=C(N)n2c(sc(=Cc3ccco3)c2=O)=C(C(N)=O)C1c1ccco1		CHEMBL1989805	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617733	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	NC(COCc1ccccc1)COc1cncc(C=Cc2ccncc2)c1		CHEMBL1993781	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617734	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC(C)Cn1c(N)nc2ccc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc21		CHEMBL1965423	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617735	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(OCC(F)(F)F)nccn23)n1		CHEMBL2001957	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617736	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COCCNc1nccc(-c2c(-c3ccc(F)cc3)nc3cnccn23)n1		CHEMBL1969372	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617737	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCC(N)(C#Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12)CC		CHEMBL1983025	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617738	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	NC(Cc1c[nH]c2ccccc12)C(=O)Nc1cncc(C=Cc2ccncc2)c1		CHEMBL1983945	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617739	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C(NCc1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1977135	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617740	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C1NC(=S)SC1=C1C(=O)Nc2ccc(Br)cc21		CHEMBL2001920	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617741	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1nc2ccc(NS(=O)(=O)c3ccc(N)cc3)cc2nc1C		CHEMBL2006263	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9617742	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1cc(Nc2ncc([N+](=O)[O-])c(Nc3ccccc3C(N)=O)n2)cc(OC)c1OC		CHEMBL1241473	=	Ki	nM	7.943	CHEMBL5469	Homo sapiens	pKi		8.1
inactive	9617743	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	OC(COc1cncc(C=Cc2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL1993584	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617744	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCn1c(C)c(-c2ccnc(Nc3cccc(OC)c3)n2)sc1=O		CHEMBL1986263	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617745	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CSc1c[nH]c2ncnc(NCCCO)c12		CHEMBL2000114	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617746	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCN(CC)CC#Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL2001257	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617747	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9617748	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1ccccc1-c1c(C(=O)O)n(CCCOc2cccc3ccccc23)c2ccccc12		CHEMBL1987793	=	Ki	nM	1000.0	CHEMBL5469	Homo sapiens	pKi		6.0
inactive	9617749	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C(Nc1cnccn1)Nc1ccnc2c(F)cccc12		CHEMBL1975647	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617750	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1ccc(CNc2c(Nc3ccc4[nH]ncc4c3)c(=O)c2=O)cc1		CHEMBL1992536	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9617751	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCC1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL1968380	=	Ki	nM	630.96	CHEMBL5469	Homo sapiens	pKi		6.2
inactive	9617752	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C(NCc1ccccc1)Nc1ncc([N+](=O)[O-])s1		CHEMBL1964644	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617753	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C(NCc1ccc(Cl)c(Cl)c1)Nc1ccc2[nH]ncc2c1		CHEMBL1981782	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617754	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCN1CCN(CCCC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1		CHEMBL1992740	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617755	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CNC(=O)c1cc2c(-c3ccccc3F)n[nH]c2s1		CHEMBL1977681	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617756	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CNC(=O)C(C)n1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5ccc(C)cc5)cc4)csc23)cn1		CHEMBL1970142	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617757	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	OCCNc1cc2cc(-c3cccnc3)ccc2cn1		CHEMBL1990912	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617758	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	OCCCn1cnc(-c2ccccc2)c1-c1ccncc1		CHEMBL2002373	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617759	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617760	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Nc1ncnc2scc(-c3ccc(NC(=O)Nc4ccccc4)cc3)c12		CHEMBL1967531	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617761	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCCC(=O)Nc1nn(C(=O)CC)c2nc3ccccc3cc12		CHEMBL1970913	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617762	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(NC(C)=O)c3c2)cc1		CHEMBL1973893	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617763	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9617764	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	NC(=O)Cn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL1985095	=	Ki	nM	1000.0	CHEMBL5469	Homo sapiens	pKi		6.0
inactive	9617765	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1996500	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617766	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C1CCCc2oc3cc(C(F)(F)F)ccc3c(=O)c21		CHEMBL2006493	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9617767	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)O)c5)cnc(N)c34)cc2)c1		CHEMBL1989708	=	Ki	nM	158.49	CHEMBL5469	Homo sapiens	pKi		6.8
inactive	9617768	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	c1cnc2nc(-c3ccc4[nH]ncc4c3)cn2c1		CHEMBL1682540	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617769	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1ccc(CNc2c(Nc3ccncc3)c(=O)c2=O)cc1C		CHEMBL1983449	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617770	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=c1[nH]cnc2c1oc1ccc(Cl)cc12		CHEMBL1992323	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617771	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(Cl)nccn23)n1		CHEMBL1969735	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617772	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1ccc2c(c1)C(=Cc1c[nH]cn1)C(=O)N2		CHEMBL2002649	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617773	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1ccc(CNc2c(Nc3ccncc3)c(=O)c2=O)cc1		CHEMBL1994864	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617774	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CN1CCN(Cc2ccc3c(c2)Cc2c(-c4csc(C#CCOCC5CC5)c4)n[nH]c2-3)CC1		CHEMBL2002446	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617775	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=c1nc(-c2cc3c(Oc4ccc(I)cc4)cncc3s2)[nH]o1		CHEMBL497151	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617776	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	NCC1CCC(CNc2nc(NCc3ccccc3Cl)ncc2[N+](=O)[O-])CC1		CHEMBL246970	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9617777	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCNS(C)(=O)=O)cnc(N)c34)cc2)c1		CHEMBL1994321	=	Ki	nM	1000.0	CHEMBL5469	Homo sapiens	pKi		6.0
active	9617778	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cc(O)ccc1-n1cc(C(N)=O)c(=O)c2ccc(-c3ccncc3)cc21		CHEMBL340921	=	Ki	nM	1000.0	CHEMBL5469	Homo sapiens	pKi		6.0
active	9617779	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C1NCCc2[nH]c(-c3ccnc(C=Cc4ccccc4)c3)cc21		CHEMBL1997129	=	Ki	nM	630.96	CHEMBL5469	Homo sapiens	pKi		6.2
active	9617780	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C1Nc2ccc3ncsc3c2C1=CNc1ccc(S(=O)(=O)Nc2ccccn2)cc1		CHEMBL1973540	=	Ki	nM	251.19	CHEMBL5469	Homo sapiens	pKi		6.6
inactive	9617781	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C1Nc2ccccc2Nc2nnc(I)cc21		CHEMBL1977346	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617782	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3ccc4nccnc4c3N)cc2)c1		CHEMBL1971649	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617783	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Fc1ccc(-c2nc3sccn3c2-c2ccncc2)cc1		CHEMBL2000508	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617784	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCCCNc1n[s+]([O-])nc1Nc1ccc(F)cc1		CHEMBL1971694	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617785	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL2001547	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617786	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617787	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1Cl		CHEMBL210928	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617788	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9617789	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1ccc(-c2ccc(NC(=O)Nc3cc(F)cc(F)c3)cc2)c2c(N)noc12		CHEMBL1969190	=	Ki	nM	794.33	CHEMBL5469	Homo sapiens	pKi		6.1
inactive	9617790	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CCO)c5)cnc(N)c34)cc2)cc1		CHEMBL1977148	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617791	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1ccc(-c2ccc(NC(=O)Nc3cccc(Br)c3)cc2)c2c(N)n[nH]c12		CHEMBL1973937	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617792	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1cc(C=C2SC(=O)NC2=O)ccc1O		CHEMBL2003286	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617793	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)ccn1		CHEMBL1992306	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9617794	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC(O)Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL2002165	=	Ki	nM	501.19	CHEMBL5469	Homo sapiens	pKi		6.3
inactive	9617795	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	NC(=O)c1ccc(-c2c[nH]c3nccc(Cl)c23)cc1		CHEMBL1982711	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617796	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	NCCOc1cncc(C=Cc2ccncc2)c1		CHEMBL1989518	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9617797	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Nc1ncnc2scc(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL1998585	=	Ki	nM	125.89	CHEMBL5469	Homo sapiens	pKi		6.9
inactive	9617798	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CN(C(=O)C1CCCCC1)c1ccc2c(c1)nc(NC(=O)c1ccc(C#N)cc1)n2C		CHEMBL519697	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617799	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1cc(C=C(C#N)c2nc3ccccc3[nH]2)c(Br)cc1O		CHEMBL1994241	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617800	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCN(CC)CC#Cc1ccc2c(c1)-c1[nH]nc(-c3ccc(C#N)nc3)c1C2		CHEMBL2007044	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617801	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CS(=O)(=O)Nc1cc2c(cc1Cl)NC(=O)Nc1cnc(C#N)c(n1)OCCCCCO2		CHEMBL223460	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617802	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3I)cc12		CHEMBL1975128	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617803	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C(Nc1cnc2[nH]cc(-c3ccccc3)c2c1)c1ccc(Cl)cc1		CHEMBL1998829	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617804	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9617805	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cnc(Nc2cccc(S(N)(=O)=O)c2)nc1Nc1ccc(OCC(N)=O)cc1		CHEMBL1988838	=	Ki	nM	100.0	CHEMBL5469	Homo sapiens	pKi		7.0
inactive	9617806	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C(C)C(=O)N(C)C)c5)cnc(N)c34)cc2)cc1		CHEMBL2001485	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617807	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617808	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cc(NC(=O)Cc2ccc(-c3cccc4[nH]nc(N)c34)cc2)ccc1F		CHEMBL1984363	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9617809	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CNC(=O)COc1ccc(Nc2nc(Nc3ccc(C)c(S(N)(=O)=O)c3)ncc2F)cc1		CHEMBL1978099	=	Ki	nM	199.53	CHEMBL5469	Homo sapiens	pKi		6.7
inactive	9617810	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC(=O)Nc1cccc(CNc2c(Nc3ccc4[nH]ncc4c3)c(=O)c2=O)c1		CHEMBL1988608	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617811	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1ccc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)cc2)cc1C		CHEMBL184847	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617812	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COCCn1cc(-c2ccncn2)c(-c2ccc(Cl)cc2)n1		CHEMBL1982866	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617813	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CN(C)c1ccc(CNC(=O)c2cc3c(-c4ccccc4)n[nH]c3s2)cc1		CHEMBL1984367	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617814	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=c1[nH]c2sc3c(c2c2nc(-c4ccccc4)nn12)CCCC3		CHEMBL2007592	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617815	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Nc1ncc(-c2ccoc2)c2scc(-c3ccc(NC(=O)Nc4ccccc4F)cc3)c12		CHEMBL1965570	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9617816	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1n[nH]c2cnc(-c3cncc(OCC(N)Cc4cccc(C(F)(F)F)c4)c3)cc12		CHEMBL1998159	=	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617817	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COCC(C)(C)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(C)nccn23)n1		CHEMBL1982563	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617818	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	NC(COc1cncc(-c2ccc3[nH]c(=O)oc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL1987679	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617819	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1C#N		CHEMBL210963	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9617820	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5ccc(OC(F)F)cc5)cc4)csc23)cn1		CHEMBL1988387	=	Ki	nM	63.1	CHEMBL5469	Homo sapiens	pKi		7.2
inactive	9617821	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cncc2cccc(S(=O)(=O)N3CCCNCC3C)c12		CHEMBL1082440	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617822	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C(CO)N1CCC(c2[nH]nc(-c3ccc(Cl)cc3F)c2-c2ccncn2)CC1		CHEMBL1614705	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9617823	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)O)c5)cnc(N)c34)cc2)c1		CHEMBL1989708	=	Ki	nM	398.11	CHEMBL5469	Homo sapiens	pKi		6.4
inactive	9617824	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC(Nc1nccc(-c2c(-c3ccc(F)cc3)nc3occn23)n1)c1ccccc1		CHEMBL1990288	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617825	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL1970074	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617826	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617827	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COCCN(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1		CHEMBL1986970	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617828	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	NC(=O)c1cccc2[nH]c(-c3ccncc3)nc12		CHEMBL1990482	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617829	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Fc1ccc(-c2nc3cnccn3c2-c2ccnc(NCC3CC3)n2)cc1		CHEMBL1990904	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617830	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C(NCC1CCCCC1)c1cc2c(-c3ccccc3)n[nH]c2s1		CHEMBL2005475	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617831	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=c1[nH]c2cc(-c3ccccc3)cnc2[nH]1		CHEMBL2003456	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617832	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC(=O)N1CCN(C2CCC(n3nc(-c4ccc(NC(=O)c5cc6ccccc6n5C)cc4)c4c(N)ncnc43)CC2)CC1		CHEMBL1972584	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617833	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cncc4c3c(N)nn4C)cc2)c1		CHEMBL402846	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617834	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC(N)C1CCC(C(=O)Nc2ccnc3[nH]ccc23)CC1		CHEMBL2002992	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617835	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)cc2C)c1		CHEMBL183844	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617836	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	N#Cc1cnc(NC(=O)Nc2ccc3cc(C(=O)O)ccc3c2)cn1		CHEMBL560813	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617837	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL220057	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617838	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	c1ccc(Nc2nc(-c3ccc4[nH]ncc4c3)cs2)cc1		CHEMBL1682545	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617839	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	NC(COc1cncc(C=Cc2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL1974935	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617840	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cc(OC2CCCC2)c(NC(=O)Nc2cnc(C#N)cn2)cc1Cl		CHEMBL2001224	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617841	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1c(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc2n1C1CC(CN2CCCC2)C1		CHEMBL1968791	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617842	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617843	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC(C)(C)OC(=O)n1ncc2cc(Nc3c(NCc4ccc(S(N)(=O)=O)cc4)c(=O)c3=O)ccc21		CHEMBL1969506	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617844	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C(NC(CO)c1ccccc1)N1CC=C(c2c[nH]c3ncccc23)CC1		CHEMBL1964937	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617845	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1		CHEMBL1980163	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617846	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Fc1ccc(-c2nc3occn3c2-c2ccnc(NC3CCNCC3)n2)cc1		CHEMBL1971186	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617847	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C(Cc1ccc(Cl)cc1)Nc1[nH]nc2c1CCC2		CHEMBL2003482	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9617848	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN5CCCC5)cnc(N)c34)cc2)c1		CHEMBL1973211	=	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617849	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC(C)Oc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1984700	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617850	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC(=O)N(c1ccncc1)c1c(NC(C)C(C)(C)C)c(=O)c1=O		CHEMBL2005899	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617851	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	c1cnc2nc(-c3ccc4[nH]ncc4c3)c(NC3CCCCC3)n2c1		CHEMBL1682552	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617852	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617853	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Nc1ccc(-c2cncc(OCC(N)Cc3c[nH]c4ccccc34)c2)cc1C(=O)c1ccccc1		CHEMBL1972125	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9617854	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4cccc(Cl)c4)c3)cc12		CHEMBL1974870	=	Ki	nM	501.19	CHEMBL5469	Homo sapiens	pKi		6.3
active	9617855	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cc(C)c(C=C2C(=O)Nc3ccccc32)[nH]1		CHEMBL2002702	=	Ki	nM	316.23	CHEMBL5469	Homo sapiens	pKi		6.5
inactive	9617856	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617857	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	c1cc2cc(-c3ccc4cn[nH]c4c3)cnc2[nH]1		CHEMBL1976134	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617858	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1ccc(C(=O)Nc2c(C(N)=O)sc3ccc(Cl)c(Cl)c23)cc1		CHEMBL1965131	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617859	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL1970903	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617860	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cccc(Nc2nccc(Nc3c(NC(C)C(C)(C)C)c(=O)c3=O)n2)c1		CHEMBL1969523	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617861	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC(=O)N1CCC(Nc2nccc(-c3c(-c4ccc(F)cc4)nc4occn34)n2)CC1		CHEMBL1986781	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617862	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Nc1noc2cccc(-c3cccc(O)c3)c12		CHEMBL1970340	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617863	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC(C)NC(=O)COc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1		CHEMBL2005186	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617864	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC3CCOCC3)nc21		CHEMBL1230122	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617865	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	NCC(O)C(O)Cn1cc(I)c2c(N)ncnc21		CHEMBL1975534	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617866	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C1NCc2c1cccc2-c1ccc(Nc2nc3ccccc3[nH]2)cc1		CHEMBL1979057	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617867	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1n[nH]c2c1C(c1ccccc1F)C1=C(CC(C)(C)CC1=O)N2		CHEMBL1966703	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617868	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COCCOCC#Cc1cc(-c2n[nH]c3c2C(=O)c2cc(CN4CCN(C)CC4)ccc2-3)cs1		CHEMBL387971	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617869	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC(C)N(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1		CHEMBL1969561	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617870	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC(NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1		CHEMBL1999428	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617871	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCN1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL1967560	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617872	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cccc(NC(=O)Nc2ccc(-c3noc4ncnc(N)c34)cc2)c1		CHEMBL211378	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617873	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CN(C)c1cc2sncc2cc1NC(=O)C(=O)O		CHEMBL1997023	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9617874	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	NC(COc1cncc(-c2ccc3c(c2)C(=Cc2ccco2)C(=O)N3)c1)Cc1c[nH]c2ccccc12		CHEMBL2001751	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621438	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN5CCOCC5)cnc(N)c34)cc2)c1		CHEMBL1982465	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621439	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cc(C)cc(NC(=O)Nc2ccc3c(c2)CCc2sc4ncnc(N)c4c2-3)c1		CHEMBL1964687	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621440	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1ccccc1NC(=O)Nc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL1984586	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9621441	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCOc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C)c5)cnc(N)c34)cc2)cc1		CHEMBL1974254	=	Ki	nM	1000.0	CHEMBL5469	Homo sapiens	pKi		6.0
inactive	9621442	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1c(O)ccc2c1CCCC2=NNC(=O)Cc1cccc2ccccc12		CHEMBL1972659	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621443	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1ccc(NC(=O)Nc2ccc(-c3cccc4onc(N)c34)cc2)cc1Cl		CHEMBL272453	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621444	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1ccc(C(=O)N2c3ccccc3Sc3c(Cl)cncc32)cc1		CHEMBL1988537	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621445	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1ccc(NC(=O)Nc2ccc(-c3coc4ncnc(N)c34)cc2)cc1		CHEMBL2005828	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621446	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCOC(=O)c1ccc2[nH]c3c(c2c1)CCNC3=O		CHEMBL2005528	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621447	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)cc2)c1		CHEMBL185569	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621448	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	c1cc2[nH]ncc2cc1-c1cn(CC2CCOCC2)nn1		CHEMBL1969843	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621449	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCc1nc(-c2cccc(C)c2)c(-c2ccnc(NC(=O)c3ccccc3)c2)s1		CHEMBL363648	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621450	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1cc(-c2ccc3[nH]nc(C(=O)Nc4ccccc4)c3c2)ccc1O		CHEMBL2007002	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621451	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CN1CCC(NC(=O)c2cc3c(-c4ccccc4)n[nH]c3s2)CC1		CHEMBL1987007	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621452	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC(Nc1nccc(-c2c(-c3ccc(F)cc3)nc3occn23)n1)c1ccccc1		CHEMBL1990288	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621453	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621454	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	NC(=O)c1sc2c(Br)ccc(Cl)c2c1N		CHEMBL1998611	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9621455	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1cc(Nc2nccc(Nc3cc(C4CCCCC4)no3)n2)cc(OC)c1OC		CHEMBL1984711	=	Ki	nM	39.81	CHEMBL5469	Homo sapiens	pKi		7.4
active	9621456	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cc(Nc2ncc(F)c(NC3C4C=CC(C4)C3C(N)=O)n2)ccc1N1CCN(C)CC1		CHEMBL1967878	=	Ki	nM	79.43	CHEMBL5469	Homo sapiens	pKi		7.1
inactive	9621457	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=c1c(NCc2ccc(Cl)c(Cl)c2)c(Nc2ccncc2)c1=O		CHEMBL1975900	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621458	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1cc(C=C2SC(=S)NC2=O)ccc1O		CHEMBL1973098	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621459	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(NC(=O)CC)c3c2)cc1		CHEMBL1972221	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621460	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CNC(=O)C=Cc1cnc(N)c2c(-c3cc(F)c4[nH]c(C)cc4c3)csc12		CHEMBL2006778	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621461	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCCCn1c(NC(=O)c2ccc(C#N)cc2)nc2cc(N(C)C(=O)C3CCCCC3)ccc21		CHEMBL484390	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621462	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	NCC(NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1		CHEMBL1990254	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621463	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=c1c(NCc2cccc(C(F)(F)F)c2)c(Nc2ccncc2)c1=O		CHEMBL1979252	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621464	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1cc(S(C)(=O)=O)c(OC)cc1CC(=O)Nc1cc(N)c(C#N)c(OC(C)C)n1		CHEMBL378627	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621465	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C(Nc1cnc2[nH]cc(-c3ccccc3)c2c1)c1c(F)cccc1F		CHEMBL1996979	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621466	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCc1cccc(NC(=O)Nc2ccc3c(c2)CCc2sc4ncnc(N)c4c2-3)c1		CHEMBL1968406	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621467	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1cccc(C=C2SC(=Nc3ccccc3)NC2=O)c1		CHEMBL1972937	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621468	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)(C)O)c5)cnc(N)c34)cc2)cc1		CHEMBL2004290	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9621469	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=c1[nH]c2cnc(-n3cnc4ccc(F)cc43)nc2n1C1CCOc2c(F)cccc21		CHEMBL2000393	=	Ki	nM	100.0	CHEMBL5469	Homo sapiens	pKi		7.0
inactive	9621470	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)c(C)c2)c1		CHEMBL2004311	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621471	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Brc1cnc2[nH]cc(-c3ccccc3)c2c1		CHEMBL1992634	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621472	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cccc(NC(=O)Nc2ccc3c(c2)CCc2sc4ncnc(N)c4c2-3)c1		CHEMBL1242373	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621473	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C(NC(CO)Cc1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1998545	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621474	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1csc(NC(=O)c2sc3nc(-c4ccncc4)ccc3c2N)n1		CHEMBL1986869	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621475	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Fc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL316264	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621476	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1ccc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1988075	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621477	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1991678	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621478	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Fc1ccc(-c2ncn(CCN3CCOCC3)c2-c2ccc3[nH]ncc3c2)cc1		CHEMBL1682558	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621479	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Nc1ncnc(Nc2cc(CNC(=O)C(F)(F)F)c(O)c(-c3ccc(Cl)cc3)c2)n1		CHEMBL2001239	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621480	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cn1c(NCC(N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O		CHEMBL1990496	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621481	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Nc1ncnc2scc(C(=O)Nc3ccc(NC(=O)Nc4ccccc4)cc3)c12		CHEMBL1988594	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621482	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Nc1ncnc2c1c(I)nn2C1OC(CO)C(O)C1O		CHEMBL2001288	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621483	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1		CHEMBL253969	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621484	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C(NN=Cc1ccc(O)cc1O)Nc1cccc2nsnc12		CHEMBL1999811	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621485	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CSc1ccc2nc3c(c(Cl)c2c1)CCNC3=O		CHEMBL1985074	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621486	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Nc1nc2ccc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc2n1CC1CC1		CHEMBL1982874	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621487	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4sncc34)cc2)c1		CHEMBL1992242	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621488	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CN(C)CC(=O)NC(COc1cncc(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL1991725	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621489	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C(NCc1ccc(Cl)cc1)c1cc2c(-c3ccccc3)n[nH]c2s1		CHEMBL1967094	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621490	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C(NC(CO)c1cc(Cl)cc(Cl)c1)c1ccc(-c2ccncc2)cc1		CHEMBL2003341	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621491	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cc(C)cc(NC(=O)Nc2ccc(NC(=O)c3csc4ncnc(N)c34)cc2)c1		CHEMBL1970203	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621492	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CNC(=O)C=Cc1cnc(N)c2c(-c3ccc4sc(C)nc4c3)csc12		CHEMBL1968590	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621493	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCC1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCCCC4)cc3OC)nc2N1C1CCCC1		CHEMBL2005375	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621494	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Clc1ccc(-c2n[nH]cc2-c2ccncn2)cc1Cl		CHEMBL1984191	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621495	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Oc1cccc(Nc2ncnc3scc(Cl)c23)c1		CHEMBL1982992	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621496	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cc(-c2ccccc2)n(-c2cc(NN=Cc3ccco3)ncn2)n1		CHEMBL1999590	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9621497	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCN(C(C)=O)CC3)ccc2OC)ncc1Br		CHEMBL1971029	=	Ki	nM	1.585	CHEMBL5469	Homo sapiens	pKi		8.8
active	9621498	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C)c5)cnc(N)c34)cc2)c1		CHEMBL1967116	=	Ki	nM	251.19	CHEMBL5469	Homo sapiens	pKi		6.6
inactive	9621499	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1cc(-c2ccc3c(c2)Nc2ccc(C(=O)NCc4cccc(F)c4)cc2NC3=O)ccc1O		CHEMBL2000832	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621500	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=c1c(NCc2ccc(Cl)cc2)c(Nc2ccncc2)c1=O		CHEMBL1980489	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621501	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)c12		CHEMBL394790	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621502	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C(NCc1ccc(Br)cc1)Nc1ccc2[nH]ncc2c1		CHEMBL1970709	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621503	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C1NCCc2[nH]c(-c3ccnc(-c4ccccc4F)c3)cc21		CHEMBL226471	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621504	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1nc2c(sc3c(Br)ccc(Cl)c32)c(=O)o1		CHEMBL1974702	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621505	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CN(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1		CHEMBL1996111	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621506	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC(C)n1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)cc21		CHEMBL1969126	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621507	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1nccn2c(-c3ccnc(NCC4(O)CC4)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1965589	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621508	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Nc1ncnc2sc(Br)c(-c3ccc(NC(=O)Cc4cccc(Cl)c4)cc3)c12		CHEMBL1980896	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9621509	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC(C)(C)c1ccc2nc(-c3n[nH]c4ccccc34)[nH]c2c1		CHEMBL1970104	=	Ki	nM	316.23	CHEMBL5469	Homo sapiens	pKi		6.5
active	9621510	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)O)s3)c2cc1OC		CHEMBL474432	=	Ki	nM	501.19	CHEMBL5469	Homo sapiens	pKi		6.3
inactive	9621511	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1ccc2c(c1)NC(=O)c1ccccc1N2		CHEMBL1999714	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621512	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)C(=O)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1971149	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621513	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC(C)(O)CNc1nccc(-c2c(-c3ccc(F)cc3F)nc3c(CC4CC4)nccn23)n1		CHEMBL1994040	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621514	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1nnc(-c2cc3c(Oc4ccc(C(F)(F)F)cc4)cncc3s2)o1		CHEMBL1988153	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621515	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	NC(COc1cncc(-c2ccc3c(c2)CC(=O)N3)c1)Cc1c[nH]c2ccccc12		CHEMBL1967302	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621516	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC(=O)N1CCN(C2CCC(n3nc(-c4ccc(NC(=O)c5cc6ccccc6n5C)cc4)c4c(N)ncnc43)CC2)CC1		CHEMBL1972584	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621517	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	N#Cc1ccc(-c2n[nH]c3c2Cc2ccc(OCCCCN4CCOCC4)cc2-3)cn1		CHEMBL398951	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621518	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1cc2cnc3c(c2cc1OC)C(=O)NC3=O		CHEMBL1982506	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9621519	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCN(CC)CCNC(=O)C=Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL2004716	=	Ki	nM	398.11	CHEMBL5469	Homo sapiens	pKi		6.4
inactive	9621520	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CN(C)CC(C)(C)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3occn23)n1		CHEMBL1968127	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621521	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1cc(C)c(Cl)cc1NC(=O)Nc1cnc(C#N)cn1		CHEMBL1975233	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621522	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CNC(=O)c1ccccc1Sc1ccc2c(C=Cc3ccccn3)n[nH]c2c1		CHEMBL1988437	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621523	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCCC(=O)Nc1n[nH]c2ccc(-c3cccc(F)c3F)cc12		CHEMBL1985406	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621524	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cn1nc(C(F)(F)F)c2c(=O)c3cc(Cl)ccc3n(O)c21		CHEMBL207400	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621525	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cc(O)ccc1-n1cc(C(=O)NN)c(=O)c2ccc(-c3ccncc3)cc21		CHEMBL2000894	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621526	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CC(C)(C)N)cnc(N)c34)cc2)c1		CHEMBL1979577	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621527	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	NCCC(C(=O)Nc1ccc2[nH]ncc2c1)c1ccc(Cl)c(Cl)c1		CHEMBL1998121	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621528	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1ccccc1NC(=O)Nc1ccc2c(c1)CCc1sc3ncnc(N)c3c1-2		CHEMBL1982135	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621529	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(CC4CC4)nccn23)n1		CHEMBL1991800	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621530	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Nc1ncnc2c1sc1ncnc(N)c12		CHEMBL1976090	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621531	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CNC(=O)C=Cc1cnc(N)c2c(-c3ccc4c(c3)OCO4)csc12		CHEMBL1993243	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9621532	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	OCC(CO)Nc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL1992922	=	Ki	nM	630.96	CHEMBL5469	Homo sapiens	pKi		6.2
inactive	9621533	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1nn(-c2ccccc2)c2c1c(=O)c1cc(Cl)ccc1n2O		CHEMBL379835	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621534	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1		CHEMBL1997597	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621535	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	S=c1[nH]nc2c3c4c(sc3n3c(=S)[nH]nc3n12)CCC4		CHEMBL1969537	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621536	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CN(C)CC(C)(C)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3cnccn23)n1		CHEMBL1976093	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621537	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cn1cc(C(CN)c2cncc(C=Cc3ccncc3)c2)c2ccccc21		CHEMBL1979357	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9621538	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCCCOc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL1996817	=	Ki	nM	501.19	CHEMBL5469	Homo sapiens	pKi		6.3
inactive	9621539	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Nc1nonc1-n1nnc(C(=O)NN=Cc2cccs2)c1-c1cccs1		CHEMBL1975256	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621540	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cccc(NC(=O)Nc2ccc(-c3cnc4c(-c5cnn(C)c5)cnn4c3N)cc2)c1		CHEMBL508928	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621541	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1cccc(-c2cc3c(=O)[nH]c4ccccc4n3c2)c1		CHEMBL1991356	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621542	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1		CHEMBL2004892	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621543	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCn1c2cc(Cl)c(F)cc2c(=O)c2c(=O)o[nH]c21		CHEMBL468280	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621544	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	NC(=O)c1cc2c(Oc3ccc(Br)cc3)cncc2s1		CHEMBL116070	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621545	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cc(C)c2oc(Nc3ccc(-c4cccc(C(N)=O)c4N)cc3F)nc2c1		CHEMBL1990884	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9621546	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCN(CC)CCNC(=O)c1c(C)[nH]c(C=C2C(=O)Nc3ccc(F)cc32)c1C		CHEMBL1990885	=	Ki	nM	125.89	CHEMBL5469	Homo sapiens	pKi		6.9
inactive	9621547	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL256835	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621548	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	NC(=O)c1cc(-c2cccc(N)c2)cc2cccnc12		CHEMBL1970314	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621549	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	OCCCn1cnc(-c2ccc(F)cc2)c1-c1ccncc1		CHEMBL2004871	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621550	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CN(C)CCCC(=O)Nc1n[nH]c2nnc(-c3cccc(F)c3F)cc12		CHEMBL41783	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621551	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1cccc2c1Nc1cc(Nc3ccncc3)ccc1C(=O)N2		CHEMBL2006276	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621552	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C(Nc1cnccn1)Nc1ccnc2ccccc12		CHEMBL1981720	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9621553	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1ccc(-c2ccc(NC(=O)Nc3cccc(Br)c3)cc2)c2c(N)noc12		CHEMBL271381	=	Ki	nM	199.53	CHEMBL5469	Homo sapiens	pKi		6.7
inactive	9621554	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC(N)COc1cnc(Cl)c(C=Cc2ccncc2)c1		CHEMBL1993548	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621555	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3nsc4ncnc(N)c34)cc2)c1		CHEMBL262433	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621556	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1ccc(C(=O)Nc2c(C#N)sc3ccc(Cl)c(Cl)c23)cc1		CHEMBL2006785	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621557	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C)c5)cnc(N)c34)cc2)cc1		CHEMBL1982466	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621558	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1ccc(-c2nn(C(C)(C)C)c3ncnc(N)c23)cc1		CHEMBL306380	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9621559	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C(NNC(=S)Nc1ccc(Cl)cc1)C(O)(c1ccccc1)c1ccccc1		CHEMBL1966722	=	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621560	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1cc(-c2ccc3c(c2)Nc2ccc([N+](=O)[O-])cc2NC3=O)ccc1O		CHEMBL1995740	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621561	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1cc(-c2ccc3c(c2)Nc2ccc(C(=O)NCCNC(C)=O)cc2NC3=O)ccc1O		CHEMBL1975500	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621562	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4ccnc(N)c34)cc2)c1		CHEMBL394619	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621563	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C(O)c1c2c(nc3ccccc13)C(=C1CCCC1)CC2		CHEMBL1996831	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9621564	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Nc1ncnc2c1N=C(c1ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc1)CCN2		CHEMBL411903	=	Ki	nM	19.95	CHEMBL5469	Homo sapiens	pKi		7.7
inactive	9621565	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC1CCN(C(=O)CC#N)CC1N(C)c1ncnc2[nH]ccc12		CHEMBL234085	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9621566	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C1CC(c2ccc(Cl)cc2)Cc2[nH]c3cc(Cl)ccc3c(=O)c21		CHEMBL1990432	=	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621567	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN)cnc(N)c34)cc2)c1		CHEMBL1965988	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621568	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1995832	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9621569	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)C(O)C1		CHEMBL422897	=	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621570	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Oc1ccc(Nc2[nH]nc(-c3ccc(O)cc3)c2-c2ccc(O)cc2)cc1		CHEMBL1969042	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621571	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1cc(C=C(C#N)c2nc3cc(C)ccc3[nH]2)c(Br)cc1O		CHEMBL2000345	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621572	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C1NCCc2[nH]c(-c3ccncc3)cc21		CHEMBL225519	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621573	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621574	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1nccn2c(-c3ccnc(NCCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1978200	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621575	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1cc(C=C2SC(=Nc3ccccc3)NC2=O)ccc1O		CHEMBL1970522	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621576	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1[nH]c(C=C2C(=O)Nc3ccccc32)c(C)c1CCC(=O)O		CHEMBL2007064	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9621577	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cn1nc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)cncc21		CHEMBL1964692	=	Ki	nM	1258.93	CHEMBL5469	Homo sapiens	pKi		5.9
inactive	9621578	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C(NC(CO)Cc1ccc(Cl)cc1)c1ccc(-c2ccncc2)cc1		CHEMBL1996931	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621579	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	FC(F)(F)c1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)c(C(F)(F)F)c1		CHEMBL1964413	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9621580	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4ccc(Cl)c(Cl)c4)c3)cc12		CHEMBL1991063	=	Ki	nM	794.33	CHEMBL5469	Homo sapiens	pKi		6.1
inactive	9621581	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1cccc(C(CN)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL1976240	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621582	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C(c1cc(-c2ccc3[nH]ncc3c2)on1)N1CCCC(O)C1		CHEMBL1997340	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621583	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1cccc(Nc2ncnc3ccccc23)c1		CHEMBL117697	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621584	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1ccc(-c2ccc(NC(=O)Nc3ccc(F)c(C)c3)cc2)c2c(N)noc12		CHEMBL1979093	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621585	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cn1cc(-c2ccncn2)c(-c2ccc(F)cc2)n1		CHEMBL1989474	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621586	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1cccc(CNC(=O)c2cc3c(-c4ccccc4)n[nH]c3s2)c1		CHEMBL1987009	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9621587	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4ccccc4)c3)cc12		CHEMBL2002726	=	Ki	nM	1000.0	CHEMBL5469	Homo sapiens	pKi		6.0
inactive	9621588	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C(Nc1cnccn1)Nc1ccnc2cc(C(F)(F)F)ccc12		CHEMBL2003817	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621589	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Nc1nnc(-c2cc3c(Oc4ccc(Cl)cc4)cncc3s2)o1		CHEMBL1994830	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621590	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C(Nc1nc2ccccc2n1CCCO)c1cccc([N+](=O)[O-])c1		CHEMBL210887	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621591	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C1NCCc2[nH]c(-c3ccnc(-c4cnc5ccccc5c4)c3)cc21		CHEMBL226403	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9621592	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4cccc(OC(F)(F)F)c4)c3)cc12		CHEMBL1965836	=	Ki	nM	794.33	CHEMBL5469	Homo sapiens	pKi		6.1
inactive	9621593	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)c(C(F)(F)F)c2)c1		CHEMBL1971021	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621594	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=c1[nH]cnc2c1sc1c(Cl)ccc(Cl)c12		CHEMBL583144	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621595	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	NC(=O)c1cc2c(-c3ccc(F)cc3)cncc2s1		CHEMBL1974310	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621596	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Nc1ncnc2sc3c(c12)-c1ccc(NC(=O)Nc2ccccc2)cc1CC3		CHEMBL1994693	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621597	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cc(C)ccc4F)cc3)csc12		CHEMBL2005631	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621598	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Nc1ncc(C=CC(=O)NCCCn2ccnc2)c2scc(-c3ccc(Br)cc3)c12		CHEMBL1994938	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9621599	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL1825138	=	Ki	nM	158.49	CHEMBL5469	Homo sapiens	pKi		6.8
inactive	9621600	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCCC(=O)Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12		CHEMBL1977223	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9621601	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	NC(=O)c1cccc(-c2cnc3[nH]cc(-c4ccccc4)c3c2)c1		CHEMBL1982957	=	Ki	nM	501.19	CHEMBL5469	Homo sapiens	pKi		6.3
inactive	9621602	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC(C)(C)C(=O)Oc1ccc2c(c1)nc(NC(=O)c1cccc([N+](=O)[O-])c1)n2CCCO		CHEMBL1236126	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621603	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C(NNC(=S)Nc1ccc(F)cc1)C(O)(c1ccccc1)c1ccccc1		CHEMBL1975138	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621604	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1C#N		CHEMBL424872	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9621605	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC1=NN(c2ccc(C(=O)O)cc2)C(=O)C1=Cc1c(C)c(C#N)c2nc3ccccc3n2c1O		CHEMBL2006836	=	Ki	nM	1258.93	CHEMBL5469	Homo sapiens	pKi		5.9
inactive	9621606	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC(C)Cn1c(N)nc2c(F)cc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc21		CHEMBL2004419	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621607	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1c[nH]c(-c2cnc(NCCNc3ccc(C#N)cn3)nc2-c2ccc(Cl)cc2Cl)n1		CHEMBL412142	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621608	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cc2nnc(SCc3cn4ccccc4n3)n2c2ccccc12		CHEMBL1980704	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621609	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	NC(=O)c1sc2ccc(Cl)c(Cl)c2c1NC(=O)c1ccc(Cl)cc1		CHEMBL2003271	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621610	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC(C)(C)c1n[nH]c2c1C(c1ccccc1F)C(C#N)=C(N)O2		CHEMBL2004447	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621611	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	OCCNc1cc2cc(-c3ccsc3)ccc2cn1		CHEMBL1973860	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621612	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C(Nc1ccc2cn[nH]c2c1)c1ccc(Cl)cc1		CHEMBL1972489	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621613	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Nc1n[nH]c2nnc(-c3ccccc3)c(-c3ccccc3)c12		CHEMBL260135	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621614	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Brc1ccc2[nH]nc(-c3ccccc3)c2c1		CHEMBL1994074	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621615	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1ccc(Nc2nc3ccc([N+](=O)[O-])cc3[nH]2)nc1		CHEMBL1992937	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621616	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=c1[nH]cc(I)c2nc(-c3cccc(Cl)c3)cn12		CHEMBL1982610	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621617	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cccc(C2(c3cccc(C)c3)CC2C(=O)Nc2ccncc2)c1		CHEMBL1999496	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621618	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Nc1ccc(-c2csc3c(C=Cc4nc5ccccc5[nH]4)cnc(N)c23)cc1		CHEMBL1988300	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621619	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CN(C)C(=O)Nc1ccc2nc(-c3ccco3)c(-c3ccco3)nc2c1		CHEMBL1986328	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621620	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL95692	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621621	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)c1		CHEMBL1090356	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621622	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C(Nc1cnccn1)Nc1ccnc2ccc(C(F)(F)F)cc12		CHEMBL1976455	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621623	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=c1c(NCc2ccccc2F)c(Nc2ccncc2)c1=O		CHEMBL1982361	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621624	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCOC(=O)C1=c2sc(=Cc3ccco3)c(=O)n2C(N)=C(C#N)C1c1ccco1		CHEMBL1999112	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621625	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C(Nc1ccc(-c2cccc3sncc23)cc1)Nc1ccc(F)c(C(F)(F)F)c1		CHEMBL2000801	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621626	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	c1ccc(CNc2nc(-c3ccc4[nH]ncc4c3)cs2)cc1		CHEMBL1682546	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621627	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3cnccn23)n1		CHEMBL1991395	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621628	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C(NCc1ccccc1)c1cccc(-c2cnc3[nH]ccc3c2)c1		CHEMBL1972142	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621629	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C1NN=Cc2c[nH]c3cc(NC(=O)C4CC4c4ccccc4)cc1c23		CHEMBL1969502	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621630	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC(C)Nc1c(-c2ccc3[nH]ncc3c2)nc2ncccn12		CHEMBL1682553	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621631	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Nc1ncc(-c2ccoc2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1966514	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621632	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cccc(NC(=O)Nc2ccc(-c3coc4ncnc(N)c34)cc2)c1		CHEMBL1983963	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621633	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1ccc(C(=O)Nc2cnc3[nH]cc(-c4ccccc4)c3c2)cc1		CHEMBL1997764	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621634	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Oc1ccc(-c2n[nH]c(Nc3cccc(Cl)c3)c2-c2ccc(O)cc2)cc1		CHEMBL1985092	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621635	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CNc1ncnc2c1N=C(c1ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc1)CCN2		CHEMBL1981410	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621636	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Nc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4cc(C(=O)O)ccc4F)cc3)c12		CHEMBL1993722	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621637	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=c1[nH]c2sc3c(c2c2nc(-c4cccnc4)nn12)CCCC3		CHEMBL1970806	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621638	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1ccc(C=C2C(=O)ON=C2c2ccc(Br)cc2)cc1OC		CHEMBL1991434	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621639	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CN(C)c1cccc2c(S(=O)(=O)N(CCN)c3cncc(-c4ccc5cnccc5c4)c3)cccc12		CHEMBL1967544	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621640	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1nc(COc2ccccc2Cl)sc1-c1ccnc(N)n1		CHEMBL1375640	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621641	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCCC(=O)Nc1n[nH]c2nnc(-c3cccc(F)c3F)cc12		CHEMBL1979970	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621642	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	N#Cc1ncc2nc1OCCCCCOc1cc(CCCO)c(Cl)cc1NC(=O)N2		CHEMBL223367	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621643	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	N#Cc1ccc(-c2n[nH]c3c2Cc2ccc(OCCN4CCOCC4)cc2-3)cn1		CHEMBL249282	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621644	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	NC(=O)c1cn(-c2ccc(O)cc2Cl)c2cc(-c3ccncc3)ccc2c1=O		CHEMBL340384	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621645	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CS(=O)(=O)NCCOc1cncc(-c2ccc3cnccc3c2)c1		CHEMBL1964804	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621646	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1ccc(-c2cnc3c(Br)cnn3c2)cc1		CHEMBL443962	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621647	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1ccc(C=C2SC(=Nc3ccccc3)NC2=O)cc1O		CHEMBL2000354	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621648	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cccc(NC(=O)Nc2ccc(NC(=O)c3csc4ncnc(N)c34)cc2)c1		CHEMBL1965507	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621649	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CN1CCN(CCCNc2cccc(-c3nc4c(C(N)=O)cccc4[nH]3)n2)CC1		CHEMBL2006237	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621650	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621651	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCCC(=O)Nc1n[nH]c2nc3ccccc3cc12		CHEMBL1967564	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9621652	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	OCCCNc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL2000071	=	Ki	nM	794.33	CHEMBL5469	Homo sapiens	pKi		6.1
active	9621653	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	NCCCn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL592030	=	Ki	nM	251.19	CHEMBL5469	Homo sapiens	pKi		6.6
active	9621654	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC(C)(C(N)=O)n1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1967720	=	Ki	nM	501.19	CHEMBL5469	Homo sapiens	pKi		6.3
inactive	9621655	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc2c(C)n1		CHEMBL2000408	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621656	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Nc1nccn2c(C3CC(CN4CCCC4)C3)nc(-c3cccc(OCc4ccccc4)c3)c12		CHEMBL1991138	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621657	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)csc12		CHEMBL1979516	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621658	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C(NC(CO)Cc1ccccc1)c1ccc(-c2ccncc2)cc1F		CHEMBL1969755	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621659	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC(N)C1CCC(C(=O)Nc2ccncc2)CC1		CHEMBL1994526	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621660	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	N#Cc1ncc2nc1OCCCCOc1cc(NCc3cncs3)c(Cl)cc1NC(=O)N2		CHEMBL248757	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621661	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CN1CCC(C(=O)n2nc(N)c3cc(-c4cn(Cc5ccccc5)nn4)ccc32)CC1		CHEMBL1978014	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621662	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC(C)OC1=NNC(=O)C1=Cc1c[nH]c2ccccc12		CHEMBL1989029	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9621663	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Ki	nM	158.49	CHEMBL5469	Homo sapiens	pKi		6.8
inactive	9621664	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C(Nc1cnccn1)Nc1ccnc2c(C(F)(F)F)cccc12		CHEMBL1994538	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621665	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CN(C)CC(=O)Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12		CHEMBL1965631	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621666	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1ccccc1NC(=O)Nc1ccc(NC(=O)c2csc3ncnc(N)c23)cc1		CHEMBL1980144	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621667	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Clc1csc2ncnc(Nc3ccccc3)c12		CHEMBL1986139	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621668	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCOc1nc(C(=O)NCc2ccccc2S(N)(=O)=O)cc(N)c1C#N		CHEMBL377408	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621669	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN(C)C)cnc(N)c34)cc2)c1		CHEMBL1979883	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9621670	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL231209	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9625220	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COCCOC1CCC(n2nc(-c3ccc(Nc4nc5cc(C)cc(C)c5o4)cc3)c3c(N)ncnc32)CC1		CHEMBL1984162	=	Ki	nM	398.11	CHEMBL5469	Homo sapiens	pKi		6.4
inactive	9625221	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4cccc(Br)c4)cc3)c12		CHEMBL1976220	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9625222	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Fc1cnc(Nc2ccccc2)nc1Nc1ccccc1		CHEMBL491758	=	Ki	nM	1000.0	CHEMBL5469	Homo sapiens	pKi		6.0
inactive	9625223	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1ccc(C(=O)Nc2ccon2)cc1Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL259922	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9625224	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CN1CCN(C2CCC(n3cc(-c4ccc(Oc5ccccc5)cc4)c4c(N)ncnc43)CC2)CC1		CHEMBL1997617	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9625225	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CCCCn1c(NC(=O)c2cccc(C#N)c2)nc2cc(N(C)C(=O)C3CCCCC3)ccc21		CHEMBL1969301	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9625226	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(CCN)nccn23)n1		CHEMBL1982383	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9625227	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC(Nc1c(Nc2ccncc2)c(=O)c1=O)C(C)(C)C		CHEMBL1986186	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9625228	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CSc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17370	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9625229	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1n[nH]c2c1C(c1ccccc1Cl)C(C#N)=C(N)O2		CHEMBL1970189	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9625230	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3c(C)sc4ncnc(N)c34)cc2)c1		CHEMBL371206	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9625231	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Nc1ncnc2c1c(I)nn2C1CCC(O)CC1		CHEMBL1996791	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9625232	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	COc1ccc(C=NNc2ncnc3c2[nH]c2ccccc23)cc1OC		CHEMBL1974664	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9625233	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4ccccc4C(F)(F)F)cc3)c12		CHEMBL1987910	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9625234	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC(C)(C)c1ccc2nc(-c3n[nH]c4ccccc34)[nH]c2c1		CHEMBL1970104	=	Ki	nM	316.23	CHEMBL5469	Homo sapiens	pKi		6.5
active	9625235	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1980297	=	Ki	nM	1258.93	CHEMBL5469	Homo sapiens	pKi		5.9
inactive	9625236	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C(NC(CO)c1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1974288	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9625237	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9625238	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cc(OCC2CCC(C(=O)O)C2)c(NC(=O)Nc2cnc(C#N)cn2)cc1Cl		CHEMBL1991285	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9625239	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4ncnc(N)c34)cc2)c1		CHEMBL196363	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
active	9625240	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cc2cc(-c3csc4c(-c5cccc(S(C)(=O)=O)c5)cnc(N)c34)ccc2[nH]1		CHEMBL1997822	=	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9625241	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C(Nc1cnc2[nH]cc(-c3ccccc3)c2c1)c1cccc(F)c1F		CHEMBL1974416	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9625242	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	O=C(c1cccc(-c2cnc3[nH]ccc3c2)c1)N1CCOCC1		CHEMBL1997872	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9625243	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	CC(C)Cc1cc(-c2ccc3[nH]nc(N)c3c2)on1		CHEMBL1966343	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
inactive	9625244	CHEMBL1963760	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: PTK2B	F	Cc1cccc(NC(=O)Nc2ccc(-c3cncc4c3c(N)nn4C)cc2)c1		CHEMBL404367	<	Ki	nM	1584.89	CHEMBL5469	Homo sapiens	pKi		5.8
	10838624	CHEMBL2014502	Inhibition of PYK2 at 10 uM	B	COc1ccc2c3ccnc(C(F)(F)F)c3n(CCCCN)c2c1		CHEMBL2012574	=	Inhibition	%	0.0	CHEMBL5469	Homo sapiens	INH	%	0.0
	10850666	CHEMBL2019786	Inhibition of human Pyk2 at 1 uM	B	Cn1cc(-c2cccc(-c3cnc(N)c(C(=O)N[C@H]4C5CC6CC4C[C@@](O)(C6)C5)n3)c2)cn1		CHEMBL2018022	<	Inhibition	%	50.0	CHEMBL5469	Homo sapiens	INH	%	50.0
	10888357	CHEMBL2033180	Inhibition of human recombinant PYK2 by ESI-MS analysis	B	CCCCc1c(-c2ccc(OC)cc2)[nH]c2nccnc12		CHEMBL306498	=	Ki	nM	933.25	CHEMBL5469	Homo sapiens	pKi		6.03
	10888358	CHEMBL2033180	Inhibition of human recombinant PYK2 by ESI-MS analysis	B	NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1		CHEMBL319467	<	Ki	nM	10000.0	CHEMBL5469	Homo sapiens	pKi		5.0
	10888359	CHEMBL2033180	Inhibition of human recombinant PYK2 by ESI-MS analysis	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Br)cc32)cc1		CHEMBL411491	<	Ki	nM	10000.0	CHEMBL5469	Homo sapiens	pKi		5.0
	10888360	CHEMBL2033180	Inhibition of human recombinant PYK2 by ESI-MS analysis	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc32)c(C)c1C(=O)N1CCN(C)CC1		CHEMBL261641	=	Ki	nM	10.47	CHEMBL5469	Homo sapiens	pKi		7.98
	10888361	CHEMBL2033180	Inhibition of human recombinant PYK2 by ESI-MS analysis	B	N#CC(C#N)=Cc1ccc(O)c(O)c1		CHEMBL76904	=	Ki	nM	162.18	CHEMBL5469	Homo sapiens	pKi		6.79
	10888362	CHEMBL2033180	Inhibition of human recombinant PYK2 by ESI-MS analysis	B	O=C1C(C2=C3c4ccccc4NC3/C(=C\c3ccc(O)cc3)C2=O)=C2C(=Nc3ccccc32)/C1=C\c1ccc(O)cc1		CHEMBL505177	<	Ki	nM	10000.0	CHEMBL5469	Homo sapiens	pKi		5.0
	10888363	CHEMBL2033180	Inhibition of human recombinant PYK2 by ESI-MS analysis	B	CN(C)c1ncnc2nc[nH]c12		CHEMBL407391	<	Ki	nM	10000.0	CHEMBL5469	Homo sapiens	pKi		5.0
	10921396	CHEMBL2044778	Inhibition of PYK2 at 1 uM	B	CCN1C(=O)CCCc2c1ccc(Nc1ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)n1)c2OC		CHEMBL2042829	=	Inhibition	%	99.0	CHEMBL5469	Homo sapiens	INH	%	99.0
	10921397	CHEMBL2044779	Inhibition of PYK2 at 0.1 uM	B	CCN1C(=O)CCCc2c1ccc(Nc1ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)n1)c2OC		CHEMBL2042829	=	Inhibition	%	90.0	CHEMBL5469	Homo sapiens	INH	%	90.0
	10984757	CHEMBL2072053	Inhibition of human Pyk2 at 1 uM	B	Nc1cc(Nc2cnccn2)nc(-c2ccnc(N3CCNCC3)c2)c1		CHEMBL2069349	<	Inhibition	%	50.0	CHEMBL5469	Homo sapiens	INH	%	50.0
	12046301	CHEMBL2156631	Inhibition of FAK2 at 1 uM	B	CC(C)(O)C1CCN(Cc2ccc3nc(-c4c(F)ccc5[nH]ccc45)nc(N4CCOCC4)c3n2)CC1		CHEMBL2152768	=	Inhibition	%	2.1	CHEMBL5469	Homo sapiens	INH	%	2.1
	12172240	CHEMBL2212020	Inhibition of PYK2 assessed as residual activity at 10 uM relative to control	B	O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1		CHEMBL2204495	=	Activity	%	100.0	CHEMBL5469	Homo sapiens	Activity	%	100.0
	12183823	CHEMBL2214437	Inhibition of PTK2B	B	CC(C)(C)NS(=O)(=O)c1cncc(-c2ccn3nc(N)nc3c2)c1		CHEMBL2205766	<	IC50	nM	10000.0	CHEMBL5469	Homo sapiens	pIC50		5.0
	12197192	CHEMBL2209550	Inhibition of PYK2 after 2hrs by fluorescence polarization assay	B	COc1ccc(-c2cc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc(C)cc3)n[nH]2)nc1		CHEMBL2207432	=	IC50	nM	3819.0	CHEMBL5469	Homo sapiens	IC50	nM	3819.0
	12197194	CHEMBL2209550	Inhibition of PYK2 after 2hrs by fluorescence polarization assay	B	CNC(=O)c1cc2cccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc(C)cc3)c2[nH]1		CHEMBL2207426	=	IC50	nM	1700.0	CHEMBL5469	Homo sapiens	IC50	nM	1700.0
	12197195	CHEMBL2209550	Inhibition of PYK2 after 2hrs by fluorescence polarization assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cc(-c3ccc(O)nn3)[nH]n2)cc1		CHEMBL2207436	=	IC50	nM	1350.0	CHEMBL5469	Homo sapiens	IC50	nM	1350.0
	12197196	CHEMBL2209550	Inhibition of PYK2 after 2hrs by fluorescence polarization assay	B	COc1ccc(-c2cc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc(C)cc3)n[nH]2)c(C)c1		CHEMBL2207431	=	IC50	nM	1200.0	CHEMBL5469	Homo sapiens	IC50	nM	1200.0
	12197197	CHEMBL2209550	Inhibition of PYK2 after 2hrs by fluorescence polarization assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cc(COc3cccnc3)n[nH]2)cc1		CHEMBL1084269	=	IC50	nM	637.0	CHEMBL5469	Homo sapiens	IC50	nM	637.0
	12197204	CHEMBL2209550	Inhibition of PYK2 after 2hrs by fluorescence polarization assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cc(-c3ccc(=O)n(C)c3)[nH]n2)cc1		CHEMBL2207437	=	IC50	nM	429.0	CHEMBL5469	Homo sapiens	IC50	nM	429.0
	12197205	CHEMBL2209550	Inhibition of PYK2 after 2hrs by fluorescence polarization assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3cc(C(=O)N(C)CCc4ccccn4)[nH]c23)cc1		CHEMBL2207429	=	IC50	nM	398.0	CHEMBL5469	Homo sapiens	IC50	nM	398.0
	12197206	CHEMBL2209550	Inhibition of PYK2 after 2hrs by fluorescence polarization assay	B	COc1ccc(-c2cc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc(C)cc3)n[nH]2)cn1		CHEMBL2207433	=	IC50	nM	361.0	CHEMBL5469	Homo sapiens	IC50	nM	361.0
	12197211	CHEMBL2209552	Inhibition of human recombinant C-terminal His-tagged PYK2 using ATP as substrate incubated for 1 hr prior to substrate addition	B	COc1ccc(-c2cc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc(C)cc3)n[nH]2)cc1		CHEMBL2207822	=	IC50	nM	225.0	CHEMBL5469	Homo sapiens	IC50	nM	225.0
	12197213	CHEMBL2209552	Inhibition of human recombinant C-terminal His-tagged PYK2 using ATP as substrate incubated for 1 hr prior to substrate addition	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3cc(C(=O)Nc4cccc(Cl)c4)[nH]c23)cc1		CHEMBL2207821	=	IC50	nM	173.0	CHEMBL5469	Homo sapiens	IC50	nM	173.0
	12197214	CHEMBL2209550	Inhibition of PYK2 after 2hrs by fluorescence polarization assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cc(-c3ccc(=O)[nH]c3)[nH]n2)cc1		CHEMBL2207435	=	IC50	nM	141.0	CHEMBL5469	Homo sapiens	IC50	nM	141.0
	12197216	CHEMBL2209550	Inhibition of PYK2 after 2hrs by fluorescence polarization assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3cc(C(=O)NC(C)C)[nH]c23)cc1		CHEMBL2207427	=	IC50	nM	78.0	CHEMBL5469	Homo sapiens	IC50	nM	78.0
	12197217	CHEMBL2209550	Inhibition of PYK2 after 2hrs by fluorescence polarization assay	B	CCOCCCNC(=O)c1cc2cccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc(C)cc3)c2[nH]1		CHEMBL2207430	=	IC50	nM	75.0	CHEMBL5469	Homo sapiens	IC50	nM	75.0
	12197218	CHEMBL2209550	Inhibition of PYK2 after 2hrs by fluorescence polarization assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cc(-c3ccc4c(c3)OCCO4)[nH]n2)cc1		CHEMBL2207438	=	IC50	nM	69.0	CHEMBL5469	Homo sapiens	IC50	nM	69.0
	12197220	CHEMBL2209550	Inhibition of PYK2 after 2hrs by fluorescence polarization assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3cc(C(=O)N4CCC5(CCNC5)C4)[nH]c23)cc1		CHEMBL2207428	=	IC50	nM	57.0	CHEMBL5469	Homo sapiens	IC50	nM	57.0
	12197221	CHEMBL2209550	Inhibition of PYK2 after 2hrs by fluorescence polarization assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3cc(C(=O)N4CCCC4)[nH]c23)cc1		CHEMBL2207823	=	IC50	nM	31.0	CHEMBL5469	Homo sapiens	IC50	nM	31.0
	12197222	CHEMBL2209550	Inhibition of PYK2 after 2hrs by fluorescence polarization assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cc(-c3ccc4nccn4c3)[nH]n2)cc1		CHEMBL2207439	=	IC50	nM	25.0	CHEMBL5469	Homo sapiens	IC50	nM	25.0
	12197223	CHEMBL2209550	Inhibition of PYK2 after 2hrs by fluorescence polarization assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cc(-c3ccc4nccnc4c3)[nH]n2)cc1		CHEMBL2207441	=	IC50	nM	12.5	CHEMBL5469	Homo sapiens	IC50	nM	12.5
	12197224	CHEMBL2209552	Inhibition of human recombinant C-terminal His-tagged PYK2 using ATP as substrate incubated for 1 hr prior to substrate addition	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	=	IC50	nM	11500.0	CHEMBL5469	Homo sapiens	IC50	uM	11.5
	12197225	CHEMBL2209550	Inhibition of PYK2 after 2hrs by fluorescence polarization assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cc(-c3ccc4ncccc4c3)[nH]n2)cc1		CHEMBL2207440	=	IC50	nM	6.4	CHEMBL5469	Homo sapiens	IC50	nM	6.4
	12197233	CHEMBL2209550	Inhibition of PYK2 after 2hrs by fluorescence polarization assay	B	COc1cnc(-c2cc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc(C)cc3)n[nH]2)cn1		CHEMBL2207434	>	IC50	nM	10000.0	CHEMBL5469	Homo sapiens	IC50	nM	10000.0
	12197234	CHEMBL2209550	Inhibition of PYK2 after 2hrs by fluorescence polarization assay	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cc(CO)[nH]n2)cc1		CHEMBL2207442	>	IC50	nM	100000.0	CHEMBL5469	Homo sapiens	IC50	uM	100.0
	12262912	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O		CHEMBL2218926	=	Residual Activity	%	112.0	CHEMBL5469	Homo sapiens	Residual Activity	%	112.0
	12262913	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12		CHEMBL266487	=	Residual Activity	%	97.0	CHEMBL5469	Homo sapiens	Residual Activity	%	97.0
	12262914	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2cc(Nc3cccc(C(F)(F)F)c3)ncn2)c1)C1CC1		CHEMBL387187	=	Residual Activity	%	104.0	CHEMBL5469	Homo sapiens	Residual Activity	%	104.0
	12262915	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12		CHEMBL439259	=	Residual Activity	%	121.0	CHEMBL5469	Homo sapiens	Residual Activity	%	121.0
	12262916	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1		CHEMBL53753	=	Residual Activity	%	116.0	CHEMBL5469	Homo sapiens	Residual Activity	%	116.0
	12262917	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL65063	=	Residual Activity	%	120.0	CHEMBL5469	Homo sapiens	Residual Activity	%	120.0
	12262918	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Residual Activity	%	22.0	CHEMBL5469	Homo sapiens	Residual Activity	%	22.0
	12262919	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC		CHEMBL7917	=	Residual Activity	%	117.0	CHEMBL5469	Homo sapiens	Residual Activity	%	117.0
	12262920	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc2cc3nc(-c4cccs4)cnc3cc2n1C		CHEMBL2218927	=	Residual Activity	%	123.0	CHEMBL5469	Homo sapiens	Residual Activity	%	123.0
	12262921	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cnc2cc3c(Nc4cccc(Br)c4)ncnc3cc21		CHEMBL174426	=	Residual Activity	%	119.0	CHEMBL5469	Homo sapiens	Residual Activity	%	119.0
	12262922	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1		CHEMBL203644	=	Residual Activity	%	120.0	CHEMBL5469	Homo sapiens	Residual Activity	%	120.0
	12262923	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1nc2ccccc2n1CCN1CCOCC1)c1cccc([N+](=O)[O-])c1		CHEMBL379787	=	Residual Activity	%	114.0	CHEMBL5469	Homo sapiens	Residual Activity	%	114.0
	12262924	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL188762	=	Residual Activity	%	126.0	CHEMBL5469	Homo sapiens	Residual Activity	%	126.0
	12262925	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21		CHEMBL573578	=	Residual Activity	%	89.0	CHEMBL5469	Homo sapiens	Residual Activity	%	89.0
	12262926	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NCCNc1ncc(C(N)=O)c(Nc2cccc(C(F)(F)F)c2)n1		CHEMBL471901	=	Residual Activity	%	27.0	CHEMBL5469	Homo sapiens	Residual Activity	%	27.0
	12262927	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccccc32)c1C		CHEMBL86943	=	Residual Activity	%	80.0	CHEMBL5469	Homo sapiens	Residual Activity	%	80.0
	12262928	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC[n+]1c(/C=C/N(C)c2ccccc2)n(-c2ccccc2)c2ccc(-c3nc4ccccc4s3)cc21		CHEMBL1186409	=	Residual Activity	%	139.0	CHEMBL5469	Homo sapiens	Residual Activity	%	139.0
	12262929	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c[n+](C)c3c4cc5c(cc4ccc23)OCO5)c1OC		CHEMBL13045	=	Residual Activity	%	133.0	CHEMBL5469	Homo sapiens	Residual Activity	%	133.0
	12262930	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C(=O)Nc2sc3c(c2C(N)=O)CCCC3)cc1OC		CHEMBL210833	=	Residual Activity	%	121.0	CHEMBL5469	Homo sapiens	Residual Activity	%	121.0
	12262931	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	=	Residual Activity	%	17.0	CHEMBL5469	Homo sapiens	Residual Activity	%	17.0
	12262932	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCC(=O)Oc1ccc2[nH]c(C(=O)c3cc4ccccc4[nH]3)cc2c1		CHEMBL266325	=	Residual Activity	%	122.0	CHEMBL5469	Homo sapiens	Residual Activity	%	122.0
	12262933	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2cc(Nc3ccc(F)cc3)c(Nc3ccc(F)cc3)cc21		CHEMBL7939	=	Residual Activity	%	119.0	CHEMBL5469	Homo sapiens	Residual Activity	%	119.0
	12262934	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])/C=C/c1ccc2c(c1)OCO2		CHEMBL596380	=	Residual Activity	%	129.0	CHEMBL5469	Homo sapiens	Residual Activity	%	129.0
	12262935	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1ccc(Cl)cc1)c1ccccc1NCc1ccncc1		CHEMBL101683	=	Residual Activity	%	128.0	CHEMBL5469	Homo sapiens	Residual Activity	%	128.0
	12262936	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN1N=C(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL331237	=	Residual Activity	%	130.0	CHEMBL5469	Homo sapiens	Residual Activity	%	130.0
	12262937	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCC		CHEMBL35820	=	Residual Activity	%	110.0	CHEMBL5469	Homo sapiens	Residual Activity	%	110.0
	12262938	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1cc2cc(O)ccc2[nH]1)c1cc2cc(O)ccc2[nH]1		CHEMBL377193	=	Residual Activity	%	68.0	CHEMBL5469	Homo sapiens	Residual Activity	%	68.0
	12262939	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC		CHEMBL473773	=	Residual Activity	%	85.0	CHEMBL5469	Homo sapiens	Residual Activity	%	85.0
	12262940	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(N3CCN(C(=O)Nc4ccc(Oc5ccccc5)cc4)CC3)c2cc1OC		CHEMBL102346	=	Residual Activity	%	122.0	CHEMBL5469	Homo sapiens	Residual Activity	%	122.0
	12262941	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1		CHEMBL366266	=	Residual Activity	%	121.0	CHEMBL5469	Homo sapiens	Residual Activity	%	121.0
	12262942	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454	=	Residual Activity	%	109.0	CHEMBL5469	Homo sapiens	Residual Activity	%	109.0
	12262943	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	=	Residual Activity	%	34.0	CHEMBL5469	Homo sapiens	Residual Activity	%	34.0
	12262944	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Residual Activity	%	128.0	CHEMBL5469	Homo sapiens	Residual Activity	%	128.0
	12262945	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12		CHEMBL104468	=	Residual Activity	%	130.0	CHEMBL5469	Homo sapiens	Residual Activity	%	130.0
	12262946	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Residual Activity	%	103.0	CHEMBL5469	Homo sapiens	Residual Activity	%	103.0
	12262947	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1		CHEMBL596674	=	Residual Activity	%	109.0	CHEMBL5469	Homo sapiens	Residual Activity	%	109.0
	12262948	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2		CHEMBL120077	=	Residual Activity	%	79.0	CHEMBL5469	Homo sapiens	Residual Activity	%	79.0
	12262949	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	=	Residual Activity	%	119.0	CHEMBL5469	Homo sapiens	Residual Activity	%	119.0
	12262950	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cccc(-c2[nH]c(C(C)(C)C)nc2-c2ccc3c(c2)OCO3)n1		CHEMBL226838	=	Residual Activity	%	124.0	CHEMBL5469	Homo sapiens	Residual Activity	%	124.0
	12262951	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Br)cc2/C1=C\c1cc2c([nH]1)CCCC2		CHEMBL2218925	=	Residual Activity	%	75.0	CHEMBL5469	Homo sapiens	Residual Activity	%	75.0
	12262952	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc21		CHEMBL1398474	=	Residual Activity	%	131.0	CHEMBL5469	Homo sapiens	Residual Activity	%	131.0
	12262953	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)c1ccc(N2CCOCC2)cc1O		CHEMBL1317546	=	Residual Activity	%	124.0	CHEMBL5469	Homo sapiens	Residual Activity	%	124.0
	12262954	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Residual Activity	%	4.0	CHEMBL5469	Homo sapiens	Residual Activity	%	4.0
	12262955	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(-c3cccnc3)cc2/C1=C\c1ccc[nH]1		CHEMBL2218929	=	Residual Activity	%	84.0	CHEMBL5469	Homo sapiens	Residual Activity	%	84.0
	12262956	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=S)NC(=O)c4ccccc4C)cc3)c2cc1OC		CHEMBL2218930	=	Residual Activity	%	82.0	CHEMBL5469	Homo sapiens	Residual Activity	%	82.0
	12262957	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc2c(-c3ccncc3)c[nH]c2c1		CHEMBL380071	=	Residual Activity	%	127.0	CHEMBL5469	Homo sapiens	Residual Activity	%	127.0
	12262958	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C=C(C#N)C#N)cc1		CHEMBL77456	=	Residual Activity	%	133.0	CHEMBL5469	Homo sapiens	Residual Activity	%	133.0
	12262959	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1		CHEMBL276711	=	Residual Activity	%	34.0	CHEMBL5469	Homo sapiens	Residual Activity	%	34.0
	12262960	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-c2nc3nnnn3nc21		CHEMBL599894	=	Residual Activity	%	146.0	CHEMBL5469	Homo sapiens	Residual Activity	%	146.0
	12262961	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	=	Residual Activity	%	142.0	CHEMBL5469	Homo sapiens	Residual Activity	%	142.0
	12262962	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)c(C1=C(c3c[nH]c4ccccc34)C(=O)NC1=O)cn2CCCN(C)C		CHEMBL261491	=	Residual Activity	%	116.0	CHEMBL5469	Homo sapiens	Residual Activity	%	116.0
	12262963	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C1CCCC1		CHEMBL47940	=	Residual Activity	%	86.0	CHEMBL5469	Homo sapiens	Residual Activity	%	86.0
	12262964	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc3ncsc3c2/C1=C/c1c[nH]cn1		CHEMBL235641	=	Residual Activity	%	79.0	CHEMBL5469	Homo sapiens	Residual Activity	%	79.0
	12262965	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cncc2cccc(S(=O)(=O)N3CCCN(C(=O)CN)C[C@H]3C)c12		CHEMBL2218931	=	Residual Activity	%	122.0	CHEMBL5469	Homo sapiens	Residual Activity	%	122.0
	12262966	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1		CHEMBL56543	=	Residual Activity	%	146.0	CHEMBL5469	Homo sapiens	Residual Activity	%	146.0
	12262967	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(-c2cnc3c(-c4ccsc4)cnn3c2)cc1		CHEMBL92461	=	Residual Activity	%	136.0	CHEMBL5469	Homo sapiens	Residual Activity	%	136.0
	12262968	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(NC(=O)c4ccccc4)cc3)c2cc1OC		CHEMBL382590	=	Residual Activity	%	134.0	CHEMBL5469	Homo sapiens	Residual Activity	%	134.0
	12262969	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1c2ccccc2[nH]c(=S)n1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1		CHEMBL261131	=	Residual Activity	%	136.0	CHEMBL5469	Homo sapiens	Residual Activity	%	136.0
	12262970	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]c3c2oc2ccccc23)cc1		CHEMBL406375	=	Residual Activity	%	112.0	CHEMBL5469	Homo sapiens	Residual Activity	%	112.0
	12262971	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12		CHEMBL98350	=	Residual Activity	%	127.0	CHEMBL5469	Homo sapiens	Residual Activity	%	127.0
	12262972	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Cl)cc2/C1=C/c1cc(Cl)c(O)c(Cl)c1		CHEMBL2218932	=	Residual Activity	%	96.0	CHEMBL5469	Homo sapiens	Residual Activity	%	96.0
	12262973	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Residual Activity	%	16.0	CHEMBL5469	Homo sapiens	Residual Activity	%	16.0
	12262974	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CC(C#N)=C(N)/C(C#N)=C/c1ccc(O)cc1		CHEMBL76589	=	Residual Activity	%	129.0	CHEMBL5469	Homo sapiens	Residual Activity	%	129.0
	12262975	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1ccccc1)c1ccc(N2CCOCC2)cc1O		CHEMBL478980	=	Residual Activity	%	130.0	CHEMBL5469	Homo sapiens	Residual Activity	%	130.0
	12262976	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1cccc(-c2cc(Nc3ccc(OC(F)(F)F)cc3)ncn2)c1		CHEMBL483847	=	Residual Activity	%	128.0	CHEMBL5469	Homo sapiens	Residual Activity	%	128.0
	12262977	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)c1ccc(/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL328710	=	Residual Activity	%	103.0	CHEMBL5469	Homo sapiens	Residual Activity	%	103.0
	12262978	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1/C=C/C=C(\C)C(=O)NC2=CC(=O)C=C(C2=O)[C@H](OC)[C@@H](C)C[C@H](OC)[C@H](OC)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O		CHEMBL479533	=	Residual Activity	%	124.0	CHEMBL5469	Homo sapiens	Residual Activity	%	124.0
	12262979	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCNCC2)oc2c(-c3ccccc3)cccc12		CHEMBL1363184	=	Residual Activity	%	112.0	CHEMBL5469	Homo sapiens	Residual Activity	%	112.0
	12262980	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C\c2ccc3nccnc3c2)S1		CHEMBL2218934	=	Residual Activity	%	124.0	CHEMBL5469	Homo sapiens	Residual Activity	%	124.0
	12262981	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC		CHEMBL97771	=	Residual Activity	%	96.0	CHEMBL5469	Homo sapiens	Residual Activity	%	96.0
	12262982	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc2ncc(-c3ccccc3)nc2cc1C		CHEMBL7724	=	Residual Activity	%	126.0	CHEMBL5469	Homo sapiens	Residual Activity	%	126.0
	12262983	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2nccc(Nc3cccc(C(F)(F)F)c3)n2)c1)C1CC1		CHEMBL383899	=	Residual Activity	%	55.0	CHEMBL5469	Homo sapiens	Residual Activity	%	55.0
	12262984	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL7463	=	Residual Activity	%	115.0	CHEMBL5469	Homo sapiens	Residual Activity	%	115.0
	12262985	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2cc1OC		CHEMBL563845	=	Residual Activity	%	111.0	CHEMBL5469	Homo sapiens	Residual Activity	%	111.0
	12262986	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2cnc(Nc3ccc(OCCN4CCCC4)cc3)s2)cc1		CHEMBL2218935	=	Residual Activity	%	105.0	CHEMBL5469	Homo sapiens	Residual Activity	%	105.0
	12262987	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC1=C(C(=O)N2CCN(C)CC2)C(C)=C(/C=C2\C(=O)Nc3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc32)C1		CHEMBL2218936	=	Residual Activity	%	43.0	CHEMBL5469	Homo sapiens	Residual Activity	%	43.0
	12262988	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C/c2ccc3c(c2)OC(F)(F)O3)S1		CHEMBL1231533	=	Residual Activity	%	135.0	CHEMBL5469	Homo sapiens	Residual Activity	%	135.0
	12262989	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(Cl)cc32)c1C		CHEMBL13485	=	Residual Activity	%	15.0	CHEMBL5469	Homo sapiens	Residual Activity	%	15.0
	12262990	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncc(-c3ccccc3)nc2cc1OC		CHEMBL71191	=	Residual Activity	%	119.0	CHEMBL5469	Homo sapiens	Residual Activity	%	119.0
	12262991	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Residual Activity	%	2.0	CHEMBL5469	Homo sapiens	Residual Activity	%	2.0
	12262992	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(c2ccccc2)CC1)S(=O)(=O)c1cccc2cnccc12		CHEMBL28324	=	Residual Activity	%	98.0	CHEMBL5469	Homo sapiens	Residual Activity	%	98.0
	12262993	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Residual Activity	%	55.0	CHEMBL5469	Homo sapiens	Residual Activity	%	55.0
	12262994	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3cc(Br)ccc3c21		CHEMBL64758	=	Residual Activity	%	71.0	CHEMBL5469	Homo sapiens	Residual Activity	%	71.0
	12262995	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Residual Activity	%	115.0	CHEMBL5469	Homo sapiens	Residual Activity	%	115.0
	12262996	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Residual Activity	%	13.0	CHEMBL5469	Homo sapiens	Residual Activity	%	13.0
	12262997	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(CCCc1ccc(-c2ccccc2F)cc1)Nc1ccc(O)cc1		CHEMBL235658	=	Residual Activity	%	105.0	CHEMBL5469	Homo sapiens	Residual Activity	%	105.0
	12262998	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)c3ccccc3)c2)[nH]1		CHEMBL111364	=	Residual Activity	%	105.0	CHEMBL5469	Homo sapiens	Residual Activity	%	105.0
	12262999	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	=	Residual Activity	%	115.0	CHEMBL5469	Homo sapiens	Residual Activity	%	115.0
	12263000	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(-c2cccc3c2Sc2ccccc2S3)oc(N2CCOCC2)c1		CHEMBL222102	=	Residual Activity	%	91.0	CHEMBL5469	Homo sapiens	Residual Activity	%	91.0
	12263001	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=Nc1c(-c2c(O)[nH]c3ccccc23)[nH]c2ccccc12		CHEMBL126077	=	Residual Activity	%	14.0	CHEMBL5469	Homo sapiens	Residual Activity	%	14.0
	12263002	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(OC)c2c(=S)c3ccccc3[nH]c12		CHEMBL1331734	=	Residual Activity	%	79.0	CHEMBL5469	Homo sapiens	Residual Activity	%	79.0
	12263003	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL259551	=	Residual Activity	%	95.0	CHEMBL5469	Homo sapiens	Residual Activity	%	95.0
	12263004	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(Nc2nc(-c3ccccc3)nc3ccccc23)n[nH]1		CHEMBL359482	=	Residual Activity	%	20.0	CHEMBL5469	Homo sapiens	Residual Activity	%	20.0
	12263005	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	=	Residual Activity	%	98.0	CHEMBL5469	Homo sapiens	Residual Activity	%	98.0
	12263006	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1ccc(Cl)cc1		CHEMBL91730	=	Residual Activity	%	90.0	CHEMBL5469	Homo sapiens	Residual Activity	%	90.0
	12263007	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Residual Activity	%	104.0	CHEMBL5469	Homo sapiens	Residual Activity	%	104.0
	12263008	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(NC(NC(=S)Nc1ccc(F)c([N+](=O)[O-])c1)C(Cl)(Cl)Cl)C(c1ccccc1)c1ccccc1		CHEMBL1221601	=	Residual Activity	%	108.0	CHEMBL5469	Homo sapiens	Residual Activity	%	108.0
	12263009	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(S(=O)(=O)/C=C/C#N)cc1		CHEMBL403183	=	Residual Activity	%	102.0	CHEMBL5469	Homo sapiens	Residual Activity	%	102.0
	12263010	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1		CHEMBL290904	=	Residual Activity	%	108.0	CHEMBL5469	Homo sapiens	Residual Activity	%	108.0
	12263011	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL2218938	=	Residual Activity	%	102.0	CHEMBL5469	Homo sapiens	Residual Activity	%	102.0
	12263012	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1n1cncc21		CHEMBL413188	=	Residual Activity	%	32.0	CHEMBL5469	Homo sapiens	Residual Activity	%	32.0
	12263013	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	=	Residual Activity	%	3.0	CHEMBL5469	Homo sapiens	Residual Activity	%	3.0
	12263014	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cccc(-c2cc(=O)c3ccccc3o2)c1N		CHEMBL35482	=	Residual Activity	%	106.0	CHEMBL5469	Homo sapiens	Residual Activity	%	106.0
	12263015	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1		CHEMBL304428	=	Residual Activity	%	90.0	CHEMBL5469	Homo sapiens	Residual Activity	%	90.0
	12263016	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Residual Activity	%	45.0	CHEMBL5469	Homo sapiens	Residual Activity	%	45.0
	12263017	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2c(NCc3ccccc3)nc(NCCCO)nc21		CHEMBL83980	=	Residual Activity	%	102.0	CHEMBL5469	Homo sapiens	Residual Activity	%	102.0
	12263018	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN1/C(=C/C(C)=O)Sc2ccc(OC)cc21		CHEMBL408982	=	Residual Activity	%	109.0	CHEMBL5469	Homo sapiens	Residual Activity	%	109.0
	12263019	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-[n+]2ccc3c([nH]c4ccccc43)c21		CHEMBL602937	=	Residual Activity	%	101.0	CHEMBL5469	Homo sapiens	Residual Activity	%	101.0
	12263020	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc(OC)c(/C=C2\C(=O)Nc3ccccc32)c(OC)c1		CHEMBL404941	=	Residual Activity	%	114.0	CHEMBL5469	Homo sapiens	Residual Activity	%	114.0
	12263021	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Residual Activity	%	89.0	CHEMBL5469	Homo sapiens	Residual Activity	%	89.0
	12263022	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17331	=	Residual Activity	%	114.0	CHEMBL5469	Homo sapiens	Residual Activity	%	114.0
	12263023	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc(-c2ccccc2)c(-c2ccncc2)o1		CHEMBL36450	=	Residual Activity	%	91.0	CHEMBL5469	Homo sapiens	Residual Activity	%	91.0
	12263024	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CCCc1ccc2c(c1)-c1[nH]c3ccc([N+](=O)[O-])cc3c1CC(=O)N2		CHEMBL260138	=	Residual Activity	%	19.0	CHEMBL5469	Homo sapiens	Residual Activity	%	19.0
	12263025	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C\c1c(Cl)[nH]c2ccccc12		CHEMBL261425	=	Residual Activity	%	96.0	CHEMBL5469	Homo sapiens	Residual Activity	%	96.0
	12263026	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc2[nH]c(-c3ccc(Oc4ccc(Cl)cc4)cc3)nc2c1		CHEMBL179583	=	Residual Activity	%	100.0	CHEMBL5469	Homo sapiens	Residual Activity	%	100.0
	12263027	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1sc(=O)n(Cc2ccccc2)c1=O		CHEMBL284861	=	Residual Activity	%	99.0	CHEMBL5469	Homo sapiens	Residual Activity	%	99.0
	12263028	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167	=	Residual Activity	%	56.0	CHEMBL5469	Homo sapiens	Residual Activity	%	56.0
	12263029	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(S(=O)(=O)N(CCO)c2ccccc2CN(C)C/C=C/c2ccc(Cl)cc2)cc1		CHEMBL155333	=	Residual Activity	%	109.0	CHEMBL5469	Homo sapiens	Residual Activity	%	109.0
	12263030	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	=	Residual Activity	%	107.0	CHEMBL5469	Homo sapiens	Residual Activity	%	107.0
	12263031	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL313417	=	Residual Activity	%	109.0	CHEMBL5469	Homo sapiens	Residual Activity	%	109.0
	12263032	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12		CHEMBL75680	=	Residual Activity	%	54.0	CHEMBL5469	Homo sapiens	Residual Activity	%	54.0
	12263033	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL367625	=	Residual Activity	%	49.0	CHEMBL5469	Homo sapiens	Residual Activity	%	49.0
	12263034	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2/c(=N/c3cccc(Cl)c3)nc(NCCO)[nH]c21		CHEMBL311228	=	Residual Activity	%	56.0	CHEMBL5469	Homo sapiens	Residual Activity	%	56.0
	12263035	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Ic1cccc(CSc2nnc(-c3ccncc3)o2)c1		CHEMBL288064	=	Residual Activity	%	103.0	CHEMBL5469	Homo sapiens	Residual Activity	%	103.0
	12263036	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C1/Nc2ccccc2/C1=N\OCCC(O)CO		CHEMBL1802727	=	Residual Activity	%	7.0	CHEMBL5469	Homo sapiens	Residual Activity	%	7.0
	12263037	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(/N)SC1C=CC=CC1)c1cccc(C(O)c2ccncc2)c1		CHEMBL2218939	=	Residual Activity	%	98.0	CHEMBL5469	Homo sapiens	Residual Activity	%	98.0
	12263038	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	=	Residual Activity	%	35.0	CHEMBL5469	Homo sapiens	Residual Activity	%	35.0
	12263039	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(Nc2nc(-c3ccc(Cl)cc3)cs2)cc1		CHEMBL1076555	=	Residual Activity	%	109.0	CHEMBL5469	Homo sapiens	Residual Activity	%	109.0
	12263040	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(OC)cc2)[nH]c2nccnc12		CHEMBL306498	=	Residual Activity	%	54.0	CHEMBL5469	Homo sapiens	Residual Activity	%	54.0
	12263041	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=S)Nc1c(F)cccc1F		CHEMBL261720	=	Residual Activity	%	4.0	CHEMBL5469	Homo sapiens	Residual Activity	%	4.0
	12263042	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNc2nc(N(CCO)CCO)nc3c2ncn3C(C)C)cc1		CHEMBL80713	=	Residual Activity	%	83.0	CHEMBL5469	Homo sapiens	Residual Activity	%	83.0
	12263043	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	=	Residual Activity	%	72.0	CHEMBL5469	Homo sapiens	Residual Activity	%	72.0
	12263044	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Residual Activity	%	68.0	CHEMBL5469	Homo sapiens	Residual Activity	%	68.0
	12263045	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1C(Cl)=C(N2C(=O)CCC2=O)C(=O)c2ccccc21		CHEMBL404939	=	Residual Activity	%	91.0	CHEMBL5469	Homo sapiens	Residual Activity	%	91.0
	12263046	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1cccc(-c2cc3c(Oc4cccc(O)c4)ncnc3[nH]2)c1		CHEMBL405759	=	Residual Activity	%	25.0	CHEMBL5469	Homo sapiens	Residual Activity	%	25.0
	12263047	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL286721	=	Residual Activity	%	59.0	CHEMBL5469	Homo sapiens	Residual Activity	%	59.0
	12263048	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nc3ccccc3nc12		CHEMBL259389	=	Residual Activity	%	107.0	CHEMBL5469	Homo sapiens	Residual Activity	%	107.0
	12263049	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)C(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1		CHEMBL1802728	=	Residual Activity	%	22.0	CHEMBL5469	Homo sapiens	Residual Activity	%	22.0
	12263050	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O		CHEMBL409450	=	Residual Activity	%	10.0	CHEMBL5469	Homo sapiens	Residual Activity	%	10.0
	12263051	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1nc2c3c(cccc31)C(=O)c1ccccc1-2		CHEMBL1802485	=	Residual Activity	%	106.0	CHEMBL5469	Homo sapiens	Residual Activity	%	106.0
	12263052	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(\N)Sc1ccc(N)cc1)c1ccccc1C(F)(F)F		CHEMBL2218940	=	Residual Activity	%	100.0	CHEMBL5469	Homo sapiens	Residual Activity	%	100.0
	12263053	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Residual Activity	%	103.0	CHEMBL5469	Homo sapiens	Residual Activity	%	103.0
	12263054	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)c1ccc2c3c1cccc3c(=O)n1c3ccccc3nc21		CHEMBL1182777	=	Residual Activity	%	88.0	CHEMBL5469	Homo sapiens	Residual Activity	%	88.0
	12263055	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1		CHEMBL478629	=	Residual Activity	%	110.0	CHEMBL5469	Homo sapiens	Residual Activity	%	110.0
	12263056	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1		CHEMBL410456	=	Residual Activity	%	117.0	CHEMBL5469	Homo sapiens	Residual Activity	%	117.0
	12263057	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)c1nn(-c2c(Cl)cccc2Cl)c2nc(Cc3ccc(OCCO)cc3)[nH]c(=O)c12		CHEMBL258721	=	Residual Activity	%	109.0	CHEMBL5469	Homo sapiens	Residual Activity	%	109.0
	12263058	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)O/N=C1C(=C2\C(=O)Nc3cc(Br)ccc32)\Nc2ccccc2\1		CHEMBL2218941	=	Residual Activity	%	79.0	CHEMBL5469	Homo sapiens	Residual Activity	%	79.0
	12263059	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Residual Activity	%	106.0	CHEMBL5469	Homo sapiens	Residual Activity	%	106.0
	12263060	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12		CHEMBL1240885	=	Residual Activity	%	101.0	CHEMBL5469	Homo sapiens	Residual Activity	%	101.0
	12263061	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCc1nc(-c2ccc(OC)cc2)[nH]c1-c1ccncc1		CHEMBL278724	=	Residual Activity	%	115.0	CHEMBL5469	Homo sapiens	Residual Activity	%	115.0
	12263062	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL258805	=	Residual Activity	%	89.0	CHEMBL5469	Homo sapiens	Residual Activity	%	89.0
	12263063	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)/C=C/c1cc(Br)c(Br)c(Br)c1Br		CHEMBL270724	=	Residual Activity	%	111.0	CHEMBL5469	Homo sapiens	Residual Activity	%	111.0
	12263064	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N/C(=N\[N+](=O)[O-])N/N=C\c1ccc(-c2cccc([N+](=O)[O-])c2)o1		CHEMBL221271	=	Residual Activity	%	111.0	CHEMBL5469	Homo sapiens	Residual Activity	%	111.0
	12263065	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1cnccn1		CHEMBL272629	=	Residual Activity	%	100.0	CHEMBL5469	Homo sapiens	Residual Activity	%	100.0
	12263066	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Residual Activity	%	115.0	CHEMBL5469	Homo sapiens	Residual Activity	%	115.0
	12263067	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1		CHEMBL522502	=	Residual Activity	%	88.0	CHEMBL5469	Homo sapiens	Residual Activity	%	88.0
	12263068	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	=	Residual Activity	%	111.0	CHEMBL5469	Homo sapiens	Residual Activity	%	111.0
	12263069	CHEMBL2219147	Millipore: Percentage of residual kinase activity of PTK2B at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1cnc2cnc(NCc3cccnc3)cc2c1Nc1ccc(F)c(Cl)c1		CHEMBL200381	=	Residual Activity	%	66.0	CHEMBL5469	Homo sapiens	Residual Activity	%	66.0
	12263070	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O		CHEMBL2218926	=	Residual Activity	%	85.0	CHEMBL5469	Homo sapiens	Residual Activity	%	85.0
	12263071	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12		CHEMBL266487	=	Residual Activity	%	28.0	CHEMBL5469	Homo sapiens	Residual Activity	%	28.0
	12263072	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2cc(Nc3cccc(C(F)(F)F)c3)ncn2)c1)C1CC1		CHEMBL387187	=	Residual Activity	%	63.0	CHEMBL5469	Homo sapiens	Residual Activity	%	63.0
	12263073	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12		CHEMBL439259	=	Residual Activity	%	85.0	CHEMBL5469	Homo sapiens	Residual Activity	%	85.0
	12263074	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1		CHEMBL53753	=	Residual Activity	%	64.0	CHEMBL5469	Homo sapiens	Residual Activity	%	64.0
	12263075	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL65063	=	Residual Activity	%	97.0	CHEMBL5469	Homo sapiens	Residual Activity	%	97.0
	12263076	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Residual Activity	%	5.0	CHEMBL5469	Homo sapiens	Residual Activity	%	5.0
	12263077	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC		CHEMBL7917	=	Residual Activity	%	76.0	CHEMBL5469	Homo sapiens	Residual Activity	%	76.0
	12263078	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc2cc3nc(-c4cccs4)cnc3cc2n1C		CHEMBL2218927	=	Residual Activity	%	87.0	CHEMBL5469	Homo sapiens	Residual Activity	%	87.0
	12263079	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cnc2cc3c(Nc4cccc(Br)c4)ncnc3cc21		CHEMBL174426	=	Residual Activity	%	77.0	CHEMBL5469	Homo sapiens	Residual Activity	%	77.0
	12263080	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1		CHEMBL203644	=	Residual Activity	%	92.0	CHEMBL5469	Homo sapiens	Residual Activity	%	92.0
	12263081	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1nc2ccccc2n1CCN1CCOCC1)c1cccc([N+](=O)[O-])c1		CHEMBL379787	=	Residual Activity	%	86.0	CHEMBL5469	Homo sapiens	Residual Activity	%	86.0
	12263082	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL188762	=	Residual Activity	%	95.0	CHEMBL5469	Homo sapiens	Residual Activity	%	95.0
	12263083	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21		CHEMBL573578	=	Residual Activity	%	29.0	CHEMBL5469	Homo sapiens	Residual Activity	%	29.0
	12263084	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NCCNc1ncc(C(N)=O)c(Nc2cccc(C(F)(F)F)c2)n1		CHEMBL471901	=	Residual Activity	%	3.0	CHEMBL5469	Homo sapiens	Residual Activity	%	3.0
	12263085	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccccc32)c1C		CHEMBL86943	=	Residual Activity	%	45.0	CHEMBL5469	Homo sapiens	Residual Activity	%	45.0
	12263086	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC[n+]1c(/C=C/N(C)c2ccccc2)n(-c2ccccc2)c2ccc(-c3nc4ccccc4s3)cc21		CHEMBL1186409	=	Residual Activity	%	83.0	CHEMBL5469	Homo sapiens	Residual Activity	%	83.0
	12263087	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c[n+](C)c3c4cc5c(cc4ccc23)OCO5)c1OC		CHEMBL13045	=	Residual Activity	%	89.0	CHEMBL5469	Homo sapiens	Residual Activity	%	89.0
	12263088	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C(=O)Nc2sc3c(c2C(N)=O)CCCC3)cc1OC		CHEMBL210833	=	Residual Activity	%	89.0	CHEMBL5469	Homo sapiens	Residual Activity	%	89.0
	12263089	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	=	Residual Activity	%	11.0	CHEMBL5469	Homo sapiens	Residual Activity	%	11.0
	12263090	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCC(=O)Oc1ccc2[nH]c(C(=O)c3cc4ccccc4[nH]3)cc2c1		CHEMBL266325	=	Residual Activity	%	85.0	CHEMBL5469	Homo sapiens	Residual Activity	%	85.0
	12263091	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2cc(Nc3ccc(F)cc3)c(Nc3ccc(F)cc3)cc21		CHEMBL7939	=	Residual Activity	%	81.0	CHEMBL5469	Homo sapiens	Residual Activity	%	81.0
	12263092	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])/C=C/c1ccc2c(c1)OCO2		CHEMBL596380	=	Residual Activity	%	92.0	CHEMBL5469	Homo sapiens	Residual Activity	%	92.0
	12263093	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1ccc(Cl)cc1)c1ccccc1NCc1ccncc1		CHEMBL101683	=	Residual Activity	%	74.0	CHEMBL5469	Homo sapiens	Residual Activity	%	74.0
	12263094	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN1N=C(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL331237	=	Residual Activity	%	102.0	CHEMBL5469	Homo sapiens	Residual Activity	%	102.0
	12263095	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCC		CHEMBL35820	=	Residual Activity	%	58.0	CHEMBL5469	Homo sapiens	Residual Activity	%	58.0
	12263096	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1cc2cc(O)ccc2[nH]1)c1cc2cc(O)ccc2[nH]1		CHEMBL377193	=	Residual Activity	%	20.0	CHEMBL5469	Homo sapiens	Residual Activity	%	20.0
	12263097	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC		CHEMBL473773	=	Residual Activity	%	42.0	CHEMBL5469	Homo sapiens	Residual Activity	%	42.0
	12263098	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(N3CCN(C(=O)Nc4ccc(Oc5ccccc5)cc4)CC3)c2cc1OC		CHEMBL102346	=	Residual Activity	%	104.0	CHEMBL5469	Homo sapiens	Residual Activity	%	104.0
	12263099	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1		CHEMBL366266	=	Residual Activity	%	81.0	CHEMBL5469	Homo sapiens	Residual Activity	%	81.0
	12263100	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454	=	Residual Activity	%	96.0	CHEMBL5469	Homo sapiens	Residual Activity	%	96.0
	12263101	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	=	Residual Activity	%	8.0	CHEMBL5469	Homo sapiens	Residual Activity	%	8.0
	12263102	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Residual Activity	%	89.0	CHEMBL5469	Homo sapiens	Residual Activity	%	89.0
	12263103	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12		CHEMBL104468	=	Residual Activity	%	100.0	CHEMBL5469	Homo sapiens	Residual Activity	%	100.0
	12263104	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Residual Activity	%	100.0	CHEMBL5469	Homo sapiens	Residual Activity	%	100.0
	12263105	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1		CHEMBL596674	=	Residual Activity	%	100.0	CHEMBL5469	Homo sapiens	Residual Activity	%	100.0
	12263106	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2		CHEMBL120077	=	Residual Activity	%	32.0	CHEMBL5469	Homo sapiens	Residual Activity	%	32.0
	12263107	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	=	Residual Activity	%	99.0	CHEMBL5469	Homo sapiens	Residual Activity	%	99.0
	12263108	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cccc(-c2[nH]c(C(C)(C)C)nc2-c2ccc3c(c2)OCO3)n1		CHEMBL226838	=	Residual Activity	%	103.0	CHEMBL5469	Homo sapiens	Residual Activity	%	103.0
	12263109	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Br)cc2/C1=C\c1cc2c([nH]1)CCCC2		CHEMBL2218925	=	Residual Activity	%	49.0	CHEMBL5469	Homo sapiens	Residual Activity	%	49.0
	12263110	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc21		CHEMBL1398474	=	Residual Activity	%	115.0	CHEMBL5469	Homo sapiens	Residual Activity	%	115.0
	12263111	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)c1ccc(N2CCOCC2)cc1O		CHEMBL1317546	=	Residual Activity	%	103.0	CHEMBL5469	Homo sapiens	Residual Activity	%	103.0
	12263112	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Residual Activity	%	4.0	CHEMBL5469	Homo sapiens	Residual Activity	%	4.0
	12263113	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(-c3cccnc3)cc2/C1=C\c1ccc[nH]1		CHEMBL2218929	=	Residual Activity	%	25.0	CHEMBL5469	Homo sapiens	Residual Activity	%	25.0
	12263114	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=S)NC(=O)c4ccccc4C)cc3)c2cc1OC		CHEMBL2218930	=	Residual Activity	%	60.0	CHEMBL5469	Homo sapiens	Residual Activity	%	60.0
	12263115	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc2c(-c3ccncc3)c[nH]c2c1		CHEMBL380071	=	Residual Activity	%	93.0	CHEMBL5469	Homo sapiens	Residual Activity	%	93.0
	12263116	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C=C(C#N)C#N)cc1		CHEMBL77456	=	Residual Activity	%	91.0	CHEMBL5469	Homo sapiens	Residual Activity	%	91.0
	12263117	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1		CHEMBL276711	=	Residual Activity	%	10.0	CHEMBL5469	Homo sapiens	Residual Activity	%	10.0
	12263118	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-c2nc3nnnn3nc21		CHEMBL599894	=	Residual Activity	%	107.0	CHEMBL5469	Homo sapiens	Residual Activity	%	107.0
	12263119	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	=	Residual Activity	%	95.0	CHEMBL5469	Homo sapiens	Residual Activity	%	95.0
	12263120	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)c(C1=C(c3c[nH]c4ccccc34)C(=O)NC1=O)cn2CCCN(C)C		CHEMBL261491	=	Residual Activity	%	32.0	CHEMBL5469	Homo sapiens	Residual Activity	%	32.0
	12263121	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C1CCCC1		CHEMBL47940	=	Residual Activity	%	25.0	CHEMBL5469	Homo sapiens	Residual Activity	%	25.0
	12263122	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc3ncsc3c2/C1=C/c1c[nH]cn1		CHEMBL235641	=	Residual Activity	%	17.0	CHEMBL5469	Homo sapiens	Residual Activity	%	17.0
	12263123	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cncc2cccc(S(=O)(=O)N3CCCN(C(=O)CN)C[C@H]3C)c12		CHEMBL2218931	=	Residual Activity	%	55.0	CHEMBL5469	Homo sapiens	Residual Activity	%	55.0
	12263124	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1		CHEMBL56543	=	Residual Activity	%	101.0	CHEMBL5469	Homo sapiens	Residual Activity	%	101.0
	12263125	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(-c2cnc3c(-c4ccsc4)cnn3c2)cc1		CHEMBL92461	=	Residual Activity	%	94.0	CHEMBL5469	Homo sapiens	Residual Activity	%	94.0
	12263126	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(NC(=O)c4ccccc4)cc3)c2cc1OC		CHEMBL382590	=	Residual Activity	%	75.0	CHEMBL5469	Homo sapiens	Residual Activity	%	75.0
	12263127	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1c2ccccc2[nH]c(=S)n1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1		CHEMBL261131	=	Residual Activity	%	91.0	CHEMBL5469	Homo sapiens	Residual Activity	%	91.0
	12264770	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]c3c2oc2ccccc23)cc1		CHEMBL406375	=	Residual Activity	%	66.0	CHEMBL5469	Homo sapiens	Residual Activity	%	66.0
	12264771	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12		CHEMBL98350	=	Residual Activity	%	94.0	CHEMBL5469	Homo sapiens	Residual Activity	%	94.0
	12264772	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Cl)cc2/C1=C/c1cc(Cl)c(O)c(Cl)c1		CHEMBL2218932	=	Residual Activity	%	28.0	CHEMBL5469	Homo sapiens	Residual Activity	%	28.0
	12264773	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Residual Activity	%	10.0	CHEMBL5469	Homo sapiens	Residual Activity	%	10.0
	12264774	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CC(C#N)=C(N)/C(C#N)=C/c1ccc(O)cc1		CHEMBL76589	=	Residual Activity	%	94.0	CHEMBL5469	Homo sapiens	Residual Activity	%	94.0
	12264775	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1ccccc1)c1ccc(N2CCOCC2)cc1O		CHEMBL478980	=	Residual Activity	%	105.0	CHEMBL5469	Homo sapiens	Residual Activity	%	105.0
	12264776	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1cccc(-c2cc(Nc3ccc(OC(F)(F)F)cc3)ncn2)c1		CHEMBL483847	=	Residual Activity	%	95.0	CHEMBL5469	Homo sapiens	Residual Activity	%	95.0
	12264777	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)c1ccc(/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL328710	=	Residual Activity	%	47.0	CHEMBL5469	Homo sapiens	Residual Activity	%	47.0
	12264778	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1/C=C/C=C(\C)C(=O)NC2=CC(=O)C=C(C2=O)[C@H](OC)[C@@H](C)C[C@H](OC)[C@H](OC)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O		CHEMBL479533	=	Residual Activity	%	100.0	CHEMBL5469	Homo sapiens	Residual Activity	%	100.0
	12264779	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCNCC2)oc2c(-c3ccccc3)cccc12		CHEMBL1363184	=	Residual Activity	%	96.0	CHEMBL5469	Homo sapiens	Residual Activity	%	96.0
	12264780	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C\c2ccc3nccnc3c2)S1		CHEMBL2218934	=	Residual Activity	%	103.0	CHEMBL5469	Homo sapiens	Residual Activity	%	103.0
	12264781	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC		CHEMBL97771	=	Residual Activity	%	69.0	CHEMBL5469	Homo sapiens	Residual Activity	%	69.0
	12264782	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc2ncc(-c3ccccc3)nc2cc1C		CHEMBL7724	=	Residual Activity	%	101.0	CHEMBL5469	Homo sapiens	Residual Activity	%	101.0
	12264783	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2nccc(Nc3cccc(C(F)(F)F)c3)n2)c1)C1CC1		CHEMBL383899	=	Residual Activity	%	12.0	CHEMBL5469	Homo sapiens	Residual Activity	%	12.0
	12264784	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL7463	=	Residual Activity	%	42.0	CHEMBL5469	Homo sapiens	Residual Activity	%	42.0
	12264785	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2cc1OC		CHEMBL563845	=	Residual Activity	%	67.0	CHEMBL5469	Homo sapiens	Residual Activity	%	67.0
	12264786	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2cnc(Nc3ccc(OCCN4CCCC4)cc3)s2)cc1		CHEMBL2218935	=	Residual Activity	%	43.0	CHEMBL5469	Homo sapiens	Residual Activity	%	43.0
	12264787	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC1=C(C(=O)N2CCN(C)CC2)C(C)=C(/C=C2\C(=O)Nc3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc32)C1		CHEMBL2218936	=	Residual Activity	%	11.0	CHEMBL5469	Homo sapiens	Residual Activity	%	11.0
	12264788	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C/c2ccc3c(c2)OC(F)(F)O3)S1		CHEMBL1231533	=	Residual Activity	%	101.0	CHEMBL5469	Homo sapiens	Residual Activity	%	101.0
	12264789	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(Cl)cc32)c1C		CHEMBL13485	=	Residual Activity	%	3.0	CHEMBL5469	Homo sapiens	Residual Activity	%	3.0
	12264790	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncc(-c3ccccc3)nc2cc1OC		CHEMBL71191	=	Residual Activity	%	76.0	CHEMBL5469	Homo sapiens	Residual Activity	%	76.0
	12264791	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Residual Activity	%	1.0	CHEMBL5469	Homo sapiens	Residual Activity	%	1.0
	12264792	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(c2ccccc2)CC1)S(=O)(=O)c1cccc2cnccc12		CHEMBL28324	=	Residual Activity	%	95.0	CHEMBL5469	Homo sapiens	Residual Activity	%	95.0
	12264793	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Residual Activity	%	14.0	CHEMBL5469	Homo sapiens	Residual Activity	%	14.0
	12264794	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3cc(Br)ccc3c21		CHEMBL64758	=	Residual Activity	%	84.0	CHEMBL5469	Homo sapiens	Residual Activity	%	84.0
	12264795	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Residual Activity	%	114.0	CHEMBL5469	Homo sapiens	Residual Activity	%	114.0
	12264796	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Residual Activity	%	7.0	CHEMBL5469	Homo sapiens	Residual Activity	%	7.0
	12264797	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(CCCc1ccc(-c2ccccc2F)cc1)Nc1ccc(O)cc1		CHEMBL235658	=	Residual Activity	%	104.0	CHEMBL5469	Homo sapiens	Residual Activity	%	104.0
	12264798	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)c3ccccc3)c2)[nH]1		CHEMBL111364	=	Residual Activity	%	85.0	CHEMBL5469	Homo sapiens	Residual Activity	%	85.0
	12264799	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	=	Residual Activity	%	101.0	CHEMBL5469	Homo sapiens	Residual Activity	%	101.0
	12264800	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(-c2cccc3c2Sc2ccccc2S3)oc(N2CCOCC2)c1		CHEMBL222102	=	Residual Activity	%	112.0	CHEMBL5469	Homo sapiens	Residual Activity	%	112.0
	12264801	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=Nc1c(-c2c(O)[nH]c3ccccc23)[nH]c2ccccc12		CHEMBL126077	=	Residual Activity	%	2.0	CHEMBL5469	Homo sapiens	Residual Activity	%	2.0
	12264802	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(OC)c2c(=S)c3ccccc3[nH]c12		CHEMBL1331734	=	Residual Activity	%	105.0	CHEMBL5469	Homo sapiens	Residual Activity	%	105.0
	12264803	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL259551	=	Residual Activity	%	72.0	CHEMBL5469	Homo sapiens	Residual Activity	%	72.0
	12264804	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(Nc2nc(-c3ccccc3)nc3ccccc23)n[nH]1		CHEMBL359482	=	Residual Activity	%	4.0	CHEMBL5469	Homo sapiens	Residual Activity	%	4.0
	12264805	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	=	Residual Activity	%	91.0	CHEMBL5469	Homo sapiens	Residual Activity	%	91.0
	12264806	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1ccc(Cl)cc1		CHEMBL91730	=	Residual Activity	%	85.0	CHEMBL5469	Homo sapiens	Residual Activity	%	85.0
	12264807	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Residual Activity	%	112.0	CHEMBL5469	Homo sapiens	Residual Activity	%	112.0
	12264808	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(NC(NC(=S)Nc1ccc(F)c([N+](=O)[O-])c1)C(Cl)(Cl)Cl)C(c1ccccc1)c1ccccc1		CHEMBL1221601	=	Residual Activity	%	107.0	CHEMBL5469	Homo sapiens	Residual Activity	%	107.0
	12264809	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(S(=O)(=O)/C=C/C#N)cc1		CHEMBL403183	=	Residual Activity	%	104.0	CHEMBL5469	Homo sapiens	Residual Activity	%	104.0
	12264810	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1		CHEMBL290904	=	Residual Activity	%	102.0	CHEMBL5469	Homo sapiens	Residual Activity	%	102.0
	12264811	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL2218938	=	Residual Activity	%	88.0	CHEMBL5469	Homo sapiens	Residual Activity	%	88.0
	12264812	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1n1cncc21		CHEMBL413188	=	Residual Activity	%	19.0	CHEMBL5469	Homo sapiens	Residual Activity	%	19.0
	12264813	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	=	Residual Activity	%	-1.0	CHEMBL5469	Homo sapiens	Residual Activity	%	-1.0
	12264814	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cccc(-c2cc(=O)c3ccccc3o2)c1N		CHEMBL35482	=	Residual Activity	%	112.0	CHEMBL5469	Homo sapiens	Residual Activity	%	112.0
	12264815	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1		CHEMBL304428	=	Residual Activity	%	107.0	CHEMBL5469	Homo sapiens	Residual Activity	%	107.0
	12264816	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Residual Activity	%	38.0	CHEMBL5469	Homo sapiens	Residual Activity	%	38.0
	12264817	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2c(NCc3ccccc3)nc(NCCCO)nc21		CHEMBL83980	=	Residual Activity	%	83.0	CHEMBL5469	Homo sapiens	Residual Activity	%	83.0
	12264818	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN1/C(=C/C(C)=O)Sc2ccc(OC)cc21		CHEMBL408982	=	Residual Activity	%	96.0	CHEMBL5469	Homo sapiens	Residual Activity	%	96.0
	12264819	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-[n+]2ccc3c([nH]c4ccccc43)c21		CHEMBL602937	=	Residual Activity	%	97.0	CHEMBL5469	Homo sapiens	Residual Activity	%	97.0
	12264820	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc(OC)c(/C=C2\C(=O)Nc3ccccc32)c(OC)c1		CHEMBL404941	=	Residual Activity	%	104.0	CHEMBL5469	Homo sapiens	Residual Activity	%	104.0
	12264821	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Residual Activity	%	58.0	CHEMBL5469	Homo sapiens	Residual Activity	%	58.0
	12264822	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17331	=	Residual Activity	%	105.0	CHEMBL5469	Homo sapiens	Residual Activity	%	105.0
	12264823	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc(-c2ccccc2)c(-c2ccncc2)o1		CHEMBL36450	=	Residual Activity	%	79.0	CHEMBL5469	Homo sapiens	Residual Activity	%	79.0
	12264824	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CCCc1ccc2c(c1)-c1[nH]c3ccc([N+](=O)[O-])cc3c1CC(=O)N2		CHEMBL260138	=	Residual Activity	%	9.0	CHEMBL5469	Homo sapiens	Residual Activity	%	9.0
	12264825	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C\c1c(Cl)[nH]c2ccccc12		CHEMBL261425	=	Residual Activity	%	65.0	CHEMBL5469	Homo sapiens	Residual Activity	%	65.0
	12264826	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc2[nH]c(-c3ccc(Oc4ccc(Cl)cc4)cc3)nc2c1		CHEMBL179583	=	Residual Activity	%	86.0	CHEMBL5469	Homo sapiens	Residual Activity	%	86.0
	12264827	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1sc(=O)n(Cc2ccccc2)c1=O		CHEMBL284861	=	Residual Activity	%	104.0	CHEMBL5469	Homo sapiens	Residual Activity	%	104.0
	12264828	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167	=	Residual Activity	%	10.0	CHEMBL5469	Homo sapiens	Residual Activity	%	10.0
	12264829	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(S(=O)(=O)N(CCO)c2ccccc2CN(C)C/C=C/c2ccc(Cl)cc2)cc1		CHEMBL155333	=	Residual Activity	%	96.0	CHEMBL5469	Homo sapiens	Residual Activity	%	96.0
	12264830	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	=	Residual Activity	%	95.0	CHEMBL5469	Homo sapiens	Residual Activity	%	95.0
	12264831	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL313417	=	Residual Activity	%	107.0	CHEMBL5469	Homo sapiens	Residual Activity	%	107.0
	12264832	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12		CHEMBL75680	=	Residual Activity	%	26.0	CHEMBL5469	Homo sapiens	Residual Activity	%	26.0
	12264833	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL367625	=	Residual Activity	%	9.0	CHEMBL5469	Homo sapiens	Residual Activity	%	9.0
	12264834	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2/c(=N/c3cccc(Cl)c3)nc(NCCO)[nH]c21		CHEMBL311228	=	Residual Activity	%	18.0	CHEMBL5469	Homo sapiens	Residual Activity	%	18.0
	12264835	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Ic1cccc(CSc2nnc(-c3ccncc3)o2)c1		CHEMBL288064	=	Residual Activity	%	101.0	CHEMBL5469	Homo sapiens	Residual Activity	%	101.0
	12264836	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C1/Nc2ccccc2/C1=N\OCCC(O)CO		CHEMBL1802727	=	Residual Activity	%	2.0	CHEMBL5469	Homo sapiens	Residual Activity	%	2.0
	12264837	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(/N)SC1C=CC=CC1)c1cccc(C(O)c2ccncc2)c1		CHEMBL2218939	=	Residual Activity	%	102.0	CHEMBL5469	Homo sapiens	Residual Activity	%	102.0
	12264838	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	=	Residual Activity	%	4.0	CHEMBL5469	Homo sapiens	Residual Activity	%	4.0
	12264839	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(Nc2nc(-c3ccc(Cl)cc3)cs2)cc1		CHEMBL1076555	=	Residual Activity	%	106.0	CHEMBL5469	Homo sapiens	Residual Activity	%	106.0
	12264840	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(OC)cc2)[nH]c2nccnc12		CHEMBL306498	=	Residual Activity	%	32.0	CHEMBL5469	Homo sapiens	Residual Activity	%	32.0
	12264841	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=S)Nc1c(F)cccc1F		CHEMBL261720	=	Residual Activity	%	1.0	CHEMBL5469	Homo sapiens	Residual Activity	%	1.0
	12264842	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNc2nc(N(CCO)CCO)nc3c2ncn3C(C)C)cc1		CHEMBL80713	=	Residual Activity	%	85.0	CHEMBL5469	Homo sapiens	Residual Activity	%	85.0
	12264843	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	=	Residual Activity	%	77.0	CHEMBL5469	Homo sapiens	Residual Activity	%	77.0
	12264844	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Residual Activity	%	23.0	CHEMBL5469	Homo sapiens	Residual Activity	%	23.0
	12264845	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1C(Cl)=C(N2C(=O)CCC2=O)C(=O)c2ccccc21		CHEMBL404939	=	Residual Activity	%	106.0	CHEMBL5469	Homo sapiens	Residual Activity	%	106.0
	12264846	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1cccc(-c2cc3c(Oc4cccc(O)c4)ncnc3[nH]2)c1		CHEMBL405759	=	Residual Activity	%	5.0	CHEMBL5469	Homo sapiens	Residual Activity	%	5.0
	12264847	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL286721	=	Residual Activity	%	7.0	CHEMBL5469	Homo sapiens	Residual Activity	%	7.0
	12264848	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nc3ccccc3nc12		CHEMBL259389	=	Residual Activity	%	92.0	CHEMBL5469	Homo sapiens	Residual Activity	%	92.0
	12264849	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)C(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1		CHEMBL1802728	=	Residual Activity	%	0.0	CHEMBL5469	Homo sapiens	Residual Activity	%	0.0
	12264850	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O		CHEMBL409450	=	Residual Activity	%	3.0	CHEMBL5469	Homo sapiens	Residual Activity	%	3.0
	12264851	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1nc2c3c(cccc31)C(=O)c1ccccc1-2		CHEMBL1802485	=	Residual Activity	%	76.0	CHEMBL5469	Homo sapiens	Residual Activity	%	76.0
	12264852	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(\N)Sc1ccc(N)cc1)c1ccccc1C(F)(F)F		CHEMBL2218940	=	Residual Activity	%	97.0	CHEMBL5469	Homo sapiens	Residual Activity	%	97.0
	12264853	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Residual Activity	%	58.0	CHEMBL5469	Homo sapiens	Residual Activity	%	58.0
	12264854	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)c1ccc2c3c1cccc3c(=O)n1c3ccccc3nc21		CHEMBL1182777	=	Residual Activity	%	42.0	CHEMBL5469	Homo sapiens	Residual Activity	%	42.0
	12264855	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1		CHEMBL478629	=	Residual Activity	%	77.0	CHEMBL5469	Homo sapiens	Residual Activity	%	77.0
	12264856	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1		CHEMBL410456	=	Residual Activity	%	115.0	CHEMBL5469	Homo sapiens	Residual Activity	%	115.0
	12264857	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)c1nn(-c2c(Cl)cccc2Cl)c2nc(Cc3ccc(OCCO)cc3)[nH]c(=O)c12		CHEMBL258721	=	Residual Activity	%	99.0	CHEMBL5469	Homo sapiens	Residual Activity	%	99.0
	12264858	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)O/N=C1C(=C2\C(=O)Nc3cc(Br)ccc32)\Nc2ccccc2\1		CHEMBL2218941	=	Residual Activity	%	32.0	CHEMBL5469	Homo sapiens	Residual Activity	%	32.0
	12264859	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Residual Activity	%	58.0	CHEMBL5469	Homo sapiens	Residual Activity	%	58.0
	12264860	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12		CHEMBL1240885	=	Residual Activity	%	79.0	CHEMBL5469	Homo sapiens	Residual Activity	%	79.0
	12264861	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCc1nc(-c2ccc(OC)cc2)[nH]c1-c1ccncc1		CHEMBL278724	=	Residual Activity	%	114.0	CHEMBL5469	Homo sapiens	Residual Activity	%	114.0
	12264862	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL258805	=	Residual Activity	%	38.0	CHEMBL5469	Homo sapiens	Residual Activity	%	38.0
	12264863	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)/C=C/c1cc(Br)c(Br)c(Br)c1Br		CHEMBL270724	=	Residual Activity	%	81.0	CHEMBL5469	Homo sapiens	Residual Activity	%	81.0
	12264864	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N/C(=N\[N+](=O)[O-])N/N=C\c1ccc(-c2cccc([N+](=O)[O-])c2)o1		CHEMBL221271	=	Residual Activity	%	103.0	CHEMBL5469	Homo sapiens	Residual Activity	%	103.0
	12264865	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1cnccn1		CHEMBL272629	=	Residual Activity	%	79.0	CHEMBL5469	Homo sapiens	Residual Activity	%	79.0
	12264866	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Residual Activity	%	103.0	CHEMBL5469	Homo sapiens	Residual Activity	%	103.0
	12264867	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1		CHEMBL522502	=	Residual Activity	%	72.0	CHEMBL5469	Homo sapiens	Residual Activity	%	72.0
	12264868	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	=	Residual Activity	%	86.0	CHEMBL5469	Homo sapiens	Residual Activity	%	86.0
	12264869	CHEMBL2219148	Millipore: Percentage of residual kinase activity of PTK2B at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1cnc2cnc(NCc3cccnc3)cc2c1Nc1ccc(F)c(Cl)c1		CHEMBL200381	=	Residual Activity	%	45.0	CHEMBL5469	Homo sapiens	Residual Activity	%	45.0
	12626675	CHEMBL2317124	Inhibition of PYK2 (unknown origin) at 1 uM	B	COc1cc(Nc2ncc(Cl)c(-c3cccc(CC#N)c3)n2)ccc1N1CCN(C)CC1		CHEMBL2312140	=	Inhibition	%	50.0	CHEMBL5469	Homo sapiens	INH	%	50.0
	12668254	CHEMBL2345062	Inhibition of FAK2 (unknown origin) at 10 uM relative to control	B	CC(C)Nc1c(C(N)=O)nnc2cc(N3CCOCC3)ccc12		CHEMBL2333120	=	Inhibition	%	39.0	CHEMBL5469	Homo sapiens	INH	%	39.0
	12668255	CHEMBL2345062	Inhibition of FAK2 (unknown origin) at 10 uM relative to control	B	CC(C)Nc1c(C(N)=O)nnc2ccc(-c3cn[nH]c3)cc12		CHEMBL2333115	=	Inhibition	%	70.0	CHEMBL5469	Homo sapiens	INH	%	70.0
	12668256	CHEMBL2345062	Inhibition of FAK2 (unknown origin) at 10 uM relative to control	B	CC(C)Nc1c(C(N)=O)nnc2ccc(-c3ccncc3)cc12		CHEMBL2333114	=	Inhibition	%	26.0	CHEMBL5469	Homo sapiens	INH	%	26.0
	12668257	CHEMBL2345062	Inhibition of FAK2 (unknown origin) at 10 uM relative to control	B	CC(C)Nc1c(C(N)=O)nnc2cc(-c3ccncc3)ccc12		CHEMBL2333112	=	Inhibition	%	78.0	CHEMBL5469	Homo sapiens	INH	%	78.0
	12668258	CHEMBL2345062	Inhibition of FAK2 (unknown origin) at 10 uM relative to control	B	CS(=O)(=O)c1ccc(-c2ccc3c(NC4CCC4)c(C(N)=O)nnc3c2)cc1		CHEMBL2333129	=	Inhibition	%	28.0	CHEMBL5469	Homo sapiens	INH	%	28.0
	12668259	CHEMBL2345062	Inhibition of FAK2 (unknown origin) at 10 uM relative to control	B	C[C@@H](Nc1c(C(N)=O)nnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12)C1CC1		CHEMBL2333128	=	Inhibition	%	24.0	CHEMBL5469	Homo sapiens	INH	%	24.0
	12668260	CHEMBL2345062	Inhibition of FAK2 (unknown origin) at 10 uM relative to control	B	CC(C)Nc1c(C(N)=O)cnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12		CHEMBL2333125	=	Inhibition	%	47.0	CHEMBL5469	Homo sapiens	INH	%	47.0
	12693177	CHEMBL2345779	Inhibition of PYK2 (unknown origin)	B	Cc1c(C(=O)N2CCOc3ccc(-c4ccc(N)nc4)cc3C2)ccc(S(C)(=O)=O)c1F		CHEMBL2333365	>	IC50	nM	10000.0	CHEMBL5469	Homo sapiens	IC50	nM	10000.0
	12705270	CHEMBL2345800	Inhibition of Pyk2 (unknown origin)	B	CN1c2ccc(NCc3ccc(C(C)(C)C)cc3)cc2-c2c(cnn2C)S1(=O)=O		CHEMBL2333444	>	IC50	nM	10000.0	CHEMBL5469	Homo sapiens	IC50	uM	10.0
	12705271	CHEMBL2345800	Inhibition of Pyk2 (unknown origin)	B	CCc1ccc(-c2ccc3c(c2)-c2c(cnn2C)S(=O)(=O)N3C)cc1		CHEMBL2333435	>	IC50	nM	10000.0	CHEMBL5469	Homo sapiens	IC50	uM	10.0
	12705272	CHEMBL2345800	Inhibition of Pyk2 (unknown origin)	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	=	IC50	nM	9000.0	CHEMBL5469	Homo sapiens	IC50	uM	9.0
	12723644	CHEMBL2350475	Inhibition of PTK2B (unknown origin) at 10 uM by single point assay	B	C[C@@H](Nc1c(C#N)cnc2cc(-c3ccc(-n4ccoc4=O)cc3)ccc12)C1CC1		CHEMBL2347818	=	Inhibition	%	16.0	CHEMBL5469	Homo sapiens	INH	%	16.0
	12723692	CHEMBL2350782	Inhibition of PTK2B (unknown origin) at 1 uM by single point assay	B	CC(C)Nc1c(C#N)cnc2cc(-c3cnn(C)c3)ccc12		CHEMBL2347824	=	Inhibition	%	12.0	CHEMBL5469	Homo sapiens	INH	%	12.0
	12724731	CHEMBL2350782	Inhibition of PTK2B (unknown origin) at 1 uM by single point assay	B	CC(C)Nc1c(C#N)cnc2cc(-c3ccc(S(C)(=O)=O)cc3)ccc12		CHEMBL2347823	=	Inhibition	%	33.0	CHEMBL5469	Homo sapiens	INH	%	33.0
	12727674	CHEMBL2351138	Inhibition of PTK2B (unknown origin) assessed as remaining activity at 10 uM relative to control	B	O=c1[nH]c2ncc(-c3ccc(-c4nc[nH]n4)cc3)nc2n1CCC1CCOCC1		CHEMBL2348865	=	Activity	%	96.0	CHEMBL5469	Homo sapiens	Activity	%	96.0
	12728960	CHEMBL2349894	Inhibition of PTK2B (unknown origin) assessed as remaining activity at 1 uM relative to control	B	CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1		CHEMBL2348862	=	Activity	%	97.0	CHEMBL5469	Homo sapiens	Activity	%	97.0
	12729742	CHEMBL2349753	Inhibition of human 6His-tagged unphosphorylated PYK2 (1 to 967) using Poly-(GT)-biotin as substrate by AlphaScreen assay in presence of [gamma-33P]ATP	B	CCc1ccc(-c2ccc3c(c2)-c2c(cnn2CC)S(=O)(=O)N3C)cc1		CHEMBL2333436	>	IC50	nM	30000.0	CHEMBL5469	Homo sapiens	IC50	uM	30.0
	12729743	CHEMBL2349753	Inhibition of human 6His-tagged unphosphorylated PYK2 (1 to 967) using Poly-(GT)-biotin as substrate by AlphaScreen assay in presence of [gamma-33P]ATP	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	=	IC50	nM	6800.0	CHEMBL5469	Homo sapiens	IC50	uM	6.8
	12729744	CHEMBL2349754	Inhibition of human GST-tagged phosphorylated full length PYK2 (1 to 967) using Poly-(GT)-biotin as substrate by HTRF analysis in presence of [gamma-33P]ATP	B	CCc1ccc(-c2ccc3c(c2)-c2c(cnn2CC)S(=O)(=O)N3C)cc1		CHEMBL2333436	>	IC50	nM	30000.0	CHEMBL5469	Homo sapiens	IC50	uM	30.0
	12729745	CHEMBL2349754	Inhibition of human GST-tagged phosphorylated full length PYK2 (1 to 967) using Poly-(GT)-biotin as substrate by HTRF analysis in presence of [gamma-33P]ATP	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	=	IC50	nM	10000.0	CHEMBL5469	Homo sapiens	IC50	uM	10.0
	12729837	CHEMBL2352168	Inhibition of PYK2 (unknown origin) using [gamma-33P]ATP assessed as residual activity at 3 uM	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	=	Activity	%	75.0	CHEMBL5469	Homo sapiens	Activity	%	75.0
	12730103	CHEMBL2351138	Inhibition of PTK2B (unknown origin) assessed as remaining activity at 10 uM relative to control	B	CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1		CHEMBL2348862	=	Activity	%	100.0	CHEMBL5469	Homo sapiens	Activity	%	100.0
	13374367	CHEMBL2406500	Inhibition of PTK2B (unknown origin) at 10 uM relative to control	B	CC[C@@H]1C(=O)N(C)c2cnc(-n3ccnc3-c3ccc(F)cc3)nc2N1c1ccn(C)n1		CHEMBL2402081	=	Inhibition	%	2.0	CHEMBL5469	Homo sapiens	INH	%	2.0
	13439934	CHEMBL2429477	Competitive binding affinity to PTK2B (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3ccc4ccccc43)n2)CC1		CHEMBL2425646	<	Inhibition	%	50.0	CHEMBL5469	Homo sapiens	INH	%	50.0
	13441125	CHEMBL2427450	Inhibition of PYK2 (unknown origin)	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnc4c(N)ncnc43)cc2)cc1		CHEMBL2425144	=	IC50	nM	414.0	CHEMBL5469	Homo sapiens	IC50	nM	414.0
	13445444	CHEMBL2429477	Competitive binding affinity to PTK2B (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-c3n[nH]c4ccccc34)n2)CC1		CHEMBL2425644	=	Inhibition	%	77.0	CHEMBL5469	Homo sapiens	INH	%	77.0
	13448499	CHEMBL2429477	Competitive binding affinity to PTK2B (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3ncc4ccccc43)n2)CC1		CHEMBL2425645	<	Inhibition	%	50.0	CHEMBL5469	Homo sapiens	INH	%	50.0
	13448635	CHEMBL2429477	Competitive binding affinity to PTK2B (unknown origin) at 10 uM in presence of ATP relative to control	B	O=C([C@H]1CC[C@H](Nc2nccc(-n3nnc4ccccc43)n2)CC1)N1CCOCC1		CHEMBL2425649	<	Inhibition	%	50.0	CHEMBL5469	Homo sapiens	INH	%	50.0
	13451430	CHEMBL2429477	Competitive binding affinity to PTK2B (unknown origin) at 10 uM in presence of ATP relative to control	B	N[C@H]1CC[C@H](Nc2nccc(-n3nnc4ccccc43)n2)CC1		CHEMBL2425652	<	Inhibition	%	50.0	CHEMBL5469	Homo sapiens	INH	%	50.0
	13454615	CHEMBL2429477	Competitive binding affinity to PTK2B (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3nnc4ccccc43)n2)CC1		CHEMBL2425654	<	Inhibition	%	50.0	CHEMBL5469	Homo sapiens	INH	%	50.0
	13464771	CHEMBL2432165	Inhibition of Pyk2 (unknown origin)	B	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O.O=S(=O)(O)c1ccccc1		CHEMBL2430359	=	IC50	nM	14.0	CHEMBL5469	Homo sapiens	IC50	nmol/L	14.0
	13871761	CHEMBL3100926	Inhibition of human Pyk2 assessed as residual activity at 1 uM relative to control	B	O=C1Nc2ncccc2/C1=C1/Nc2ncccc2C1=O		CHEMBL3099673	=	Activity	%	119.0	CHEMBL5469	Homo sapiens	Activity	%	119.0
	13941191	CHEMBL3129256	Inhibition of PTK2B (unknown origin) using Km levels of ATP	B	Cc1nc([C@](C)(O)CO)sc1-c1cnc(N)c(O[C@H](C)c2cc(F)ccc2-n2nccn2)c1		CHEMBL3128069	=	IC50	nM	12.0	CHEMBL5469	Homo sapiens	IC50	nM	12.0
	13973090	CHEMBL3136747	Inhibition of PTK2 (unknown origin)	B	COc1cc(Nc2nccc(-c3ccc(Cl)cc3)n2)cc(OC)c1OC		CHEMBL3134612	=	IC50	nM	10143.0	CHEMBL5469	Homo sapiens	IC50	uM	10.143
	14582496	CHEMBL3242348	Inhibition of human FAK2 assessed as enzyme activity at 1 uM relative to control	B	CCCS(=O)(=O)Nc1cccc(Nc2ccc3ncn(C)c(=O)c3c2)c1C#N		CHEMBL3236464	=	Activity	%	85.5	CHEMBL5469	Homo sapiens	Activity	%	85.5
	14672870	CHEMBL3267949	Inhibition of PTK2B (unknown origin) at 1 uM by Z'-LYTE assay relative to control	B	CN(C)CCN(Cc1ccc(Cl)cc1)c1ccc2ccccc2n1		CHEMBL3265344	=	Inhibition	%	0.0	CHEMBL5469	Homo sapiens	INH	%	0.0
	14713705	CHEMBL3296770	Binding affinity to PYK2 (unknown origin)	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1NC(=O)CCN1CCN(C)CC1		CHEMBL3288854	=	Ki	nM	340.0	CHEMBL5469	Homo sapiens	Ki	uM	0.34
	14713736	CHEMBL3296859	Inhibition of PYK2 (unknown origin) at 1 uM relative to control	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1NC(=O)CCN1CCN(C)CC1		CHEMBL3288854	=	Inhibition	%	72.0	CHEMBL5469	Homo sapiens	INH	%	72.0
Not Determined	14713762	CHEMBL3296770	Binding affinity to PYK2 (unknown origin)	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535		Ki			CHEMBL5469	Homo sapiens	Ki		
	14722521	CHEMBL3293405	Inhibition of PTK2B (unknown origin) by TR-FRET-based Z'-LYTE assay	B	C[C@H]1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)CN(C)C(=O)c2ccc(F)cc21		CHEMBL3286830	=	IC50	nM	14.0	CHEMBL5469	Homo sapiens	IC50	nM	14.0
	15009774	CHEMBL3361649	Inhibition of FAK/PTK2 (unknown origin) at 10 uM	B	C[C@H](O)CNc1nccc(-n2ccnc2Cc2cccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c2)n1		CHEMBL3309549	=	Inhibition	%	1.2	CHEMBL5469	Homo sapiens	INH	%	1.2
	15112142	CHEMBL3388154	Inhibition of PYK2 (unknown origin)	B	COc1ccc(-c2cccc3nc(NC(=O)C4CC4)nn23)cc1		CHEMBL3360318	=	IC50	nM	3184.0	CHEMBL5469	Homo sapiens	IC50	nM	3184.0
Not Active	15149833	CHEMBL3395096	Inhibition of human recombinant Pyk2 using poly[Glu:Tyr] as substrate at 1 uM by [gamma-33P]ATP-based assay	B	C=COC(=O)NCc1ccc(Nc2nc(Nc3ccccc3C(=O)NC)n3ccnc3n2)cc1		CHEMBL3393280		Inhibition	%		CHEMBL5469	Homo sapiens	INH		
	15756833	CHEMBL3631109	Inhibition of PYK2 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccncc3)cc2)no1		CHEMBL166031	=	Inhibition	%	16.53	CHEMBL5469	Homo sapiens	INH	%	16.53
	15757890	CHEMBL3631109	Inhibition of PYK2 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	CS(=O)(=O)c1cccc(Nc2nccc(-c3sc(N4CCOCC4)nc3-c3cccc(NS(=O)(=O)c4c(F)cccc4F)c3)n2)c1		CHEMBL3628627	=	Inhibition	%	23.66	CHEMBL5469	Homo sapiens	INH	%	23.66
	15758869	CHEMBL3631109	Inhibition of PYK2 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	COCCNC(=O)c1ccc2c(c1)nc(-c1cnc(-c3ccc(Cl)cc3)[nH]1)n2CCOC		CHEMBL3628628	=	Inhibition	%	7.67	CHEMBL5469	Homo sapiens	INH	%	7.67
	16379627	CHEMBL3738542	Inhibition of PYK2 (unknown origin) at 200 nM by electrophoretic mobility shift assay	B	COc1ccc2c(c1CN1CCNCC1)O/C(=C\c1n[nH]c3ncccc13)C2=O		CHEMBL3735816	=	Inhibition	%	-0.4	CHEMBL5469	Homo sapiens	INH	%	-0.4
	16379628	CHEMBL3738542	Inhibition of PYK2 (unknown origin) at 200 nM by electrophoretic mobility shift assay	B	COc1ccc2c(c1C(C)N1CCNCC1)O/C(=C\c1n[nH]c3ncccc13)C2=O		CHEMBL3735890	=	Inhibition	%	11.2	CHEMBL5469	Homo sapiens	INH	%	11.2
	16425326	CHEMBL3751266	Inhibition of FAK2 (unknown origin) at 1 uM	B	Cc1c(-c2cc(Nc3cc4n(n3)CCN(C)C4)c(=O)[nH]n2)ccc(F)c1NC(=O)c1cc2ccccc2s1		CHEMBL3746293	=	Inhibition	%	4.0	CHEMBL5469	Homo sapiens	INH	%	4.0
	16431985	CHEMBL3750024	Inhibition of human PYK2 using poly[Glu:Tyr] (4:1) as substrate	B	Cn1c(=O)c(S(=O)(=O)c2ccc(F)cc2F)cc2cnc(Nc3ccc4[nH]ccc4c3)nc21		CHEMBL3745885	>	IC50	nM	10000.0	CHEMBL5469	Homo sapiens	IC50	uM	10.0
	16450840	CHEMBL3762696	Inhibition of FAK2 (unknown origin) at 100 nM	B	CC1(C)OCc2c(Nc3n[nH]c4ccccc34)nc(-c3cn[nH]c3)nc21		CHEMBL3758502	=	Inhibition	%	9.7	CHEMBL5469	Homo sapiens	INH	%	9.7
	16451715	CHEMBL3762696	Inhibition of FAK2 (unknown origin) at 100 nM	B	CC1(C)OCc2c(Nc3n[nH]c4c(Cl)cccc34)nc(-c3cn[nH]c3)nc21		CHEMBL3758602	=	Inhibition	%	9.1	CHEMBL5469	Homo sapiens	INH	%	9.1
	16495205	CHEMBL3777747	Inhibition of N-terminal His6-tagged recombinant human PYK2 expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	Cn1cc(-c2ccc(Cc3n[nH]c4ccc(C(=O)N5CC[C@@H](O)C5)cc34)cc2)cn1		CHEMBL3775317	=	Activity	%	-12.0	CHEMBL5469	Homo sapiens	Activity	%	-12.0
	16496124	CHEMBL3777747	Inhibition of N-terminal His6-tagged recombinant human PYK2 expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	Cn1cc(-c2ccc(Cc3n[nH]c4ccc(C(=O)N5CCOCC5)cc34)cc2)cn1		CHEMBL3774885	=	Activity	%	8.0	CHEMBL5469	Homo sapiens	Activity	%	8.0
	16508914	CHEMBL3777747	Inhibition of N-terminal His6-tagged recombinant human PYK2 expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	CNC(=O)c1ccc2[nH]nc(Cc3ccc4c(cnn4C)c3)c2c1		CHEMBL3775576	=	Activity	%	-10.0	CHEMBL5469	Homo sapiens	Activity	%	-10.0
	16534412	CHEMBL3789288	Inhibition of human PYK2 at 1 uM after 30 mins by fluorescence assay in presence of ATP	B	COc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)CCC(N)C2(C)C		CHEMBL3786892	=	Inhibition	%	98.0	CHEMBL5469	Homo sapiens	INH	%	98.0
	16559658	CHEMBL3794818	Inhibition of full length human N-terminal GST-tagged PYK2 (1 to 967 residues) expressed in baculovirus expression system using fluorescence labelled Blk/Lyntide as substrate at 50 times IC50 by electrophoretic mobility shift assay relative to control	B	O=C(Nc1ccccc1)c1n[nH]c2ccccc12		CHEMBL508964	=	Inhibition	%	49.5	CHEMBL5469	Homo sapiens	INH	%	49.5
	16559659	CHEMBL3794818	Inhibition of full length human N-terminal GST-tagged PYK2 (1 to 967 residues) expressed in baculovirus expression system using fluorescence labelled Blk/Lyntide as substrate at 50 times IC50 by electrophoretic mobility shift assay relative to control	B	O=C(Nc1ccc(C(=O)N2CCN(c3ccccc3)CC2)cc1)c1n[nH]c2ccccc12		CHEMBL3793843	=	Inhibition	%	34.9	CHEMBL5469	Homo sapiens	INH	%	34.9
	16559660	CHEMBL3794818	Inhibition of full length human N-terminal GST-tagged PYK2 (1 to 967 residues) expressed in baculovirus expression system using fluorescence labelled Blk/Lyntide as substrate at 50 times IC50 by electrophoretic mobility shift assay relative to control	B	O=C(Nc1ccc(CN2CCN(c3ccccc3)CC2)cc1)c1n[nH]c2ccccc12		CHEMBL3792850	=	Inhibition	%	14.2	CHEMBL5469	Homo sapiens	INH	%	14.2
	16614613	CHEMBL3815969	Inhibition of human PYK2 at 1 uM using poly[Glu:Tyr] (4:1) as substrate	B	CNS(=O)(=O)c1ccc(N(C)C)c(Nc2ncnc3cc(OC)c(OC)cc23)c1		CHEMBL3815093	=	Inhibition	%	-7.0	CHEMBL5469	Homo sapiens	INH	%	-7.0
	16618221	CHEMBL3816333	Inhibition of full length recombinant human N-terminal GST-tagged cytoplasmic FAK2 expressed in baculovirus expression system at 1 uM relative to control	B	CC1(C)OCCn2c1nc1c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12		CHEMBL3813842	<	Inhibition	%	50.0	CHEMBL5469	Homo sapiens	INH	%	50.0
	16824302	CHEMBL3873676	Inhibition of full length recombinant human N-terminal His6-tagged PYK2 expressed in baculovirus infected sf21 cells	B	CS(=O)(=O)N1Cc2cccc(c2)C(=O)N2CCc3cc(ccc32)Nc2ncc(C(F)(F)F)c(n2)NCc2cccnc21		CHEMBL3939286	=	IC50	nM	26.0	CHEMBL5469	Homo sapiens	IC50	nM	26.0
	16824303	CHEMBL3873676	Inhibition of full length recombinant human N-terminal His6-tagged PYK2 expressed in baculovirus infected sf21 cells	B	O=C1CCCNS(=O)(=O)c2ncccc2CNc2nc(ncc2C(F)(F)F)Nc2ccc3c(c2)CCN13		CHEMBL3912281	=	IC50	nM	3.5	CHEMBL5469	Homo sapiens	IC50	nM	3.5
	16824304	CHEMBL3873676	Inhibition of full length recombinant human N-terminal His6-tagged PYK2 expressed in baculovirus infected sf21 cells	B	CS(=O)(=O)N1CCCC(=O)N2CCc3cc(ccc32)Nc2ncc(C(F)(F)F)c(n2)NCc2cccnc21		CHEMBL3914036	=	IC50	nM	30.0	CHEMBL5469	Homo sapiens	IC50	nM	30.0
	16824305	CHEMBL3873676	Inhibition of full length recombinant human N-terminal His6-tagged PYK2 expressed in baculovirus infected sf21 cells	B	CN1Cc2ccncc2N(S(C)(=O)=O)C/C=C/c2cc(ccc2N2CCOCC2)Nc2ncc(C(F)(F)F)c1n2		CHEMBL3977870	=	IC50	nM	2.7	CHEMBL5469	Homo sapiens	IC50	nM	2.7
	16824306	CHEMBL3873676	Inhibition of full length recombinant human N-terminal His6-tagged PYK2 expressed in baculovirus infected sf21 cells	B	C=CCN(c1cnccc1CN(C)c1nc(Nc2ccc(N3CCOCC3)c(Br)c2)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL3898282	=	IC50	nM	6625.0	CHEMBL5469	Homo sapiens	IC50	nM	6625.0
	16824307	CHEMBL3873676	Inhibition of full length recombinant human N-terminal His6-tagged PYK2 expressed in baculovirus infected sf21 cells	B	CN1Cc2cccnc2N(S(C)(=O)=O)C/C=C/c2cc(ccc2N2CCOCC2)Nc2ncc(C(F)(F)F)c1n2		CHEMBL3969464	=	IC50	nM	1.55	CHEMBL5469	Homo sapiens	IC50	nM	1.55
	16824308	CHEMBL3873676	Inhibition of full length recombinant human N-terminal His6-tagged PYK2 expressed in baculovirus infected sf21 cells	B	CS(=O)(=O)N1CCCc2cc(ccc2N2CCOCC2)Nc2ncc(C(F)(F)F)c(n2)NCc2cccnc21		CHEMBL3987106	=	IC50	nM	1.31	CHEMBL5469	Homo sapiens	IC50	nM	1.31
	16824309	CHEMBL3873676	Inhibition of full length recombinant human N-terminal His6-tagged PYK2 expressed in baculovirus infected sf21 cells	B	CS(=O)(=O)N1C/C=C/c2cc(ccc2N2CCOCC2)Nc2ncc(C(F)(F)F)c(n2)NCc2cccnc21		CHEMBL3958414	=	IC50	nM	0.84	CHEMBL5469	Homo sapiens	IC50	nM	0.84
	16824310	CHEMBL3873676	Inhibition of full length recombinant human N-terminal His6-tagged PYK2 expressed in baculovirus infected sf21 cells	B	C=CCN(c1ncccc1CNc1nc(Nc2ccc(N3CCOCC3)c(Br)c2)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL3965256	=	IC50	nM	19.5	CHEMBL5469	Homo sapiens	IC50	nM	19.5
	16824311	CHEMBL3873676	Inhibition of full length recombinant human N-terminal His6-tagged PYK2 expressed in baculovirus infected sf21 cells	B	CS(=O)(=O)N1CCCc2cccc(c2)Nc2ncc(C(F)(F)F)c(n2)NCc2cccnc21		CHEMBL3949755	=	IC50	nM	0.67	CHEMBL5469	Homo sapiens	IC50	nM	0.67
	16824312	CHEMBL3873676	Inhibition of full length recombinant human N-terminal His6-tagged PYK2 expressed in baculovirus infected sf21 cells	B	CS(=O)(=O)N1C/C=C/c2cccc(c2)Nc2ncc(C(F)(F)F)c(n2)NCc2cccnc21		CHEMBL3961368	=	IC50	nM	2.6	CHEMBL5469	Homo sapiens	IC50	nM	2.6
	16824313	CHEMBL3873676	Inhibition of full length recombinant human N-terminal His6-tagged PYK2 expressed in baculovirus infected sf21 cells	B	C=CCN(c1ncccc1CNc1nc(Nc2cccc(Br)c2)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL3892377	=	IC50	nM	122.0	CHEMBL5469	Homo sapiens	IC50	nM	122.0
	16824314	CHEMBL3873676	Inhibition of full length recombinant human N-terminal His6-tagged PYK2 expressed in baculovirus infected sf21 cells	B	CN1Cc2ccccc2N(S(C)(=O)=O)CCCCC(=O)N2CCc3cc(ccc32)Nc2ncc(C(F)(F)F)c1n2		CHEMBL3899046	=	IC50	nM	1.5	CHEMBL5469	Homo sapiens	IC50	nM	1.5
	16824315	CHEMBL3873676	Inhibition of full length recombinant human N-terminal His6-tagged PYK2 expressed in baculovirus infected sf21 cells	B	CN(Cc1ccccc1N(CCCCC(=O)O)S(C)(=O)=O)c1nc(Nc2ccc3c(c2)CCN3)ncc1C(F)(F)F		CHEMBL3927099	=	IC50	nM	201.0	CHEMBL5469	Homo sapiens	IC50	nM	201.0
	16824316	CHEMBL3873676	Inhibition of full length recombinant human N-terminal His6-tagged PYK2 expressed in baculovirus infected sf21 cells	B	CCS(=O)(=O)N1CCCCC(=O)N2CCc3cc(ccc32)Nc2ncc(C(F)(F)F)c(n2)NCc2ccccc21		CHEMBL3908093	=	IC50	nM	1.9	CHEMBL5469	Homo sapiens	IC50	nM	1.9
	16824317	CHEMBL3873676	Inhibition of full length recombinant human N-terminal His6-tagged PYK2 expressed in baculovirus infected sf21 cells	B	CCS(=O)(=O)N(CCCCC(=O)O)c1ccccc1CNc1nc(Nc2ccc3c(c2)CCN3)ncc1C(F)(F)F		CHEMBL3936048	=	IC50	nM	256.0	CHEMBL5469	Homo sapiens	IC50	nM	256.0
	16824318	CHEMBL3873676	Inhibition of full length recombinant human N-terminal His6-tagged PYK2 expressed in baculovirus infected sf21 cells	B	CS(=O)(=O)N1CCCCC(=O)N2CCc3cc(ccc32)Nc2ncc(C(F)(F)F)c(n2)NCc2ccccc21		CHEMBL3956954	=	IC50	nM	0.9	CHEMBL5469	Homo sapiens	IC50	nM	0.9
	16824319	CHEMBL3873676	Inhibition of full length recombinant human N-terminal His6-tagged PYK2 expressed in baculovirus infected sf21 cells	B	CS(=O)(=O)N1CCCCC(=O)N2CCc3cc(ccc32)Nc2ncc(C(F)(F)F)c(n2)NCc2cccnc21		CHEMBL3889951	=	IC50	nM	3.1	CHEMBL5469	Homo sapiens	IC50	nM	3.1
	16824352	CHEMBL3873676	Inhibition of full length recombinant human N-terminal His6-tagged PYK2 expressed in baculovirus infected sf21 cells	B	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	=	IC50	nM	13.0	CHEMBL5469	Homo sapiens	IC50	nM	13.0
Active	16840527	CHEMBL3876699	Inhibition of full length human PYK2 (M1 to E967 residues) expressed in bacterial expression system at 1 uM by KINOMEScan assay	B	CCC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1Cl		CHEMBL3884293		Inhibition	%		CHEMBL5469	Homo sapiens	INH		
	16844157	CHEMBL3877193	Inhibition of N-terminal His6-tagged thrombin cleavage site-fused human recombinant PYK2 catalytic domain (416 to 692 residues) expressed in baculovirus expression system	B	CN(c1ccccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL472212	=	IC50	nM	11.0	CHEMBL5469	Homo sapiens	IC50	nM	11.0
428150	17789820	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1CCN2		CHEMBL3944283	<	IC50	nM	100.0	CHEMBL5469	Homo sapiens	IC50	nM	100.0
428151	17789821	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccc2c(c1Nc1nc(Nc3ccc(N4CCOCC4)cc3OC)nc3c1CCN3)OCO2		CHEMBL3975819	>	IC50	nM	1000.0	CHEMBL5469	Homo sapiens	IC50	nM	1000.0
428152	17789822	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3C(=O)N3CCCC3)n1)CCN2		CHEMBL3972759	>	IC50	nM	1000.0	CHEMBL5469	Homo sapiens	IC50	nM	1000.0
428153	17789823	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1CCN2		CHEMBL3982124	<	IC50	nM	50.0	CHEMBL5469	Homo sapiens	IC50	nM	50.0
428154	17789824	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CCCNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1CCN2		CHEMBL3965442	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428155	17789825	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC3CCC3)n1)CCN2		CHEMBL3896626	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428156	17789826	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC3CCCC3)n1)CCN2		CHEMBL3971472	<	IC50	nM	100.0	CHEMBL5469	Homo sapiens	IC50	nM	100.0
428157	17789827	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC3CCCCC3)n1)CCN2		CHEMBL3967692	<	IC50	nM	500.0	CHEMBL5469	Homo sapiens	IC50	nM	500.0
428158	17789828	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3NC(C)=O)n1)CCN2		CHEMBL3897679	<	IC50	nM	1000.0	CHEMBL5469	Homo sapiens	IC50	nM	1000.0
428159	17789829	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3N(C)S(C)(=O)=O)n1)CCN2		CHEMBL3901273	<	IC50	nM	50.0	CHEMBL5469	Homo sapiens	IC50	nM	50.0
428160	17789830	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(NCc3ccccc3N(C)S(C)(=O)=O)n1)CCN2		CHEMBL3906683	>	IC50	nM	2000.0	CHEMBL5469	Homo sapiens	IC50	nM	2000.0
428161	17789831	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3cccc(C)n3)n1)CCN2		CHEMBL3975221	<	IC50	nM	100.0	CHEMBL5469	Homo sapiens	IC50	nM	100.0
428162	17789832	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccc(F)c(F)c3)n1)CCN2		CHEMBL3904353	<	IC50	nM	1000.0	CHEMBL5469	Homo sapiens	IC50	nM	1000.0
428163	17789833	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2CO)nc2c1CCN2		CHEMBL3950487	>	IC50	nM	1000.0	CHEMBL5469	Homo sapiens	IC50	nM	1000.0
428164	17789834	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2cccc3c2OCCO3)nc2c1CCN2		CHEMBL3894129	<	IC50	nM	500.0	CHEMBL5469	Homo sapiens	IC50	nM	500.0
428165	17789835	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)c3c2OCCO3)nc2c1CCN2		CHEMBL3959184	<	IC50	nM	200.0	CHEMBL5469	Homo sapiens	IC50	nM	200.0
428166	17789836	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CCN1C(=O)CCCc2c1ccc(Nc1nc3c(c(Nc4ccccc4C(=O)NC)n1)CCN3)c2OC		CHEMBL3928192	<	IC50	nM	200.0	CHEMBL5469	Homo sapiens	IC50	nM	200.0
428167	17789837	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2cccc3ccoc23)nc2c1CCN2		CHEMBL3966923	<	IC50	nM	100.0	CHEMBL5469	Homo sapiens	IC50	nM	100.0
428168	17789838	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2cc(C)nn2C)nc2c1CCN2		CHEMBL3937170	<	IC50	nM	500.0	CHEMBL5469	Homo sapiens	IC50	nM	500.0
428169	17789839	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)nc2c1CCN2		CHEMBL3975406	<	IC50	nM	300.0	CHEMBL5469	Homo sapiens	IC50	nM	300.0
428170	17789840	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2cccc3c2ccn3CCCN2CCOCC2)nc2c1CCN2		CHEMBL3949502	<	IC50	nM	200.0	CHEMBL5469	Homo sapiens	IC50	nM	200.0
428171	17789841	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1C(C)CN2		CHEMBL3942938	<	IC50	nM	50.0	CHEMBL5469	Homo sapiens	IC50	nM	50.0
428172	17789842	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3C(=O)N3CCCC3)n1)C(C)CN2		CHEMBL3914954	<	IC50	nM	500.0	CHEMBL5469	Homo sapiens	IC50	nM	500.0
428173	17789843	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1C(C)CN2		CHEMBL3920980	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428174	17789844	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CCCNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1C(C)CN2		CHEMBL3952170	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428175	17789845	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC3CCC3)n1)C(C)CN2		CHEMBL3947913	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428176	17789846	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC3CCCC3)n1)C(C)CN2		CHEMBL3920974	<	IC50	nM	50.0	CHEMBL5469	Homo sapiens	IC50	nM	50.0
428177	17789847	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC3CCCCC3)n1)C(C)CN2		CHEMBL3942382	<	IC50	nM	500.0	CHEMBL5469	Homo sapiens	IC50	nM	500.0
428178	17789848	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3NC(C)=O)n1)C(C)CN2		CHEMBL3968458	<	IC50	nM	200.0	CHEMBL5469	Homo sapiens	IC50	nM	200.0
428179	17789849	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3N(C)S(C)(=O)=O)n1)C(C)CN2		CHEMBL3937080	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428180	17789850	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc(NCc2ccccc2N(C)S(C)(=O)=O)c2c(n1)NCC2C		CHEMBL3957442	>	IC50	nM	1000.0	CHEMBL5469	Homo sapiens	IC50	nM	1000.0
428181	17789851	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3cccc(C)n3)n1)C(C)CN2		CHEMBL3913196	<	IC50	nM	1000.0	CHEMBL5469	Homo sapiens	IC50	nM	1000.0
428182	17789852	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccc(F)c(F)c3)n1)C(C)CN2		CHEMBL3928184	<	IC50	nM	1000.0	CHEMBL5469	Homo sapiens	IC50	nM	1000.0
428183	17789853	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1[C@H](C)CN2		CHEMBL4107431	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428184	17789854	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC3CCC3)n1)[C@H](C)CN2		CHEMBL4112034	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428185	17789855	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1C(C)(C)CN2		CHEMBL3949300	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428186	17789856	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)N(C)C)n1)CCN2		CHEMBL3921504	<	IC50	nM	200.0	CHEMBL5469	Homo sapiens	IC50	nM	200.0
428187	17789857	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CCCCNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1CCN2		CHEMBL3943967	<	IC50	nM	100.0	CHEMBL5469	Homo sapiens	IC50	nM	100.0
428188	17789858	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3912539	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428189	17789859	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(N)(=O)=O)n1)CCN2		CHEMBL3935002	<	IC50	nM	200.0	CHEMBL5469	Homo sapiens	IC50	nM	200.0
428190	17789860	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC3CC3)n1)CCN2		CHEMBL3907045	<	IC50	nM	50.0	CHEMBL5469	Homo sapiens	IC50	nM	50.0
428191	17789861	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CCNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1CCN2		CHEMBL3967797	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428192	17789862	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CCC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1CCN2		CHEMBL3941707	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428193	17789863	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NCC(C)C)n1)CCN2		CHEMBL3892176	<	IC50	nM	100.0	CHEMBL5469	Homo sapiens	IC50	nM	100.0
428194	17789864	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3912539	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428195	17789865	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)(C)C)n1)CCN2		CHEMBL3897579	<	IC50	nM	100.0	CHEMBL5469	Homo sapiens	IC50	nM	100.0
428196	17789866	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COCCCNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1CCN2		CHEMBL3929098	<	IC50	nM	100.0	CHEMBL5469	Homo sapiens	IC50	nM	100.0
428197	17789867	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NCCN(C)C)n1)CCN2		CHEMBL3906581	<	IC50	nM	500.0	CHEMBL5469	Homo sapiens	IC50	nM	500.0
428198	17789868	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COCCNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1CCN2		CHEMBL3934545	<	IC50	nM	50.0	CHEMBL5469	Homo sapiens	IC50	nM	50.0
428199	17789869	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)Nc3ccccc3)n1)CCN2		CHEMBL3890905	<	IC50	nM	500.0	CHEMBL5469	Homo sapiens	IC50	nM	500.0
428200	17789870	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2)nc2c1CCN2		CHEMBL3915406	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428201	17789871	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccc(Nc2nc3c(c(Nc4ccccc4S(=O)(=O)NC(C)C)n2)CCN3)cc1		CHEMBL3899895	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428202	17789872	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(CO)cc2)nc2c1CCN2		CHEMBL3927886	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428203	17789873	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2F)nc2c1CCN2		CHEMBL3911069	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428204	17789874	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1nc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3939030	<	IC50	nM	50.0	CHEMBL5469	Homo sapiens	IC50	nM	50.0
428205	17789875	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)nc2)nc2c1CCN2		CHEMBL3895395	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428206	17789876	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cn2)nc2c1CCN2		CHEMBL3919894	<	IC50	nM	50.0	CHEMBL5469	Homo sapiens	IC50	nM	50.0
428207	17789877	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CCOc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3896574	<	IC50	nM	100.0	CHEMBL5469	Homo sapiens	IC50	nM	100.0
428208	17789878	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2C(F)(F)F)nc2c1CCN2		CHEMBL3924601	>	IC50	nM	1000.0	CHEMBL5469	Homo sapiens	IC50	nM	1000.0
428209	17789879	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(C(F)(F)F)cc2)nc2c1CCN2		CHEMBL3902048	<	IC50	nM	500.0	CHEMBL5469	Homo sapiens	IC50	nM	500.0
428210	17789880	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)N(C)C)cc2)nc2c1CCN2		CHEMBL3933520	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428211	17789881	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CC(=O)Nc1ccc(Nc2nc3c(c(Nc4ccccc4S(=O)(=O)NC(C)C)n2)CCN3)cc1		CHEMBL3918815	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428212	17789882	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNS(=O)(=O)c1ccc(Nc2nc3c(c(Nc4ccccc4S(=O)(=O)NC(C)C)n2)CCN3)cc1		CHEMBL3946639	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428213	17789883	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)nc2c1CCN2		CHEMBL3974350	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428214	17789884	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	Cc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3941437	<	IC50	nM	50.0	CHEMBL5469	Homo sapiens	IC50	nM	50.0
428215	17789885	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3965861	<	IC50	nM	100.0	CHEMBL5469	Homo sapiens	IC50	nM	100.0
428216	17789886	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCCCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3935969	<	IC50	nM	200.0	CHEMBL5469	Homo sapiens	IC50	nM	200.0
428217	17789887	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(C(C)O)cc2)nc2c1CCN2		CHEMBL3889853	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428218	17789888	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(OCCN2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3962392	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428219	17789889	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(OC(F)(F)F)cc2)nc2c1CCN2		CHEMBL3979231	<	IC50	nM	100.0	CHEMBL5469	Homo sapiens	IC50	nM	100.0
428220	17789890	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CC(C)NC(C)c1ccc(Nc2nc3c(c(Nc4ccccc4S(=O)(=O)NC(C)C)n2)CCN3)cc1		CHEMBL3950186	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428221	17789891	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2cccc(NS(C)(=O)=O)c2)nc2c1CCN2		CHEMBL3966943	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428222	17789892	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1cccc(Nc2nc3c(c(Nc4ccccc4S(=O)(=O)NC(C)C)n2)CCN3)c1		CHEMBL3933674	<	IC50	nM	50.0	CHEMBL5469	Homo sapiens	IC50	nM	50.0
428223	17789893	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CC(=O)Nc1cccc(Nc2nc3c(c(Nc4ccccc4S(=O)(=O)NC(C)C)n2)CCN3)c1		CHEMBL3946772	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428224	17789894	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCC(N(C)C)CC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3980018	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428225	17789895	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(-n2ccnc2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3942329	<	IC50	nM	500.0	CHEMBL5469	Homo sapiens	IC50	nM	500.0
428226	17789896	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(C(=O)N3CCCC3)cc2)nc2c1CCN2		CHEMBL3971936	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428227	17789897	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCC(CO)CC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3906918	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428228	17789898	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCC(O)C2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3967319	<	IC50	nM	100.0	CHEMBL5469	Homo sapiens	IC50	nM	100.0
428229	17789899	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCCC(O)C2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3956331	<	IC50	nM	50.0	CHEMBL5469	Homo sapiens	IC50	nM	50.0
428230	17789900	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(C(C)N3CCCCC3)cc2)nc2c1CCN2		CHEMBL3932107	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428231	17789901	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(-n2ccccc2=O)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3955195	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428232	17789902	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2C(C)COCC2C)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3889594	<	IC50	nM	100.0	CHEMBL5469	Homo sapiens	IC50	nM	100.0
428233	17789903	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(NCCN2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3904434	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428234	17789904	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCC(O)CC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3975280	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428235	17789905	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCS(=O)(=O)CC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3913439	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428236	17789906	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(-n2ncnn2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3980132	<	IC50	nM	200.0	CHEMBL5469	Homo sapiens	IC50	nM	200.0
428237	17789907	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCC(N(C)C)C2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3918922	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428238	17789908	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(-n2cc(C)nc2C)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3890853	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428239	17789909	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	Cc1csc(Nc2nc3c(c(Nc4ccccc4S(=O)(=O)NC(C)C)n2)CCN3)n1		CHEMBL3899700	<	IC50	nM	1000.0	CHEMBL5469	Homo sapiens	IC50	nM	1000.0
428240	17789910	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCC(N3CCCCC3)CC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3901728	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428241	17789911	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCC(N3CCCC3)CC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3928389	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428242	17789912	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(-n2cccn2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3982199	<	IC50	nM	200.0	CHEMBL5469	Homo sapiens	IC50	nM	200.0
428243	17789913	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCC(N3CCOCC3)CC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3970653	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428244	17789914	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3899477	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428245	17789915	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCC(N3CCNCC3)CC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3912145	<	IC50	nM	500.0	CHEMBL5469	Homo sapiens	IC50	nM	500.0
428246	17789916	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCCCC2=O)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3908536	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428247	17789917	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2C(=O)CCc3ccccc32)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2		CHEMBL3967584	<	IC50	nM	500.0	CHEMBL5469	Homo sapiens	IC50	nM	500.0
428248	17789918	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)C(C)C)n1)CCN2		CHEMBL3898470	<	IC50	nM	50.0	CHEMBL5469	Homo sapiens	IC50	nM	50.0
428249	17789919	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)C(C)CN2		CHEMBL3943268	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428250	17789920	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1[C@@H](C)CN2		CHEMBL3909548	<	IC50	nM	50.0	CHEMBL5469	Homo sapiens	IC50	nM	50.0
428251	17789921	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1C(C)(C)CN2		CHEMBL3899566	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428252	17789922	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC3CCC3)n1)C(C)(C)CN2		CHEMBL3935375	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428253	17789923	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)C(C)(C)CN2		CHEMBL3932350	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428254	17789924	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CCCNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1C(C)(C)CN2		CHEMBL3971896	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428255	17789925	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NCC(C)C)n1)C(C)(C)CN2		CHEMBL3933115	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428256	17789926	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC3CCCC3)n1)C(C)(C)CN2		CHEMBL3954762	<	IC50	nM	500.0	CHEMBL5469	Homo sapiens	IC50	nM	500.0
428257	17789927	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC3CCCCC3)n1)C(C)(C)CN2		CHEMBL3917972	<	IC50	nM	200.0	CHEMBL5469	Homo sapiens	IC50	nM	200.0
428258	17789928	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CCCCNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1C(C)(C)CN2		CHEMBL3896031	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428259	17789929	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)N(C)C)n1)C(C)(C)CN2		CHEMBL3923581	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428260	17789930	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CCC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1C(C)(C)CN2		CHEMBL3979330	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428261	17789931	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CCNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1C(C)(C)CN2		CHEMBL3940192	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428262	17789932	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COCCCNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1C(C)(C)CN2		CHEMBL3915673	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428263	17789933	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COCCNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1C(C)(C)CN2		CHEMBL3947737	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428264	17789934	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)Nc3ccccc3)n1)C(C)(C)CN2		CHEMBL3899645	<	IC50	nM	500.0	CHEMBL5469	Homo sapiens	IC50	nM	500.0
428265	17789935	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)(C)C)n1)C(C)(C)CN2		CHEMBL3984491	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428266	17789936	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NCC3CC3)n1)C(C)(C)CN2		CHEMBL3954373	<	IC50	nM	50.0	CHEMBL5469	Homo sapiens	IC50	nM	50.0
428267	17789937	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NCCO)n1)C(C)(C)CN2		CHEMBL3926549	<	IC50	nM	200.0	CHEMBL5469	Homo sapiens	IC50	nM	200.0
428268	17789938	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NCCN(C)C)n1)C(C)(C)CN2		CHEMBL3957554	<	IC50	nM	50.0	CHEMBL5469	Homo sapiens	IC50	nM	50.0
428269	17789939	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3C(=O)N3CCCC3)n1)C(C)(C)CN2		CHEMBL3981963	<	IC50	nM	200.0	CHEMBL5469	Homo sapiens	IC50	nM	200.0
428270	17789940	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3N(C)S(C)(=O)=O)n1)C(C)(C)CN2		CHEMBL3948905	<	IC50	nM	100.0	CHEMBL5469	Homo sapiens	IC50	nM	100.0
428271	17789941	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3cccc(C)n3)n1)C(C)(C)CN2		CHEMBL3912131	<	IC50	nM	500.0	CHEMBL5469	Homo sapiens	IC50	nM	500.0
428272	17789942	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3NC(C)=O)n1)C(C)(C)CN2		CHEMBL3936573	<	IC50	nM	200.0	CHEMBL5469	Homo sapiens	IC50	nM	200.0
428273	17789943	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccc(F)c(F)c3)n1)C(C)(C)CN2		CHEMBL3892608	>	IC50	nM	1000.0	CHEMBL5469	Homo sapiens	IC50	nM	1000.0
428274	17789944	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccc2c(c1Nc1nc(Nc3ccc(N4CCOCC4)cc3OC)nc3c1C(C)(C)CN3)OCO2		CHEMBL3968717	>	IC50	nM	1000.0	CHEMBL5469	Homo sapiens	IC50	nM	1000.0
428275	17789945	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(NC3CCCCC3N(C)S(C)(=O)=O)n1)C(C)(C)CN2		CHEMBL3906560	<	IC50	nM	100.0	CHEMBL5469	Homo sapiens	IC50	nM	100.0
428276	17789946	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2cccc3c2OCCO3)nc2c1C(C)(C)CN2		CHEMBL3942677	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428277	17789947	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)c3c2OCCO3)nc2c1C(C)(C)CN2		CHEMBL3948194	<	IC50	nM	100.0	CHEMBL5469	Homo sapiens	IC50	nM	100.0
428278	17789948	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)nc2c1C(C)(C)CN2		CHEMBL3964456	<	IC50	nM	200.0	CHEMBL5469	Homo sapiens	IC50	nM	200.0
428279	17789949	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2cccc3ccoc23)nc2c1C(C)(C)CN2		CHEMBL3942122	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428280	17789950	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2cc(C)nn2C)nc2c1C(C)(C)CN2		CHEMBL3957673	<	IC50	nM	50.0	CHEMBL5469	Homo sapiens	IC50	nM	50.0
428281	17789951	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CCN1C(=O)CCCc2c1ccc(Nc1nc3c(c(Nc4ccccc4C(=O)NC)n1)C(C)(C)CN3)c2OC		CHEMBL3889834	<	IC50	nM	50.0	CHEMBL5469	Homo sapiens	IC50	nM	50.0
428282	17789952	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc3c(ccn3CCCN3CCOCC3)c2)nc2c1C(C)(C)CN2		CHEMBL3958881	<	IC50	nM	200.0	CHEMBL5469	Homo sapiens	IC50	nM	200.0
428283	17789953	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1C1(CC1)CN2		CHEMBL3961668	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428284	17789954	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)(C)C)n1)C1(CC1)CN2		CHEMBL3892670	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428285	17789955	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NCC(C)C)n1)C1(CC1)CN2		CHEMBL3975901	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428286	17789956	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)C1(CC1)CN2		CHEMBL3901621	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428287	17789957	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CCNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1C1(CC1)CN2		CHEMBL3936925	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428288	17789958	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NCC3CC3)n1)C1(CC1)CN2		CHEMBL3914879	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428289	17789959	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COCCNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1C1(CC1)CN2		CHEMBL3985139	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428290	17789960	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NCCO)n1)C1(CC1)CN2		CHEMBL3974734	>	IC50	nM	1000.0	CHEMBL5469	Homo sapiens	IC50	nM	1000.0
428291	17789961	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)Nc3ccccc3)n1)C1(CC1)CN2		CHEMBL3954119	<	IC50	nM	200.0	CHEMBL5469	Homo sapiens	IC50	nM	200.0
428292	17789962	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	C=CCNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1C1(CC1)CN2		CHEMBL3982805	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428293	17789963	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC3CCCC3)n1)C1(CC1)CN2		CHEMBL3932524	<	IC50	nM	100.0	CHEMBL5469	Homo sapiens	IC50	nM	100.0
428294	17789964	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC3CC3)n1)C1(CC1)CN2		CHEMBL3901039	>	IC50	nM	1000.0	CHEMBL5469	Homo sapiens	IC50	nM	1000.0
428295	17789965	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CCC(C)NS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1C1(CC1)CN2		CHEMBL3923580	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428296	17789966	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CCCNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1C1(CC1)CN2		CHEMBL3895587	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428297	17789967	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC3CCCCC3)n1)C1(CC1)CN2		CHEMBL3915483	<	IC50	nM	500.0	CHEMBL5469	Homo sapiens	IC50	nM	500.0
428298	17789968	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC3CCC3)n1)C1(CC1)CN2		CHEMBL3908546	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428299	17789969	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)N(C)C)n1)C1(CC1)CN2		CHEMBL3986981	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428300	17789970	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)nc2c1C1(CC1)CN2		CHEMBL3915096	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428301	17789971	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccc(F)c(F)c3)n1)C1(CC1)CN2		CHEMBL3898958	<	IC50	nM	500.0	CHEMBL5469	Homo sapiens	IC50	nM	500.0
428302	17789972	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3cccc(C)n3)n1)C1(CC1)CN2		CHEMBL3952455	<	IC50	nM	100.0	CHEMBL5469	Homo sapiens	IC50	nM	100.0
428303	17789973	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3NC(C)=O)n1)C1(CC1)CN2		CHEMBL3910134	<	IC50	nM	50.0	CHEMBL5469	Homo sapiens	IC50	nM	50.0
428304	17789974	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3N(C)S(C)(=O)=O)n1)C1(CC1)CN2		CHEMBL3908380	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428305	17789975	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)nc2c1C1(CC1)CN2		CHEMBL3963488	<	IC50	nM	20.0	CHEMBL5469	Homo sapiens	IC50	nM	20.0
428306	17789976	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2)nc2c1CCN2		CHEMBL3971195	<	IC50	nM	100.0	CHEMBL5469	Homo sapiens	IC50	nM	100.0
428307	17789977	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccccc2OC)nc2c1CCN2		CHEMBL3972273	<	IC50	nM	200.0	CHEMBL5469	Homo sapiens	IC50	nM	200.0
428308	17789978	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3C(=O)O)n1)CCN2		CHEMBL3893960	<	IC50	nM	1000.0	CHEMBL5469	Homo sapiens	IC50	nM	1000.0
428309	17789979	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3C=O)n1)CCN2		CHEMBL3980333	<	IC50	nM	1000.0	CHEMBL5469	Homo sapiens	IC50	nM	1000.0
428310	17789980	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCOCC2)ccc1Nc1nc2c(c(Nc3ccccc3CCO)n1)CCN2		CHEMBL3948742	<	IC50	nM	1000.0	CHEMBL5469	Homo sapiens	IC50	nM	1000.0
428311	17789981	CHEMBL3888996	Biochemical Assay: To measure inhibitory activity of FAK/PYK2 inhibitors, compounds were first prepare as a 1 mM stock in 100% DMSO and 3-fold serial dilution was performed in a 96-well plate (Corning, 3897) to generate 12 different concentration of 100 stock. A 5 l of 100 stock of each concentration was added to wells containing 95 l of 1 reaction buffer (40 mM Tris, pH7.5, mM MgCl2, 1 mM DTT and 1 mM CHAPS) to generate 5 stock. Then 2 l of 5 stock of each concentration was added to a 384 wells-OptiPlate (PerkinElmer, 6007299). For FAK, 4 l of 2.5 nM FAK, 1 l of 8 g/l BSA and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 33.3 M ATP. The reaction was allowed to proceed for 120 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). For PYK2, 5 l of 2 nM PYK2 and 1.5 l of 666 nM ULight-poly Glu, Ala, Tyr (1:1:1) peptide substrate, prepared in above reaction buffer, were added to each well. The reaction was initiated by adding 1.5 l of 46.6 M ATP. The reaction was allowed to proceed for 40 min before being quenched with 5 l of 40 mM EDTA stop buffer prepared in 1LANCE detection buffer (PerkinElmer, CR97-100). Upon quenching of the reaction, 5 l of 8 nM anti-phosphotyrosine antibody was added to each well and incubated for 60 minutes.	B	COc1cc(N2CCC(N3CCNCC3)CC2)ccc1Nc1nc2c(c(Nc3ccccc3P(C)(C)=O)n1)CCN2		CHEMBL3928548	<	IC50	nM	50.0	CHEMBL5469	Homo sapiens	IC50	nM	50.0
Inactive	17932633	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C		CHEMBL1233528	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932634	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932635	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932636	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Uncertain	17932637	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	1088.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	1088.0
Inactive	17932638	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1		CHEMBL1908397	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932639	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Active	17932640	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)c1cccc(-c2cc(C(=O)NC3CCN(C)CC3)c(C)c3[nH]c4ncc(C)cc4c23)c1		CHEMBL3544932	=	Kd	nM	190.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	190.0
Inactive	17932641	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932642	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cc(Cl)ccc1O		CHEMBL536151	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932643	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2cnc3ccc4ccc(CS(=O)(=O)NCc5ccccn5)cc4c(=O)c3c2)cn1		CHEMBL2323775	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932644	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932645	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932646	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccccc5)cc4F)c3s2)c1		CHEMBL254760	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932647	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NC[C@H](O)CO)c1ccncc1Nc1ccc(I)cc1F		CHEMBL2107832	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932648	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932649	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1		CHEMBL496102	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932650	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1.Cl		CHEMBL3991929	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932651	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932652	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1cccc(Cl)c1)Nc1ncc(CCN=c2[nH]cnc3ccsc23)s1		CHEMBL482767	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932653	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1		CHEMBL3402762	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932654	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C1NC(=O)[C@@H](c2cn3c4c(cccc24)CCC3)[C@@H]1c1c[nH]c2ccccc12		CHEMBL2103882	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932655	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc([C@@H](C)Nc2ccccc2C(=O)O)c2nc(N3CCOCC3)cc(=O)n2c1		CHEMBL2165191	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932656	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932657	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1		CHEMBL3348923	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Active	17932658	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1		CHEMBL482967	=	Kd	nM	7540.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	7540.0
Inactive	17932659	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932660	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1		CHEMBL3301612	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932661	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Active	17932662	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(Nc2[nH]nc3c2CN(C(=O)N[C@H](CN(C)C)c2ccccc2)C3(C)C)c2sccc2n1		CHEMBL3128043	=	Kd	nM	1400.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	1400.0
Inactive	17932663	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CO		CHEMBL1801204	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Active	17932664	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)NCC(=O)N1C2CCC1c1cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc12		CHEMBL1983111	=	Kd	nM	267.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	267.0
Inactive	17932665	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	c1cc(OCCN2CCCCC2)cc(-c2n[nH]c3ccc(-c4nnc[nH]4)cc23)c1		CHEMBL1614713	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932666	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](N)c1ccc(C(=O)Nc2ccnc3[nH]ccc23)cc1		CHEMBL571948	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932667	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1		CHEMBL270995	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932668	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2cnn3c(N)c(Br)c([C@@H]4CCCNC4)nc23)cn1		CHEMBL2386889	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932669	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1		CHEMBL3989868	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932670	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1		CHEMBL483321	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932671	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL3353410	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932672	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1		CHEMBL1236107	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932673	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CC[C@@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@@H]1CO.Cl		CHEMBL3991935	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932674	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL507361	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Active	17932675	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@]1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)n[nH]2)c2cccn2n1		CHEMBL575448	=	Kd	nM	98.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	98.0
Inactive	17932676	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932677	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1		CHEMBL3545157	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932678	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932679	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2ccc3ncc4c(c3c2)n(-c2ccc(N3CCNCC3)c(C(F)(F)F)c2)c(=O)n4C)cn1		CHEMBL3218578	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932680	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932681	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1cc(-c2ccnc3[nH]c(-c4cccc(CN(C)C)c4)cc23)c(-c2ccc(NC(=O)N(C)C)cc2)n1		CHEMBL1090479	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932682	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1		CHEMBL2079588	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932683	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(S(=O)(=O)Nc2nc3ccccc3nc2Nc2ccc3nsnc3c2)cc1		CHEMBL3218575	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932684	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2		CHEMBL564829	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932685	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932686	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932687	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932688	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c21		CHEMBL1614725	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932689	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(Cn2c(C)nc3c(C(=O)O)cc(N4CCOCC4)cc32)cccc1C(F)(F)F		CHEMBL3188551	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932690	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932691	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc2cc(-c3nn(C(C)C)c4ncnc(N)c34)ccc2o1		CHEMBL3991933	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Active	17932692	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL1230609	=	Kd	nM	661.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	661.0
Inactive	17932693	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1		CHEMBL3186534	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Active	17932694	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1		CHEMBL1738757	=	Kd	nM	9240.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	9240.0
Inactive	17932695	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21		CHEMBL3334567	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932696	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(=O)c(-c2cc[nH]n2)cc2c(C)nc(N)nc21		CHEMBL3545366	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932697	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1		CHEMBL2396661	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932698	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ncc(-c2ccc3nccc(-c4ccnnc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F		CHEMBL1236962	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932699	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932700	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)oc1Cl		CHEMBL3137336	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932701	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21		CHEMBL3545215	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932702	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)c1ccc(N(C(N)=O)c2c(F)cccc2F)nc1-c1ccc(F)cc1F		CHEMBL1090090	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932703	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(-c4cnn(C)c4)cc3c(=O)c2c1		CHEMBL1822792	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932704	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1		CHEMBL2336325	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932705	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1C#CC(C)(C)N1CCN(C)CC1		CHEMBL2138625	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932706	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1		CHEMBL3301610	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932707	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC(Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2OC)CC1		CHEMBL3545154	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Active	17932708	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)NCc2cc(F)ccc2Oc2ccc3c(cnn3CCO)c2)cc1		CHEMBL3991932	=	Kd	nM	30414.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30414.0
Inactive	17932709	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1		CHEMBL592445	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932710	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1nccc1Nc1nccc(-c2ccn([C@H](CO)c3ccc(Cl)c(F)c3)c(=O)c2)n1		CHEMBL3544964	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932711	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1		CHEMBL377300	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932712	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1		CHEMBL3813873	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932713	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](C)(C)CC1		CHEMBL372764	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932714	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1		CHEMBL3545328	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932715	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1		CHEMBL2028663	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932716	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O		CHEMBL3182621	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932717	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N[C@@H]1CCCN(c2c(/C=C3\SC(=O)NC3=O)cccc2-c2ccccc2)C1		CHEMBL2048872	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932718	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1		CHEMBL1287853	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932719	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC		CHEMBL2029988	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932720	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932721	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O[C@H]1CC[C@H](Nc2ncc3nc(Nc4c(F)cc(F)cc4F)n([C@H]4CCOC4)c3n2)CC1		CHEMBL1950289	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932722	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Active	17932723	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL3545360	=	Kd	nM	273.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	273.0
Inactive	17932724	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1		CHEMBL495727	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932725	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21		CHEMBL3218576	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932726	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1[nH]c(C2CCCN2)nc2c1oc1ccc(Cl)cc12		CHEMBL3544944	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932727	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1		CHEMBL217092	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932728	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1		CHEMBL460702	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Active	17932729	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	=	Kd	nM	1360.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	1360.0
Inactive	17932730	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932731	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	FC(F)(F)c1ccc(/C=C/c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1		CHEMBL1614707	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932732	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)CN1CCC(Oc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)CC1		CHEMBL2408045	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Active	17932733	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1		CHEMBL3301622	=	Kd	nM	510.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	510.0
Active	17932734	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)C1(Cc2cccc(Nc3nccs3)n2)CCC(Oc2cccc(Cl)c2F)CC1		CHEMBL3182444	=	Kd	nM	343.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	343.0
Inactive	17932735	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932736	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1		CHEMBL3544960	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932737	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O		CHEMBL189963	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932738	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1		CHEMBL3301607	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932739	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC(C)(C)C)cn1		CHEMBL1088752	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932740	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl		CHEMBL2219422	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932741	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1		CHEMBL1078178	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932742	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Cc1ccc(-c2ccc(OCCN3CCOCC3)cc2)cn1)NCc1ccccc1		CHEMBL571546	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932743	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Active	17932744	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1		CHEMBL3545085	=	Kd	nM	118.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	118.0
Inactive	17932745	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932746	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL1201182	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932747	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc3nnc(C(F)(F)c4ccc5ncccc5c4)n3n2)cn1		CHEMBL2133806	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932748	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12		CHEMBL1614710	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932749	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc3[nH]ncc23)CC1		CHEMBL3545076	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932750	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O		CHEMBL1289601	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932751	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL180022	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932752	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932753	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCNC(=O)C#Cc1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(CN(C)C)cc1)c1ccccc1		CHEMBL3699142	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932754	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1		CHEMBL2103851	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932755	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(CN2CCN(C(=O)[C@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12		CHEMBL1922094	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932756	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1908394	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932757	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1		CHEMBL1946170	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932758	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2[C@H]1C[C@H](N2CCC2)C1		CHEMBL551064	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932759	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1		CHEMBL253969	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932760	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1		CHEMBL2105728	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932761	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21		CHEMBL3187723	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932762	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1		CHEMBL2105759	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932763	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932764	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F		CHEMBL3264002	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932765	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(-c2cc(O)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12		CHEMBL400402	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932766	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CCN(/C=C1/C(=O)O[C@H](COC)[C@@]2(C)C1=C(O)C(=O)C1=C2[C@H](OC(C)=O)C[C@]2(C)C(=O)CC[C@@H]12)CC=C		CHEMBL411907	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932767	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932768	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn32)C1		CHEMBL1091644	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932769	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1		CHEMBL1236682	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932770	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932771	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)Nc1cc(-c2c[nH]c(C(=O)N[C@H](CO)c3cccc(Cl)c3)c2)c(Cl)cn1		CHEMBL3590106	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932772	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932773	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1		CHEMBL2110732	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932774	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1		CHEMBL1983268	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932775	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1		CHEMBL2017974	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932776	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(N2CCN(C)CC2)cc1Nc1ncc2c(n1)-c1c(c(C(N)=O)nn1C)CC2		CHEMBL1094408	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Active	17932777	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL574737	=	Kd	nM	191.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	191.0
Inactive	17932778	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1		CHEMBL482968	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Active	17932779	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	=	Kd	nM	79.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	79.0
Inactive	17932780	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(OC)c(/C=C/S(=O)(=O)Cc2ccc(OC)c(NCC(=O)O)c2)c(OC)c1		CHEMBL1241855	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Active	17932781	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)Nc1cc(-c2cccc(F)c2)sc1C(=O)N[C@H]1CCCNC1		CHEMBL2041933	=	Kd	nM	608.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	608.0
Inactive	17932782	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12		CHEMBL2220486	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932783	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F		CHEMBL3188267	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Active	17932784	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3688339	=	Kd	nM	30.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30.0
Inactive	17932785	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932786	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1		CHEMBL587723	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932787	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932788	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932789	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1		CHEMBL2216870	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932790	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@@H]23)OCO4)cc(OC)c1OC		CHEMBL283120	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932791	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1		CHEMBL1944698	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932792	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932793	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1		CHEMBL1976040	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932794	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(S(=O)(=O)N(C(C)=O)c2ccccc2/C=C/c2cc[n+]([O-])cc2)cc1		CHEMBL3991927	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932795	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC		CHEMBL2105717	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932796	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OP(C)(C)=O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL2103839	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932797	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCCCC(=O)NO)cc23)c1		CHEMBL598797	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932798	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F		CHEMBL1229517	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932799	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(C)c(-n2c(C)cc(OCc3ccc(F)cc3F)c(Br)c2=O)c1		CHEMBL1088751	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932800	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932801	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12		CHEMBL403989	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932802	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Nc1cc(F)cc(F)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12		CHEMBL3408248	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932803	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932804	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	OCCn1cc(-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2)cn1		CHEMBL2001019	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932805	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C1NC(=O)/C(=C/c2ccc3nccc(-c4ccncc4)c3c2)S1		CHEMBL3544966	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932806	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1N=C(N)c2cn([C@@H]3O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL462018	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932807	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O		CHEMBL1738797	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932808	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1		CHEMBL2035187	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Active	17932809	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1		CHEMBL402548	=	Kd	nM	50.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	50.0
Inactive	17932810	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B			CHEMBL4084193	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932811	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932812	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NOCCO)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL1614766	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932813	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C		CHEMBL488436	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932814	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1		CHEMBL2103875	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932815	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(=O)c(F)c(Nc2ccc(I)cc2F)c2c(=O)n(C[C@@H](O)CO)cnc21		CHEMBL1615025	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932816	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cccc(-c2nn3c(c2-c2ccnc4ccc(C(N)=O)cc24)CCC3)n1		CHEMBL2364611	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932817	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932818	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1		CHEMBL2087361	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932819	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1		CHEMBL3545308	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932820	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1		CHEMBL1173655	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932821	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@H](OCCO)CC3)c2=O)cn1		CHEMBL1234354	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932822	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cccc2cc(-c3nc([C@H]4CC[C@H](C(=O)O)CC4)n4ncnc(N)c34)[nH]c12		CHEMBL3120215	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932823	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C		CHEMBL1230607	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932824	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1		CHEMBL1908391	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932825	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC[C@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3991931	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Active	17932826	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331	=	Kd	nM	423.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	423.0
Inactive	17932827	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc3c2cc1OCCCCCN(C)Cc1ccc(Br)cc1N3		CHEMBL3109738	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932828	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1		CHEMBL2180604	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932829	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1		CHEMBL2146883	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932830	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325741	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Active	17932831	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1		CHEMBL3039525	=	Kd	nM	1006.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	1006.0
Inactive	17932832	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=S(=O)(c1cccc2c(O)nccc12)N1CCCNCC1		CHEMBL1233300	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932833	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL1908360	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932834	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(CCc2cc(NC(=O)c3ccc(N4CC(C)NC(C)C4)cc3)n[nH]2)cc(OC)c1		CHEMBL3184679	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932835	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCc1c(-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)c(F)c2)c2c(N)ncnn2c1CN1CCOCC1		CHEMBL3991934	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932836	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1		CHEMBL1952329	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932837	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc2ccc(-n3ncc(C(=O)c4cc5ccccc5[nH]4)c3N)cc2[nH]1		CHEMBL3907479	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932838	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1		CHEMBL3545110	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932839	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1		CHEMBL3545307	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932840	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(C2=Nc3cc(NC(=O)C(N)C4CCCCC4)cc4c3C2=CNNC4=O)cn1		CHEMBL3545137	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932841	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932842	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCCN1CCN(Cc2ccc(-c3n[nH]c4c3C(=O)c3c(NC(=O)NN5CCOCC5)cccc3-4)cc2)CC1		CHEMBL3545083	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932843	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC1(c2ccc(-c3nc4ccn5c(=O)[nH]nc5c4cc3-c3ccccc3)cc2)CCC1		CHEMBL1079175	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932844	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O		CHEMBL274654	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932845	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932846	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1		CHEMBL2103842	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932847	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(C(=O)Nc2ccc(C(=O)N3CCN(C)CC3)cc2)nnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL2376648	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932848	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@H]1CN(C(=O)c2cc3c(C(=O)C(=O)N(C)C)cn(C)c3cc2Cl)[C@H](C)CN1Cc1ccc(F)cc1		CHEMBL514201	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932849	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21		CHEMBL1879463	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932850	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12		CHEMBL1645462	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932851	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@](C)(Nc1ccnc(-c2c[nH]c3ncccc23)n1)C(=O)NCC(F)(F)F		CHEMBL3039513	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932852	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12		CHEMBL2103840	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932853	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1		CHEMBL3545396	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932854	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(=O)(O)O		CHEMBL415049	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Active	17932855	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1		CHEMBL1231124	=	Kd	nM	1884.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	1884.0
Inactive	17932856	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932857	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1		CHEMBL3039517	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932858	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932859	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12		CHEMBL3426621	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932860	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932861	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(O)cc3)c2cc1OC		CHEMBL405130	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932862	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O		CHEMBL483158	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932863	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@@H]1C[C@@H]2CN(C)C[C@@H]2C1		CHEMBL3544983	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932864	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932865	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932866	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL513909	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932867	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1		CHEMBL206834	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932868	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21		CHEMBL1614701	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Active	17932869	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1		CHEMBL2403108	=	Kd	nM	18357.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	18357.0
Active	17932870	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12		CHEMBL1171837	=	Kd	nM	295.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	295.0
Inactive	17932871	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932872	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932873	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1[nH]ccc2cc(OC3CCNCC3)ccc12		CHEMBL1667969	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932874	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1csc(-c2nnc(Nc3ccc(Oc4ncccc4-c4ccnc(N)n4)cc3)c3ccccc23)c1		CHEMBL2140408	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17932875	CHEMBL3991856	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL2103830	>	Kd	nM	30000.0	CHEMBL5469	Homo sapiens	Kd apparent	nM	30000.0
	18053038	CHEMBL4011885	Inhibition of PYK2 (unknown origin) at 0.1 uM pretreated for 30 mins followed by substrate addition measured after 5 hrs in presence of 1 mM ATP relative to control	B	COC(=O)C1=C(Nc2ccccc2Cl)O/C(=C\c2c[nH]c3ncccc23)C1=O		CHEMBL4089159	=	Inhibition	%	24.2	CHEMBL5469	Homo sapiens	INH	%	24.2
	18096494	CHEMBL4021283	Reversible inhibition of PYK2 (unknown origin)	B	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	=	IC50	nM	13.0	CHEMBL5469	Homo sapiens	IC50	nM	13.0
	18114821	CHEMBL4025351	Inhibition of wild-type human full length PYK2 (M1 to E967 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077123	=	Activity	%	100.0	CHEMBL5469	Homo sapiens	Activity	%	100.0
	18203875	CHEMBL4044162	Inhibition of wild-type human full length PYK2 (M1 to E967 residues) expressed in Escherichia coli BL21 assessed as residual activity at 1000 nM after 30 mins by Kinomescan method relative to control	B	COc1cc(OC)c(Cl)c(N2Cc3cnc(Nc4ccc(F)cc4)nc3N(C3CCN(C(=O)/C=C/CN(C)C)CC3)C2=O)c1Cl		CHEMBL4092508	=	Activity	%	91.0	CHEMBL5469	Homo sapiens	Activity	%	91.0
	18211719	CHEMBL4045815	Inhibition of PYK2 conserved Lys1 (INVAVKTCK) in human PBMC at 1 uM	B	CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1	Outside typical range	CHEMBL3971067	=	Inhibition	%	-24.8	CHEMBL5469	Homo sapiens	INH	%	-24.8
	18211960	CHEMBL4046056	Inhibition of PYK2 conserved Lys1 (INVAVKTCK) in human PBMC at 0.1 uM	B	CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1	Outside typical range	CHEMBL3971067	=	Inhibition	%	-22.2	CHEMBL5469	Homo sapiens	INH	%	-22.2
	18253935	CHEMBL4055252	Inhibition of wild-type human full length PYK2 (M1 to E967 residues) expressed in bacterial expression system assessed as residual activity at 50 nM by Kinomescan method relative to control	B	CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccccc4)cc23)CC[C@]1(C)N		CHEMBL4096145	=	Activity	%	100.0	CHEMBL5469	Homo sapiens	Activity	%	100.0
	18253936	CHEMBL4055252	Inhibition of wild-type human full length PYK2 (M1 to E967 residues) expressed in bacterial expression system assessed as residual activity at 50 nM by Kinomescan method relative to control	B	COc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cn1		CHEMBL4080797	=	Activity	%	93.0	CHEMBL5469	Homo sapiens	Activity	%	93.0
	18265933	CHEMBL4057383	Inhibition of PYK2 (unknown origin) at 0.45 uM relative to control	B	Cc1n[nH]c(C)c1-c1ccc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2c1		CHEMBL4095072	=	Inhibition	%	4.7	CHEMBL5469	Homo sapiens	INH	%	4.7
	18266149	CHEMBL4057599	Inhibition of PYK2 (unknown origin) at 0.49 uM relative to control	B	Cc1[nH]nc(C2CC2)c1-c1ccc2c(NC(=O)C3CC3)noc2c1		CHEMBL4088455	=	Inhibition	%	1.3	CHEMBL5469	Homo sapiens	INH	%	1.3
	18282847	CHEMBL4120432	Inhibition of PYK2 (unknown origin) at 0.45 uM relative to control	B	Cc1n[nH]c(C)c1-c1ccc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2c1		CHEMBL4095072	=	Inhibition	%	4.7	CHEMBL5469	Homo sapiens	INH	%	4.7
	18283067	CHEMBL4120652	Inhibition of PYK2 (unknown origin) at 0.19 uM relative to control	B	Cc1[nH]nc(C2CC2)c1-c1ccc2c(-c3ccc(N4CCN(C)CC4)nc3)n[nH]c2c1		CHEMBL4125807	=	Inhibition	%	-1.7	CHEMBL5469	Homo sapiens	INH	%	-1.7
	18283287	CHEMBL4120872	Inhibition of PYK2 (unknown origin) at 0.164 uM relative to control	B	COC(=O)Nc1cc(-c2c(C3CC3)n[nH]c2C)cc2[nH]ncc12		CHEMBL4129737	=	Inhibition	%	2.7	CHEMBL5469	Homo sapiens	INH	%	2.7
	18440417	CHEMBL4157241	Binding affinity to wild-type human full length PYK2 (M1 to E967 residues) expressed in bacterial expression system assessed as residual binding at 1 uM by Kinomescan method relative to control	B	Cc1cccc(S(=O)(=O)Nc2cc(-c3sc(NC(=O)[C@@H](N)C(C)C)nc3C)cnc2Cl)c1		CHEMBL4174988	=	Activity	%	100.0	CHEMBL5469	Homo sapiens	Activity	%	100.0
	18464427	CHEMBL4181424	Inhibition of recombinant full length GST-tagged human PYK2 cytoplasmic domain expressed in baculovirus expression system at 100 nM relative to control	B	CCOP(=O)(CCCOc1ccc(Nc2ncc([N+](=O)[O-])c(Nc3ccccc3C(=O)NC)n2)cc1)N1CCOCC1		CHEMBL4216755	=	Inhibition	%	71.0	CHEMBL5469	Homo sapiens	INH	%	71.0
	18484373	CHEMBL4186020	Binding affinity to wild-type human full length PYK2 (M1 to E967 residues) expressed in Escherichia coli BL21 at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL3969370	=	Activity	%	97.0	CHEMBL5469	Homo sapiens	Activity	%	97.0
	18484857	CHEMBL4186020	Binding affinity to wild-type human full length PYK2 (M1 to E967 residues) expressed in Escherichia coli BL21 at 1 uM by Kinomescan method relative to control	B	CCC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL4206831	=	Activity	%	95.0	CHEMBL5469	Homo sapiens	Activity	%	95.0
	18507629	CHEMBL4191162	Inhibition of recombinant full-length human Pyk2 at 1 uM using poly(Glu,Tyr) 4:1 as substrate after 40 mins in presence of [gamma-33P]ATP by scintillation counting method	B	CS(=O)(=O)c1ccc(-n2nc(-c3cnc4[nH]ccc4c3)c3c(N)ncnc32)cc1		CHEMBL4207014	=	Inhibition	%	25.0	CHEMBL5469	Homo sapiens	INH	%	25.0
	18653393	CHEMBL4230209	Inhibition of PYK2 (unknown origin) at 1 uM by mobility shift microfluidics platform based assay relative to control	B	CC(C)n1nc(C#Cc2cccc(NC(=O)c3cccc(C(F)(F)F)c3)c2)c2c(N)ncnc21		CHEMBL3736320	=	Inhibition	%	74.0	CHEMBL5469	Homo sapiens	INH	%	74.0
	18653394	CHEMBL4230209	Inhibition of PYK2 (unknown origin) at 1 uM by mobility shift microfluidics platform based assay relative to control	B	CC(C)n1nc(C#Cc2cccc3cc(-c4cccc(C(F)(F)F)c4)ncc23)c2c(N)ncnc21		CHEMBL4247506	=	Inhibition	%	1.0	CHEMBL5469	Homo sapiens	INH	%	1.0
	18655315	CHEMBL4230920	Binding affinity to wild-type human full length PYK2 (M1 to E967 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	Cc1ccc(NC(=O)c2ccc(CN(CCN(C)C)C(=O)c3cccnc3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL4247298	=	Activity	%	99.0	CHEMBL5469	Homo sapiens	Activity	%	99.0
	18665520	CHEMBL4233396	Inhibition of PYK2 (unknown origin)	B	O=C(Cc1cccc(OCCCN2CCNCC2)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL4245507	>	IC50	nM	1000.0	CHEMBL5469	Homo sapiens	IC50	nM	1000.0
	18674869	CHEMBL4235425	Inhibition of PYK2 (unknown origin)	B	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1		CHEMBL4249925	>	Ki	nM	2000.0	CHEMBL5469	Homo sapiens	Ki	nM	2000.0
	18674870	CHEMBL4235425	Inhibition of PYK2 (unknown origin)	B	O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1		CHEMBL4245242	>	Ki	nM	2000.0	CHEMBL5469	Homo sapiens	Ki	nM	2000.0
Not Determined	18674871	CHEMBL4235425	Inhibition of PYK2 (unknown origin)	B	CN1CCN(CCCOc2cccc(CC(=O)Nc3nc(-c4c[nH]c5ncccc45)cs3)c2)CC1		CHEMBL4248525		Ki			CHEMBL5469	Homo sapiens	Ki		
	18751223	CHEMBL4263932	Inhibition of PYK2 (unknown origin) at 1 uM relative to control	B	NC1(c2ccc(-c3cnc4c(-c5ccc(S(N)(=O)=O)c6ccccc56)cnn4c3)cc2)CCC1		CHEMBL4278763	=	Inhibition	%	11.0	CHEMBL5469	Homo sapiens	INH	%	11.0
	18752172	CHEMBL4264509	Binding affinity to wild-type human full length PYK2 (M1 to E967 residues) expressed in bacterial expression system assessed as remaining unbound target protein level at 1000 nM by Kinomescan method relative to control	B	COCCN[C@H]1CC[C@H](Nc2cc(-c3csc(NCC4(C#N)CCOCC4)n3)c(Cl)cn2)CC1		CHEMBL4281048	=	Activity	%	90.0	CHEMBL5469	Homo sapiens	Activity	%	90.0
	18849486	CHEMBL4305552	Inhibition of recombinant N-terminal GST-fusion protein tagged human full length PYK2 (1 to 967 residues) expressed in baculovirus expression system assessed as decrease in fluorescence labelled Blk/Lyntide phosphorylation at 200 nM by off-chip mobility shift assay relative to control	B	Cc1cccc(Nc2nc(N[C@@H]3CCCC[C@@H]3N)c(C#N)c3cn[nH]c(=O)c23)c1		CHEMBL4461851	>	Inhibition	%	90.0	CHEMBL5469	Homo sapiens	INH	%	90.0
	18858172	CHEMBL4308018	Binding affinity to wild-type human full length PYK2 (M1 to E967 residues) expressed in bacterial expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	CC(C)N1C(=O)C(NCCCN(C)C)=C(c2cn(C)c3ccccc23)C1=O.Cl		CHEMBL4533018	=	Activity	%	100.0	CHEMBL5469	Homo sapiens	Activity	%	100.0
	18892957	CHEMBL4314923	Inhibition of recombinant full-length human Pyk2 assessed as residual activity at 10 uM using poly(Glu, Tyr) 4:1 as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	Cc1cc(C)c(CNc2nc(Cl)nc3c2ncn3C2CCCC2)c(=O)[nH]1		CHEMBL4557538	=	Activity	%	97.0	CHEMBL5469	Homo sapiens	Activity	%	97.0
	18919453	CHEMBL4322810	Binding affinity to recombinant full-length N-terminal His-FLAG-tagged PTK2B (unknown origin) expressed in baculovirus infected Sf9 insect cells incubated for 1 hr by TR-FRET assay	B	CO[C@@H]1[C@H](NCCOCCOCCOCCNC(=O)CCC2=[N+]3C(=Cc4c(C)cc(C)n4[B-]3(F)F)C=C2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL4465866	=	Kd	nM	59.0	CHEMBL5469	Homo sapiens	Kd	nM	59.0
	18919641	CHEMBL4322810	Binding affinity to recombinant full-length N-terminal His-FLAG-tagged PTK2B (unknown origin) expressed in baculovirus infected Sf9 insect cells incubated for 1 hr by TR-FRET assay	B	CO[C@@H]1[C@H](N(C)CCOCCOCCOCCNC(=O)CCC2=[N+]3C(=Cc4c(C)cc(C)n4[B-]3(F)F)C=C2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL4576489	=	Kd	nM	73.0	CHEMBL5469	Homo sapiens	Kd	nM	73.0
	18938261	CHEMBL4327857	Inhibition of human PYK2 assessed as residual activity at 1 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	B	ClC/C=C/C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4438024	=	Activity	%	102.54	CHEMBL5469	Homo sapiens	Activity	%	102.54
	18938262	CHEMBL4327857	Inhibition of human PYK2 assessed as residual activity at 1 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	B	C(=C/c1ccccc1)\C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4446405	=	Activity	%	100.34	CHEMBL5469	Homo sapiens	Activity	%	100.34
	18938702	CHEMBL4328221	Inhibition of human PYK2 assessed as residual activity at 100 uM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay relative to control	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	<	Activity	%	65.0	CHEMBL5469	Homo sapiens	Activity	%	65.0
	18939086	CHEMBL4328585	Inhibition of human PYK2 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	10.6	CHEMBL5469	Homo sapiens	IC50	10'-8M	1.06
	18958588	CHEMBL4333603	Binding affinity to wild-type human full length PYK2 (M1 to E967 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	CC(C)Nc1sc(C(=O)c2ccc(Cl)s2)c(N)c1C#N		CHEMBL4563315	=	Activity	%	100.0	CHEMBL5469	Homo sapiens	Activity	%	100.0
	18964644	CHEMBL4335263	Inhibition of recombinant human full length PYK2 assessed as residual activity at 1 uM using poly(Glu, Tyr) 4:1 as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	N=C1NC(=O)/C(=C\c2ccc(-c3cccc([N+](=O)[O-])c3)o2)S1		CHEMBL4455512	=	Activity	%	103.0	CHEMBL5469	Homo sapiens	Activity	%	103.0
	18964645	CHEMBL4335263	Inhibition of recombinant human full length PYK2 assessed as residual activity at 1 uM using poly(Glu, Tyr) 4:1 as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	C=CCOC(=O)c1cc(-c2ccc(/C=C3/NC(=S)NC3=O)o2)ccc1Cl		CHEMBL4568120	=	Activity	%	104.0	CHEMBL5469	Homo sapiens	Activity	%	104.0
	18972076	CHEMBL4337086	Inhibition of recombinant human full length PYK2 assessed as residual activity at 10 uM using poly(Glu, Tyr) 4:1 as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay relative to control	B	C[C@@H](c1ccccc1)n1nnc2cnc3ccc(-c4cnc5[nH]ccc5c4)cc3c21		CHEMBL4472294	=	Activity	%	59.0	CHEMBL5469	Homo sapiens	Activity	%	59.0
Active	18995251	CHEMBL4342188	Inhibition of PYK2 phosphorylation in human K562 cells up to 10 uM incubated for 48 hrs by human phospho-kinase array	B	O=C(Nc1ccc(C(F)(F)F)cc1)Nc1nnc(Sc2cc(NCCCN3CCOCC3)ncn2)s1		CHEMBL4537984		Inhibition	%		CHEMBL5469	Homo sapiens	INH		
	19021556	CHEMBL4347778	Inhibition of recombinant human PYK2 at 20 nM using Ulight-TK peptide as substrate measured after 15 mins by LANCE method relative to control	B	O=C(CCCCCn1cc(Nc2ncc(Cl)c(Nc3ccc(Cl)cc3)n2)cn1)NO		CHEMBL4526274	=	Inhibition	%	1.0	CHEMBL5469	Homo sapiens	INH	%	1.0
	19021557	CHEMBL4347779	Inhibition of recombinant human PYK2 at 200 nM using Ulight-TK peptide as substrate measured after 15 mins by LANCE method relative to control	B	O=C(CCCCCn1cc(Nc2ncc(Cl)c(Nc3ccc(Cl)cc3)n2)cn1)NO		CHEMBL4526274	=	Inhibition	%	26.0	CHEMBL5469	Homo sapiens	INH	%	26.0
Not Active	19040134	CHEMBL4352035	Inhibition of recombinant full-length human Pyk2 at 10 uM using poly(Glu, Tyr) 4:1 as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	CN1C[C@H](Nc2nc3cc[nH]c3c(=O)n2C)C[C@H](c2ccc3c(c2)OCCO3)C1		CHEMBL4574669		Inhibition	%		CHEMBL5469	Homo sapiens	INH		
Active	19041263	CHEMBL4352524	Inhibition of human PYK2 at 10 uM using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP	B	CC(C)(C)C(=O)N1N=CC[C@H]1c1ccccc1		CHEMBL4521353		Inhibition	%		CHEMBL5469	Homo sapiens	INH		
	19059797	CHEMBL4358098	Binding affinity to wild-type human full length PYK2 (M1 to E967 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1C(=O)Nc1c(C)cccc1Cl		CHEMBL4515441	=	Activity	%	100.0	CHEMBL5469	Homo sapiens	Activity	%	100.0
	19072917	CHEMBL4362092	Effect on PYK2 at Y402 phosphorylation level in human NCI-H1975 incubated for 12 hrs by human phosphokinase proteome profiler array relative to control	B	CCOc1ccc(-c2nc(C(=O)NO)c3[nH]c(=O)n(-c4ccccc4OC)c3n2)cc1		CHEMBL4443725	=	FC		1.13	CHEMBL5469	Homo sapiens	FC		1.13
	19072956	CHEMBL4362131	Effect on PYK2 at Y402 phosphorylation level in human NCI-H1975 incubated for 12 hrs by human phosphokinase proteome profiler array relative to beta-catenin	B	CCOc1ccc(-c2nc(C(=O)NO)c3[nH]c(=O)n(-c4ccccc4OC)c3n2)cc1		CHEMBL4443725	=	FC		1.27	CHEMBL5469	Homo sapiens	FC		1.27
	19072995	CHEMBL4362092	Effect on PYK2 at Y402 phosphorylation level in human NCI-H1975 incubated for 12 hrs by human phosphokinase proteome profiler array relative to control	B	CCOc1ccc(-c2nc(C(=O)NO)c3[nH]c(=O)n(-c4ccccc4OC)c3n2)cc1		CHEMBL4443725	=	log2FC		0.18	CHEMBL5469	Homo sapiens	log2FC		0.18
	19073034	CHEMBL4362131	Effect on PYK2 at Y402 phosphorylation level in human NCI-H1975 incubated for 12 hrs by human phosphokinase proteome profiler array relative to beta-catenin	B	CCOc1ccc(-c2nc(C(=O)NO)c3[nH]c(=O)n(-c4ccccc4OC)c3n2)cc1		CHEMBL4443725	=	log2FC		0.35	CHEMBL5469	Homo sapiens	log2FC		0.35
	19073096	CHEMBL4362092	Effect on PYK2 at Y402 phosphorylation level in human NCI-H1975 incubated for 12 hrs by human phosphokinase proteome profiler array relative to control	B	CCOc1ccc(-c2nc(/C(N)=N/O)c3[nH]c(=O)n(-c4ccccc4OC)c3n2)cc1		CHEMBL4515196	=	FC		1.43	CHEMBL5469	Homo sapiens	FC		1.43
	19073135	CHEMBL4362131	Effect on PYK2 at Y402 phosphorylation level in human NCI-H1975 incubated for 12 hrs by human phosphokinase proteome profiler array relative to beta-catenin	B	CCOc1ccc(-c2nc(/C(N)=N/O)c3[nH]c(=O)n(-c4ccccc4OC)c3n2)cc1		CHEMBL4515196	=	FC		1.67	CHEMBL5469	Homo sapiens	FC		1.67
	19073174	CHEMBL4362092	Effect on PYK2 at Y402 phosphorylation level in human NCI-H1975 incubated for 12 hrs by human phosphokinase proteome profiler array relative to control	B	CCOc1ccc(-c2nc(/C(N)=N/O)c3[nH]c(=O)n(-c4ccccc4OC)c3n2)cc1		CHEMBL4515196	=	log2FC		0.51	CHEMBL5469	Homo sapiens	log2FC		0.51
	19073213	CHEMBL4362131	Effect on PYK2 at Y402 phosphorylation level in human NCI-H1975 incubated for 12 hrs by human phosphokinase proteome profiler array relative to beta-catenin	B	CCOc1ccc(-c2nc(/C(N)=N/O)c3[nH]c(=O)n(-c4ccccc4OC)c3n2)cc1		CHEMBL4515196	=	log2FC		0.74	CHEMBL5469	Homo sapiens	log2FC		0.74
	19090361	CHEMBL4365935	Inhibition of wild-type human full length PYK2 (M1 to E967 residues) expressed in bacterial expression system assessed as residual activity at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccnc1)c1cc(C(=O)c2c(F)cccc2Br)c[nH]1		CHEMBL4436895	=	Activity	%	96.0	CHEMBL5469	Homo sapiens	Activity	%	96.0
	19092096	CHEMBL4366570	Inhibition of human PYK2 at 100 nM using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	B	COc1ccc(N2C(=O)COc3ccc(-c4cnc(OC)c(NS(=O)(=O)c5ccc(F)cc5)c4)cc32)cc1		CHEMBL4528675	=	Inhibition	%	6.22	CHEMBL5469	Homo sapiens	INH	%	6.22
	19114726	CHEMBL4371459	Binding affinity to PYK2 in SILAC-labeled human MDA-MB-231 cells lysate by mass spectrometry based kinAffinity assay	B	COc1cc2c(Oc3ccc(NS(=O)(=O)c4c(F)cccc4F)cc3F)ccnc2cc1OCCCN1CCN(C)CC1		CHEMBL4462318	=	Kd	nM	6928.0	CHEMBL5469	Homo sapiens	Kd(free)	uM	6.928
	19144823	CHEMBL4377839	Inhibition of recombinant full-length human Pyk2 at 1 uM using poly(Glu, Tyr) 4:1 as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(NC(=O)CCCCCCCN=C=S)cc3)nc2n1C1CCCC1		CHEMBL4548580	=	Inhibition	%	46.0	CHEMBL5469	Homo sapiens	INH	%	46.0
	19148018	CHEMBL4379414	Inhibition of recombinant human full length PYK2 using poly(Glu, Tyr) 4:1 as substrate incubated for 40 mins in presence of [gamma33P]ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4438748	>	IC50	nM	10000.0	CHEMBL5469	Homo sapiens	IC50	uM	10.0
	19159625	CHEMBL4382729	Binding affinity to wild-type human full length PYK2 (M1 to E967 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL4473365	=	Activity	%	0.5	CHEMBL5469	Homo sapiens	Activity	%	0.5
	19191382	CHEMBL4389448	Inhibition of wild-type human full length PYK2 (M1 to E967 residues) expressed in bacterial expression system at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@H]2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1N1CCCC1		CHEMBL4555459	=	Inhibition	%	96.0	CHEMBL5469	Homo sapiens	INH	%	96.0
	19192111	CHEMBL4389925	Inhibition of wild-type human full length PYK2 (M1 to E967 residues) expressed in bacterial expression system at 1 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@@H]2CN(c3ncnc4[nH]ccc34)CCN2CCO)c1)Nc1c(F)cccc1N1CCCC1		CHEMBL4564973	=	Inhibition	%	84.0	CHEMBL5469	Homo sapiens	INH	%	84.0
	19200367	CHEMBL4391551	Binding affinity to wild-type human full length PYK2 (M1 to E967 residues) expressed in bacterial expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cc(-c2cn(CCNc3c4c(nc5ccccc35)CCCC4)nn2)ccn1)Nc1cccc2c1C1CCCCN1C2=O		CHEMBL4559936	=	Activity	%	74.0	CHEMBL5469	Homo sapiens	Activity	%	74.0
	19266590	CHEMBL4405540	Inhibition of wild-type human full length PYK2 (M1 to E967 residues) expressed in bacterial expression system at 1 uM by Kinomescan method relative to control	B	CC[C@H](Nc1nc(N)nc(C)c1C#N)c1nc2cccc(NCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1		CHEMBL4455923	<	Inhibition	%	50.0	CHEMBL5469	Homo sapiens	INH	%	50.0
	19276107	CHEMBL4408110	Inhibition of recombinant human full length PYK2 at 1 uM using poly(Glu, Tyr) 4:1 as substrate incubated for 40 mins in presence of [gamma-33P]-ATP by scintillation counting method relative to control	B	Cc1ccc(NC(=O)C2(C(=O)Nc3ccc(Nc4ncc(F)c(-c5cc(F)c6nc(C)n(C(C)C)c6c5)n4)cc3)CC2)cc1		CHEMBL4445335	=	Inhibition	%	73.0	CHEMBL5469	Homo sapiens	INH	%	73.0
	20598203	CHEMBL4602930	Inhibition of human PTK2beta	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	<	IC50	nM	1000.0	CHEMBL5469	Homo sapiens	IC50	uM	1.0
	20600653	CHEMBL4603605	Inhibition of recombinant full length human N-terminal GST-tagged PTK2B cytoplasmic domain expressed in baculovirus expression system using tyr01 peptide as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	C[C@@H]1C[C@H]1C(=O)N1CCN(c2cnc(C#N)c(-c3cnn(C)c3)n2)C[C@H]1C		CHEMBL4634634	>	IC50	nM	100000.0	CHEMBL5469	Homo sapiens	IC50	uM	100.0
	20669059	CHEMBL4620302	Inhibition of biotinylated ligand binding to wild-type human full length PYK2 (M1 to E967 residues) expressed in bacterial expression system at 50 nM measured after 1 hr by kinomescan assay relative to control	B	CN(C)[C@@H]1CC[C@@]2(C)[C@@H](CC[C@H]3[C@@H]4CC=C(c5ccc6ccncc6c5)[C@@]4(C)CC[C@@H]32)C1		CHEMBL4637411	>	Inhibition	%	80.0	CHEMBL5469	Homo sapiens	INH	%	80.0
	22423076	CHEMBL4674091	Inhibition of human PYK2 using poly[Glu:Tyr] (4:1) as substrate at 0.5 uM by [gamma-33P]-ATP assay relative to control	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	>	Inhibition	%	80.0	CHEMBL5469	Homo sapiens	INH	%	80.0
	22423283	CHEMBL4674217	Inhibition of human PYK2 using poly[Glu:Tyr] (4:1) as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OC1CCCCC1		CHEMBL4785602	=	Activity	%	81.41	CHEMBL5469	Homo sapiens	Activity	%	81.41
	22423284	CHEMBL4674217	Inhibition of human PYK2 using poly[Glu:Tyr] (4:1) as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OCc1ccncc1		CHEMBL4749141	=	Activity	%	75.85	CHEMBL5469	Homo sapiens	Activity	%	75.85
	22445682	CHEMBL4679487	Inhibition of Pyk2 (unknown origin)	B	CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4c(c3)CCC(=O)N4)ncc2C(F)(F)F)c1		CHEMBL514554	<	IC50	nM	1000.0	CHEMBL5469	Homo sapiens	IC50	uM	1.0
	22771676	CHEMBL4704539	Inhibition of recombinant human full length PYK2 at 100 nM in presence of [gamma32P]-ATP by radiometric analysis relative to control	B	C=CC(=O)NCCNc1c(NCc2ccc(Nc3ncc(Cl)c(Nc4ccccc4C(=O)NC)n3)cc2)c(=O)c1=O		CHEMBL4752642	=	Inhibition	%	97.6	CHEMBL5469	Homo sapiens	INH	%	97.6
	22771677	CHEMBL4704539	Inhibition of recombinant human full length PYK2 at 100 nM in presence of [gamma32P]-ATP by radiometric analysis relative to control	B	C=CC(=O)NCCNc1c(NCc2ccc(Nc3ncc(Cl)c(NCc4cccnc4N(C)S(C)(=O)=O)n3)cc2)c(=O)c1=O		CHEMBL4751164	=	Inhibition	%	68.3	CHEMBL5469	Homo sapiens	INH	%	68.3
	22771678	CHEMBL4704539	Inhibition of recombinant human full length PYK2 at 100 nM in presence of [gamma32P]-ATP by radiometric analysis relative to control	B	C=CC(=O)NCCNc1c(NCc2ccc(Nc3ncc(C(F)(F)F)c(Nc4ccccc4C(=O)NC)n3)cc2)c(=O)c1=O		CHEMBL4777260	=	Inhibition	%	99.8	CHEMBL5469	Homo sapiens	INH	%	99.8
	22771679	CHEMBL4704539	Inhibition of recombinant human full length PYK2 at 100 nM in presence of [gamma32P]-ATP by radiometric analysis relative to control	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(CNc3c(NCCNC(=O)/C(C#N)=C/C(C)C)c(=O)c3=O)cc2)ncc1Cl		CHEMBL4783568	=	Inhibition	%	97.5	CHEMBL5469	Homo sapiens	INH	%	97.5
	22820564	CHEMBL4716284	Inhibition of recombinant full length N-terminal His6-tagged human PYK2 expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control	B	Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1		CHEMBL2403108	=	Activity	%	7.0	CHEMBL5469	Homo sapiens	Activity	%	7.0
	22820565	CHEMBL4716284	Inhibition of recombinant full length N-terminal His6-tagged human PYK2 expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control	B	COc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)CCNC2		CHEMBL4782674	=	Activity	%	3.0	CHEMBL5469	Homo sapiens	Activity	%	3.0
	22843586	CHEMBL4720572	Inhibition of human PYK2 using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	8.44	CHEMBL5469	Homo sapiens	IC50	10^-9M	8.44
	22843931	CHEMBL4720917	Inhibition of human PYK2 assessed as residual activity using poly[Glu:Tyr] (4:1) as substrate at 1 uM by [gamma-33P]-ATP assay relative to control	B	O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)c1cc([N+](=O)[O-])ccc1F		CHEMBL4750196	=	Activity	%	90.12	CHEMBL5469	Homo sapiens	Activity	%	90.12
	22844848	CHEMBL4721523	Inhibition of wild-type human full length PYK2 (M1 to E967 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	CCOc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)nc2[nH]ccc12		CHEMBL4794578	=	Activity	%	36.1	CHEMBL5469	Homo sapiens	Activity	%	36.1
	22950605	CHEMBL4766172	Inhibition of human full length recombinant PYK2 using poly(Glu,Tyr)4:1 as substrate incubated for 40 mins in presence of [gamma33P-ATP] by radiometric scintillation counting analysis	B	Cc1ccc(NC(=O)c2ccc(C)c(C(F)(F)F)c2)cc1C#Cc1nn([C@H]2CC[C@H](O)CC2)c2ncnc(N)c12		CHEMBL4798527	=	IC50	nM	116.0	CHEMBL5469	Homo sapiens	IC50	uM	0.11599999999999999
	22952980	CHEMBL4766917	Inhibition of recombinant human full length PYK2 assessed as residual activity at 10 uM using poly(Glu, Tyr) 4:1 as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay relative to control	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Nc3ncnc4c3OCCCN4)cc2)no1		CHEMBL4793380	=	Activity	%	63.0	CHEMBL5469	Homo sapiens	Activity	%	63.0
	23122408	CHEMBL4804763	Inhibition of PYK2 in human NCI-H929 cells by mass spectroscopic analysis	B	COc1cc(NS(=O)(=O)C2CC2)ccc1-c1cnc(N)c(-c2ccc3c(c2)CCNC3=O)c1		CHEMBL4867931	=	IC50	nM	31500.0	CHEMBL5469	Homo sapiens	IC50	uM	31.5
	23122409	CHEMBL4804763	Inhibition of PYK2 in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855730	=	IC50	nM	30100.0	CHEMBL5469	Homo sapiens	IC50	uM	30.1
	23122410	CHEMBL4804763	Inhibition of PYK2 in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2OC2CCCCC2)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4868141	=	IC50	nM	38700.0	CHEMBL5469	Homo sapiens	IC50	uM	38.7
	23122411	CHEMBL4804764	Inhibition of PYK2 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	COc1cc(NS(=O)(=O)C2CC2)ccc1-c1cnc(N)c(-c2ccc3c(c2)CCNC3=O)c1		CHEMBL4867931	=	Inhibition	%	0.0	CHEMBL5469	Homo sapiens	INH	%	0.0
	23122412	CHEMBL4804764	Inhibition of PYK2 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855730	=	Inhibition	%	0.0	CHEMBL5469	Homo sapiens	INH	%	0.0
	23122413	CHEMBL4804764	Inhibition of PYK2 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2OC2CCCCC2)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4868141	=	Inhibition	%	35.0	CHEMBL5469	Homo sapiens	INH	%	35.0
	23122782	CHEMBL4805133	Inhibition of human PYK2 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN1CCN(C(=O)c2ccc3cc(CCNc4ccnc5ccc(C#N)cc45)ccc3c2)CC1		CHEMBL4878072	=	Activity	%	92.0	CHEMBL5469	Homo sapiens	Activity	%	92.0
	23123477	CHEMBL4805721	Inhibition of human PYK2 assessed as percent of control at 1000 nM by KINOMEscan assay relative to control	B	COc1cc2nc(NC3CC3)nc(NC3CCN(C(C)C)CC3)c2cc1OC.O=C(O)C(F)(F)F		CHEMBL4870304	=	Activity	%	93.0	CHEMBL5469	Homo sapiens	Activity	%	93.0
	23123932	CHEMBL4806176	Inhibition of DNA-tagged human PYK2 assessed as percent of control at 50000 nM by qPCR analysis relative to control	B	CN1C(=O)/C(=C2/C(=O)Nc3ccccc32)c2ccccc21		CHEMBL607535	=	Activity	%	100.0	CHEMBL5469	Homo sapiens	Activity	%	100.0
	23125044	CHEMBL4806738	Inhibition of human PYK2 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	97.0	CHEMBL5469	Homo sapiens	Activity	%	97.0
	23125045	CHEMBL4806738	Inhibition of human PYK2 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	84.0	CHEMBL5469	Homo sapiens	Activity	%	84.0
	23128515	CHEMBL4807980	Inhibition of PYK2 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)csc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL4867844	>	Activity	%	75.0	CHEMBL5469	Homo sapiens	Activity	%	75.0
	23128516	CHEMBL4807980	Inhibition of PYK2 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(Cl)ccnc3C)s2)cc(NN2CCN(CCO)CC2)n1		CHEMBL4855726	>	Activity	%	75.0	CHEMBL5469	Homo sapiens	Activity	%	75.0
	23128517	CHEMBL4807980	Inhibition of PYK2 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Activity	%	75.0	CHEMBL5469	Homo sapiens	Activity	%	75.0
	23170860	CHEMBL4814453	Inhibition of pyk2 (unknown origin)	B	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	=	IC50	nM	1.4	CHEMBL5469	Homo sapiens	IC50	nM	1.4
	23170861	CHEMBL4814453	Inhibition of pyk2 (unknown origin)	B	CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4c(c3)CC(=O)N4)ncc2C(F)(F)F)c1		CHEMBL487246	=	IC50	nM	1000.0	CHEMBL5469	Homo sapiens	IC50	uM	1.0
	23170862	CHEMBL4814453	Inhibition of pyk2 (unknown origin)	B	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2)ncc1Cl		CHEMBL545839	=	IC50	nM	33.0	CHEMBL5469	Homo sapiens	IC50	nM	33.0
	23170874	CHEMBL4814465	Inhibition of human pyk2	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3cccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL4862042	=	IC50	nM	0.6	CHEMBL5469	Homo sapiens	IC50	nM	0.6
	23218815	CHEMBL4824343	Inhibition of Pyk2 (unknown origin) measured after 40 mins by HTRF	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3ccccc3Cl)n2)cc1		CHEMBL4850588	=	IC50	nM	116.2	CHEMBL5469	Homo sapiens	IC50	nM	116.2
	23218816	CHEMBL4824343	Inhibition of Pyk2 (unknown origin) measured after 40 mins by HTRF	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(Nc3ccccc3OC)n2)cc1		CHEMBL4874046	=	IC50	nM	24.47	CHEMBL5469	Homo sapiens	IC50	nM	24.47
	23218817	CHEMBL4824343	Inhibition of Pyk2 (unknown origin) measured after 40 mins by HTRF	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331	=	IC50	nM	87.41	CHEMBL5469	Homo sapiens	IC50	nM	87.41
Not Active	23317618	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CCC(=N\O)/C(C)=C/c1ccc(F)cc1		CHEMBL3697701		% Control	%	99.0	CHEMBL5469	Homo sapiens	% Control	%	99.0
Not Active	23318086	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CCC(=N\O)/C(C)=C/c1ccc(F)c(C)c1		CHEMBL3701197		% Control	%	98.0	CHEMBL5469	Homo sapiens	% Control	%	98.0
Not Active	23318752	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	Cn1cncc1[C@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4586794		% Control	%	62.0	CHEMBL5469	Homo sapiens	% Control	%	62.0
Not Active	23319236	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	Cn1cncc1[C@@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4526341		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23319873	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CCCCN(CCCC)C(=O)CN1C[C@H](c2cc(OC)c3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1CC(C)(C)CCC		CHEMBL111612		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23320348	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CCCCN(CCCC)C(=O)CN1C[C@@H](c2cc(OC)c3c(c2)OCO3)[C@H](C(=O)O)[C@H]1CC(C)(C)CCC		CHEMBL4513786		% Control	%	93.4	CHEMBL5469	Homo sapiens	% Control	%	93.4
Not Active	23321026	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	c1ccc(N2CCN(Cc3nc4ccccc4[nH]3)CC2)nc1		CHEMBL440687		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23321494	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CSc1cccnc1N1CCN(Cc2nc3ccccc3[nH]2)CC1		CHEMBL4630641		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23322124	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CCCOc1ccc([C@H]2[C@H](C(=O)O)[C@@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL332794		% Control	%	98.0	CHEMBL5469	Homo sapiens	% Control	%	98.0
Not Active	23322592	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CCCOc1ccc([C@@H]2[C@@H](C(=O)O)[C@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL4533479		% Control	%	97.0	CHEMBL5469	Homo sapiens	% Control	%	97.0
Not Active	23323281	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	COc1ccc2c(c1)O[C@@H](c1ccc(OC)c(OC)c1)C[C@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4093612		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23323749	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	COc1ccc2c(c1)O[C@H](c1ccc(OC)c(OC)c1)C[C@@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4066040		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23324117	CHEMBL4880736	Pyk2 (h) Millipore kinase activity assay	B	CC1=C(C#N)C(c2ccc3[nH]nc(C)c3c2)C(C#N)=C(C)N1		CHEMBL4593677		Inhibition	%	17.0	CHEMBL5469	Homo sapiens	% inhibition	%	17.0
Not Active	23324603	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CC1=C(C#N)[C@@H](c2ccc3[nH]nc(C)c3c2)C(C#N)=C(c2ccc(Cl)cc2)N1		CHEMBL4522773		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23325238	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@H]1CC[C@@H](Cn2nnc3ccccc3c2=O)[C@@H]1C(=O)O		CHEMBL4585243		% Control	%	75.0	CHEMBL5469	Homo sapiens	% Control	%	75.0
Not Active	23325706	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@@H]1CC[C@H](Cn2nnc3ccccc3c2=O)[C@H]1C(=O)O		CHEMBL4539943		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23326353	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	NS(=O)(=O)c1cc(NC(=O)Cc2ccccc2)ccc1Oc1cccc(Cl)c1		CHEMBL4521594		% Control	%	79.0	CHEMBL5469	Homo sapiens	% Control	%	79.0
Not Active	23326821	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	NS(=O)(=O)c1cc(NC(=O)C2(c3ccccc3Cl)CC2)ccc1Oc1cccc(Cl)c1		CHEMBL4516843		% Control	%	91.0	CHEMBL5469	Homo sapiens	% Control	%	91.0
Not Active	23327521	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4537788		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23327989	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4564312		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23328576	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C#N)cc1		CHEMBL4448899		% Control	%	95.0	CHEMBL5469	Homo sapiens	% Control	%	95.0
Not Active	23329044	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C(C)(C)C)cc1		CHEMBL4552180		% Control	%	92.0	CHEMBL5469	Homo sapiens	% Control	%	92.0
Not Active	23329506	CHEMBL4881213	Pyk2(h) Eurofins Kinase panel	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% residual kinase activity	%	103.0	CHEMBL5469	Homo sapiens	% residual kinase activity	%	103.0
Not Active	23329990	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23330458	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	Cc1nc(C2CCN(C(=O)c3ccc(OC(F)(F)F)cc3N)CC2)c2ncc(N3CCN(C)CC3)cc2n1		CHEMBL4455582		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23331214	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	O=C(N1CCS(=O)(=O)CC1)N1C[C@H](c2ccc(OC(F)(F)F)cc2)C[C@H](c2nc(C3CC3)no2)C1		CHEMBL4630644		% Control	%	99.0	CHEMBL5469	Homo sapiens	% Control	%	99.0
Not Active	23331682	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	Cc1noc([C@H]2C[C@@H](c3ccc(C(F)(F)F)cc3)CN(C(=O)N3CCS(=O)(=O)C3)C2)n1		CHEMBL4630643		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23332269	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	Cc1cc(C)c(-n2ccn3nc(-c4cccnc4)cc23)cc1NC(=O)c1cc(C#N)cc(S(F)(F)(F)(F)F)c1		CHEMBL3907057		% Control	%	81.4	CHEMBL5469	Homo sapiens	% Control	%	81.4
Not Active	23332735	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	Cc1cc(NC(=O)c2cccc(S(F)(F)(F)(F)F)c2)cc(-n2ccn3nc(-c4cccnc4)cc23)c1		CHEMBL4526351		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23333453	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CC(=O)C1=C(C)N(c2cccc(C(F)(F)F)c2)C(=O)N[C@@H]1c1ccc(C#N)nc1		CHEMBL3617968		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23334092	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CNCc1ccccc1-c1csc([C@@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4535474		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23334560	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CNCc1ccccc1-c1csc([C@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4520788		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23335539	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943		% Control	%	90.0	CHEMBL5469	Homo sapiens	% Control	%	90.0
Not Active	23336007	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	Cn1cc(Cl)c2c(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)ccnc21		CHEMBL4546802		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23336634	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	O=C(NC[C@H]1[C@@H]2CN(C(=O)OCc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C[C@H]12)c1ccc2[nH]nnc2c1		CHEMBL4165749		% Control	%	85.0	CHEMBL5469	Homo sapiens	% Control	%	85.0
Not Active	23337102	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	Cc1nccc(COC(=O)N2C[C@H]3[C@H](CNC(=O)c4ccc5[nH]nnc5c4)[C@H]3C2)n1		CHEMBL4552354		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23337751	CHEMBL4882122	PTK2B Invitrogen selectivity data (BI)	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Ctrl	%	86.0	CHEMBL5469	Homo sapiens	% Ctrl	%	86.0
Not Active	23338183	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Control	%	87.0	CHEMBL5469	Homo sapiens	% Control	%	87.0
Not Active	23338651	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CN(C)C(=O)Cn1cc(-c2nc(C3(c4ccc(-c5cnc(N)nc5)cc4)CC3)no2)cn1		CHEMBL4560241		% Control	%	90.0	CHEMBL5469	Homo sapiens	% Control	%	90.0
Not Active	23339263	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CCS(=O)(=O)c1cc2cc(C[C@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL3358954		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23339731	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CCS(=O)(=O)c1cc2cc(C[C@@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL4531220		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23340368	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CS(=O)(=O)c1cc(C2(NC(=O)c3cncc4c3cnn4-c3ccc(F)cc3)CC2)ccn1		CHEMBL4456123		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23340836	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CS(=O)(=O)NCC[C@H](NC(=O)c1cncc2c1cnn2-c1ccc(F)cc1)c1ccnc(S(C)(=O)=O)c1		CHEMBL4539555		% Control	%	84.0	CHEMBL5469	Homo sapiens	% Control	%	84.0
Not Active	23341493	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CC(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1		CHEMBL2170610		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23341961	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CC(=O)N1CCC(c2ccc(C(=O)NC3=NCCN3)cc2C(F)(F)F)CC1		CHEMBL4540759		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23342577	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CCC(=O)N[C@H]1CC[C@@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834184		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23343045	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CCC(=O)N[C@@H]1CC[C@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834199		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23343675	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CCOC(=O)c1cc2cc(-c3cc(C(=O)NCc4ccc(C(=O)O)cc4)nn3C)ccc2[nH]1		CHEMBL1939876		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23344143	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	Cn1nc(C(=O)NCc2ccc(C(=O)O)cc2)cc1-c1ccc2[nH]ccc2c1		CHEMBL1939880		% Control	%	96.0	CHEMBL5469	Homo sapiens	% Control	%	96.0
Not Active	23344781	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CCOCCn1cc(C(=O)Nc2ccc(-n3nc(-c4cccnc4)cc3C(F)(F)F)cn2)ccc1=O		CHEMBL4516982		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23345354	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)O)CC5/C=C\CCCCC[C@H](NC(=O)OC5CCCC5)C(=O)N4C3)cc(-c3csc(NC(=O)C(C)C)n3)nc2c1C		CHEMBL4588900		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23345822	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	O=C(N[C@H]1CCCCC/C=C\C2C[C@@]2(C(=O)O)NC(=O)[C@@H]2C[C@@H](Oc3ccncc3)CN2C1=O)OC1CCCC1		CHEMBL4516471		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23346399	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	Cc1cc(Nc2nccc(C)n2)cc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)c1		CHEMBL3685796		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23346867	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	Cc1ccc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)cc1Nc1cccc(C(F)(F)F)n1		CHEMBL4530401		% Control	%	72.5	CHEMBL5469	Homo sapiens	% Control	%	72.5
Not Active	23347469	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	C[C@@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccc1		CHEMBL4538174		% Control	%	75.0	CHEMBL5469	Homo sapiens	% Control	%	75.0
Not Active	23347959	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	C[C@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccn1		CHEMBL4557026		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23348538	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CC(=O)Nc1c(C(C)=O)c(=O)n(C)c2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc12		CHEMBL204232		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23349006	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CC(=O)c1c(NS(C)(=O)=O)c2cc(-c3ccc(Cl)cc3)c(-c3ccc(Cl)cc3Cl)nc2n(C)c1=O		CHEMBL4578164		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23349593	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	O=S(=O)(NC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1)C(F)(F)F		CHEMBL1091513		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23350211	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	COc1cc(-c2cn(C3CCc4c(F)cccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1		CHEMBL3609637		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23350679	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	COc1cc(-c2cn(C3CCc4ccccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1ccc(C)n1		CHEMBL4534005		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23351284	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL561132		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23351752	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CN([C@@H]1CCc2c(CC(=O)O)c3cc(S(C)(=O)=O)ccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL1643772		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23352204	CHEMBL4882893	PTK2B (FAK2) Kinase screen	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		Inhibition	%	2.482	CHEMBL5469	Homo sapiens	% Inhibition	%	2.482
Not Active	23352776	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23353244	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	C[C@H]1CN(c2cc(-c3nn(C)c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4560589		% Control	%	77.0	CHEMBL5469	Homo sapiens	% Control	%	77.0
Not Active	23354126	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	O=C(O)c1cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2c1		CHEMBL1800685		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23354594	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	Cc1c(C(=O)O)cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc12		CHEMBL4566600		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23355326	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	COCCOc1nc(-c2ccc(Cl)nc2)nc2c1CN(C(=O)c1ncn3ccccc13)CC2		CHEMBL2204538		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23355794	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CC(C)CC(=O)N1CCc2nc(-c3ccc(Br)cc3)nc(N(C)Cc3ccccc3)c2C1		CHEMBL4518342		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23356430	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1		CHEMBL3582478		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23356898	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	FC(F)(F)c1ccc2c(c1)nc(-c1cccnc1)n2C1CC1		CHEMBL3582461		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23357507	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	C[C@H](c1ccc(F)cc1)N(Cc1cccc(C(=O)O)c1)C(=O)c1cnc2ccccc2c1		CHEMBL3577885		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23358154	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1		CHEMBL1651534		% Control	%	97.0	CHEMBL5469	Homo sapiens	% Control	%	97.0
Not Active	23358622	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	O=C(Nc1cccnn1)N1CC(C/C=C/c2cncc(Oc3ccc(C(F)(F)F)cn3)n2)C1		CHEMBL4780458		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23359208	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	COc1cccc(CNC(=O)c2nc3scc(COCc4ccc(C(=O)O)cc4)c3c(=O)[nH]2)c1		CHEMBL3337894		% Control	%	85.3	CHEMBL5469	Homo sapiens	% Control	%	85.3
Not Active	23359806	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	C[C@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3799292		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23360274	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	C[C@@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3797887		% Control	%	87.0	CHEMBL5469	Homo sapiens	% Control	%	87.0
Not Active	23360859	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	Cn1nc(C(F)(F)F)cc1-c1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4455357		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23361327	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	Nc1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4585920		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23361900	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	Cc1nc(N2CC[C@@H](O)C2)ncc1-c1cc(C(F)(F)F)cc2[nH]ncc12		CHEMBL3799512		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23362436	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	Cc1cc(-n2nc(Cc3cc(F)cc(C(F)(F)F)c3)nc2C)ccc1C(N)=O		CHEMBL4082756		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23362904	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	Cc1nc(Cc2cccc(C(F)(F)F)c2)sc1-c1ccc(C(N)=O)nc1		CHEMBL4100408		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23364546	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CO[C@H]1CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1		CHEMBL4228713		% Control	%	87.0	CHEMBL5469	Homo sapiens	% Control	%	87.0
Not Active	23365014	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCN(Cc3ccc(C(F)(F)F)cc3-c3ccc(Cl)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1		CHEMBL4551344		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23365753	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CN(C)CC#Cc1ccc(OCCCc2sc(N3CCc4cccc(C(=O)Nc5nc6ccccc6s5)c4C3)nc2C(=O)O)c(F)c1		CHEMBL3342332		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23366296	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	Cc1c(Oc2c(F)cccc2F)c(OC(C)C)nn1-c1ncc(C2CC2)cc1F		CHEMBL3589752		% Control	%	81.0	CHEMBL5469	Homo sapiens	% Control	%	81.0
Not Active	23366886	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	Nc1c(C(=O)NCc2ccc(C(=O)NCCCC3CCCCC3)cc2)cnn1-c1ccccc1		CHEMBL4436748		% Control	%	99.0	CHEMBL5469	Homo sapiens	% Control	%	99.0
Not Active	23367354	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	O=C(NCCCC1CCCCC1)c1ccc(CNC(=O)c2cnn(-c3ccccc3)c2C(F)(F)F)cc1		CHEMBL4531775		% Control	%	93.0	CHEMBL5469	Homo sapiens	% Control	%	93.0
Not Active	23367722	CHEMBL4884075	PYK2 ProQinase selectivity panel	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OC[C@H](O)CO)cc21		CHEMBL2152944		% Residual activity with Skepinone-L	%	102.0	CHEMBL5469	Homo sapiens	% Residual activity with Skepinone-L	%	102.0
Not Active	23368232	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	O=C(Nc1cnc(Oc2ccc(F)cc2)nc1)N1CCc2ncccc2[C@@H]1c1ccc(F)cc1		CHEMBL4458424		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23368700	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)N1CCc2ncccc2[C@H]1c1ccc(F)cc1		CHEMBL4592872		% Control	%	89.0	CHEMBL5469	Homo sapiens	% Control	%	89.0
Not Active	23369299	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4537673		% Control	%	91.0	CHEMBL5469	Homo sapiens	% Control	%	91.0
Not Active	23369767	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CN(C)c1ncnc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)c1Cl		CHEMBL4538591		% Control	%	85.0	CHEMBL5469	Homo sapiens	% Control	%	85.0
Not Active	23370221	CHEMBL4884463	Pyk2(h) Eurofins kinase panel	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% residual kinase activity	%	76.0	CHEMBL5469	Homo sapiens	% residual kinase activity	%	76.0
Not Active	23370735	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% Control	%	92.0	CHEMBL5469	Homo sapiens	% Control	%	92.0
Not Active	23371203	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CC1=C(C#N)C(c2ccc3c(c2)c(NC(=O)c2ccccc2C)nn3C)C(C#N)=C(C)N1		CHEMBL4630642		% Control	%	83.0	CHEMBL5469	Homo sapiens	% Control	%	83.0
Not Active	23372012	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNC(=O)c3cnc4ccccn34)cc2)C1		CHEMBL4591082		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23372480	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNc3ncnc4c3nnn4-c3ccccc3)cc2)C1		CHEMBL4568183		% Control	%	94.0	CHEMBL5469	Homo sapiens	% Control	%	94.0
	23372873	CHEMBL4884838	PYK2(PT2BLHF1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(Cc4ccccc4)nc3C2=O)COc2ccccc21		CHEMBL4088216		IC50	nM	1000.0	CHEMBL5469	Homo sapiens	pIC50		6.0
	23373282	CHEMBL4885129	PYK2(PT2BLHF1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3c(nn(Cc4ccccc4)c3Br)C2=O)COc2ccccc21		CHEMBL4549667		IC50	nM	1000.0	CHEMBL5469	Homo sapiens	pIC50		6.0
	23373638	CHEMBL4885415	PYK2(PT2BLHF1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(CC4CCS(=O)(=O)CC4)nc3C2=O)COc2ccccc21		CHEMBL4097778		IC50	nM	1000.0	CHEMBL5469	Homo sapiens	pIC50		6.0
Not Active	23375362	CHEMBL4886344	PTK2B protein tyrosine kinase 2 beta  Millipore kinase panel	B	COCCc1ccc(-c2c(C)nc3c(N4CCOCC4)ccnn23)cn1		CHEMBL2180408		Inhibition	%	-4.0	CHEMBL5469	Homo sapiens	% inhibition	%	-4.0
Not Active	23375907	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	O=C1CCc2cc(Nc3cc(OC4CCOCC4)c([N+](=O)[O-])cc3Cl)ccc2N1		CHEMBL4075278		% Control	%	83.0	CHEMBL5469	Homo sapiens	% Control	%	83.0
Not Active	23376375	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	N#Cc1ccc(Nc2ccc3[nH]c(=O)[nH]c3c2)c(Cl)c1		CHEMBL4063249		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23376952	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	O=c1nc(-c2ccccn2)sc2ccccc12		CHEMBL4516611		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23377420	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	O=C1NC(c2ccccn2)Sc2ccccc21		CHEMBL4561806		% Control	%	76.0	CHEMBL5469	Homo sapiens	% Control	%	76.0
Not Active	23378280	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CNC(=O)Nc1ccc2c(c1)CC[C@@]21OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4282264		% Control	%	73.0	CHEMBL5469	Homo sapiens	% Control	%	73.0
Not Active	23378748	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CNC(=O)Nc1ccc2c(c1)[C@@]1(CC2)OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4536197		% Control	%	83.0	CHEMBL5469	Homo sapiens	% Control	%	83.0
Not Active	23379915	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)O)c(=O)n3ccccc23)CC1		CHEMBL1800285		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23380383	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)N3CCCC3)c(=O)n3ccccc23)CC1		CHEMBL2204283		% Control	%	86.0	CHEMBL5469	Homo sapiens	% Control	%	86.0
Not Active	23381077	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	COc1ccc2cc(OCC3(C(=O)O)CN(C(=O)c4ccc(F)cc4)C3)ccc2c1		CHEMBL3286797		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23381725	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	C[C@H](NC(=O)c1cnc2n1[C@](C)(Cc1ccc(C#N)cc1)C(=O)N2c1cc(Cl)c(F)c(Cl)c1)C(=O)NC1(c2ccccn2)CC1		CHEMBL4530740		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Not Active	23382193	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	C[C@@]1(Cc2ccc(C#N)cc2)C(=O)N(c2cc(Cl)cc(Cl)c2)c2ncc(C(=O)NC3(c4nc(C5CCC5)no4)CC3)n21		CHEMBL4577237		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
Active	23382440	CHEMBL4887101	Binding assay (PTK2B)	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331		IC50	nM	0.2	CHEMBL5469	Homo sapiens	IC50	nM	0.2
Not Active	23382447	CHEMBL4887101	Binding assay (PTK2B)	B	CN(c1ccnc(CNc2nc(Nc3ccc4c(c3)CC(=O)N4)ncc2C(F)(F)F)n1)S(C)(=O)=O		CHEMBL4518706		IC50	nM	721.0	CHEMBL5469	Homo sapiens	IC50	nM	721.0
Active	23382817	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331		% Control	%	8.3	CHEMBL5469	Homo sapiens	% Control	%	8.3
Not Active	23383285	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CN(c1ccnc(CNc2nc(Nc3ccc4c(c3)CC(=O)N4)ncc2C(F)(F)F)n1)S(C)(=O)=O		CHEMBL4518706		% Control	%	59.0	CHEMBL5469	Homo sapiens	% Control	%	59.0
Not Active	23383964	CHEMBL4887571	PTK2B Invitrogen Lab (UK) kinase screen (BI)	B	CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12		CHEMBL4522930		% Ctrl	%	91.0	CHEMBL5469	Homo sapiens	% Ctrl	%	91.0
Not Active	23383965	CHEMBL4887571	PTK2B Invitrogen Lab (UK) kinase screen (BI)	B	CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12		CHEMBL4522930		% Ctrl	%	70.0	CHEMBL5469	Homo sapiens	% Ctrl	%	70.0
Not Active	23384443	CHEMBL4888038	Pyk2(h) Millipore kinase panel	B	CC[C@@H](Nc1c(C#N)c(-c2ccc(-c3cccc(C)c3F)cc2)nc2cnccc12)C(=O)O		CHEMBL4802045		Inhibition	%	10.72	CHEMBL5469	Homo sapiens	% inhibition	%	10.72
Not Active	23385200	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CO[C@@H](C)c1c(Nc2ccc([C@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4568735		% Control	%	83.0	CHEMBL5469	Homo sapiens	% Control	%	83.0
Not Active	23385667	CHEMBL4879924	KinomeScan assay: inhibition of PYK2	B	CO[C@@H](C)c1c(Nc2ccc([C@@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4584981		% Control	%	100.0	CHEMBL5469	Homo sapiens	% Control	%	100.0
